Introducing PHARMAC 2

Part I  General Rules  4

Part II  Alimentary Tract and Metabolism  5
          Blood and Blood Forming Organs  23
          Cardiovascular System  37
          Dermatologicals  51
          Genito-Urinary System  57
          Hormone Preparations  62
          Infections  72
          Musculoskeletal System  94
          Nervous System  103
          Oncology Agents and Immunosuppressants  128
          Respiratory System and Allergies  192
          Sensory Organs  200
          Various  207
          Extemporaneous Compounds (ECPs)  215
          Special Foods  218
          Vaccines  233

Part III  Optional Pharmaceuticals  243

Index  244
Introducing PHARMAC
The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC’s role:

“Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided.”

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures. Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.health.nz/about.

Glossary

Units of Measure
gram ............................................... g  
kilogram ........................................... kg  
international unit ............................ iu

microgram ................................. mcg  
milligram .................................... mg  
millilitre ........................................ ml

millimole ....................................... mmol
unit ................................................. u

Abbreviations
application ................................. app  
capsule ......................................... cap  
cream ........................................... crm

dispersible .................................... disp  
effervescent ................................. eff  
emulsion ...................................... emul

enteric coated .............................. EC  
granules ....................................... grans
injection ....................................... inj

liquid ........................................... liq
lotion ............................................ lotn
ointment ....................................... oint

solution ....................................... soln  
suppository ................................. suppos
tablet ........................................... tab

tincture ....................................... tinc

HSS Hospital Supply Status
<table>
<thead>
<tr>
<th>ANATOMICAL HEADING</th>
<th>Price (ex man. Excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEMICAL A - Restricted see terms below</td>
<td>10.00</td>
<td>100</td>
<td>Brand A</td>
</tr>
<tr>
<td>CHEMICAL B - Some items restricted see terms below</td>
<td>1,589.00</td>
<td>1</td>
<td>Brand B1</td>
</tr>
<tr>
<td>CHEMICAL C - Restricted see terms below</td>
<td>15.00</td>
<td>28</td>
<td>Brand C</td>
</tr>
<tr>
<td>CHEMICAL D - Restricted see terms below</td>
<td>38.65</td>
<td>500</td>
<td>Brand D</td>
</tr>
<tr>
<td>CHEMICAL E - Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**THERAPEUTIC HEADING**

- **CHEMICAL A**
  - Presentation A
  - Restricted see terms below
  - Only for use in children under 12 years of age
  - 1% DV Limit Jan-12 to 2014
- **CHEMICAL B**
  - Presentation B1
  - Restricted
  - -1% DV Limit Jan-12 to 2014
- **CHEMICAL C**
  - Presentation C
  - Restricted
  - -1% DV Limit Jan-12 to 2014
- **CHEMICAL D**
  - Presentation D
  - Restricted
  - Limited to five weeks' treatment
  - -1% DV Limit Mar-13 to 2014
- **CHEMICAL E**
  - Presentation E
  - Restricted

- Items restricted (see above): Items restricted (see below)
- Products with Hospital Supply Status (HSS) are in **bold**
General Rules for Section H of the Pharmaceutical Schedule are included in Section A General Rules and are located on the PHARMAC website.
### Antacids and Antiflatulents

#### Antacids and Reflux Barrier Agents

**Aluminium Hydroxide with Magnesium Hydroxide and Simeticone**
- Tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg
- Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml
  
  *e.g.* Mylanta

**Simeticone**
- Oral drops 100 mg per ml
- Oral drops 20 mg per 0.3 ml

**Sodium Alginate with Magnesium Alginate**
- Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet
  
  *e.g.* Gaviscon Infant

**Sodium Alginate with Sodium Bicarbonate and Calcium Carbonate**
- Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg
- Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml
  
  4.95 500 ml Acidex

**Sodium Citrate**
- Oral liq 8.8% (300 mmol/l)

#### Phosphate Binding Agents

**Aluminium Hydroxide**
- Tab 600 mg

**Calcium Carbonate – Restricted**
- Oral liq 250 mg per ml (100 mg elemental per ml):
  - Restricted (RS1025)
  
  39.00 500 ml Roxane

**Budesonide – Restricted**
- Cap 3 mg

**Loperamide Hydrochloride**
- Tab 2 mg
- Cap 2 mg – 1% DV Oct-19 to 2022:
  
  10.75 400 Nodia
  6.25 400 Diamide Relief

**Rectal and Colonic Anti-Inflammatories**

**Budesonide – Restricted**
- Cap 3 mg

**Initiation – Crohn's disease**

Both:

*continued…*
continued…

1 Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and
2 Any of the following:
   2.1 Diabetes; or
   2.2 Cushingoid habitus; or
   2.3 Osteoporosis where there is significant risk of fracture; or
   2.4 Severe acne following treatment with conventional corticosteroid therapy; or
   2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
   2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid
treatment causing relapse is considered to be high; or
   2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initiation – Collagenous and lymphocytic colitis (microscopic colitis)
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initiation – Gut Graft versus Host disease
Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

HYDROCORTISONE ACETATE
Rectal foam 10%, CFC free (14 applications) .................................................26.55 21.1 g Colifoam

HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE
Topical Aerosol foam, 1% with pramoxine hydrochloride 1%

MESALAZINE
Tab EC 400 mg ..........................................................49.50 100 Asacol
Tab EC 500 mg ..........................................................49.50 100 Asamax
Tab long-acting 500 mg ...............................................59.05 100 Pentasa
Tab 800 mg ............................................................85.50 90 Asacol
Modified release granules 1 g .....................................141.72 120 g Pentasa
Suppos 500 mg .........................................................22.80 20 Asacol
Suppos 1 g ............................................................54.60 30 Pentasa
Enema 1 g per 100 ml .............................................41.30 7 Pentasa

OLSALAZINE
Tab 500 mg ............................................................93.37 100 Dipentum
Cap 250 mg ............................................................53.00 100 Dipentum

SODIUM CROMOGLICATE
Cap 100 mg

SULFASALAZINE
Tab 500 mg ..........................................................14.00 100 Salazopyrin
Tab EC 500 mg – 1% DV Dec-19 to 2022 .....................................................15.53 100 Salazopyrin EN

Local Preparations for Anal and Rectal Disorders

Antihaeorrhoidal Preparations

CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE
Oint 5 mg with hydrocortisone 5 mg per g ...........................................15.00 30 g Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g ......................................9.90 12 Proctosedyl

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine
hydrochloride 5 mg per g ..................................................6.35 30 g Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine
hydrochloride 1 mg ......................................................2.66 12 Ultraproct
## Management of Anal Fissures

GLYCERYL TRINITRATE  
Oint 0.2% .................................................. 22.00 30 g Rectogesic

## Rectal Sclerosants

OILY PHENOL [PHENOL OILY]  
Inj 5%, 5 ml vial

## Antispasmodics and Other Agents Altering Gut Motility

GLYCOPHYRONIUM BROMIDE  
Inj 200 mcg per ml, 1 ml ampoule .............................................. 17.14 10 Max Health

HYOSCINE BUTYLBRONIDE  
Tab 10 mg – 1% DV Dec-17 to 2020 ............................................ 8.75 100 Buscopan  
Inj 20 mg, 1 ml ampoule ...................................................... 9.57 5 Buscopan

MEBEVERINE HYDROCHLORIDE  
Tab 135 mg .................................................. 18.00 90 Colofac

## Antiulcerants

### Antisecretory and Cytoprotective

MISOPROSTOL  
Tab 200 mcg ................................................ 41.50 120 Cytotec

### H2 Antagonists

CIMETIDINE  
Tab 200 mg  
Tab 400 mg  
RANITIDINE  
Tab 150 mg – 1% DV Oct-17 to 2020 ............................................. 12.91 500 Ranitidine Relief  
Tab 300 mg – 1% DV Oct-17 to 2020 ............................................. 18.21 500 Ranitidine Relief  
Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020 ...................... 5.14 300 ml Peptisoothe  
Inj 25 mg per ml, 2 ml ampoule .............................................. 13.40 5 Zantac

## Proton Pump Inhibitors

LANSOPRAZOLE  
Cap 15 mg – 1% DV Sep-18 to 2021 .......................................... 4.58 100 Lanzol Relief  
Cap 30 mg – 1% DV Sep-18 to 2021 .......................................... 5.41 100 Lanzol Relief

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (ex man. excl. GST)</td>
</tr>
<tr>
<td>Per</td>
</tr>
</tbody>
</table>

**OMEPRAZOLE**
- Tab dispersible 20 mg
  - Restricted (RS1027)
  - Initiation
    - Only for use in tube-fed patients.
    - Cap 10 mg – 1% DV Mar-18 to 2020................................. 1.98 90 Omeprazole actavis 10
    - Cap 20 mg – 1% DV Mar-18 to 2020................................. 1.96 90 Omeprazole actavis 20
    - Cap 40 mg – 1% DV Mar-18 to 2020................................. 3.12 90 Omeprazole actavis 40
    - Powder for oral liq..................................................... 42.50 5 g Midwest
    - Inj 40 mg ampoule with diluent – 1% DV Oct-19 to 2022........ 33.98 5 Dr Reddy’s Omeprazole
    - Inj 40 mg vial – 1% DV Oct-19 to 2022............................ 11.46 5 Omezol IV

**PANTOPRAZOLE**
- Tab EC 20 mg – 1% DV Oct-19 to 2022................................. 2.02 100 Panzop Relief
- Tab EC 40 mg – 1% DV Oct-19 to 2022................................. 2.85 100 Panzop Relief
- Inj 40 mg vial

**Site Protective Agents**

**COLLOIDAL BISMUTH SUBCITRATE**
- Tab 120 mg................................................................. 14.51 50 Gastrodenol

**SUCRALFATE**
- Tab 1 g

**Bile and Liver Therapy**

**L-ORNITHINE L-ASPARTATE** – Restricted see terms below
- Grans for oral liquid 3 g
  - Restricted (RS1261)
  - Initiation
    - For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

**RIFAXIMIN** – Restricted see terms below
- Tab 550 mg – 1% DV Sep-17 to 2020..................................... 625.00 56 Xifaxan
  - Restricted (RS1416)
  - Initiation
    - For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

**Diabetes**

**Alpha Glucosidase Inhibitors**

**ACARBOSE**
- Tab 50 mg – 1% DV Sep-18 to 2021..................................... 3.50 90 Glucobay
- Tab 100 mg – 1% DV Sep-18 to 2021.................................. 6.40 90 Glucobay

**Hyperglycaemic Agents**

**DIAZOXIDE** – Restricted see terms on the next page
- Cap 25 mg................................................................. 110.00 100 Proglicem
- Cap 100 mg.............................................................. 280.00 100 Proglicem
- Oral liq 50 mg per ml .................................................. 620.00 30 ml Proglycem

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
ALIMENTARY TRACT AND METABOLISM

Price (ex man. excl. GST) Per Brand or Generic Manufacturer

RestRICTED (RS1028)

Initiation
For patients with confirmed hypoglycaemia caused by hyperinsulinism.

GLUCAGON HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg syringe kit</td>
<td>32.00</td>
<td>Glucagen Hypokit</td>
</tr>
</tbody>
</table>

GLUCOSE [DEXTROSE]

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1.5 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 3.1 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 4 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 40%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GLUCOSE WITH SUCROSE AND FRUCTOSE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Insulin - Intermediate-Acting Preparations

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen</td>
<td>52.15</td>
<td>NovoMix 30 FlexPen</td>
</tr>
</tbody>
</table>

INSULIN ISOPHANE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj insulin human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

INSULIN LYSPRO WITH INSULIN LYSPRO PROTAMINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge</td>
<td>42.66</td>
<td>Humalog Mix 25</td>
</tr>
<tr>
<td>Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge</td>
<td>42.66</td>
<td>Humalog Mix 50</td>
</tr>
</tbody>
</table>

INSULIN NEUTRAL WITH INSULIN ISOPHANE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Insulin - Long-Acting Preparations

INSULIN GLARGINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>94.50</td>
<td>Lantus SoloStar</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>94.50</td>
<td>Lantus</td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>63.00</td>
<td>Lantus</td>
</tr>
</tbody>
</table>

Insulin - Rapid-Acting Preparations

INSULIN ASPART

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml syringe</td>
<td>51.19</td>
<td>NovoRapid FlexPen</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN GLULISINE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>$27.03 1 Apidra</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>$46.07 5 Apidra</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>$46.07 5 Apidra Solostar</td>
</tr>
</tbody>
</table>

| **INSULIN LISPRO**       |                               |
| Inj 100 u per ml, 10 ml vial |                           |
| Inj 100 u per ml, 3 ml cartridge |                           |

#### Insulin - Short-Acting Preparations

| **INSULIN NEUTRAL**      |                               |
| Inj human 100 u per ml, 10 ml vial |                           |
| Inj human 100 u per ml, 3 ml cartridge |                           |

#### Oral Hypoglycaemic Agents

| **GLIBENCLAMIDE**        |                               |
| Tab 5 mg – 1% DV Oct-18 to 2021 | $6.00 100 Daonil |

| **GLICLAZIDE**           |                               |
| Tab 80 mg – 1% DV Sep-17 to 2020 | $10.29 500 Glizide |

| **GLIPIZIDE**            |                               |
| Tab 5 mg – 1% DV Dec-18 to 2021 | $3.27 100 Minidiab |

| **METFORMIN HYDROCHLORIDE** |                               |
| Tab immediate-release 500 mg – 1% DV Feb-19 to 2021 | $8.63 1,000 Apotex |
| Tab immediate-release 850 mg – 1% DV Feb-19 to 2021 | $7.04 500 Apotex |

| **PIOGLITAZONE**         |                               |
| Tab 15 mg – 1% DV Oct-18 to 2021 | $3.47 90 Vexazone |
| Tab 30 mg – 1% DV Oct-18 to 2021 | $5.06 90 Vexazone |
| Tab 45 mg – 1% DV Oct-18 to 2021 | $7.10 90 Vexazone |

| **VILDAGLIPTIN**         |                               |
| Tab 50 mg                   | $40.00 60 Galvus |

| **VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE** |                               |
| Tab 50 mg with 1,000 mg metformin hydrochloride | $40.00 60 Galvumet |
| Tab 50 mg with 850 mg metformin hydrochloride | $40.00 60 Galvumet |

#### Digestives Including Enzymes

| **PANCREATIC ENZYME**    |                               |
| Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease)) |                           |
| Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 1% DV Sep-18 to 2021 | $34.93 100 Creon 10000 |
| Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – 1% DV Sep-18 to 2021 | $94.38 100 Creon 25000 |
| Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylace, 5,000 Ph. Eur. u/lipase and 200 Ph. Eur. u/protease) |                           |

| **URSODEOXYCHOLIC ACID – Restricted** | see terms on the next page |

| Cap 250 mg – 1% DV Sep-17 to 2020 | $37.95 100 Ursosan |

---

1 Item restricted (see ➡️ above); 2 Item restricted (see ➡️ below)

* e.g. *Brand* indicates brand example only. It is not a contracted product.*
Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis
Either:
1. Patient has been diagnosed with Alagille syndrome; or
2. Patient has progressive familial intrahepatic cholestasis.

Initiation – Chronic severe drug induced cholestatic liver injury
All of the following:
1. Patient has chronic severe drug induced cholestatic liver injury; and
2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initiation – Primary biliary cholangitis
Both:
1. Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
2. Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

Initiation – Pregnancy
Patient diagnosed with cholestasis of pregnancy.

Initiation – Haematological transplant
Both:
1. Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
2. Treatment for up to 13 weeks.

Initiation – Total parenteral nutrition induced cholestasis
Both:
1. Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
2. Liver function has not improved with modifying the TPN composition.

Laxatives

Bowel-Cleansing Preparations

CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE
Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet
e.g. PicoPrep

MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet
e.g. Glycoprep-C

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet – 1% DV Aug-19 to 2022 .........................................14.31 4 Klean Prep

Bulk-Forming Agents

ISPAGHULA (PSYLLIUM) HUSK
Powder for oral soln – 1% DV Oct-17 to 2020 .......................................................6.05 500 g Konsyl-D
### Faecal Softeners

**DOCUSATE SODIUM**
- Tab 50 mg – 1% DV Sep-17 to 2020 .................................................. 2.31 100 Coloxyl
- Tab 120 mg – 1% DV Sep-17 to 2020 ............................................ 3.13 100 Coloxyl

**DOCUSATE SODIUM WITH SENNOSIDES**
- Tab 50 mg with sennosides 8 mg – 1% DV Jun-18 to 2021 ......... 3.10 200 Laxsol

**PARAFFIN**
- Oral liquid 1 mg per ml
- Enema 133 ml

**POLOXAMER**
- Oral drops 10% – 1% DV Sep-17 to 2020 .................................. 3.78 30 ml Coloxyl

### Opioid Receptor Antagonists - Peripheral

**METHYLNALTREXONE BROMIDE** – Restricted see terms below
- Inj 12 mg per 0.6 ml vial .......................................................... 36.00 1 Relistor
- 246.00 7 Relistor

- Restricted (RS1601)

Initiation – Opioid induced constipation
Both:
- 1 The patient is receiving palliative care; and
- 2 Either:
  - 2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
  - 2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

### Osmotic Laxatives

**GLYCEROL**
- Suppos 1.27 g
- Suppos 2.55 g
- Suppos 3.6 g – 1% DV Oct-18 to 2021 ........................................ 9.25 20 PSM

**LACTULOSE**
- Oral liq 10 g per 15 ml – 1% DV Nov-19 to 2022.................... 3.33 500 ml Laevolac

**MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE**
- Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg
- Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Feb-18 to 2020 .................................................. 6.78 30 Molaxole

**SODIUM CITRATE WITH PHOSPHORIC ACID**
- Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% 
  - DV Nov-19 to 2022 .......................................................... 29.98 50 Micolette
- Enema 10% with phosphoric acid 6.58% ................................... 2.50 1 Fleet Phosphate Enema
### Stimulant Laxatives

**BISACODYL**
- Tab 5 mg – 1% DV Sep-18 to 2021 ................................................................. 5.99 200 Lax-Tabs
- Suppos 10 mg – 1% DV Sep-18 to 2021 ......................................................... 3.74 10 Lax-Suppositories

**SENNOSIDES**
- Tab 7.5 mg

### Metabolic Disorder Agents

**ALGLUCOSIDASE ALFA – Restricted** see terms below

- **Initiation**
  - Metabolic physician
  - *Re-assessment required after 12 months*
  - All of the following:
    1. The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
    2. Any of the following:
      1. Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
      2. Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
      3. Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
      4. Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
    3. Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
    4. Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
    5. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

**Continuation**
- Metabolic physician
  - *Re-assessment required after 12 months*
  - All of the following:
    1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
    2. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
    3. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
    4. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
    5. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
    6. There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
    7. There is no evidence of new or progressive cardiomyopathy.

**ARGININE**
- Powder
  - Inj 600 mg per ml, 25 ml vial

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BETAINE – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for oral soln</td>
<td>575.00</td>
<td>180 g Cystadane</td>
</tr>
<tr>
<td>→ Restricted (RS1639)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**

Metabolic physician

**Re-assessment required after 12 months**

All of the following:

1. The patient has a confirmed diagnosis of homocystinuria; and
2. Any of the following:
   2.1 A cystathionine beta-synthase (CBS) deficiency; or
   2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
   2.3 A disorder of intracellular cobalamin metabolism; and
3. An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

**Continuation**

Metabolic physician

**Re-assessment required after 12 months**

The treatment remains appropriate and the patient is benefiting from treatment.

BIOTIN – Restricted see terms below

- Cap 50 mg
- Cap 100 mg
- Inj 10 mg per ml, 5 ml vial

→ Restricted (RS1330)

**Initiation**

Metabolic physician or metabolic disorders dietitian

**GALSULFASE – Restricted see terms below**

- Inj 1 mg per ml, 5 ml vial

→ Restricted (RS1523)

**Initiation**

Metabolic physician

**Re-assessment required after 12 months**

Both:

1. The patient has been diagnosed with mucopolysaccharidosis VI; and
2. Either:
   2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts; or
   2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

**Continuation**

Metabolic physician

**Re-assessment required after 12 months**

All of the following:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

**HAEM ARGINATE**

Inj 25 mg per ml, 10 ml ampoule

---

Item restricted (see ➞ above); Item restricted (see ➞ below)

e.g. Brand indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product</th>
<th>Status</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDURSULFASE – Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Inj 2 mg per ml, 3 ml vial | Restricted (RS1546) | Initiation
Metabolic physician
Limited to 24 weeks treatment
All of the following:
1 The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
2 Either:
   2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week. | 4,608.30 | Elaprase |
| LARONIDASE – Restricted see terms below | | | | |
| Inj 100 U per ml, 5 ml vial | Restricted (RS1607) | Initiation
Metabolic physician
Limited to 24 weeks treatment
All of the following:
1 The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
2 Either:
   2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week. | 1,335.16 | Aldurazyme |
| LEVOCARNITINE – Restricted see terms below | | | | |
| Cap 500 mg | Restricted (RS1035) | Neurologist, metabolic physician or metabolic disorders dietitian
| Oral soln 1,000 mg per 10 ml | | | |
| Inj 200 mg per ml, 5 ml vial | | | |
| PYRIDOXAL-5-PHOSPHATE – Restricted see terms below | | | | |
| Tab 50 mg | Restricted (RS1331) | Neurologist, metabolic physician or metabolic disorders dietitian
| SAPROPTERIN DIHYDROCHLORIDE – Restricted see terms on the next page | | | |
| Tab soluble 100 mg | | | |

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**ALIMENTARY TRACT AND METABOLISM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Restricted (RS1656)**

**Initiation**

*Metabolic physician*

*Re-assessment required after 1 month*

All of the following:

1. Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
2. Treatment with sapropterin is required to support management of PKU during pregnancy; and
3. Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
4. Sapropterin to be used alone or in combination with PKU dietary management; and
5. Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

**Continuation**

*Metabolic physician or any relevant practitioner on the recommendation of a metabolic physician*

*Re-assessment required after 12 months*

All of the following:

1. Either:
   1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
   1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
2. Any of the following:
   2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
   2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
   2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
3. Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
4. Sapropterin to be used alone or in combination with PKU dietary management; and
5. Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

**SODIUM BENZOATE**

- Cap 500 mg
- Powder
- Soln 100 mg per ml
- Inj 20%, 10 ml ampoule

**SODIUM PHENYL BUTYRATE** – *Some items restricted* see terms below

- Tab 500 mg
  - Grans 483 mg per g..........................1,920.00 174 g Pheburane
  - Oral liq 250 mg per ml
  - Inj 200 mg per ml, 10 ml ampoule

**Restricted (RS1526)**

**Initiation**

*Metabolic physician*

*Re-assessment required after 12 months*

For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

**Continuation**

*Metabolic physician*

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TALIGLUCERASE ALFA</strong> – Restricted see terms below</td>
<td>$1,072.00</td>
<td>Elelyso</td>
</tr>
<tr>
<td><strong>Initiation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Only for use in patients with approval by the Gaucher Treatment Panel.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TRIENTINE DIHYDROCHLORIDE**
- Cap 300 mg

### Minerals

#### Calcium

**CALCIUM CARBONATE**
- Tab 1.25 g (500 mg elemental) – 1% DV Mar-18 to 2020 .................7.52 250 Arrow-Calcium
- Tab eff 1.75 g (1 g elemental)

#### Fluoride

**SODIUM FLUORIDE**
- Tab 1.1 mg (0.5 mg elemental)

#### Iodine

**POTASSIUM IODATE**
- Tab 253 mcg (150 mcg elemental iodine) – 1% DV Mar-19 to 2020 ........4.69 90 NeuroTabs
- Oral liq 10% with iodine 5%

#### Iron

**FERRIC CARBOXYMALTOSE** – Restricted see terms below
- Inj 50 mg per ml, 10 ml vial....................................................150.00 1 Ferinject

**FERROUS FUMARATE**
- Tab 200 mg (65 mg elemental) – 1% DV Jan-19 to 2021 ....................3.09 100 Ferro-tab
- Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 1% DV Jun-18 to 2021.........................................................4.68 60 Ferro-F-Tabs
- Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg

**FERROUS SULFATE**
- Oral liq 30 mg (6 mg elemental) per ml – 1% DV Nov-19 to 2022 ..........12.08 500 ml Ferodan
- Tab long-acting 325 mg (105 mg elemental) – 1% DV Jun-18 to 2021 ......2.06 30 Ferrograd
- Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg

**IRON POLYMALTOSE**
- Inj 50 mg per ml, 2 ml ampoule ....................................................34.50 5 Ferrosig
- 15.22 Ferrum H

*Products with Hospital Supply Status (HSS) are in **bold**

*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
IRON SUCROSE
Inj 20 mg per ml, 5 ml ampoule .................................................................100.00

Magnesium

MAGNESIUM AMINO ACID CHELATE
Cap 750 mg (150 mg elemental)

MAGNESIUM CHLORIDE
Inj 1 mmol per 1 ml, 100 ml bag

MAGNESIUM HYDROXIDE
Tab 311 mg (130 mg elemental)

MAGNESIUM OXIDE
Cap 663 mg (400 mg elemental)
Cap 696 mg (420 mg elemental)

MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE
Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)

MAGNESIUM SULPHATE
Inj 0.4 mmol per ml, 250 ml bag
Inj 2 mmol per ml, 5 ml ampoule – 1% DV Sep-17 to 2020 .............................10.21

Zinc

ZINC
Oral liq 5 mg per 5 drops

ZINC CHLORIDE
Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule

ZINC SULPHATE
Cap 137.4 mg (50 mg elemental) – 1% DV Dec-19 to 2022 ..............................11.00

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYMADINE HYDROCHLORIDE
Soln 0.15%
Spray 0.15%
Spray 0.3%

BENZYMADINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLORIDE
Lozenge 3 mg with cetarylpyridinium chloride

CARBOXYMETHYLCELLULOSE
Oral spray

CARAMELOOSE SODIUM WITH PECTIN AND GELATINE
Paste
Powder

CHLORHEXIDINE GLUCONATE
Mouthwash 0.2% .................................................................2.57
200 ml healthE

CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE
Adhesive gel 8.7% with cetalkonium chloride 0.01%
DICHLOROBENZYL ALCOHOL WITH AMYLMECATRESOL
Lozenge 1.2 mg with amylmetacresol 0.6 mg

TRIAMCINOLONE ACETONIDE
Paste 0.1% – 1% DV Sep-17 to 2020 .............................................................. 5.33 5 g Kenalog in Orabase

Oropharyngeal Anti-Infectives

AMPHOTERICIN B
Lozenge 10 mg .................................................................................................. 5.86 20 Fungilin

MICONAZOLE
Oral gel 20 mg per g – 1% DV Sep-18 to 2021 ................................................ 4.74 40 g Decozol

NYSTATIN
Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020 ................................. 1.95 24 ml Nilstat

Other Oral Agents

HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE]
Inj 20 mg per ml

SODIUM HYALURONATE [HYALURONIC ACID] – Restricted see terms below
⇒ Inj 20 mg per ml, 1 ml syringe
⇒ Restricted (RS1175)
Otolaryngologist

THYMOL GLYCERIN
Compound, BPC .............................................................................................. 9.15 500 ml PSM

Vitamins

Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – Restricted see terms below
⇒ Inj ............................................................................................................... 23.35 180 Clinicians Multivit & Mineral Boost
⇒ Restricted (RS1498)
Initiation
Limited to 3 months treatment
Both:
1 Patient was admitted to hospital with burns; and
2 Any of the following:
   2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
   2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
   2.3 Nutritional status prior to admission or dietary intake is poor.

MULTIVITAMIN RENAL – Restricted see terms below
⇒ Inj ............................................................................................................. 6.49 30 Clinicians Renal Vit
⇒ Restricted (RS1499)
Initiation
Either:
1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA).
MULTIVITAMINS

Tab (BPC cap strength)................................................................. 10.50 1,000 Mvite

- cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha
  tocoherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg,
  ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg,
  riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg,
  cyanocobalamine 3 mcg, zinc 7.5 mg and biotin 100 mcg

→ Restricted (RS1620)

Initiation

Any of the following:

1. Patient has cystic fibrosis with pancreatic insufficiency; or
2. Patient is an infant or child with liver disease or short gut syndrome; or
3. Patient has severe malabsorption syndrome.

- Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E
  21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg,
  riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid
  303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid
  17 mg, choline 350 mg and inositol 700 mg

→ Restricted (RS1178)

Initiation

Patient has inborn errors of metabolism.

- Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine
  hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg
  with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)
  e.g. Pabrinex IV

- Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine
  hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg
  with nicotinamide 160 mg, 2 ml ampoule (1)
  e.g. Pabrinex IM

- Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine
  hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid
  1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml
  ampoule (1)
  e.g. Pabrinex IV

VITAMIN A WITH VITAMINS D AND C

- Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops
  e.g. Vitadol C

(e.g. Vitadol C Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops to be delisted 1 December 2019)

Vitamin A

RETINOL

Tab 10,000 iu
Cap 25,000 iu
Oral liq 150,000 iu per ml
Oral liq 5,000 iu per drop, 30 ml

Vitamin B

HYDROXOCOBALAMIN

Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021.......................... 1.89 3 Neo-B12
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PYRIDOXINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-18 to 2020</td>
<td>2.70</td>
<td>Vitamin B6 25</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Oct-17 to 2020</td>
<td>13.63</td>
<td>Apo-Pyridoxine</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 30 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>THIAMINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Nov-18 to 2020</td>
<td>4.89</td>
<td>Max Health</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial</td>
<td></td>
<td>e.g. Benerva</td>
</tr>
<tr>
<td><strong>VITAMIN B COMPLEX</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab strong, BPC</td>
<td>7.15</td>
<td>Bplex</td>
</tr>
<tr>
<td><strong>Vitamin C</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASCORBIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>8.10</td>
<td>Cvite</td>
</tr>
<tr>
<td>Tab chewable 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin D</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALFACALCIDOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 0.25 mcg – 1% DV Aug-17 to 2020</td>
<td>26.32</td>
<td>One-Alpha</td>
</tr>
<tr>
<td>Cap 1 mcg – 1% DV Aug-17 to 2020</td>
<td>87.98</td>
<td>One-Alpha</td>
</tr>
<tr>
<td>Oral drops 2 mcg per ml – 1% DV Aug-17 to 2020</td>
<td>60.68</td>
<td>One-Alpha</td>
</tr>
<tr>
<td>CALCITRIOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 0.25 mcg – 1% DV Oct-19 to 2022</td>
<td>7.95</td>
<td>Calcitriol-AFT</td>
</tr>
<tr>
<td>Cap 0.5 mcg – 1% DV Oct-19 to 2022</td>
<td>13.75</td>
<td>Calcitriol-AFT</td>
</tr>
<tr>
<td>Oral liq 1 mcg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COLECALCIFEROL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020</td>
<td>2.50</td>
<td>Vit.D3</td>
</tr>
<tr>
<td>Oral liq 188 mcg per ml (7,500 iu per ml)</td>
<td>9.00</td>
<td>Puria</td>
</tr>
<tr>
<td><strong>Vitamin E</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALPHA TOCOPHERYL – Restricted see terms below</td>
<td>156 u per ml</td>
<td></td>
</tr>
<tr>
<td>Oral liq 156 u per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1632)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation – Cystic fibrosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Cystic fibrosis patient; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation – Osteoradionecrosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For the treatment of osteoradionecrosis.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued…
Initiation – Other indications
All of the following:
1 Infant or child with liver disease or short gut syndrome; and
2 Requires vitamin supplementation; and
3 Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

ALPHA TOCOPHERYL ACETATE – Restricted see terms below

- Cap 100 u
- Cap 500 u
- Oral liq 156 u per ml

Initiation – Cystic fibrosis
Both:
1 Cystic fibrosis patient; and
2 Either:
   2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
   2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis
For the treatment of osteoradionecrosis.

Initiation – Other indications
All of the following:
1 Infant or child with liver disease or short gut syndrome; and
2 Requires vitamin supplementation; and
3 Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.
## Antianaemics

### Hypoplastic and Haemolytic

**EPOETIN ALFA** – Restricted see terms below

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,000 iu in 0.5 ml syringe</td>
<td>250.00</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>2,000 iu in 1 ml syringe</td>
<td>100.00</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>3,000 iu in 0.3 ml syringe</td>
<td>150.00</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>4,000 iu in 0.4 ml syringe</td>
<td>96.50</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>5,000 iu in 0.5 ml syringe</td>
<td>125.00</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>6,000 iu in 0.6 ml syringe</td>
<td>145.00</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>8,000 iu in 0.8 ml syringe</td>
<td>175.00</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>10,000 iu in 1 ml syringe</td>
<td>197.50</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
<tr>
<td>40,000 iu in 1 ml syringe</td>
<td>250.00</td>
<td>Apr-19 to 2022</td>
<td>Binocrit</td>
</tr>
</tbody>
</table>

#### Initiation – chronic renal failure

All of the following:
1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

#### Initiation – myelodysplasia*

*Re-assessment required after 2 months*

All of the following:
1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum epoetin level of < 500 IU/L; and
6. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

#### Continuation – myelodysplasia*

*Re-assessment required after 12 months*

All of the following:
1. The patient’s transfusion requirement continues to be reduced with epoetin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

#### Initiation – all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with * are unapproved indications.
EPOETIN BETA – Restricted see terms below
Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

Initiation – chronic renal failure
All of the following:
1 Patient in chronic renal failure; and
2 Haemoglobin is less than or equal to 100g/L; and
3 Either:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4 Patient is on haemodialysis or peritoneal dialysis.

Initiation – myelodysplasia*
Re-assessment required after 12 months
All of the following:
1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5 Patient has a serum epoetin level of < 500 IU/L; and
6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*
Re-assessment required after 2 months
All of the following:
1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
2 Transformation to acute myeloid leukaemia has not occurred; and
3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation – all other indications
Haematologist.
For use in patients where blood transfusion is not a viable treatment alternative.
*Note: Indications marked with * are unapproved indications.

Megaloblastic

FOLIC ACID

<table>
<thead>
<tr>
<th>Tab 0.8 mg – 1% DV Oct-18 to 2021</th>
<th>21.84</th>
<th>1,000</th>
<th>Apo-Folic Acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>12.12</td>
<td>500</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Oral liq 50 mcg per ml</td>
<td>26.00</td>
<td>25 ml</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Antifibrinolytics, Haemostatics and Local Sclerosants

**ALUMINIUM CHLORIDE – Restricted** see terms below

- **Topical soln 20% w/v**

  - **Restricted (RS1500)**

  **Initiation**

  For use as a haemostatis agent.

**APROTININ – Restricted** see terms below

- **Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial**

  - **Restricted (RS1332)**

  **Initiation**

  Cardiac anaesthetist

  Either:

  1. Paediatric patient undergoing cardiopulmonary bypass procedure; or
  2. Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

**ELTROMBOPAG – Restricted** see terms below

- **Tab 25 mg** 1,550.00 28 Revolade
- **Tab 50 mg** 3,100.00 28 Revolade

  - **Restricted (RS1648)**

  **Initiation** – idiopathic thrombocytopenic purpura - post-splenectomy

  Haematologist

  *Re-assessment required after 6 weeks*

  All of the following:

  1. Patient has had a splenectomy; and
  2. Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
  3. Any of the following:

     3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
     3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
     3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

**Initiation** – idiopathic thrombocytopenic purpura - preparation for splenectomy

Haematologist

*Limited to 6 weeks treatment*

The patient requires eltrombopag treatment as preparation for splenectomy.

**Continuation** – idiopathic thrombocytopenic purpura - post-splenectomy

Haematologist

*Re-assessment required after 12 months*

The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

**Note:** Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre

**Initiation** – idiopathic thrombocytopenic purpura contraindicated to splenectomy

Haematologist

*Re-assessment required after 3 months*

All of the following:

1. Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

continued…
continued…

2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and

3 Either:
   3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
   3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation – idiopathic thrombocytopenic purpura contraindicated to splenectomy

Haematologist

Re-assessment required after 12 months

All of the following:
1 The patient’s significant contraindication to splenectomy remains; and
2 The patient has obtained a response from treatment during the initial approval period; and
3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
4 Further treatment with eltrombopag is required to maintain response.

Initiation – severe aplastic anaemia

Haematologist

Re-assessment required after 3 months

Both:
1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
2 Either:
   2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
   2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation – severe aplastic anaemia

Haematologist

Re-assessment required after 12 months

Both:
1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

FERRIC SUBSULFATE

Gel 25.9%
Soln 500 ml

POLIDOCANOL

Inj 0.5%, 30 ml vial

SODIUM TETRADECYL SULPHATE

Inj 3%, 2 ml ampoule

THROMBIN

Powder

TRANEXAMIC ACID

Tab 500 mg ........................................................................................................20.67 100 Cyklokapron
Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021.................................6.95 5 Tranexamic-AFT
Inj 100 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021...............................10.95 5 Tranexamic-AFT

Anticoagulant Reversal Agents

IDARUCIZUMAB – Restricted see terms on the next page

Item restricted (see ➥ above); Item restricted (see ➥ below)

Example: Brand indicates brand example only. It is not a contracted product.
BLOOD AND BLOOD FORMING ORGANS

Price (ex man. excl. GST)  Per
Brand or Generic Manufacturer

→ Restricted (RS1535)

Initiation
For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

Blood Factors

EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – Restricted see terms below

↓ Inj 250 iu vial.................................................................612.50 1 Alprolix
↓ Inj 500 iu vial...............................................................1,225.00 1 Alprolix
↓ Inj 1,000 iu vial............................................................2,450.00 1 Alprolix
↓ Inj 2,000 iu vial............................................................4,900.00 1 Alprolix
↓ Inj 3,000 iu vial............................................................7,350.00 1 Alprolix

→ Restricted (RS1684)

Initiation
For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – Restricted see terms below

↓ Inj 1 mg syringe ..........................................................1,178.30 1 NovoSeven RT
↓ Inj 2 mg syringe ..........................................................2,356.60 1 NovoSeven RT
↓ Inj 5 mg syringe ..........................................................5,891.50 1 NovoSeven RT
↓ Inj 8 mg syringe ..........................................................9,426.40 1 NovoSeven RT

→ Restricted (RS1676)

Initiation
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

FACTOR EIGHT INHIBITOR BYPASSING FRACTION – Restricted see terms below

↓ Inj 500 U........................................................................1,315.00 1 FEIBA NF
↓ Inj 1,000 U.....................................................................2,630.00 1 FEIBA NF
↓ Inj 2,500 U.....................................................................6,575.00 1 FEIBA NF

→ Restricted (RS1677)

Initiation
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – Restricted see terms below

↓ Inj 250 iu prefilled syringe............................................210.00 1 Xyntha
↓ Inj 500 iu prefilled syringe............................................420.00 1 Xyntha
↓ Inj 1,000 iu prefilled syringe...........................................840.00 1 Xyntha
↓ Inj 2,000 iu prefilled syringe.........................................1,680.00 1 Xyntha
↓ Inj 3,000 iu prefilled syringe.........................................2,520.00 1 Xyntha
## BLOOD AND BLOOD FORMING ORGANS

### NONACOG ALFA [RECOMBINANT FACTOR IX] – Restricted see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>$310.00 1 BeneFIX</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>$620.00 1 BeneFIX</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$1,240.00 1 BeneFIX</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$2,480.00 1 BeneFIX</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>$3,720.00 1 BeneFIX</td>
</tr>
</tbody>
</table>

(BeneFIX Inj 250 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 500 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 1,000 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 2,000 iu vial to be delisted 1 November 2019)
(BeneFIX Inj 3,000 iu vial to be delisted 1 November 2019)

**Initiation**

When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### NONACOG GAMMA, [RECOMBINANT FACTOR IX] – Restricted see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 iu vial</td>
<td>$435.00 1 RIXUBIS</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$870.00 1 RIXUBIS</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$1,740.00 1 RIXUBIS</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>$2,610.00 1 RIXUBIS</td>
</tr>
</tbody>
</table>

**Initiation**

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – Restricted see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>$210.00 1 Advate</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>$420.00 1 Advate</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$840.00 1 Advate</td>
</tr>
<tr>
<td>Inj 1,500 iu vial</td>
<td>$1,260.00 1 Advate</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$1,680.00 1 Advate</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>$2,520.00 1 Advate</td>
</tr>
</tbody>
</table>

**Initiation**

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – Restricted see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>$237.50 1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>$475.00 1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$950.00 1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$1,900.00 1 Kogenate FS</td>
</tr>
<tr>
<td>Inj 3,000 iu vial</td>
<td>$2,850.00 1 Kogenate FS</td>
</tr>
</tbody>
</table>

**Initiation**

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 iu vial</td>
<td>$300.00 1 Adynovate</td>
</tr>
<tr>
<td>Inj 500 iu vial</td>
<td>$600.00 1 Adynovate</td>
</tr>
<tr>
<td>Inj 1,000 iu vial</td>
<td>$1,200.00 1 Adynovate</td>
</tr>
<tr>
<td>Inj 2,000 iu vial</td>
<td>$2,400.00 1 Adynovate</td>
</tr>
</tbody>
</table>

**Initiation**

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

---

*Item restricted (see ➤ above); Item restricted (see ➤ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
**BLOOD AND BLOOD FORMING ORGANS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**→ Restricted (RS1682)**

**Initiation**

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

### Vitamin K

**PHYTOMENADIONE**

- Inj 2 mg in 0.2 ml ampoule ................................................................. 8.00  5 Konakion MM
- Inj 10 mg per ml, 1 ml ampoule ......................................................... 9.21  5 Konakion MM

### Antithrombotics

#### Anticoagulants

**BIVALIRUDIN** – **Restricted** see terms below

- Inj 250 mg vial

**→ Restricted (RS1181)**

**Initiation**

Either:

1. For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or
2. For use in patients undergoing endovascular procedures.

**CITRATE SODIUM**

- Inj 4% (200 mg per 5 ml), 5 ml ampoule
- Inj 46.7% (1.4 g per 3 ml), 3 ml syringe
- Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule

**DABIGATRAN**

- Cap 75 mg.............................................................................................. 76.36  60 Pradaxa
- Cap 110 mg.............................................................................................. 76.36  60 Pradaxa
- Cap 150 mg.............................................................................................. 76.36  60 Pradaxa

**DALTEPARIN**

- Inj 2,500 iu in 0.2 ml syringe................................................................. 19.97  10 Fragmin
- Inj 5,000 iu in 0.2 ml syringe................................................................. 39.94  10 Fragmin
- Inj 7,500 iu in 0.75 ml syringe................................................................. 60.03  10 Fragmin
- Inj 10,000 iu in 1 ml syringe................................................................. 77.55  10 Fragmin
- Inj 12,500 iu in 0.5 ml syringe............................................................... 99.96  10 Fragmin
- Inj 15,000 iu in 0.6 ml syringe............................................................... 120.05  10 Fragmin
- Inj 18,000 iu in 0.72 ml syringe............................................................. 158.47  10 Fragmin

(Fragmin Inj 2,500 iu in 0.2 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 5,000 iu in 0.2 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 7,500 iu in 0.75 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 10,000 iu in 1 ml syringe to be delisted 1 April 2020)
(Fragmin Inj 12,500 iu in 0.5 ml syringe to be delisted 1 January 2020)
(Fragmin Inj 15,000 iu in 0.6 ml syringe to be delisted 1 January 2020)
(Fragmin Inj 18,000 iu in 0.72 ml syringe to be delisted 1 January 2020)

**DANAPAROID** – **Restricted** see terms below

- Inj 750 u in 0.6 ml ampoule

**→ Restricted (RS1182)**

**Initiation**

For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### DEFIBROTIDE – Restricted see terms below

- **Inj 80 mg per ml, 2.5 ml ampoule**
  - **Restricted (RS1183)**

**Initiation**

Haematologist

Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities.

### DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]

- **Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag**

### ENOXAPARIN SODIUM

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inj 20 mg in 0.2 ml syringe</strong></td>
<td>27.93</td>
<td>10</td>
<td>Clexane</td>
</tr>
<tr>
<td><strong>Inj 40 mg in 0.4 ml syringe</strong></td>
<td>37.27</td>
<td>10</td>
<td>Clexane</td>
</tr>
<tr>
<td><strong>Inj 60 mg in 0.6 ml syringe</strong></td>
<td>56.18</td>
<td>10</td>
<td>Clexane</td>
</tr>
<tr>
<td><strong>Inj 80 mg in 0.8 ml syringe</strong></td>
<td>74.90</td>
<td>10</td>
<td>Clexane</td>
</tr>
<tr>
<td><strong>Inj 100 mg in 1 ml syringe</strong></td>
<td>93.80</td>
<td>10</td>
<td>Clexane</td>
</tr>
<tr>
<td><strong>Inj 120 mg in 0.8 ml syringe</strong></td>
<td>116.55</td>
<td>10</td>
<td>Clexane</td>
</tr>
<tr>
<td><strong>Inj 150 mg in 1 ml syringe</strong></td>
<td>133.20</td>
<td>10</td>
<td>Clexane</td>
</tr>
</tbody>
</table>

### FONDAPARINUX SODIUM – Restricted see terms below

- **Inj 2.5 mg in 0.5 ml syringe**
- **Inj 7.5 mg in 0.6 ml syringe**
  - **Restricted (RS1184)**

**Initiation**

For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.

### HEPARIN SODIUM

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inj 100 iu per ml, 250 ml bag</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inj 1,000 iu per ml, 1 ml ampoule</strong></td>
<td>98.53</td>
<td>50</td>
<td>Hospira</td>
</tr>
<tr>
<td><strong>Inj 1,000 iu per ml, 5 ml ampoule</strong></td>
<td>58.57</td>
<td>50</td>
<td>Pfizer</td>
</tr>
<tr>
<td><strong>Inj 5,000 iu in 0.2 ml ampoule</strong></td>
<td>28.40</td>
<td>5</td>
<td>Hospira</td>
</tr>
<tr>
<td><strong>Inj 5,000 iu per ml, 5 ml ampoule</strong></td>
<td>203.68</td>
<td>50</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

### HEPARINISED SALINE

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inj 10 iu per ml, 5 ml ampoule</strong></td>
<td>56.94</td>
<td>50</td>
<td>Pfizer</td>
</tr>
<tr>
<td><strong>Inj 100 iu per ml, 2 ml ampoule</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inj 100 iu per ml, 5 ml ampoule</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PHENINDIONE

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PROTAMINE SULPHATE

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inj 10 mg per ml, 5 ml ampoule</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### RIVAROXABAN

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tab 10 mg</strong></td>
<td>83.10</td>
<td>30</td>
<td>Xarelto</td>
</tr>
<tr>
<td><strong>Tab 15 mg</strong></td>
<td>77.56</td>
<td>28</td>
<td>Xarelto</td>
</tr>
<tr>
<td><strong>Tab 20 mg</strong></td>
<td>77.56</td>
<td>28</td>
<td>Xarelto</td>
</tr>
</tbody>
</table>

### SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE

- **Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag**

---

* Item restricted (see  above);  Item restricted (see  below)

* e.g. Brand indicates brand example only. It is not a contracted product.
### Antiplatelets

#### ASPIRIN
- **Tab 100 mg – 10% DV Nov-19 to 2022** .................................................. 1.95 90  **Ethics Aspirin EC**
- 10.80 990  **Ethics Aspirin EC**

#### CLOPIDOGREL
- Tab 75 mg ................................................................. 5.44 84  **Arrow - Clopid**
- Suppos 300 mg

#### DIPYRIDAMOLE
- Tab 25 mg
- Tab long-acting 150 mg – 1% DV Oct-19 to 2022 ......................................... 10.90 60  **Pytazen SR**
- Inj 5 mg per ml, 2 ml ampoule

#### EPTIFIBATIDE – Restricted see terms below
- Inj 2 mg per ml, 10 ml vial – 1% DV Nov-18 to 2021 .............................. 138.75 1  **Integrilin**
- Inj 750 mcg per ml, 100 ml vial – 1% DV Nov-18 to 2021 ...................... 405.00 1  **Integrilin**

- Restricted (RS1362)

#### LYSINE ACETYLSALICYLATE [LYSINE ASPRIN] – Restricted see terms below
- Inj 500 mg  
  - e.g. Aspegic

- Restricted (RS1689)

#### PRASUGREL – Restricted see terms below
- Tab 5 mg ................................................................. 108.00 28  **Effient**
- Tab 10 mg ............................................................... 120.00 28  **Effient**

- Restricted (RS1187)

#### PRASUGREL – Bare metal stents
*Limited to 6 months* treatment
- Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.

#### PRASUGREL – Drug-eluting stents
*Limited to 12 months* treatment
- Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.

#### PRASUGREL – Stent thrombosis
- Patient has experienced cardiac stent thrombosis whilst on clopidogrel.

#### PRASUGREL – Myocardial infarction
*Limited to 1 week* treatment
- For short term use while in hospital following ST-elevated myocardial infarction.

Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

---

**Note:** Products with Hospital Supply Status (HSS) are in **bold**

**Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.**
BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$90.00 56 Brilinta</td>
<td></td>
</tr>
<tr>
<td>$8,740.00 1 Mozobil</td>
<td></td>
</tr>
</tbody>
</table>

TICAGRELOR – Restricted see terms below

Restricted (RS1496)

Initiation

Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.

TICLOPIDINE

Tab 250 mg

Fibrinolytic Agents

ALTEPLASE

Inj 2 mg vial
Inj 10 mg vial
Inj 50 mg vial

TENECTEPLASE

Inj 50 mg vial

UROKINASE

Inj 10,000 iu vial
Inj 50,000 iu vial
Inj 100,000 iu vial
Inj 500,000 iu vial

Colony-Stimulating Factors

Drugs Used to Mobilise Stem Cells

PLERIXAFOR – Restricted see terms below

Restricted (RS1536)

Initiation – Autologous stem cell transplant

Haematologist

Limited to 3 days treatment

All of the following:

1. Patient is to undergo stem cell transplantation; and
2. Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and
3. Any of the following:
   
   3.1 Both:
      
      3.1.1 Patient is undergoing G-CSF mobilisation; and
      3.1.2 Either:
         
         3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6$ /L on day 5 after 4 days of G-CSF treatment; or
         3.1.2.2 Efforts to collect $1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
   
   3.2 Both:
      
      3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and
      3.2.2 Any of the following:
         
         3.2.2.1 Both:

continued…
continued...

3.2.2.1 Has rising white blood cell counts of > $5 \times 10^9$/L; and
3.2.2.2 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6$/L; or
3.2.2.3 Efforts to collect > $1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
3.2.2.4 The peripheral blood CD34 cell counts are decreasing before the target has been received; or

3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.

Granulocyte Colony-Stimulating Factors

**FILGRASTIM** – Restricted see terms below
- Inj 300 mcg in 0.5 ml prefilled syringe – 1% DV May-19 to 2021 .................96.22 10 Nivestim
- Inj 300 mcg in 1 ml vial .................................................................................520.00 4 Neupogen
- Inj 480 mcg in 0.5 ml prefilled syringe – 1% DV Mar-19 to 2021 ..........161.50 10 Nivestim

**PEGFILGRASTIM** – Restricted see terms below
- Inj 6 mg per 0.6 ml syringe ...........................................................................1,080.00 1 Neulastim

Haematologist or oncologist

Initiation
For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

Fluids and Electrolytes

**Intravenous Administration**

**CALCIUM CHLORIDE**
- Inj 100 mg per ml, 10 ml vial
- Inj 100 mg per ml, 50 ml syringe

**CALCIUM GLUCONATE**
- Inj 10%, 10 ml ampoule

e.g. Max Health

**COMPOUND ELECTROLYTES**
- Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021 .........................................................44.10 18 Plasma-Lyte 148
- Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021 .........................................................27.24 12 Plasma-Lyte 148

e.g. Baxter

**COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]**
- Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag – 1% DV Jun-18 to 2021 ........211.92 12 Plasma-Lyte 148 & 5% Glucose
### COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]

<table>
<thead>
<tr>
<th>Item description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td>$23.40</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$15.72</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

### GLUCOSE [DEXTROSE]

<table>
<thead>
<tr>
<th>Item description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5%, 1,000 ml bag – 1% DV Aug-18 to 2021</td>
<td>$16.80</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021</td>
<td>$7.50</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 5%, 250 ml bag – 1% DV Aug-18 to 2021</td>
<td>$5.20</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 5%, 50 ml bag – 1% DV Jun-18 to 2021</td>
<td>$14.34</td>
<td>Baxter Glucose 5%</td>
</tr>
<tr>
<td>Inj 5%, 500 ml bag – 1% DV Aug-18 to 2021</td>
<td>$2.40</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$11.96</td>
<td>Baxter Glucose 10%</td>
</tr>
<tr>
<td>Inj 10%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td>$10.99</td>
<td>Baxter Glucose 10%</td>
</tr>
<tr>
<td>Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020</td>
<td>$2.95</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 50%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td>$33.73</td>
<td>Baxter Glucose 50%</td>
</tr>
<tr>
<td>Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020</td>
<td>$1.45</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

### GLUCOSE WITH POTASSIUM CHLORIDE

<table>
<thead>
<tr>
<th>Item description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5%, 1,000 ml bag – 1% DV Aug-18 to 2021</td>
<td>$16.80</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021</td>
<td>$7.50</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 5%, 250 ml bag – 1% DV Aug-18 to 2021</td>
<td>$5.20</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 5%, 50 ml bag – 1% DV Jun-18 to 2021</td>
<td>$14.34</td>
<td>Baxter Glucose 5%</td>
</tr>
<tr>
<td>Inj 5%, 500 ml bag – 1% DV Aug-18 to 2021</td>
<td>$2.40</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$11.96</td>
<td>Baxter Glucose 10%</td>
</tr>
<tr>
<td>Inj 10%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td>$10.99</td>
<td>Baxter Glucose 10%</td>
</tr>
<tr>
<td>Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020</td>
<td>$2.95</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 50%, 500 ml bag – 1% DV Jun-18 to 2021</td>
<td>$33.73</td>
<td>Baxter Glucose 50%</td>
</tr>
<tr>
<td>Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020</td>
<td>$1.45</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

### GLUCOSE WITH SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Item description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2.5% glucose with sodium chloride 0.45%, 3,000 ml bag</td>
<td>$16.80</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 ml, 500 ml bag</td>
<td>$7.50</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$203.40</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$159.96</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$282.72</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

### POTASSIUM CHLORIDE

<table>
<thead>
<tr>
<th>Item description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 75 mg (1 mmol) per ml, 10 ml ampoule</td>
<td>$16.80</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 225 mg (3 mmol) per ml, 20 ml ampoule</td>
<td>$7.50</td>
<td>Fresenius Kabi</td>
</tr>
</tbody>
</table>

### POTASSIUM CHLORIDE WITH SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Item description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag – 1% DV Jun-18 to 2021</td>
<td>$476.64</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$163.20</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>$253.32</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag – 1% DV Jun-18 to 2021</td>
<td>$772.32</td>
<td>Baxter</td>
</tr>
<tr>
<td>Product Description</td>
<td>Price (ex man. excl. GST)</td>
<td>Brand or Generic Manufacturer</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>POTASSIUM DIHYDROGEN PHOSPHATE</td>
<td>$151.80</td>
<td>Hospira</td>
</tr>
<tr>
<td>RINGER’S SOLUTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SODIUM ACETATE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SODIUM BICARBONATE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SODIUM CHLORIDE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]</td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Water</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 ml ampoule</td>
<td>7.00</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 10 ml ampoule</td>
<td>6.63</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 20 ml ampoule</td>
<td>5.00</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 250 ml bag</td>
<td>7.50</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 500 ml bag</td>
<td>5.00</td>
<td>Multichem</td>
</tr>
<tr>
<td>Inj, 1,000 ml bag</td>
<td>19.08</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

### Oral Administration

#### Calcium Polystyrene Sulphonate
- Powder: 169.85 $ 300 g Calcium Resonium

#### Compound Electrolytes
- Powder for oral soln: 2.30 $ 10 Enerlyte

#### Compound Electrolytes with Glucose [Dextrose]
- Soln with electrolytes (2 x 500 ml) – 1% DV Nov-18 to 2021: 6.55 $ 1,000 ml Pedialyte - Bubblegum

#### Phosphorus
- Tab eff 500 mg (16 mmol)

#### Potassium Chloride
- Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)
- Tab long-acting 600 mg (8 mmol) – 1% DV Oct-18 to 2021: 8.90 $ 200 Span-K

#### Sodium Bicarbonate
- Cap 840 mg: 8.52 $ 100 Sodibic

#### Sodium Chloride
- Tab 600 mg
- Oral liq 2 mmol/ml

#### Sodium Polystyrene Sulphonate
- Powder – 1% DV Sep-18 to 2021: 84.65 $ 454 g Resonium A

### Plasma Volume Expanders

#### Gelatine, Succinylated
- Inj 4%, 500 ml bag – 1% DV Jun-18 to 2021: 120.00 $ 10 Gelofusine

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
## Agents Affecting the Renin-Angiotensin System

### ACE Inhibitors

**CAPTOPRIL**
- Oral liq 5 mg per ml ......................................................................................... 94.99 95 ml Capoten

*→ Restricted (RS1263)*

**Initiation**
- Any of the following:
  1. For use in children under 12 years of age; or
  2. For use in tube-fed patients; or
  3. For management of rebound transient hypertension following cardiac surgery.

**CILAZAPRIL**
- Tab 0.5 mg – 1% DV Sep-19 to 2022 ................................................................. 2.09 90 Zapril
- Tab 2.5 mg – 1% DV Feb-20 to 2022 ............................................................... 7.20 200 Apo-Cilazapril
  - 4.80 90 Zapril
- Tab 5 mg – 1% DV Feb-20 to 2022 ................................................................. 12.00 200 Apo-Cilazapril
  - 8.35 90 Zapril

*(Apo-Cilazapril Tab 2.5 mg to be delisted 1 February 2020)*
*(Apo-Cilazapril Tab 5 mg to be delisted 1 February 2020)*

**ENALAPRIL MALEATE**
- Tab 5 mg ................................................................................................. 3.84 100 Ethics Enalapril
- Tab 10 mg ................................................................................................. 4.96 100 Ethics Enalapril
- Tab 20 mg ................................................................................................. 7.12 100 Ethics Enalapril

**LISINOPRIL**
- Tab 5 mg – 1% DV Dec-18 to 2021 ................................................................. 2.07 90 Ethics Lisinopril
- Tab 10 mg – 1% DV Dec-18 to 2021 ............................................................... 2.36 90 Ethics Lisinopril
- Tab 20 mg – 1% DV Dec-18 to 2021 ............................................................... 3.17 90 Ethics Lisinopril

**PERINDOPRIL**
- Tab 2 mg – 1% DV Sep-17 to 2020 ................................................................. 3.75 30 Apo-Perindopril
- Tab 4 mg – 1% DV Sep-17 to 2020 ................................................................. 4.80 30 Apo-Perindopril

**QUINAPRIL**
- Tab 5 mg – 1% DV Nov-18 to 2021 ................................................................. 6.01 90 Arrow-Quinapril 5
- Tab 10 mg – 1% DV Nov-18 to 2021 ............................................................... 3.16 90 Arrow-Quinapril 10
- Tab 20 mg – 1% DV Nov-18 to 2021 ............................................................... 4.89 90 Arrow-Quinapril 20

### ACE Inhibitors with Diuretics

**CILAZAPRIL WITH HYDROCHLOROTHIAZIDE**
- Tab 5 mg with hydrochlorothiazide 12.5 mg.................................................... 10.18 100 Apo-Cilazapril/ Hydrochlorothiazide

**QUINAPRIL WITH HYDROCHLOROTHIAZIDE**
- Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021 ...... 3.83 30 Accuretic 10
- Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021 ...... 4.92 30 Accuretic 20
# CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

## Angiotensin II Antagonists

### Candesartan Cilexetil
- Tab 4 mg – 1% DV Sep-18 to 2021: $1.90 90 Candestar
- Tab 8 mg – 1% DV Sep-18 to 2021: $2.28 90 Candestar
- Tab 16 mg – 1% DV Sep-18 to 2021: $3.67 90 Candestar
- Tab 32 mg – 1% DV Sep-18 to 2021: $6.39 90 Candestar

### Losartan Potassium
- Tab 12.5 mg – 1% DV Nov-17 to 2020: $1.39 84 Losartan Actavis
- Tab 25 mg – 1% DV Nov-17 to 2020: $1.63 84 Losartan Actavis
- Tab 50 mg – 1% DV Nov-17 to 2020: $2.00 84 Losartan Actavis
- Tab 100 mg – 1% DV Nov-17 to 2020: $2.31 84 Losartan Actavis

## Angiotensin II Antagonists with Diuretics

### Losartan Potassium with Hydrochlorothiazide
- Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Jan-19 to 2021: $1.88 30 Arrow-Losartan & Hydrochlorothiazide

## Angiotensin II Antagonists with Neprilysin Inhibitors

### Sacubitril with Valsartan
- Restricted see terms below
- Tab 24.3 mg with valsartan 25.7 mg: $190.00 56 Entresto 24/26
- Tab 48.6 mg with valsartan 51.4 mg: $190.00 56 Entresto 49/51
- Tab 97.2 mg with valsartan 102.8 mg: $190.00 56 Entresto 97/103
- Restricted (RS1649)

### Initiation

Re-assessment required after 12 months

All of the following:
1. Patient has heart failure; and
2. Any of the following:
   2.1 Patient is in NYHA/WHO functional class II; or
   2.2 Patient is in NYHA/WHO functional class III; or
   2.3 Patient is in NYHA/WHO functional class IV; and
3. Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; and
4. Patient is receiving concomitant optimal standard chronic heart failure treatments.

### Continuation

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

## Alpha-Adrenoceptor Blockers

### Doxazosin
- Tab 2 mg – 1% DV Sep-17 to 2020: $6.75 500 Apo-Doxazosin
- Tab 4 mg – 1% DV Sep-17 to 2020: $9.09 500 Apo-Doxazosin

### Phenoxymazine Hydrochloride
- Cap 10 mg
- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

---

*Item restricted (see ➡️ above); ➡️ Item restricted (see ➡️ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
### Cardiovascular System

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**PHENTOLAMINE MESYLATED**

- Inj 5 mg per ml, 1 ml ampoule
- Inj 10 mg per ml, 1 ml ampoule

**PRAZOSIN**

<table>
<thead>
<tr>
<th>Tab 1 mg</th>
<th>5.53</th>
<th>100</th>
<th>Apo-Prazosin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg</td>
<td>7.00</td>
<td>100</td>
<td>Apo-Prazosin</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>11.70</td>
<td>100</td>
<td>Apo-Prazosin</td>
</tr>
</tbody>
</table>

**TERAZOSIN**

<table>
<thead>
<tr>
<th>Tab 1 mg</th>
<th>0.59</th>
<th>28</th>
<th>Actavis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg</td>
<td>7.50</td>
<td>500</td>
<td>Apo-Terazosin</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>10.90</td>
<td>500</td>
<td>Apo-Terazosin</td>
</tr>
</tbody>
</table>

### Antiarrhythmics

**ADENOSINE**

- Inj 3 mg per ml, 2 ml vial – 1% DV Feb-20 to 2022
- Inj 3 mg per ml, 10 ml vial

<Restriction>(RS1266)</Restriction>

Initiation

For use in cardiac catheterisation, electrophysiology and MRI.

**AJMALINE** – <Restriction>see terms below</Restriction>

<Restriction>(RS1001)</Restriction>

**AMIODARONE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Tab 100 mg</th>
<th>3.80</th>
<th>30</th>
<th>Aratac</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4.66</td>
<td></td>
<td>Cordarone-X</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>5.25</td>
<td>30</td>
<td>Aratac</td>
</tr>
<tr>
<td></td>
<td>7.63</td>
<td></td>
<td>Cordarone-X</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 3 ml ampoule</td>
<td>11.98</td>
<td>6</td>
<td>Aratac</td>
</tr>
<tr>
<td></td>
<td>9.98</td>
<td>5</td>
<td>Lodi</td>
</tr>
<tr>
<td></td>
<td>16.37</td>
<td>10</td>
<td>Max Health</td>
</tr>
</tbody>
</table>

*(Cordarone-X Tab 100 mg to be delisted 1 December 2019)*

*(Cordarone-X Tab 200 mg to be delisted 1 December 2019)*

*(Cordarone-X Inj 50 mg per ml, 3 ml ampoule to be delisted 1 February 2020)*

*(Lodi Inj 50 mg per ml, 3 ml ampoule to be delisted 1 February 2020)*

**ATROPINE SULPHATE**

- Inj 600 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021

**DIGOXIN**

<table>
<thead>
<tr>
<th>Tab 62.5 mcg</th>
<th>7.00</th>
<th>240</th>
<th>Lanoxin PG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mcg</td>
<td>15.20</td>
<td>240</td>
<td>Lanoxin</td>
</tr>
</tbody>
</table>

**DISOPYRAMIDE PHOSPHATE**

- Cap 100 mg

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------</td>
</tr>
</tbody>
</table>

**FLECAINIDE ACETATE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg - 1% DV Feb-20 to 2022</td>
<td>.............................................................19.95 60</td>
<td>Flecainide BNM Tambocor</td>
</tr>
<tr>
<td>Cap long-acting 100 mg - 1% DV Dec-19 to 2022</td>
<td>.............................................................39.51 90</td>
<td>Flecainide Controlled Release Teva Tambocor CR</td>
</tr>
<tr>
<td>Cap long-acting 200 mg - 1% DV Dec-19 to 2022</td>
<td>.............................................................61.06 90</td>
<td>Flecainide Controlled Release Teva Tambocor CR</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 15 ml ampoule</td>
<td>.............................................................52.45 5</td>
<td>Tambocor</td>
</tr>
</tbody>
</table>

*Tambocor Tab 50 mg to be delisted 1 February 2020*
*Tambocor CR Cap long-acting 100 mg to be delisted 1 December 2019*
*Tambocor CR Cap long-acting 200 mg to be delisted 1 December 2019*

**IVABRADINE** - Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>Restricted (RS1566)</td>
<td></td>
</tr>
</tbody>
</table>

**Antihypotensives**

**MIDODRINE** - Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg</td>
<td>(\text{RS1427})</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>(\text{RS1427})</td>
<td></td>
</tr>
</tbody>
</table>

**Beta-Adrenoceptor Blockers**

**ATENOLOL**

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg - 1% DV Sep-18 to 2021</td>
<td>.............................................................4.26 500</td>
<td>Mylan Atenolol</td>
</tr>
<tr>
<td>Tab 100 mg - 1% DV Sep-18 to 2021</td>
<td>.............................................................7.30 500</td>
<td>Mylan Atenolol</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>.............................................................21.25 300 ml</td>
<td>Atenolol-AFT</td>
</tr>
</tbody>
</table>

**BISOPROLOL FUMARATE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg - 1% DV Dec-17 to 2020</td>
<td>.............................................................3.53 90</td>
<td>Bosvate</td>
</tr>
<tr>
<td>Tab 5 mg - 1% DV Dec-17 to 2020</td>
<td>.............................................................5.15 90</td>
<td>Bosvate</td>
</tr>
<tr>
<td>Tab 10 mg - 1% DV Dec-17 to 2020</td>
<td>.............................................................9.40 90</td>
<td>Bosvate</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➡ above); Item restricted (see ➡ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARVEDILOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 6.25 mg – 1% DV Dec-17 to 2020</td>
<td>Carvedilol Sandoz</td>
<td>$2.24 60</td>
</tr>
<tr>
<td>Tab 12.5 mg – 1% DV Dec-17 to 2020</td>
<td>Carvedilol Sandoz</td>
<td>$2.30 60</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Dec-17 to 2020</td>
<td>Carvedilol Sandoz</td>
<td>$2.95 60</td>
</tr>
<tr>
<td><strong>CELIPROLOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>Celol</td>
<td>$21.40 180</td>
</tr>
<tr>
<td><strong>ESMOLOL HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LABETALOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>Hy bloc Presolol</td>
<td>$11.36 100</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>Hy bloc Presolol</td>
<td>$29.74 100</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METOPROLOL SUCCINATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 23.75 mg – 1% DV Mar-18 to 2020</td>
<td>Betaloc CR</td>
<td>$1.03 30</td>
</tr>
<tr>
<td>Tab long-acting 47.5 mg – 1% DV Mar-18 to 2020</td>
<td>Betaloc CR</td>
<td>$1.25 30</td>
</tr>
<tr>
<td>Tab long-acting 95 mg – 1% DV Mar-18 to 2020</td>
<td>Betaloc CR</td>
<td>$1.99 30</td>
</tr>
<tr>
<td>Tab long-acting 190 mg – 1% DV Mar-18 to 2020</td>
<td>Betaloc CR</td>
<td>$3.00 30</td>
</tr>
<tr>
<td><strong>METOPROLOL TARTRATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Metoprolol</td>
<td>$5.66 100</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Metoprolol</td>
<td>$7.55 60</td>
</tr>
<tr>
<td>Tab long-acting 200 mg</td>
<td>Slow-Lopresor</td>
<td>$23.40 28</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml vial – 1% DV Feb-19 to 31 Jan 2022</td>
<td>Metroprolol IV Mylan</td>
<td>$29.50 5</td>
</tr>
<tr>
<td><strong>NADOLOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Nadolol</td>
<td>$16.69 100</td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Nadolol</td>
<td>$26.43 100</td>
</tr>
<tr>
<td><strong>PINDOLOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Pindolol</td>
<td>$13.22 100</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Pindolol</td>
<td>$23.12 100</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Pindolol</td>
<td>$33.31 100</td>
</tr>
<tr>
<td><strong>PROPRANOLOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Propranolol</td>
<td>$4.64 100</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Oct-18 to 2021</td>
<td>Apo-Propranolol</td>
<td>$5.72 100</td>
</tr>
<tr>
<td>Cap long-acting 160 mg</td>
<td>Cardinol LA</td>
<td>$18.17 100</td>
</tr>
<tr>
<td>Oral liq 4 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SOTALOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Oct-19 to 2022</td>
<td>Mylan</td>
<td>$32.58 500</td>
</tr>
<tr>
<td>Tab 160 mg – 1% DV Oct-19 to 2022</td>
<td>Mylan</td>
<td>$10.98 100</td>
</tr>
<tr>
<td><strong>TIMOLOL MALEATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# Calcium Channel Blockers

## Dihydropyridine Calcium Channel Blockers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMLODIPINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Sep-17 to 2020</td>
<td>1.72</td>
<td>100 Apo-Amlodipine</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Sep-17 to 2020</td>
<td>3.33</td>
<td>250 Apo-Amlodipine</td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Sep-17 to 2020</td>
<td>4.40</td>
<td>250 Apo-Amlodipine</td>
<td></td>
</tr>
<tr>
<td><strong>FELODIPINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 2.5 mg – 1% DV Sep-18 to 2021</td>
<td>1.45</td>
<td>30 Plendil ER</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 5 mg – 1% DV Dec-18 to 2021</td>
<td>3.93</td>
<td>90 Felo 5 ER</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 10 mg – 1% DV Dec-18 to 2021</td>
<td>4.32</td>
<td>90 Felo 10 ER</td>
<td></td>
</tr>
<tr>
<td><strong>ISRADIPINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2.5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 2.5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NICARDIPINE HYDROCHLORIDE</strong> – Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1474)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INITIATION</strong></td>
<td>Anaesthetist, intensivist or paediatric cardiologist</td>
<td>Both:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 Patient is a Paediatric Patient; and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 Any of the following:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.1 Patient has hypertension requiring urgent treatment with an intravenous agent; or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.2 Patient has excessive ventricular afterload; or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.</td>
<td></td>
</tr>
<tr>
<td><strong>NIFEDIPINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 10 mg – 1% DV Aug-17 to 2020</td>
<td>10.63</td>
<td>60 Adalat 10</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 20 mg</td>
<td>9.59</td>
<td>100 Nyefax Retard</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td>3.14</td>
<td>30 Adalat Oros</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 60 mg – 1% DV Dec-17 to 2020</td>
<td>5.67</td>
<td>30 Adalat Oros</td>
<td></td>
</tr>
<tr>
<td>Cap 5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NIMODIPINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 50 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Other Calcium Channel Blockers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DILTIAZEM HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td></td>
<td>4.60</td>
<td>100 Dilzem</td>
</tr>
<tr>
<td>Tab 60 mg</td>
<td></td>
<td>8.50</td>
<td>100 Dilzem</td>
</tr>
<tr>
<td>Cap long-acting 120 mg – 1% DV Oct-18 to 2021</td>
<td>33.42</td>
<td>500 Apo-Diltiazem CD</td>
<td></td>
</tr>
<tr>
<td>Cap long-acting 180 mg – 1% DV Oct-18 to 2021</td>
<td>50.05</td>
<td>500 Apo-Diltiazem CD</td>
<td></td>
</tr>
<tr>
<td>Cap long-acting 240 mg – 1% DV Oct-18 to 2021</td>
<td>66.76</td>
<td>500 Apo-Diltiazem CD</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PERHEXILINE MALEATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Oct-19 to 2022</td>
<td>62.90</td>
<td>100 Pexsig</td>
<td></td>
</tr>
</tbody>
</table>
### CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

**VERAPAMIL HYDROCHLORIDE**

- Tab 40 mg ........................................... 7.01 100 Isoptin
- Tab 80 mg ........................................... 11.74 100 Isoptin
- Tab long-acting 120 mg ................................ 15.20 250 Verpamil SR
- Tab long-acting 240 mg ................................ 25.00 250 Verpamil SR
- Inj 2.5 mg per ml, 2 ml ampoule ................... 25.00 5 Isoptin

**Centrally-Acting Agents**

**CLONIDINE**

- Patch 2.5 mg, 100 mcg per day – 1% DV Sep-17 to 2020 ......................... 7.40 4 Mylan
- Patch 5 mg, 200 mcg per day – 1% DV Sep-17 to 2020 ......................... 10.04 4 Mylan
- Patch 7.5 mg, 300 mcg per day – 1% DV Sep-17 to 2020 ......................... 12.34 4 Mylan

**CLONIDINE HYDROCHLORIDE**

- Tab 25 mcg – 1% DV Oct-18 to 2021 ........................................... 8.75 112 Clonidine BNM
- Tab 150 mcg ........................................... 34.32 100 Catapres
- Inj 150 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021 ................. 25.96 10 Medsurge

**METHYLDOPA**

- Tab 250 mg ........................................... 15.10 100 Methyldopa Mylan

**Diuretics**

**Loop Diuretics**

**BUMETANIDE**

- Tab 1 mg ........................................... 16.36 100 Burinex
- Inj 500 mcg per ml, 4 ml vial

**FUROSEMIDE [FRUSEMIDE]**

- Tab 40 mg – 1% DV Dec-19 to 2022 ........................................... 7.24 1,000 Apo-Furosemide Diurin 40
- Tab 500 mg – 1% DV Mar-19 to 2021 ........................................... 8.00 Urex Forte
- Oral liq 10 mg per ml – 1% DV Jan-20 to 2022 ................................ 25.00 50 Lasix
- Inj 10 mg per ml, 2 ml ampoule – 1% DV Oct-19 to 2022 ..................... 11.20 5 Furosemide-Claris
- Inj 10 mg per ml, 25 ml ampoule – 1% DV Jan-20 to 2022 .................... 60.65 6 Lasix

*(Diurin 40 Tab 40 mg to be delisted 1 December 2019)*

**Osmotic Diuretics**

**MANNITOL**

- Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021 ................................ 747.24 12 Baxter
- Inj 20%, 500 ml bag – 1% DV Jun-18 to 2021 ................................ 1,096.92 18 Baxter

**Potassium Sparing Combination Diuretics**

**AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE**

- Tab 5 mg with furosemide 40 mg

**AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE**

- Tab 5 mg with hydrochlorothiazide 50 mg

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Potassium Sparing Diuretics

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMILORIDE HYDROCHLORIDE</td>
<td>Tab 5 mg</td>
<td>$30.00</td>
<td>Biomed</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPLERENONE – Restricted</td>
<td>Tab 25 mg – 1% DV Sep-18 to 2021</td>
<td>$11.87</td>
<td>Inspra</td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg – 1% DV Dec-18 to 2021</td>
<td>$17.00</td>
<td>Inspra</td>
</tr>
<tr>
<td></td>
<td>Initiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 Patient has heart failure with ejection fraction less than 40%; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.1 Patient is intolerant to optimal dosing of spironolactone; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPIRONOLACTONE</td>
<td>Tab 25 mg</td>
<td>$4.38</td>
<td>Spiractin</td>
</tr>
<tr>
<td></td>
<td>Tab 100 mg</td>
<td>$11.80</td>
<td>Spiractin</td>
</tr>
<tr>
<td></td>
<td>Oral liq 5 mg per ml – 1% DV Nov-19 to 2022</td>
<td>$30.60</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

### Thiazide and Related Diuretics

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]</td>
<td>Tab 2.5 mg – 1% DV Mar-18 to 2020</td>
<td>$12.50</td>
<td>Arrow-Bendrofluazide</td>
</tr>
<tr>
<td></td>
<td>Tab 5 mg – 1% DV Mar-18 to 2020</td>
<td>$20.42</td>
<td>Arrow-Bendrofluazide</td>
</tr>
<tr>
<td>CHLOROTHIAZIDE</td>
<td>Oral liq 50 mg per ml</td>
<td>$26.00</td>
<td>Biomed</td>
</tr>
<tr>
<td>CHLORTALIDONE [CHLORTHALIDONE]</td>
<td>Tab 25 mg – 1% DV Dec-19 to 2022</td>
<td>$6.50</td>
<td>Hygroton</td>
</tr>
<tr>
<td>INDAPAMIDE</td>
<td>Tab 2.5 mg</td>
<td>$2.60</td>
<td>Dapa-Tabs</td>
</tr>
<tr>
<td>METOLAZONE</td>
<td>Tab 5 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Lipid-Modifying Agents

#### Fibrates

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEZAFIBRATE</td>
<td>Tab 200 mg – 1% DV Dec-18 to 2021</td>
<td>$19.01</td>
<td>Be zalip</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 400 mg – 1% DV Dec-18 to 2021</td>
<td>$12.89</td>
<td>Be zalip Retard</td>
</tr>
<tr>
<td>GEMFIBROZIL</td>
<td>Tab 600 mg</td>
<td>$19.56</td>
<td>Lipazil</td>
</tr>
</tbody>
</table>

#### HMG CoA Reductase Inhibitors (Statins)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATORVASTATIN</td>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td>$6.96</td>
<td>Lorstat</td>
</tr>
<tr>
<td></td>
<td>Tab 20 mg – 1% DV Sep-18 to 2021</td>
<td>$9.99</td>
<td>Lorstat</td>
</tr>
<tr>
<td></td>
<td>Tab 40 mg – 1% DV Sep-18 to 2021</td>
<td>$15.93</td>
<td>Lorstat</td>
</tr>
<tr>
<td></td>
<td>Tab 80 mg – 1% DV Sep-18 to 2021</td>
<td>$27.19</td>
<td>Lorstat</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
CARDIOVASCULAR SYSTEM

PRAVASTATIN

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apo-Pravastatin</td>
<td>$4.72</td>
</tr>
<tr>
<td>100</td>
<td>Apo-Pravastatin</td>
</tr>
<tr>
<td>Apo-Pravastatin</td>
<td>$8.06</td>
</tr>
<tr>
<td>100</td>
<td>Apo-Pravastatin</td>
</tr>
<tr>
<td>Apo-Pravastatin</td>
<td>$0.95</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Apo-Pravastatin</td>
<td>$1.52</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Apo-Pravastatin</td>
<td>$2.63</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Apo-Pravastatin</td>
<td>$6.00</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
</tbody>
</table>

SIMVASTATIN

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simvastatin Mylan</td>
<td>$0.95</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Simvastatin Mylan</td>
<td>$1.52</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Simvastatin Mylan</td>
<td>$2.63</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Simvastatin Mylan</td>
<td>$6.00</td>
</tr>
<tr>
<td>90</td>
<td>Simvastatin Mylan</td>
</tr>
</tbody>
</table>

Resins

CHOLESTYRAMINE

Powder for oral liq 4 g

COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetimibe Sandoz</td>
<td>$2.00</td>
</tr>
<tr>
<td>30</td>
<td>Ezetimibe Sandoz</td>
</tr>
</tbody>
</table>

Restricted (RS1005)

Initiation

All of the following:

1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. Any of the following:
   3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 x normal) when treated with one statin; or
   3.2 The patient is intolerant to both simvastatin and atorvastatin; or
   3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

EZETIMIBE WITH SIMVASTATIN – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zimybe</td>
<td>$5.15</td>
</tr>
<tr>
<td>30</td>
<td>Zimybe</td>
</tr>
<tr>
<td>Zimybe</td>
<td>$6.15</td>
</tr>
<tr>
<td>30</td>
<td>Zimybe</td>
</tr>
<tr>
<td>Zimybe</td>
<td>$7.15</td>
</tr>
<tr>
<td>30</td>
<td>Zimybe</td>
</tr>
<tr>
<td>Zimybe</td>
<td>$8.15</td>
</tr>
<tr>
<td>30</td>
<td>Zimybe</td>
</tr>
</tbody>
</table>

Restricted (RS1006)

Initiation

All of the following:

1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

NICOTINIC ACID

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apo-Nicotinic Acid</td>
<td>$4.12</td>
</tr>
<tr>
<td>100</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td>Apo-Nicotinic Acid</td>
<td>$17.89</td>
</tr>
<tr>
<td>100</td>
<td>Apo-Nicotinic Acid</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

## Nitrates

**GLYCERYL TRINITRATE**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule</td>
<td>100.00</td>
<td>Hospira</td>
</tr>
<tr>
<td>Oral pump spray, 400 mcg per dose</td>
<td>4.45</td>
<td>Nitrolingual Pump Spray</td>
</tr>
<tr>
<td>Oral spray, 400 mcg per dose</td>
<td>4.45</td>
<td>Glytrin</td>
</tr>
<tr>
<td>Patch 25 mg, 5 mg per day</td>
<td>15.73</td>
<td>Nitroderm TTS 5</td>
</tr>
<tr>
<td>Patch 50 mg, 10 mg per day</td>
<td>18.62</td>
<td>Nitroderm TTS 10</td>
</tr>
</tbody>
</table>

**ISOSORBIDE MONONITRATE**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 20 mg – 1% DV Oct-17 to 2020</td>
<td>18.80</td>
<td>Ismo-20</td>
</tr>
<tr>
<td>Tab long-acting 40 mg</td>
<td>7.50</td>
<td>Ismo 40 Retard</td>
</tr>
<tr>
<td>Tab long-acting 60 mg – 1% DV Sep-17 to 2020</td>
<td>8.29</td>
<td>Duride</td>
</tr>
</tbody>
</table>

## Other Cardiac Agents

**LEVOSIMENDAN – Restricted** see terms below

- Inj 2.5 mg per ml, 5 ml vial
- Inj 2.5 mg per ml, 10 ml vial
- Restricted (RS1007)

**Initiation – Heart transplant**

Either:

1. For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
2. For the treatment of heart failure following heart transplant.

**Initiation – Heart failure**

Cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

## Sympathomimetics

**ADRENALINE**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 in 1,000, 1 ml ampoule</td>
<td>4.98</td>
<td>Aspen Adrenaline</td>
</tr>
<tr>
<td>Inj 1 in 1,000, 30 ml vial</td>
<td>5.25</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml ampoule</td>
<td>49.00</td>
<td>Aspen Adrenaline</td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml syringe</td>
<td>27.00</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

**DOBUTAMINE**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 12.5 mg per ml, 20 ml ampoule – 1% DV Jan-19 to 2021</td>
<td>61.13</td>
<td>Dobutamine-hameln</td>
</tr>
</tbody>
</table>

**DOPAMINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>29.73</td>
<td>Max Health Ltd</td>
</tr>
</tbody>
</table>

**EPHEDRINE**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 3 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>36.04</td>
<td>Max Health</td>
</tr>
</tbody>
</table>

**ISOPRENA LINE [ISOPROTERENOL]**

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 200 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### METARAMINOL
- Inj 0.5 mg per ml, 20 ml syringe
- Inj 1 mg per ml, 1 ml ampoule
- Inj 1 mg per ml, 10 ml syringe
- Inj 10 mg per ml, 1 ml ampoule

### NORADRENALINE
- Inj 0.06 mg per ml, 100 ml bag
- Inj 0.06 mg per ml, 50 ml syringe
- Inj 0.1 mg per ml, 100 ml bag
- Inj 0.1 mg per ml, 50 ml syringe
- Inj 0.12 mg per ml, 100 ml bag
- Inj 0.16 mg per ml, 50 ml syringe
- Inj 1 mg per ml, 100 ml bag
- Inj 1 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022 .......................... 45.00 10 Noradrenaline BNM

### PHENYLEPHRINE HYDROCHLORIDE
- Inj 10 mg per ml, 1 ml ampoule .............................................................. 115.50 25 Neosynephrine HCL

### Vasodilators

#### ALPROSTADIL HYDROCHLORIDE
- Inj 500 mcg per ml, 1 ml ampoule – 1% DV Dec-18 to 2021 .................. 1,765.50 5 Prostin VR

#### DIAZOXIDE
- Inj 15 mg per ml, 20 ml ampoule

#### HYDRAZINE HYDROCHLORIDE
- Tab 25 mg
  - Restricted (RS1008)

  **Initiation**
  Either:
  1. For the treatment of refractory hypertension; or
  2. For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

- Inj 20 mg ampoule ............................................................................... 25.90 5 Apresoline

#### MILRINONE
- Inj 1 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021 ..................... 99.00 10 Primacor

#### MINOXIDIL
- Tab 10 mg .............................................................................................. 70.00 100 Loniten

#### NICORANDIL
- Tab 10 mg – 1% DV Dec-19 to 2022 .................................................... 25.57 60 Ikorel
- Tab 20 mg – 1% DV Dec-19 to 2022 .................................................... 32.28 60 Ikorel

#### PAPAVERINE HYDROCHLORIDE
- Inj 30 mg per ml, 1 ml vial
- Inj 12 mg per ml, 10 ml ampoule ......................................................... 217.90 5 Hospira

#### PENTOXIFYLLINE [OXPENTIFYLLINE]
- Tab 400 mg

#### SODIUM NITROPRUSSIDE
- Inj 50 mg vial

**Products with Hospital Supply Status (HSS) are in bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Endothelin Receptor Antagonists

**AMBRISENTAN** – **Restricted** see terms below

- **Tab 5 mg** ................................................................. 4,585.00 30 Volibris
- **Tab 10 mg** ................................................................. 4,585.00 30 Volibris

**BOSENTAN** – **Restricted** see terms below

- **Tab 62.5 mg** – 1% DV Dec-18 to 2021 ........................................ 141.00 60 Bosentan Dr Reddy’s
- **Tab 125 mg** – 1% DV Dec-18 to 2021 ........................................ 141.00 60 Bosentan Dr Reddy’s

**Initiation**

**Pulmonary arterial hypertension**

*Re-assessment required after 6 months*

Either:

1. For use in patients with a valid Special Authority approval for ambrisentan by the Pulmonary Arterial Hypertension Panel; or
2. In-hospital stabilisations in emergency situations.

**Continuation**

*Re-assessment required after 6 months*

Any of the following:

**BOSENTAN** – **Restricted** see terms below

- **Tab 62.5 mg** – 1% DV Dec-18 to 2021 ........................................ 141.00 60 Bosentan Dr Reddy’s
- **Tab 125 mg** – 1% DV Dec-18 to 2021 ........................................ 141.00 60 Bosentan Dr Reddy’s

2 In-hospital stabilisation in emergency situations.

**Continuation – Pulmonary arterial hypertension**

*Re-assessment required after 6 months*

Any of the following:

1. All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
   1.3 PAH is at NYHA/WHO functional class II, III, or IV; and
   1.4 Any of the following:
      1.4.1 Both:
         1.4.1.1 Bosentan is to be used as PAH monotherapy; and
         1.4.1.2 Either:
            1.4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
            1.4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
      1.4.2 Both:
         1.4.2.1 Bosentan is to be used as PAH dual therapy; and
         1.4.2.2 Either:
            1.4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
            1.4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
      1.4.3 Both:
         1.4.3.1 Bosentan is to be used as PAH triple therapy; and
         1.4.3.2 Any of the following:
            1.4.3.2.1 Patient is on the lung transplant list; or
            1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
            1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
            1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy; or

2 In-hospital stabilisation in emergency situations.
Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Restricted see terms below

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg – 1% DV Sep-18 to 2021</td>
<td>0.64</td>
<td>Vedafil</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Sep-18 to 2021</td>
<td>0.64</td>
<td>Vedafil</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-18 to 2021</td>
<td>6.60</td>
<td>Vedafil</td>
</tr>
<tr>
<td>Inj 0.8 mg per ml, 12.5 ml vial</td>
<td>Restricted (RS1694)</td>
<td></td>
</tr>
</tbody>
</table>

Initiation – tablets Raynaud’s Phenomenon

All of the following:
1. Patient has Raynaud’s phenomenon; and
2. Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
3. Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
4. Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Initiation – tablets Pulmonary arterial hypertension

Any of the following:
1. All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 Any of the following:
      1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
      1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
      1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
   1.3 Any of the following:
      1.3.1 PAH is in NYHA/WHO functional class II; or
      1.3.2 PAH is in NYHA/WHO functional class III; or
      1.3.3 PAH is in NYHA/WHO functional class IV; and
   1.4 Either:

continued...
continued...

1.4.1 All of the following:
   1.4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
   1.4.1.2 Either:
       1.4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
       1.4.1.2.2 Patient is peri Fontan repair; and
   1.4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least
       240 International Units (dyn s cm-5); or

1.4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient’s young age; or

2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or

3 In-hospital stabilisation in emergency situations.

Initiation – tablets other conditions

Any of the following:

1 For use in weaning patients from inhaled nitric oxide; or
2 For perioperative use in cardiac surgery patients; or
3 For use in intensive care as an alternative to nitric oxide; or
4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

Initiation – injection

Both:

1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units
   and neonatal intensive care units when the enteral route is not accessible; and

2 Any of the following:
   2.1 For perioperative use following cardiac surgery; or
   2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
   2.3 For use in congenital diaphragmatic hernia.

Prostacyclin Analogues

**EPOPROSTENOL – Restricted** see terms below

- **Inj 500 mcg vial** ..........................................................36.61 1 Veletri
- **Inj 1.5 mg vial** ............................................................73.21 1 Veletri

**Initiation**

Either:

1 For use in patients with a valid Special Authority approval for epoprostenol by the Pulmonary Arterial Hypertension Panel; or
2 In-hospital stabilisation in emergency situations.

**ILOPROST**

<table>
<thead>
<tr>
<th>Inj 50 mcg in 0.5 ml ampoule – 1% DV Jan-20 to 2022</th>
<th>305.00 5 Clinect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nebuliser soln 10 mcg per ml, 2 ml ..................</td>
<td>380.00 Ilomedin</td>
</tr>
</tbody>
</table>

**Initiation**

Any of the following:

1 For use in patients with a valid Special Authority approval for iloprost by the Pulmonary Arterial Hypertension Panel; or
2 For diagnostic use in catheter laboratories; or
3 For use following mitral or tricuspid valve surgery; or
4 In-hospital stabilisation in emergency situations.

*(Ilomedin Inj 50 mcg in 0.5 ml ampoule to be delisted 1 January 2020)*
## Dermatologicals

### Anti-Infective Preparations

#### Antibacterials

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROGEN PEROXIDE</td>
<td>$8.56</td>
<td>Crystaderm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOLN 3% (10 vol)</td>
<td>$1.40</td>
<td>Pharmacy Health</td>
</tr>
</tbody>
</table>

*(Pharmacy Health Soln 3% (10 vol) to be delisted 1 July 2020)*

**MAFENIDE ACETATE** – *Restricted* see terms below

- Powder 50 g sachet
- **Restricted** *(RS1299)*

**Initiation**

For the treatment of burns patients.

**MUPIROCIN**

- Oint 2%

**SODIUM FUSIDATE** [FUSIDIC ACID]

- Crm 2% – 1% DV May-19 to 2021 ........................................................................ 1.59 5 g Foban
- Oint 2% – 1% DV May-19 to 2021 ........................................................................ 1.59 5 g Foban

**SULFADIAZINE SILVER**

- Crm 1% – 1% DV Aug-17 to 2020 ........................................................................ 10.80 50 g Flamazine

#### Antifungals

**AMOROLFINE**

- Nail soln 5% – 1% DV Sep-17 to 2020 ................................................................... 15.95 5 ml MycoNail

**CICLOPIROX OLAMINE**

- Nail soln 8% – 1% DV Sep-18 to 2021 ................................................................... 5.72 7 ml Apo-Ciclopirox
- **Soln 1% – Restricted**: For continuation only

**CLOTIRMAZOLE**

- Crm 1% – 1% DV Jan-18 to 2020 ........................................................................... 0.70 20 g Clomazol
- **Soln 1% – Restricted**: For continuation only

**ECONAZOLE NITRATE**

- **Crm 1% – Restricted**: For continuation only
- Foaming soln 1%

**KETOCONAZOLE**

- Shampoo 2% – 1% DV Sep-17 to 2020 ................................................................... 2.99 100 ml Sebizole

**METRONIDAZOLE**

- Gel 0.75%

**MICONAZOLE NITRATE**

- Crm 2% – 1% DV Jan-18 to 2020 ........................................................................... 0.74 15 g Multichem
- **Lotn 2% – Restricted**: For continuation only
- Tinc 2%

**NYSTATIN**

- Crm 100,000 u per g

#### Antiparasitics

**DIMETHICONE**

- Lotn 4% – 1% DV Oct-19 to 2022 ........................................................................... 4.98 200 ml healthE Dimethicone 4% Lotion

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Dermatologicals

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**MALATHION [MALDISON]**
- Lotn 0.5%
- Shampoo 1%

**PERMETHRIN**
- Crm 5% – 1% DV Dec-17 to 2020: 4.95 30 g
- Lotn 5% – 1% DV Oct-17 to 2020: 3.69 30 ml

**PHENOTHRIN**
- Shampoo 0.5%

#### Antiacne Preparations

**ADAPALENE**
- Crm 0.1%
- Gel 0.1%

**BENZOYL PEROXIDE**
- Soln 5%

**ISOTRETINOIN**
- Cap 5 mg – 1% DV Oct-18 to 2021: 8.14 60
- Cap 10 mg – 1% DV Oct-18 to 2021: 13.34 120
- Cap 20 mg – 1% DV Oct-18 to 2021: 20.49 120

**TRETINOIN**
- Crm 0.05% – 1% DV Jun-18 to 2021: 13.90 50 g

#### Antipruritic Preparations

**CALAMINE**
- Crm, aqueous, BP – 1% DV Nov-18 to 2021: 1.26 100 g
- Lotn, BP: 12.94 2,000 ml
- (PSM Lotn, BP to be delisted 1 July 2020)

**CROTAMITON**
- Crm 10% – 1% DV Sep-18 to 2021: 3.29 20 g

#### Barrier Creams and Emollients

**Barrier Creams**

**DIMETHICONE**
- Crm 5% tube – 1% DV Oct-19 to 2022: 1.53 100 g
- Crm 5% pump bottle: 4.48 500 ml
- Crm 10% pump bottle – 1% DV Sep-18 to 2021: 4.52 500 ml

**ZINC**
- Crm: e.g. Zinc Cream (Orion-)
- Oint: e.g. Zinc oxide (PSM)
- Paste: e.g. Zinc Cream (PSM)
### Emollients

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ZINC AND CASTOR OIL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm</td>
<td>1.63</td>
<td>Orion</td>
</tr>
<tr>
<td>Oint – 1% DV Jul-18 to 2020</td>
<td>4.25</td>
<td>Boucher</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 30 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint, BP – 1% DV Nov-17 to 2020</td>
<td>1.26</td>
<td>healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 30 g or less.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ZINC WITH WOOL FAT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm zinc 15.25% with wool fat 4%</td>
<td></td>
<td>e.g. Sudocrem</td>
</tr>
</tbody>
</table>

#### AQUEOUS CREAM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 100 g – 1% DV Oct-18 to 2021</td>
<td>1.05</td>
<td>Pharmacy Health SLS-free</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 100 g or less.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 500 g – 1% DV Dec-18 to 2021</td>
<td>1.92</td>
<td>Boucher</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 100 g.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### CETOMACROGOL

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm BP, 500 g – 1% DV Sep-18 to 2021</td>
<td>2.48</td>
<td>healthE</td>
</tr>
<tr>
<td>Crm BP, 100 g – 1% DV Sep-18 to 2021</td>
<td>1.42</td>
<td>healthE</td>
</tr>
</tbody>
</table>

#### CETOMACROGOL WITH GLYCEROL

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 90% with glycerol 10%, – 1% DV Dec-19 to 2022</td>
<td>1.65</td>
<td>healthE</td>
</tr>
<tr>
<td>Crm 90% with glycerol 10%</td>
<td>2.82</td>
<td>Pharmacy Health Sorbolene with Glycerin</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 100 g or less.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.87</td>
<td>Pharmacy Health Sorbolene with Glycerin</td>
</tr>
<tr>
<td></td>
<td>1,000 ml</td>
<td></td>
</tr>
</tbody>
</table>

#### EMULSIFYING OINTMENT

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint BP – 1% DV Oct-17 to 2020</td>
<td>1.84</td>
<td>Jaychem</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of less than 200 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint BP, 500 g – 1% DV Oct-17 to 2020</td>
<td>3.59</td>
<td>AFT</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of greater than 200 g.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### GLYCEROL WITH PARAFFIN

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e.g. QV cream</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### OIL IN WATER EMULSION

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm, 500 g – 1% DV Jan-19 to 2021</td>
<td>2.19</td>
<td>O/W Fatty Emulsion Cream</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of greater than 100 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm, 100 g – 1% DV Dec-18 to 2021</td>
<td>1.44</td>
<td>healthE Fatty Cream</td>
</tr>
</tbody>
</table>

#### PARAFFIN

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint liquid paraffin 50% with white soft paraffin 50% – 1% DV Jan-19 to 2021</td>
<td>1.97</td>
<td>healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of 100 g or greater.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White soft – 1% DV Sep-18 to 2021</td>
<td>0.79</td>
<td>healthE</td>
</tr>
<tr>
<td>Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.</td>
<td>10 g</td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Dermatologicals

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per Brand or Generic Manufacturer (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paraffin with Wool Fat</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lotn liquid paraffin 15.9% with wool fat 0.6%</td>
<td></td>
<td>e.g. AlphaKeri; BK; DP; Hydroderm Lotn</td>
</tr>
<tr>
<td>Lotn liquid paraffin 91.7% with wool fat 3%</td>
<td></td>
<td>e.g. Alpha Keri Bath Oil</td>
</tr>
<tr>
<td><strong>Urea</strong></td>
<td>1.37</td>
<td>healthE Urea Cream</td>
</tr>
<tr>
<td><strong>Wool Fat</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Corticosteroids

**Betamethasone Dipropionate**
- Crm 0.05%
- Oint 0.05%

**Betamethasone Valerate**
- Crm 0.1% - 1% DV Oct-18 to 2021
- Oint 0.1% - 1% DV Oct-18 to 2021
- Lotn 0.1% - 1% DV Dec-18 to 2021

**Clobetasol Propionate**
- Crm 0.05% - 1% DV Nov-19 to 2022
- Oint 0.05% - 1% DV Nov-19 to 2022
- Lotn 0.1% - 1% DV Dec-18 to 2021

**Clobetasone Butyrate**
- Crm 0.05%

**Diflucortolone Valerate** — Restricted: For continuation only
- Crm 0.1%
- Fatty oint 0.1%

**Hydrocortisone**
- Crm 1%, 30 g
- Crm 1%, 500 g
- Milky emul 0.1% - 1% DV Mar-19 to 2021

**Hydrocortisone Acetate**
- Crm 1%

**Hydrocortisone and Paraffin Liquid and Lanolin**
- Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% - 1% DV Sep-17 to 2020

**Hydrocortisone Butyrate**
- Crm 0.1%
- Oint 0.1% - 1% DV Mar-19 to 2021
- Milky emul 0.1% - 1% DV Mar-19 to 2021

**Methyprednisolone Aceponate**
- Crm 0.1%
- Oint 0.1%

**Mometasone Furoate**
- Crm 0.1% - 1% DV Nov-18 to 2021
- Oint 0.1% - 1% DV Nov-18 to 2021
- Lotn 0.1% - 1% DV Nov-18 to 2021

---

**Note:** DV limit applies to the pack sizes of less than or equal to 100 g.

---

*Item restricted (see ➡️ above); Item restricted (see ➡️ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
## Dermatologicals

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per 100 g</td>
<td></td>
</tr>
</tbody>
</table>

### Triamcinolone Acetonide

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.02% – 1% DV Sep-17 to 2020</td>
<td>100 g</td>
<td>Aristocort</td>
</tr>
<tr>
<td>Oint 0.02% – 1% DV Sep-17 to 2020</td>
<td>100 g</td>
<td>Aristocort</td>
</tr>
</tbody>
</table>

### Corticosteroids with Anti-Infective Agents

**BETAMETHASONE VALERATE WITH Clioquinol** – Restricted see terms below
- Crm 0.1% with clioquinol 3%
- Restricted (RS1125)

**Initiation**

Either:
1. For the treatment of intertrigo; or
2. For continuation use.

**BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]**
- Crm 0.1% with sodium fusidate (fusidic acid) 2%

### Hydrocortisone with Miconazole

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1% with miconazole nitrate 2% – 1% DV Sep-18 to 2021</td>
<td>15 g</td>
<td>Micreme H</td>
</tr>
</tbody>
</table>

### Hydrocortisone with Natamycin and Neomycin

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>15 g</td>
<td>Pimafucort</td>
</tr>
<tr>
<td>Oint 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>15 g</td>
<td>Pimafucort</td>
</tr>
</tbody>
</table>

### Triamcinolone Acetonide with Neomycin Sulphate, Gramicidin and Nystatin

- Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

### Psoriasis and Eczema Preparations

#### Acitretin

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 10 mg – 1% DV Sep-17 to 2020</td>
<td>60</td>
<td>Novatretin</td>
</tr>
<tr>
<td>Cap 25 mg – 1% DV Sep-17 to 2020</td>
<td>60</td>
<td>Novatretin</td>
</tr>
</tbody>
</table>

#### Betamethasone Diproionate with Calcipotriol

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021</td>
<td>60 g</td>
<td>Daivobet</td>
</tr>
<tr>
<td>Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021</td>
<td>30 g</td>
<td>Daivobet</td>
</tr>
</tbody>
</table>

#### Calcipotriol

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint 50 mcg per g – 1% DV Jul-17 to 2020</td>
<td>100 g</td>
<td>Daivonex</td>
</tr>
</tbody>
</table>

#### Coal Tar with Salicylic Acid and Sulphur

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint 12% with salicylic acid 2% and sulphur 4%</td>
<td>45.00</td>
</tr>
</tbody>
</table>

#### Methoxsalen [8-Methoxypsoralen]

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td>1.2%</td>
</tr>
</tbody>
</table>

#### Pine Tar with Trolamine Laurilsulfate and Fluorescein

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020</td>
<td>500 ml</td>
<td>Pinetarsol</td>
</tr>
</tbody>
</table>

#### Potassium Permanganate

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg</td>
<td>Crystals</td>
</tr>
</tbody>
</table>

### Scalp Preparations

**Betamethasone Valerate**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scalp app 0.1% – 1% DV Oct-18 to 2021</td>
<td>100 ml</td>
<td>Beta Scalp</td>
</tr>
</tbody>
</table>

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Dermatologicals

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clobetasol Propionate</strong></td>
<td>5.69</td>
<td>30 ml</td>
<td>Dermol</td>
</tr>
<tr>
<td>Scalp app 0.05% – 1% DV Nov-19 to 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hydrocortisone Butyrate</strong></td>
<td>7.30</td>
<td>100 ml</td>
<td>Locoid</td>
</tr>
<tr>
<td>Scalp lotn 0.1% – 1% DV Mar-19 to 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Wart Preparations

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imiquimod</strong></td>
<td>21.72</td>
<td>24</td>
<td>Perrigo</td>
</tr>
<tr>
<td>Crm 5%, 250 mg sachet – 1% DV Aug-18 to 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Podophyllotoxin</strong></td>
<td>33.60</td>
<td>3.5 ml</td>
<td>Condyline</td>
</tr>
<tr>
<td>Soln 0.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Silver Nitrate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sticks with applicator</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other Skin Preparations

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diphenanil Methylsulfate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder 2%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sunscreen, Proprietary</strong></td>
<td>3.30</td>
<td>100 g</td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td>Crm</td>
<td></td>
<td></td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td>Lotn</td>
<td></td>
<td></td>
<td>Marine Blue Lotion SPF 50+</td>
</tr>
<tr>
<td><strong>Antineoplastics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fluourouracil Sodium</strong></td>
<td>7.95</td>
<td>20 g</td>
<td>Efudix</td>
</tr>
<tr>
<td>Crm 5% – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methyl Aminolevulinate Hydrochloride</strong></td>
<td>Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 16%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1127)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatologist or plastic surgeon</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Wound Management Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Calcium Gluconate</strong></td>
<td>e.g. Orion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 2.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
**Anti-Infective Agents**

**ACETIC ACID**
- Soln 3%
- Soln 5%

**ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID**
- Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator

**CHLORHEXIDINE GLUCONATE**
- Crm 1% ................................................................. 1.21 50 g healthE
- Lotn 1%, 200 ml ................................................ 2.98 1 healthE

**CLOTRIMAZOLE**
- Vaginal crm 1% with applicator .................................. 1.60 35 g Clomazol
- Vaginal crm 2% with applicator .................................. 2.10 20 g Clomazol

**MICONAZOLE NITRATE**
- Vaginal crm 2% with applicator – 1% DV Sep-17 to 2020 .... 3.88 40 g Micreome

**NYSTATIN**
- Vaginal crm 100,000 u per 5 g with applicator(s) – 1% DV Aug-17 to 2020 ... 4.45 75 g Nilstat

**Contraceptives**

**Antiandrogen Oral Contraceptives**

**CYPROTERONE ACETATE WITH ETHINYLDEOSTRADIOL**
- Tab 2 mg with ethinylestradiol 35 mcg and 7 inert tablets – 1% DV Sep-17 to 2020 ................................................ 4.67 168 Ginet

**Combined Oral Contraceptives**

**ETHINYLDEOSTRADIOL WITH DESOGESTREL**
- Tab 20 mcg with desogestrel 150 mcg
- Tab 30 mcg with desogestrel 150 mcg

**ETHINYLDEOSTRADIOL WITH LEVONORGESTREL**
- Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – 1% DV Jan-18 to 2020 ........................................................... 2.18 84 Microgynon 20 ED
- Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – 1% DV Jan-18 to 2020 ........................................................... 1.77 84 Levlen ED
- Tab 20 mcg with levonorgestrel 100 mcg
- Tab 30 mcg with levonorgestrel 150 mcg
- Tab 50 mcg with levonorgestrel 125 mcg ........................................ 9.45 84 Microgynon 50 ED

**ETHINYLDEOSTRADIOL WITH NORETHISTERONE**
- Tab 35 mcg with norethisterone 1 mg
- Tab 35 mcg with norethisterone 500 mcg

**NORETHISTERONE WITH MESTRANOL**
- Tab 1 mg with mestranol 50 mcg
## GENITO-URINARY SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Contraceptive Devices

<table>
<thead>
<tr>
<th>INTRA-UTERINE DEVICE</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUD 29.1 mm length × 23.2 mm width – 1% DV Nov-19 to 2022</td>
<td>18.45</td>
<td>Choice TT380 Short</td>
</tr>
<tr>
<td>IUD 33.6 mm length × 29.9 mm width – 1% DV Nov-19 to 2022</td>
<td>18.45</td>
<td>Choice TT380 Standard</td>
</tr>
<tr>
<td>IUD 35.5 mm length × 19.6 mm width – 1% DV Nov-19 to 2022</td>
<td>15.50</td>
<td>Choice Load 375</td>
</tr>
</tbody>
</table>

### Emergency Contraception

<table>
<thead>
<tr>
<th>LEVONORGESTREL</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1.5 mg</td>
<td>4.95</td>
<td>Postinor-1</td>
</tr>
</tbody>
</table>

### Progestogen-Only Contraceptives

<table>
<thead>
<tr>
<th>LEVONORGESTREL</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 30 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intra-uterine system, 20 mcg per day</td>
<td>269.50</td>
<td>Mirena</td>
</tr>
</tbody>
</table>

#### Restricted (RS1364)

**Initiation – heavy menstrual bleeding**
Obstetrician or gynaecologist

All of the following:

1. The patient has a clinical diagnosis of heavy menstrual bleeding; and
2. The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
3. Any of the following:
   3.1 Serum ferritin level < 16 mcg/l (within the last 12 months); or
   3.2 Haemoglobin level < 120 g/l; or
   3.3 The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.

**Continuation – heavy menstrual bleeding**
Obstetrician or gynaecologist

Either:

1. Patient demonstrated clinical improvement of heavy menstrual bleeding; or
2. Previous insertion was removed or expelled within 3 months of insertion.

**Initiation – endometriosis**
Obstetrician or gynaecologist

The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.

**Continuation – endometriosis**
Obstetrician or gynaecologist

Either:

1. Patient demonstrated satisfactory management of endometriosis; or
2. Previous insertion was removed or expelled within 3 months of insertion.

**Note:** endometriosis is an unregistered indication.

<table>
<thead>
<tr>
<th>MEDROXYPROGESTERONE ACETATE</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 150 mg per ml, 1 ml syringe – 1% DV Dec-19 to 2022</td>
<td>7.98</td>
<td>Depo-Provera</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NORETHISTERONE</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 350 mcg – 1% DV Sep-18 to 2021</td>
<td>6.25</td>
<td>Noriday 28</td>
</tr>
</tbody>
</table>
Obstetric Preparations

Antiprogesterogens

MIFEPRISTONE
Tab 200 mg

Oxytocics

CARBOPROST TROMETAMOL
Inj 250 mcg per ml, 1 ml ampoule

DINOPROSTONE
Pessaries 10 mg
Vaginal gel 3 g

ERGOMETRINE MALEATE
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020

OXYSIN
Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021

OXYTOCIN WITH ERGOMETRINE MALEATE
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1%

Tocolytics

PROGESTERONE – Restricted see terms below
Cap 100 mg

Initiation
Gynaecologist or obstetrician
Re-assessment required after 12 months
Both:
1 For the prevention of pre-term labour*; and
2 Either:
   2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   2.2 The patient has a history of pre-term birth at less than 28 weeks.

Continuation
Gynaecologist or obstetrician
Re-assessment required after 12 months
All of the following:
1 For the prevention of pre-term labour*; and
2 Treatment is required for second or subsequent pregnancy; and
3 Either:
   3.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   3.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

TERBUTALINE – Restricted see terms below
Inj 500 mcg ampoule

Initiation
Obstetrician
<table>
<thead>
<tr>
<th>Oestrogens</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>OESTRIOL</td>
<td>Crm 1 mg per g with applicator – 1% DV Oct-17 to 2020</td>
<td>6.62 $</td>
<td>15 g</td>
</tr>
<tr>
<td></td>
<td>Pessaries 500 mcg – 1% DV Oct-17 to 2020</td>
<td>6.86 $</td>
<td>15</td>
</tr>
</tbody>
</table>

### 5-Alpha Reductase Inhibitors

**FINASTERIDE** – Restricted see terms below

- Tab 5 mg – 1% DV Dec-17 to 2020 | 4.81 $ | 100 | Ricit |

Initiation

Both:

1. Patient has symptomatic benign prostatic hyperplasia; and
2. Either:
   2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
   2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

### Alpha-1A Adrenoceptor Blockers

**TAMSULOSIN HYDROCHLORIDE** – Restricted see terms below

- Cap 400 mcg | 11.25 $ | 100 | Tamsulosin-Rex |

Initiation

Both:

1. Patient has symptomatic benign prostatic hyperplasia; and
2. The patient is intolerant of non-selective alpha blockers or these are contraindicated.

### Urinary Alkalisers

**POTASSIUM CITRATE** – Restricted see terms below

- Oral liq 3 mmol per ml – 1% DV Oct-18 to 2021 | 31.80 $ | 200 ml | Biomed |

Initiation

Both:

1. The patient has recurrent calcium oxalate urolithiasis; and
2. The patient has had more than two renal calculi in the two years prior to the application.

**SODIUM CITRO-TARTRATE**

- Grans eff 4 g sachets – 1% DV Sep-17 to 2020 | 2.34 $ | 28 | Ural |

### Urinary Antispasmodics

**OXYBUTYNIN**

- Tab 5 mg | 8.85 $ | 500 | Apo-Oxybutynin |
- Oral liq 5 mg per 5 ml | 60.40 $ | 473 ml | Apo-Oxybutynin |

**SOLIFENACIN SUCCINATE** – Some items restricted see terms on the next page

- Tab 5 mg – 1% DV Dec-18 to 2021 | 3.00 $ | 30 | Solifenacin Mylan |
- Tab 10 mg – 1% DV Dec-18 to 2021 | 5.50 $ | 30 | Solifenacin Mylan |
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

**GENITO-URINARY SYSTEM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**→ Restricted (RS1274)**

**Initiation**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

**TOLERODINE TARTRATE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Pack Size</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>14.56</td>
<td>56</td>
<td>Arrow-Tolterodine</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>14.56</td>
<td>56</td>
<td>Arrow-Tolterodine</td>
</tr>
</tbody>
</table>

**→ Restricted (RS1273)**

**Initiation**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.
### HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### Anabolic Agents

**OXANDROLONE**
- Tab 2.5 mg
- **Restricted (RS1302)**

**Initiation**
For the treatment of burns patients.

#### Androgen Agonists and Antagonists

**CYPROTERONE ACETATE**
- Tab 50 mg – **1% DV Dec-18 to 2021** .................................................. 13.17 50 **Siterone**
- Tab 100 mg – **1% DV Dec-18 to 2021** .................................................. 26.75 50 **Siterone**

**TESTOSTERONE**
- Patch 5 mg per day ............................................................................... 90.00 30 **Androderm**

**TESTOSTERONE CIPIONATE**
- Inj 100 mg per ml, 10 ml vial – **1% DV Sep-17 to 2020** ...................... 76.50 1 **Depo-Testosterone**

**TESTOSTERONE ESTERS**
- Inj testosterone decanoate 100 mg, testosterone isocaproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule

**TESTOSTERONE UNDECANOATE**
- Cap 40 mg – **1% DV Nov-18 to 2021** .................................................. 21.00 60 **Andriol Testocaps**
- Inj 250 mg per ml, 4 ml vial.................................................................. 86.00 1 **Reandron 1000**

#### Calcium Homeostasis

**CALCITONIN**
- Inj 100 iu per ml, 1 ml ampoule ............................................................ 121.00 5 **Miacalcic**

**CINACALCET** – **Restricted** see terms **below**
- Tab 30 mg – **1% DV Sep-18 to 2021** .................................................. 210.30 28 **Sensipar**
- **Restricted (RS1540)**

**Initiation**
Nephrologist or endocrinologist

*Re-assessment required after 6 months*

Either:

1. All of the following:
   1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
   1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
   1.3 The patient is symptomatic; or

2. All of the following:
   2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
   2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
   2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

*continued…*
continued...

Continuation

Nephrologist or endocrinologist
Both:
1. The patient’s serum calcium level has fallen to < 3mmol/L; and
2. The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

ZOLEDRONIC ACID

- Inj 4 mg per 5 ml, vial – 1% DV May-19 to 2021 ............................................. 38.03 1
  Zoledronic acid Mylan
  Restricted (RS1602)

Initiation – bone metastases

Oncologist, haematologist or palliative care specialist
Any of the following:
1. Patient has hypercalcaemia of malignancy; or
2. Both:
   2.1 Patient has bone metastases or involvement; and
   2.2 Patient has severe bone pain resistant to standard first-line treatments; or
3. Both:
   3.1 Patient has bone metastases or involvement; and
   3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

Initiation – early breast cancer

Oncologist
All of the following:
1. Treatment to be used as adjuvant therapy for early breast cancer; and
2. Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
3. Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids

BETAMETHASONE

Tab 500 mcg
Inj 4 mg per ml, 1 ml ampoule

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

DEXAMETHASONE

Tab 0.5 mg – 1% DV Oct-18 to 2021 .............................................................. 0.99 30
Tab 4 mg – 1% DV Oct-18 to 2021 ............................................................... 1.90 30
Oral liq 1 mg per ml .............................................................................. 45.00 25 ml

DEXAMETHASONE PHOSPHATE

Inj 4 mg per ml, 1 ml ampoule ................................................................. 14.19 10
Inj 4 mg per ml, 2 ml ampoule ............................................................... 25.18 10

FLUDROCORTISONE ACETATE

Tab 100 mcg ....................................................................................... 14.32 100

HYDROCORTISONE

Tab 5 mg – 1% DV Sep-18 to 2021 ............................................................. 8.10 100
Tab 20 mg – 1% DV Sep-18 to 2021 ..................................................... 20.32 100
Inj 100 mg vial ..................................................................................... 5.30 1

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### METHYLPREDNISOLONE (AS SODIUM SUCCINATE)

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg – 1% DV Dec-18 to 2021</td>
<td>$112.00</td>
<td>100 Medrol</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Dec-18 to 2021</td>
<td>$194.00</td>
<td>20 Medrol</td>
</tr>
<tr>
<td>Inj 40 mg vial – 1% DV Dec-18 to 2021</td>
<td>$18.90</td>
<td>1 Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 125 mg vial – 1% DV Dec-18 to 2021</td>
<td>$28.90</td>
<td>1 Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Dec-18 to 2021</td>
<td>$22.78</td>
<td>1 Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Dec-18 to 2021</td>
<td>$27.83</td>
<td>1 Solu-Medrol</td>
</tr>
</tbody>
</table>

### METHYLPREDNISOLONE ACETATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 40 mg per ml, 1 ml vial – 1% DV Dec-18 to 2021</td>
<td>$44.40</td>
<td>5 Depo-Medrol</td>
</tr>
</tbody>
</table>

### PREDNISOLONE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Jun-18 to 2021</td>
<td>$6.00</td>
<td>30 ml Redipred</td>
</tr>
<tr>
<td>Enema 200 mcg per ml, 100 ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PREDNISONE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Jun-17 to 2020</td>
<td>$10.68</td>
<td>500 Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Jun-17 to 2020</td>
<td>$12.09</td>
<td>500 Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Jun-17 to 2020</td>
<td>$11.09</td>
<td>500 Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jun-17 to 2020</td>
<td>$29.03</td>
<td>500 Apo-Prednisone</td>
</tr>
</tbody>
</table>

### TRIAMCINOLONE ACETONIDE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$20.80</td>
<td>5 Kenacort-A 10</td>
</tr>
<tr>
<td>Inj 40 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$51.10</td>
<td>5 Kenacort-A 40</td>
</tr>
</tbody>
</table>

### TRIAMCINOLONE HEXACETONIDE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Hormone Replacement Therapy

### Oestrogens

#### OESTRADIOL

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch 25 mcg per day</td>
<td>$6.12</td>
<td>8 Estradot</td>
</tr>
<tr>
<td>Patch 50 mcg per day</td>
<td>$7.04</td>
<td>8 Estradot</td>
</tr>
<tr>
<td>Patch 75 mcg per day</td>
<td>$7.91</td>
<td>8 Estradot</td>
</tr>
<tr>
<td>Patch 100 mcg per day</td>
<td>$7.91</td>
<td>8 Estradot</td>
</tr>
</tbody>
</table>

#### OESTRADIOL VALERATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Sep-18 to 2021</td>
<td>$12.36</td>
<td>84 Progynova</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Sep-18 to 2021</td>
<td>$12.36</td>
<td>84 Progynova</td>
</tr>
</tbody>
</table>

#### OESTROGENS (CONJUGATED EQUINE)

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 300 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 625 mcg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Progestogen and Oestrogen Combined Preparations

#### OESTRADIOL WITH NORETHISTERONE ACETATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg with 0.5 mg norethisterone acetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg with 1 mg norethisterone acetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### OESTROGENS WITH MEDROXYPROGESTERONE ACETATE
- Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate
- Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

#### Progestogens

**MEDROXYPROGESTERONE ACETATE**
- Tab 2.5 mg ................................................................. 3.75 30 Provera
- Tab 5 mg ................................................................. 14.00 100 Provera
- Tab 10 mg ............................................................... 7.15 30 Provera

#### Other Endocrine Agents

- **CABERGOLINE** – Restricted see terms below
  - Tab 0.5 mg – 1% DV Sep-18 to 2021 ........................................ 3.75 2 Dostinex
  - 15.20 8 Dostinex

- **CLOMIFENE CITRATE**
  - Tab 50 mg .............................................................. 29.84 10 Mylan Clomiph

- **DANAZOL**
  - Cap 100 mg ........................................................... 68.33 100 Azol
  - Cap 200 mg ........................................................... 97.83 100 Azol

- **GESTRINONE**
  - Cap 2.5 mg

- **METYRAPONE**
  - Cap 250 mg

- **PENTAGASTRIN**
  - Inj 250 mcg per ml, 2 ml ampoule

#### Other Oestrogen Preparations

- **ETHINYLESTRODIOL**
  - Tab 10 mcg – 1% DV Sep-18 to 2021 .................................. 17.60 100 NZ Medical and Scientific

- **OESTRADIOL**
  - Implant 50 mg

- **OESTRIOL**
  - Tab 2 mg

#### Other Progestogen Preparations

- **MEDROXYPROGESTERONE**
  - Tab 100 mg ............................................................... 101.00 100 Provera HD

- **NORETHISTERONE**
  - Tab 5 mg ............................................................... 18.29 100 Primolut N

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Pituitary and Hypothalamic Hormones and Analogues

**CORTICOTRORELIN (OVINE)**

Inj 100 mcg vial

**THYROTROPIN ALFA**

Inj 900 mcg vial

### Adrenocorticotropic Hormones

**TETRACOSACTIDE [TETRACOSACTRIN]**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>75.00</td>
<td>Synacthen</td>
</tr>
<tr>
<td>690.00</td>
<td>Synacthen Depot</td>
</tr>
</tbody>
</table>

### GnRH Agonists and Antagonists

**BUSERELIN**

Inj 1 mg per ml, 5.5 ml vial

**GONADORELIN**

Inj 100 mcg vial

**GOSERELIN**

- Implant 3.6 mg, syringe ........................................66.48 1 Zoladex
- Implant 10.8 mg, syringe ...................................177.50 1 Zoladex

**LEUPRORELIN ACETATE**

- Inj 3.75 mg prefilled dual chamber syringe.................................221.60 1 Lucrin Depot 1-month
- Inj 11.25 mg prefilled dual chamber syringe..............................591.68 1 Lucrin Depot 3-month

### Gonadotrophins

**CHORIOGONADOTROPIN ALFA**

Inj 250 mcg in 0.5 ml syringe

### Growth Hormone

**SOMATROPIN – Restricted** see terms below

- Inj 5 mg cartridge – 1% DV Oct-18 to 2021..........................34.88 1 Omnitrope
- Inj 10 mg cartridge – 1% DV Oct-18 to 2021.........................69.75 1 Omnitrope
- Inj 15 mg cartridge – 1% DV Oct-18 to 2021......................104.63 1 Omnitrope

*Initiation – growth hormone deficiency in children*

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Either:

1. Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2. All of the following:

   2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and

   continued…

---

*Item restricted (see ➡️ above); Item restricted (see ➡️ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
continued...

2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
2.5 Appropriate imaging of the pituitary gland has been obtained.

Continuation – growth hormone deficiency in children
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed since starting growth hormone.

Initiation – Turner syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

1 The patient has a post-natal genotype confirming Turner Syndrome; and
2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is < 14 years.

Continuation – Turner syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

1 Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke’s Turner Syndrome growth velocity charts); and
2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
3 A current bone age is 14 years or under; and
4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed since starting growth hormone.

Initiation – short stature without growth hormone deficiency
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

1 The patient’s height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

continued…
Continuation – short stature without growth hormone deficiency
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation – short stature due to chronic renal insufficiency
Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1. The patient's height is more than 2 standard deviations below the mean; and
2. Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
5. The patient is under the supervision of a specialist with expertise in renal medicine; and
6. Either:
   6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m$^2$ as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m$^2$)) in a child who may or may not be receiving dialysis; or
   6.2 The patient has received a renal transplant and has received < 5mg/ m$^2$/day of prednisone or equivalent for at least 6 months.

Continuation – short stature due to chronic renal insufficiency
Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
7. The patient has not received renal transplantation since starting growth hormone treatment; and
8. If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initiation – Prader-Willi syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

continued…
continued...

1. The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
2. The patient is aged six months or older; and
3. A current bone age is $< 14$ years (female patients) or $< 16$ years (male patients); and
4. Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
5. Either:
   5.1 Both:
      5.1.1 The patient is aged two years or older; and
      5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
   5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Continuation – Prader-Willi syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initiation – adults and adolescents
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:
1. The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
2. The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
3. The patient has severe growth hormone deficiency (see notes); and
4. The patient’s serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
5. The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

continued…
At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

**Continuation – adults and adolescents**

Endocrinologist or paediatric endocrinologist

**Re-assessment required after 12 months**

Either:

1. All of the following:
   1.1 The patient has been treated with somatropin for < 12 months; and
   1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
   1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
   1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or
2. All of the following:
   2.1 The patient has been treated with somatropin for more than 12 months; and
   2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
   2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
   2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

---

**Thyroid and Antithyroid Preparations**

**CARBIMAZOLE**
- Tab 5 mg

**IODINE**
- Soln BP 50 mg per ml

**LEVOTHYROXINE**
- Tab 25 mcg
- Tab 50 mcg
- Tab 100 mcg

**LIOTHYRONINE SODIUM**
- Tab 20 mcg
- **Restricted (RS1301)**

**Initiation**

For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy.

- Inj 20 mcg vial

**POTASSIUM IODATE**
- Tab 170 mg

**POTASSIUM PERCHLORATE**
- Cap 200 mg

**PROPYLTHIOURACIL – Restricted see terms below**
- Tab 50 mg ..........................................................35.00 100 PTU
- **Restricted (RS1276)**

**Initiation**

Both:

1. The patient has hyperthyroidism; and
2. The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.
Vasopressin Agents

ARGIPRESSIN [VASOPRESSIN]
   Inj 20 u per ml, 1 ml ampoule

DESMOPRESSIN ACETATE – Some items restricted see terms below
   ★ Tab 100 mcg....................................................................................................25.00 30 Minirin
   ★ Tab 200 mcg....................................................................................................54.45 30 Minirin
   Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020 ...........................................23.95 6 ml Desmopressin-PH&T
   Inj 4 mcg per ml, 1 ml ampoule
   Inj 15 mcg per ml, 1 ml ampoule
   Nasal drops 100 mcg per ml

   → Restricted (RS1339)

Initiation – Nocturnal enuresis
   Either:
   1 The nasal forms of desmopressin are contraindicated; or
   2 An enuresis alarm is contraindicated.

Note: Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated.

TERLIPRESSIN
  ../\ Tab 0.1 mg per ml, 8.5 ml ampoule .................................................................450.00 5 Glypressin
   Inj 1 mg per 8.5 ml ampoule ...........................................................................215.00 5 Glypressin
Antibacterials

Aminoglycosides

AMIKACIN – Restricted see terms below

- Inj 5 mg per ml, 10 ml syringe
- Inj 5 mg per ml, 5 ml syringe
- Inj 15 mg per ml, 5 ml syringe
- Inj 250 mg per ml, 2 ml vial – 1% DV Aug-18 to 2021

18.50 1 Biomed

- Restricted (RS1041)

Clinical microbiologist, infectious disease specialist or respiratory specialist

GENTAMICIN SULPHATE

- Inj 10 mg per ml, 1 ml ampoule
- Inj 40 mg per ml, 2 ml ampoule

25.00 5 DBL Gentamicin

17.50 10 Pfizer

PAROMOMYCIN – Restricted see terms below

- Cap 250 mg

126.00 16 Humatin

STREPTOMYCIN SULPHATE – Restricted see terms below

- Inj 400 mg per ml, 2.5 ml ampoule

STREPTOMYCIN SULPHATE – Restricted see terms below

TOBRAMYCIN

- Powder
- Inj 40 mg per ml, 2 ml vial – 1% DV Sep-18 to 2021

15.00 5 Tobramycin Mylan

- Restricted (RS1475)

Initiation
For addition to orthopaedic bone cement.

- Inj 100 mg per ml, 5 ml vial

TOBRAMYCIN

- Restricted (RS1044)

Clinical microbiologist, infectious disease specialist or respiratory specialist

- Restricted (RS1044)

Clinical microbiologist, infectious disease specialist or respiratory specialist

- Solution for inhalation 60 mg per ml, 5 ml

2,200.00 56 dose TOBI

- Restricted (RS1435)

Initiation
Patient has cystic fibrosis.

Carbapenems

ERTAPENEM – Restricted see terms below

- Inj 1 g vial – 1% DV Aug-19 to 2022

70.00 1 Invanz

- Restricted (RS1045)

Clinical microbiologist or infectious disease specialist

IMIPENEM WITH CILASTATIN – Restricted see terms below

- Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022

60.00 1 Imipenem+Cilastatin RBX

- Restricted (RS1046)

Clinical microbiologist or infectious disease specialist
## MEROPENEM – Restricted see terms below

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg vial – 1% DV Oct-18 to 2020</td>
<td>$4.00 1</td>
<td>Meropenem Ranbaxy</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Oct-18 to 2020</td>
<td>$8.00 1</td>
<td>Meropenem Ranbaxy</td>
</tr>
</tbody>
</table>

Clinical microbiologist or infectious disease specialist

## Cephalosporins and Cephamycins - 1st Generation

### CEFALEXIN

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg – 1% DV Nov-19 to 2022</td>
<td>$3.33 20</td>
<td>Cephalexin ABM</td>
</tr>
<tr>
<td>Cap 500 mg</td>
<td>$3.95 20</td>
<td>Cephalexin ABM</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021</td>
<td>$8.75 100 ml</td>
<td>Cefalexin Sandoz</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021</td>
<td>$11.75 100 ml</td>
<td>Cefalexin Sandoz</td>
</tr>
</tbody>
</table>

### CEFAZOLIN

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>$3.39 5</td>
<td>AFT</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>$3.29 5</td>
<td>AFT</td>
</tr>
</tbody>
</table>

## Cephalosporins and Cephamycins - 2nd Generation

### CEFACLOR

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg – 1% DV Oct-19 to 2022</td>
<td>$24.70 100</td>
<td>Ranbaxy-Cefaclor</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-19 to 2022</td>
<td>$3.53 100 ml</td>
<td>Ranbaxy-Cefaclor</td>
</tr>
</tbody>
</table>

### CEFOTAXIME

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg vial</td>
<td>$1.90 1</td>
<td>Cefotaxime Sandoz</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>$14.60 10 DBL Cefotaxime</td>
<td></td>
</tr>
</tbody>
</table>

## Cephalosporins and Cephamycins - 3rd Generation

### CEFTRIAXONE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg vial</td>
<td>$0.89 1</td>
<td>Ceftriaxone-AFT</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>$1.20 5 DBEVA</td>
<td></td>
</tr>
<tr>
<td>Inj 1.5 g vial – 1% DV Feb-18 to 2020</td>
<td>$1.98 1 Ceftriaxone-AFT</td>
<td></td>
</tr>
</tbody>
</table>

(DEV As Inj 500 mg vial to be delisted 1 January 2020)

(DEV As Inj 1 g vial to be delisted 1 January 2020)

## Cephalosporins and Cephamycins - 4th Generation

### CEFEPIME – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 g vial – 1% DV Sep-18 to 2021</td>
<td>$3.75 1</td>
<td>Cefepime-AFT</td>
</tr>
<tr>
<td>Inj 2 g vial – 1% DV Sep-18 to 2021</td>
<td>$5.69 1</td>
<td>Cefepime-AFT</td>
</tr>
</tbody>
</table>
INFECTIONS

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. excl. GST) $ Per</td>
<td></td>
</tr>
</tbody>
</table>

- **Restricted (RS1049)**
  Clinical microbiologist or infectious disease specialist

**Cephalosporins and Cephamycins - 5th Generation**

**CEFTAROLINE FOSAMIL** – **Restricted** see terms below

- Inj 600 mg vial ................................................................. 1,450.00 10 Zinforo

- **Restricted (RS1446)**
  Clinical microbiologist or infectious disease specialist
  
  **Initiation – multi-resistant organism salvage therapy**

  Either:
  
  1. for patients where alternative therapies have failed; or
  2. for patients who have a contraindication or hypersensitivity to standard current therapies.

**Macrolides**

**AZITHROMYCIN** – **Restricted** see terms below

- Tab 250 mg – 1% DV Sep-18 to 2021 ............................................................. 8.19 30 Apo-Azithromycin
- Tab 500 mg – 1% DV Sep-18 to 2021 ............................................................. 0.93 2 Apo-Azithromycin
- Grans for oral liq 200 mg per 5 ml (40 mg per ml) – 1% DV Dec-18 to 2021 ..................................................................................................... 14.38 15 ml Zithromax

- **Restricted (RS1598)**
  Clinical microbiologist or infectious disease specialist
  
  **Initiation – bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections**

  Any of the following:

  1. Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
  2. Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
  3. Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms*; or
  4. Patient has an atypical Mycobacterium infection.

  Note: Indications marked with * are unapproved indications

- **Initiation – non-cystic fibrosis bronchiectasis**
  Respiratory specialist or paediatrician
  
  **Re-assessment required after 12 months**

  All of the following:

  1. For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
  2. Patient is aged 18 and under; and
  3. Either:
     
     3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
     3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

  Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

- **Continuation – non-cystic fibrosis bronchiectasis**
  Respiratory specialist or paediatrician
  
  **Re-assessment required after 12 months**

  All of the following:

  1. The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
  2. Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic...
continued...

- fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- The patient will not receive more than a total of 24 months’ azithromycin cumulative treatment (see note).

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Initiation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**Continuation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**CLARITHROMYCIN – Restricted** see terms below

- Tab 250 mg – 1% DV Sep-17 to 2020 ......................................................... 3.98 14 Apo-Clarithromycin
- Tab 500 mg – 1% DV Sep-17 to 2020 ......................................................... 10.40 14 Apo-Clarithromycin
- Grans for oral liq 50 mg per ml ............................................................... 192.00 50 ml Klacid
- Inj 500 mg vial – 1% DV Dec-17 to 31 Aug 2020 ...................................... 12.04 1 Martindale

*Restricted (RS1476)*

**Initiation – Tab 250 mg and oral liquid**

Either:

1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.

**Initiation – Tab 500 mg**

Helicobacter pylori eradication.

**Initiation – Infusion**

Any of the following:

1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or

**ERYTHROMYCIN (AS EThYLSUCCINATE)**

| Tab 400 mg ................................................................. 16.95 100 E-Mycin |
| Grans for oral liq 200 mg per 5 ml ........................................ 5.00 100 ml E-Mycin |
| Grans for oral liq 400 mg per 5 ml ........................................ 6.77 100 ml E-Mycin |

**ERYTHROMYCIN (AS LACTOBIIONATE)**

| Inj 1 g vial – 1% DV Dec-19 to 2022 ............................................ 10.00 1 Erythrocinc IV |

**ERYTHROMYCIN (AS STEARATE) – Restricted**: For continuation only

- Tab 250 mg
- Tab 500 mg

**ROXITHROMYCIN – Some items restricted** see terms below

- Tab dispersible 50 mg ................................................................. 8.29 10 Rulide D
- Tab 150 mg – 1% DV Sep-19 to 2022 ........................................ 8.28 50 Arrow-Roxithromycin
- Tab 300 mg – 1% DV Sep-19 to 2022 ........................................ 16.33 50 Arrow-Roxithromycin

*Restricted (RS1569)*

**Initiation**

Only for use in patients under 12 years of age.
## INFECTIONS

<table>
<thead>
<tr>
<th>Penicillins</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMOXICILLIN</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg.....................................................................................................</td>
<td>14.97</td>
<td>500 Apo-Amoxi</td>
</tr>
<tr>
<td>Cap 500 mg.....................................................................................................</td>
<td>16.75</td>
<td>500 Apo-Amoxi</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – 1% DV Feb-18 to 2020.............................</td>
<td>1.20</td>
<td>100 ml Alphamox 125</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml – 1% DV Feb-18 to 2020.............................</td>
<td>1.31</td>
<td>100 ml Alphamox 250</td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-17 to 2020.......................................................</td>
<td>10.67</td>
<td>10 Ibiamox</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020.......................................................</td>
<td>12.41</td>
<td>10 Ibiamox</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020.........................................................</td>
<td>17.29</td>
<td>10 Ibiamox</td>
</tr>
<tr>
<td><strong>AMOXICILLIN WITH CLAVULANIC ACID</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg with clavulanic acid 125 mg – 1% DV Oct-17 to 2020.......................</td>
<td>1.88</td>
<td>20 Augmentin</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml........................</td>
<td>3.83</td>
<td>100 ml Augmentin</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml........................</td>
<td>2.20</td>
<td>100 ml Curam</td>
</tr>
<tr>
<td>Inj 500 mg with clavulanic acid 100 mg vial..............................................</td>
<td>28.18</td>
<td>10 m-Amoxiclav</td>
</tr>
<tr>
<td>Inj 1,000 mg with clavulanic acid 200 mg vial..........................................</td>
<td>43.30</td>
<td>10 m-Amoxiclav</td>
</tr>
<tr>
<td><strong>BENZATHINE BENZYLPCENICILLIN</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Dec-18 to 2021.........</td>
<td>344.93</td>
<td>10 Bicillin LA</td>
</tr>
<tr>
<td><strong>BENZYLPCENICILLIN SODIUM [PENCILLIN G]</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Inj 600 mg (1 million units) vial – 1% DV Sep-17 to 2020..................................</td>
<td>10.35</td>
<td>10 Sandoz</td>
</tr>
<tr>
<td></td>
<td>103.50</td>
<td>100 Sandoz</td>
</tr>
<tr>
<td><strong>FLUCLOXACILLIN</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Sep-18 to 2021................................................................</td>
<td>16.83</td>
<td>250 Staphlex</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Sep-18 to 2021................................................................</td>
<td>56.61</td>
<td>500 Staphlex</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021.............................</td>
<td>2.29</td>
<td>100 ml AFT</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021.............................</td>
<td>3.68</td>
<td>100 ml AFT</td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-17 to 2020.......................................................</td>
<td>9.00</td>
<td>10 Flucloxin</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020.......................................................</td>
<td>9.40</td>
<td>10 Flucloxin</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020.........................................................</td>
<td>5.22</td>
<td>5 Flucil</td>
</tr>
<tr>
<td><strong>PHENOXYMETHYLPENICILLIN [PENCILLIN V]</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Sep-18 to 2021................................................................</td>
<td>2.59</td>
<td>50 Cilicaine VK</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Sep-18 to 2021................................................................</td>
<td>4.26</td>
<td>50 Cilicaine VK</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml..............................................................</td>
<td>1.48</td>
<td>100 ml AFT</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml..............................................................</td>
<td>1.58</td>
<td>100 ml AFT</td>
</tr>
<tr>
<td><strong>PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>↓ Inj 4 g with tazobactam 0.5 g vial...............................................................</td>
<td>38.00</td>
<td>10 PipTaz Sandoz</td>
</tr>
<tr>
<td>➨ Restricted (RS1053)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROCANE PENICILLIN</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-17 to 2020 ..................................</td>
<td>123.50</td>
<td>5 Cilicaine</td>
</tr>
<tr>
<td><strong>TICARCLILLIN WITH CLAVULANIC ACID – Restricted see terms below</strong></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>↓ Inj 3 g with clavulanic acid 0.1 mg vial...................................................</td>
<td></td>
<td></td>
</tr>
<tr>
<td>➨ Restricted (RS1054)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Item restricted (see ➨ above); Item restricted (see ↓ below)

e.g. Brand indicates brand example only. It is not a contracted product.
### Quinolones

<table>
<thead>
<tr>
<th>Product</th>
<th>Price Per Unit</th>
<th>Expiry Date</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CIPROFLOXACIN</strong> – Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg – 1% DV Sep-17 to 2020</td>
<td>1.45</td>
<td>28</td>
<td>Cipflox</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Sep-17 to 2020</td>
<td>1.99</td>
<td>28</td>
<td>Cipflox</td>
</tr>
<tr>
<td>Tab 750 mg – 1% DV Sep-17 to 2020</td>
<td>3.15</td>
<td>28</td>
<td>Cipflox</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021</td>
<td>68.20</td>
<td>10</td>
<td>Cipflox</td>
</tr>
</tbody>
</table>

**MOXIFLOXACIN** – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price Per Unit</th>
<th>Expiry Date</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg</td>
<td>52.00</td>
<td>5</td>
<td>Avelox</td>
</tr>
<tr>
<td>Inj 1.6 mg per ml, 250 ml bottle</td>
<td>70.00</td>
<td>1</td>
<td>Avelox IV 400</td>
</tr>
</tbody>
</table>

**NORFLOXACIN**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price Per Unit</th>
<th>Expiry Date</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg</td>
<td>135.00</td>
<td>100</td>
<td>Arrow-Norfloxacin</td>
</tr>
</tbody>
</table>

**Initiation – Mycobacterium infection**

Infectious disease specialist, clinical microbiologist or respiratory specialist

Any of the following:

1. Both:
   1.1 Active tuberculosis; and
   1.2 Any of the following:
      1.2.1 Documented resistance to one or more first-line medications; or
      1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
      1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
      1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
      1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
2. Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or
3. Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

**Initiation – Pneumonia**

Infectious disease specialist or clinical microbiologist

Either:

1. Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
2. Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

**Initiation – Penetrating eye injury**

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury.

**Initiation – Mycoplasma genitalium**

All of the following:

1. Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and
2. Either:
   2.1 Has tried and failed to clear infection using azithromycin; or
   2.2 Has laboratory confirmed azithromycin resistance; and
3. Treatment is only for 7 days.
### Tetracyclines

**DEMECLOCYLINE HYDROCHLORIDE**
- Tab 150 mg
- Cap 150 mg
- Cap 300 mg

**DOXYCYCLINE**
- Tab 50 mg – **Restricted**: For continuation only
  - Tab 100 mg
    - Inj 5 mg per ml, 20 ml vial
    - Price: $64.43
- **Doxine**

**MINOCYCLINE**
- Tab 50 mg
- Cap 100 mg – **Restricted**: For continuation only

**TETRACYCLINE**
- Tab 250 mg
- Cap 500 mg
  - Price: $46.00
- **Tetracyclin Wolff**

**TIGECYCLINE** – **Restricted** see terms below
- Inj 50 mg vial
- **Restricted** (RS1059)
- Clinical microbiologist or infectious disease specialist

### Other Antibacterials

**AZTREONAM** – **Restricted** see terms below
- Inj 1 g vial
  - Price: $182.46
- **Azactam**

**CHLORAMPHENICOL** – **Restricted** see terms below
- Inj 1 g vial
- **Restricted** (RS1277)
- Clinical microbiologist or infectious disease specialist

**CLINDAMYCIN** – **Restricted** see terms below
- Cap 150 mg
  - Price: $4.10
- **Clindamycin ABM**
- Oral liq 15 mg per ml
- Inj 150 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022
  - Price: $39.00
- **Dalacin C**
- **Restricted** (RS1061)
- Clinical microbiologist or infectious disease specialist

**COLISTIN SULPHOMETHATE [COLESTIMETHATE]** – **Restricted** see terms below
- Inj 150 mg per ml, 1 ml vial
  - Price: $65.00
- **Colistin-Link**
- **Restricted** (RS1062)
- Clinical microbiologist, infectious disease specialist or respiratory specialist

**DAPTOMYCIN** – **Restricted** see terms below
- Inj 350 mg vial
  - Price: $175.16
- **Cubicin**
- Inj 500 mg vial
  - Price: $243.52
- **Cubicin**
- **Restricted** (RS1063)
- Clinical microbiologist or infectious disease specialist

**FOSFOMYCIN** – **Restricted** see terms on the next page
- Powder for oral solution, 3 g sachet
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

### INFECTIONS

**Restricted (RS1315)**
Clinical microbiologist or infectious disease specialist

**HEXAMINE HIPPURATE**
Tab 1 g

**Lincomycin – Restricted** see terms below
- Inj 300 mg per ml, 2 ml vial

**Restricted (RS1065)**
Clinical microbiologist or infectious disease specialist

**Linezolid – Restricted** see terms below
- Tab 600 mg – 1% DV Oct-18 to 2021.................................553.77 10 Zyvox
- Oral liq 20 mg per ml – 1% DV Dec-18 to 2021...........................1,879.00 150 ml Zyvox
- Inj 2 mg per ml, 300 ml bottle – 1% DV Feb-19 to 2021........................18.50 1 Linezolid Kabi

**Restricted (RS1066)**
Clinical microbiologist or infectious disease specialist

**Nitrofurantoin**
- Tab 50 mg – 1% DV Apr-19 to 2021.................................22.20 100 Nifuran
- Tab 100 mg – 1% DV Apr-19 to 2021.................................37.50 100 Nifuran

**Pivmecillinam – Restricted** see terms below
- Tab 200 mg

**Restricted (RS1322)**
Clinical microbiologist or infectious disease specialist

**Sodium fusidate [fusidic acid] – Restricted** see terms below
- Tab 250 mg – 1% DV Jun-17 to 2020.................................34.50 12 Fucidin

**Restricted (RS1064)**
Clinical microbiologist or infectious disease specialist

**Sulphadiazine – Restricted** see terms below
- Tab 500 mg

**Restricted (RS1067)**
Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist

**Teicoplanin – Restricted** see terms below
- Inj 400 mg vial

**Restricted (RS1068)**
Clinical microbiologist or infectious disease specialist

**Trimethoprim**
- Tab 100 mg
- Tab 300 mg – 1% DV Oct-18 to 2021.................................16.50 50 TMP

**Trimethoprim with sulphamethoxazole [co-trimoxazole]**
- Tab 80 mg with sulphamethoxazole 400 mg
  - Oral liq 8 mg with sulphamethoxazole 40 mg per ml – 1% DV Oct-17 to 2020.................................2.97 100 ml Deprim
  - Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule

**Vancomycin – Restricted** see terms below
- Inj 500 mg vial – 1% DV Sep-17 to 2020.................................2.37 1 Mylan

**Restricted (RS1069)**
Clinical microbiologist or infectious disease specialist

*Products with Hospital Supply Status (HSS) are in bold*

*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
## INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

### Antifungals

#### Imidazoles

**KETOCONAZOLE**
- Tab 200 mg
- **Restricted (RS1410)**

Oncologist

#### Polyene Antimycotics

**AMPHOTERICIN B**
- Inj (liposomal) 50 mg vial.................................3,450.00 10 AmBisome
- **Restricted (RS1071)**

Initiation
Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:
1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   2.1 Possible invasive fungal infection; and
   2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

**NYSTATIN**
- Tab 500,000 u ..........................................................17.09 50 Nilstat
- Cap 500,000 u ..........................................................15.47 50 Nilstat

#### Triazoles

**FLUCONAZOLE – Restricted see terms below**
- Cap 50 mg – 1% DV Feb-18 to 2020..........................2.09 28 Mylan
- Cap 150 mg – 1% DV Feb-18 to 2020........................0.33 1 Mylan
- Cap 200 mg – 1% DV Feb-18 to 2020........................5.08 28 Mylan
- Oral liquid 50 mg per 5 ml ........................................98.50 35 ml Diflucan
- Inj 2 mg per ml, 50 ml vial – 1% DV Oct-19 to 2022 ....2.80 1 Fluconazole-Claris
- Inj 2 mg per ml, 100 ml vial – 1% DV Oct-19 to 2022 ....3.45 1 Fluconazole-Claris
- **Restricted (RS1072)**

Consultant

**ITRACONAZOLE – Restricted see terms below**
- Cap 100 mg – 1% DV Nov-19 to 2022..........................4.27 15 Itrazole
- Oral liquid 10 mg per ml
- **Restricted (RS1073)**

Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist

**POSACONAZOLE – Restricted see terms on the next page**
- Tab modified-release 100 mg ..................................869.86 24 Noxafil
- Oral liq 40 mg per ml .................................................761.13 105 ml Noxafil

### Item restricted (see ➥ above); Item restricted (see ➥ below)

*e.g. Brand* indicates brand example only. It is not a contracted product.
-> Restricted (RS1074)

Initiation
Haematologist or infectious disease specialist
Re-assessment required after 6 weeks
Both:

1. Either:
   1.1 Patient has acute myeloid leukaemia; or
   1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and

2. Patient is to be treated with high dose remission induction therapy or re-induction therapy.

Continuation
Haematologist or infectious disease specialist
Re-assessment required after 6 weeks
Both:

1. Patient has previously received posaconazole prophylaxis during remission induction therapy; and

2. Any of the following:
   2.1 Patient is to be treated with high dose remission re-induction therapy; or
   2.2 Patient is to be treated with high dose consolidation therapy; or
   2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE – Restricted see terms below

- Tab 50 mg – 1% DV Sep-18 to 2021......................................................... 91.00 56  Vttack
- Tab 200 mg – 1% DV Sep-18 to 2021..................................................... 350.00 56  Vttack
- Powder for oral suspension 40 mg per ml – 1% DV Dec-18 to 2021........1,437.00 70 ml Vfend
- Inj 200 mg vial – 1% DV Oct-19 to 2022.................................................. 44.00 1  Neo Health

-> Restricted (RS1075)

Initiation – Proven or probable aspergillus infection
Clinical microbiologist, haematologist or infectious disease specialist
Both:

1. Patient is immunocompromised; and

2. Patient has proven or probable invasive aspergillus infection.

Initiation – Possible aspergillus infection
Clinical microbiologist, haematologist or infectious disease specialist
All of the following:

1. Patient is immunocompromised; and

2. Patient has possible invasive aspergillus infection; and

3. A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

Initiation – Resistant candidiasis infections and other moulds
Clinical microbiologist, haematologist or infectious disease specialist
All of the following:

1. Patient is immunocompromised; and

2. Either:
   2.1 Patient has fluconazole resistant candidiasis; or
   2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp.; and

3. A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.
## Other Antifungals

<table>
<thead>
<tr>
<th>CASPOFUNGIN – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Inj 50 mg vial – 1% DV Dec-19 to 2022 .......................................................... 667.50</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>✔️ Inj 70 mg vial – 1% DV Dec-19 to 2022 .......................................................... 862.50</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

(Cancidas Inj 50 mg vial to be delisted 1 December 2019)
(Cancidas Inj 70 mg vial to be delisted 1 December 2019)

→ Restricted (RS1076)

**Initiation**

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:

1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   1. Possible invasive fungal infection; and
   2. A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

<table>
<thead>
<tr>
<th>FLUCYTOSINE – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Cap 500 mg</td>
</tr>
<tr>
<td>→ Restricted (RS1279)</td>
</tr>
</tbody>
</table>

Clinical microbiologist or infectious disease specialist

<table>
<thead>
<tr>
<th>TERBINAFINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg – 1% DV Jan-18 to 2020 .......................................................... 1.33</td>
</tr>
</tbody>
</table>

## Antimycobacterials

### Antileprotics

<table>
<thead>
<tr>
<th>CLOFAZIMINE – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Cap 50 mg</td>
</tr>
<tr>
<td>→ Restricted (RS1077)</td>
</tr>
</tbody>
</table>

Clinical microbiologist, dermatologist or infectious disease specialist

<table>
<thead>
<tr>
<th>DAPSONE – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Tab 25 mg .......................................................... 268.50</td>
</tr>
<tr>
<td>✔️ Tab 100 mg .......................................................... 329.50</td>
</tr>
<tr>
<td>→ Restricted (RS1078)</td>
</tr>
</tbody>
</table>

Clinical microbiologist, dermatologist or infectious disease specialist

## Antituberculotics

<table>
<thead>
<tr>
<th>CYCLOSERINE – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Cap 250 mg</td>
</tr>
<tr>
<td>→ Restricted (RS1079)</td>
</tr>
</tbody>
</table>

Clinical microbiologist, infectious disease specialist or respiratory specialist

<table>
<thead>
<tr>
<th>ETHAMBUTOL HYDROCHLORIDE – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ Tab 100 mg</td>
</tr>
<tr>
<td>✔️ Tab 400 mg .......................................................... 49.34</td>
</tr>
<tr>
<td>→ Restricted (RS1080)</td>
</tr>
</tbody>
</table>

Clinical microbiologist, infectious disease specialist or respiratory specialist
### INFECTIONS

<table>
<thead>
<tr>
<th>Products with Hospital Supply Status (HSS) are in <strong>bold</strong></th>
<th>Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Status</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ISONIAZID – Restricted</strong> see terms below</td>
<td></td>
<td>Tab 100 mg – 1% DV Oct-18 to 2021</td>
<td>22.00</td>
<td>PSM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1281)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ISONIAZID WITH RIFAMPICIN – Restricted</strong> see terms below</td>
<td></td>
<td>Tab 100 mg with rifampicin 150 mg – 1% DV Sep-18 to 2021</td>
<td>85.54</td>
<td>Rifinah</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tab 150 mg with rifampicin 300 mg – 1% DV Sep-18 to 2021</td>
<td>170.60</td>
<td>Rifinah</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1282)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PARA-AMINOSALICYLIC ACID – Restricted</strong> see terms below</td>
<td></td>
<td>Gran for oral liq 4 g</td>
<td>280.00</td>
<td>Paser</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1083)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROTIONAMIDE – Restricted</strong> see terms below</td>
<td></td>
<td>Tab 250 mg</td>
<td>305.00</td>
<td>Peteha</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1084)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PYRAZINAMIDE – Restricted</strong> see terms below</td>
<td></td>
<td>Tab 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1085)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RIFABUTIN – Restricted</strong> see terms below</td>
<td></td>
<td>Cap 150 mg</td>
<td>275.00</td>
<td>Mycobutin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1086)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RIFAMPICIN – Restricted</strong> see terms below</td>
<td></td>
<td>Cap 150 mg – 1% DV Sep-17 to 2020</td>
<td>55.75</td>
<td>Rifadin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cap 300 mg – 1% DV Sep-17 to 2020</td>
<td>116.25</td>
<td>Rifadin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral liq 100 mg per 5 ml – 1% DV Sep-17 to 2020</td>
<td>12.00</td>
<td>Rifadin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 600 mg vial – 1% DV Sep-17 to 2020</td>
<td>128.85</td>
<td>Rifadin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1087)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antiparasitics

### Anthelmintics

<table>
<thead>
<tr>
<th>Name</th>
<th>Status</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALBENDAZOLE – Restricted</strong> see terms below</td>
<td></td>
<td>Tab 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tab 400 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1088)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IVERMECTIN – Restricted</strong> see terms below</td>
<td></td>
<td>Tab 3 mg</td>
<td>17.20</td>
<td>Stromectol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>→ Restricted (RS1283)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical microbiologist, dermatologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MEBENDAZOLE</strong></td>
<td></td>
<td>Tab 100 mg</td>
<td>24.19</td>
<td>De-Worm</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral liq 100 mg per 5 ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

PRAZIQUANTEL
Tab 600 mg

Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE – Restricted see terms below

- Tab 20 mg with lumefantrine 120 mg
  - Restricted (RS1090)
  Clinical microbiologist or infectious disease specialist

ARTESUNATE – Restricted see terms below

- Inj 60 mg vial
  - Restricted (RS1091)
  Clinical microbiologist or infectious disease specialist

ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – Restricted see terms below

- Tab 62.5 mg with proguanil hydrochloride 25 mg
  - Restricted (RS1092)
  Clinical microbiologist or infectious disease specialist

CHLOROQUINE PHOSPHATE – Restricted see terms below

- Tab 250 mg
  - Restricted (RS1093)
  Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist

MEFLOQUINE – Restricted see terms below

- Tab 250 mg
  - Restricted (RS1094)
  Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist

METRONIDAZOLE

- Tab 200 mg
  - 10.45 100 Trichozole
- Tab 400 mg
  - 18.15 100 Trichozole
- Oral liq benzoate 200 mg per 5 ml
  - 25.00 100 ml Flagyl-S
- Inj 5 mg per ml, 100 ml bottle
  - 1.39 100 ml AFT
- Inj 5 mg per ml, 100 ml bag
  - 264.00 48 Baxter
- Suppos 500 mg
  - 24.48 10 Flagyl

NITAZOXANIDE – Restricted see terms below

- Tab 500 mg
  - 1,680.00 30 Alinia
- Oral liq 100 mg per 5 ml
  - Restricted (RS1095)
  Clinical microbiologist or infectious disease specialist

ORNIDAZOLE

- Tab 500 mg
  - 23.00 10 Arrow-Ornidazole

PENTAMIDINE ISETHIONATE – Restricted see terms below

- Inj 300 mg vial
  - 1% DV Nov-19 to 2022
  - 216.00 5 Pentacarinat
  - Restricted (RS1096)
  Clinical microbiologist or infectious disease specialist

PRIMAQUINE PHOSPHATE – Restricted see terms below

- Tab 7.5 mg
  - Restricted (RS1097)
  Clinical microbiologist or infectious disease specialist
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

PYRIMETHAMINE – Restricted see terms below
- Tab 25 mg
  - Restricted (RS1098)
  Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist

QUININE DIHYDROCHLORIDE – Restricted see terms below
- Inj 60 mg per ml, 10 ml ampoule
- Inj 300 mg per ml, 2 ml vial
  - Restricted (RS1099)
  Clinical microbiologist or infectious disease specialist

QUININE SULPHATE
- Tab 300 mg

SODIUM STIBOGLUCONATE – Restricted see terms below
- Inj 100 mg per ml, 1 ml vial
  - Restricted (RS1100)
  Clinical microbiologist or infectious disease specialist

SPIRAMYCIN – Restricted see terms below
- Tab 500 mg
  - Restricted (RS1101)
  Maternal-foetal medicine specialist

Antiretrovirals

Non-Nucleoside Reverse Transcriptase Inhibitors

- Restricted (RS1571)

Initiation – Confirmed HIV
Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission
Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – Restricted see terms above
- Tab 50 mg
- Tab 200 mg
- Tab 600 mg
- Oral liq 30 mg per ml
  (Stocrin Tab 50 mg to be delisted 1 December 2019)

ETRAVIRINE – Restricted see terms above
- Tab 200 mg

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Nucleoside Reverse Transcriptase Inhibitors

**NEVIRAPINE** – **Restricted** see terms on the previous page

- Tab 200 mg – 1% DV Sep-18 to 2021 ................................................................. 60.00 60 Nevirapine Alphapharm
- Oral suspension 10 mg per ml ................................................................. 203.55 240 ml Viramune Suspension

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**
Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**
Patient has percutaneous exposure to blood known to be HIV positive.

**ABACAVIR SULPHATE** – **Restricted** see terms above

- Tab 300 mg – 1% DV Jul-19 to 2022 ................................................................. 180.00 60 Ziagen
- Oral liq 20 mg per ml ......................................................................... 256.31 240 ml Ziagen

**ABACAVIR SULPHATE WITH LAMIVUDINE** – **Restricted** see terms above

- Tab 600 mg with lamivudine 300 mg – 1% DV Jul-19 to 2022 ..................... 63.00 30 Kivexa

**EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL** – **Restricted** see terms above

- Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – 1% DV Jun-19 to 2022 ............................................ 106.88 30 Mylan

**EMTRICITABINE** – **Restricted** see terms above

- Cap 200 mg – 1% DV Jul-19 to 2022 ................................................................. 307.20 30 Emtriva

**LAMIVUDINE** – **Restricted** see terms above

- Oral liq 10 mg per ml

**STAVUDINE** – **Restricted** see terms above

- Cap 30 mg
- Cap 40 mg
- Powder for oral soln 1 mg per ml

**ZIDOVUDINE [AZT]** – **Restricted** see terms above

- Cap 100 mg .................................................................................. 152.25 100 Retrovir
- Oral liq 10 mg per ml ........................................................................ 30.45 200 ml Retrovir
- Inj 10 mg per ml, 20 ml vial ................................................................. 750.00 5 Retrovir IV

**ZIDOVUDINE [AZT] WITH LAMIVUDINE** – **Restricted** see terms above

- Tab 300 mg with lamivudine 150 mg – 1% DV Sep-17 to 2020 .................... 33.00 60 Alphapharm
Protease Inhibitors

**Restricted (RS1573)**

**Initiation – Confirmed HIV**

Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

**ATAZANAVIR SULPHATE** – Restricted see terms above

- Cap 150 mg – 1% DV Jun-19 to 2022 .........................................................141.68  60  Teva
- Cap 200 mg – 1% DV Jun-19 to 2022 .........................................................188.91  60  Teva

**DARUNAVIR** – Restricted see terms above

- Tab 400 mg – 1% DV Jun-17 to 2020 .........................................................335.00  60  Prezista
- Tab 600 mg – 1% DV Jun-17 to 2020 .........................................................476.00  60  Prezista

**INDINAVIR** – Restricted see terms above

- Cap 200 mg
- Cap 400 mg

**LOPINAVIR WITH RITONAVIR** – Restricted see terms above

- Tab 100 mg with ritonavir 25 mg ............................................................183.75  60  Kaletra
- Tab 200 mg with ritonavir 50 mg – 1% DV Sep-17 to 2020 .........................463.00  120  Kaletra
- Oral liq 80 mg with ritonavir 20 mg per ml ...................................................735.00  300 ml Kaletra

**RITONAVIR** – Restricted see terms above

- Tab 100 mg – 1% DV Jul-19 to 2022 .........................................................43.31  30  Norvir

Strand Transfer Inhibitors

**Restricted (RS1574)**

**Initiation – Confirmed HIV**

Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

continued…

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## INFECTIONS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Price (ex man. excl. GST $)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antivirals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADEFOVIR DIPIVOXIL – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg ..........................................................670.00 30 Hepsera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1104)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antivirals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENTECAVIR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 0.5 mg – 1% DV Nov-18 to 2021 ..................................................52.00 30 Entecavir Sandoz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAMIVUDINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Aug-18 to 2020 ..................................................4.20 28 Zetlam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 5 mg per ml .................270.00 240 ml Zeffix</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TENOFOVIR DISOPROXIL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 245 mg (300.6 mg as a succinate) – 1% DV Sep-18 to 2021 .................38.10 30 Tenofovir Disoproxil Teva</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Treatment course to be initiated within 72 hours post exposure; and
2 Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

DOLUTEGRAVIR – Restricted see terms on the previous page

- Tab 50 mg ..........................................................1,090.00 30 Tivicay

RALTEGRAVIR POTASSIUM – Restricted see terms on the previous page

- Tab 400 mg ..........................................................1,090.00 60 Isentress
- Tab 600 mg ..........................................................1,090.00 60 Isentress HD

Antivirals

Hepatitis B

A) Documented resistance to lamivudine defined as:

1 Patient has confirmed Hepatitis B infection (HBsAg+); and
2 Patient has raised serum ALT (> 1 × ULN); and
3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load greater than or equal to 10-fold over nadir; and
4 Detection of M204I or M204V mutation; and
5 Either:
   5.1 Both:
       5.1.1 Patient is cirrhotic; and
       5.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or
   5.2 Both:
       5.2.1 Patient is not cirrhotic; and
       5.2.2 Adefovir dipivoxil to be used as monotherapy.

ENTECAVIR
Tab 0.5 mg – 1% DV Nov-18 to 2021 ..................................................52.00 30 Entecavir Sandoz

LAMIVUDINE
Tab 100 mg – 1% DV Aug-18 to 2020 ..................................................4.20 28 Zetlam
Oral liq 5 mg per ml ..................................................270.00 240 ml Zeffix

TENOFOVIR DISOPROXIL
Tab 245 mg (300.6 mg as a succinate) – 1% DV Sep-18 to 2021 .................38.10 30 Tenofovir Disoproxil Teva

* Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)
e.g. Brand indicates brand example only. It is not a contracted product.
## Hepatitis C

**GILECAPREVIR WITH PIBRENTASVIR**

Note: the supply of treatment is via PHARMAC’s approved direct distribution supply. Further details can be found on PHARMAC’s website [https://www.pharmac.govt.nz/hepatitis-c-treatments/](https://www.pharmac.govt.nz/hepatitis-c-treatments/).

- Tab 100 mg with pibrentasvir 40 mg .......................................................... 24,750.00 84 Maviret

**LEDIPASVIR WITH SOFOSBUVIR** – **Restricted** see terms below

- Tab 90 mg with sofosbuvir 400 mg .......................................................... 24,363.46 28 Harvoni

**Initiation**

Note: Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).

### Herpesviridae

**ACICLOVIR**

- Tab dispersible 200 mg – 1% DV Oct-19 to 2022 ............................................. 1.60 25 Lovir
- Tab dispersible 400 mg – 1% DV Oct-19 to 2022 ........................................... 5.38 56 Lovir
- Tab dispersible 800 mg – 1% DV Oct-19 to 2022 ........................................... 5.98 35 Lovir
- Inj 250 mg vial – 1% DV Sep-18 to 2021 ......................................................... 9.60 5 Aciclovir-Claris

**CIDOFOVIR** – **Restricted** see terms below

- Inj 75 mg per ml, 5 ml vial

**FOSCARNET SODIUM** – **Restricted** see terms below

- Inj 24 mg per ml, 250 ml bottle

**GANCICLOVIR** – **Restricted** see terms below

- Inj 500 mg vial .......................................................... 380.00 5 Cymevene

**VALACICLOVIR**

- Tab 500 mg – 1% DV Sep-18 to 2021 .......................................................... 5.75 30 Vaclovir
- Tab 1,000 mg – 1% DV Sep-18 to 2021 ....................................................... 11.35 30 Vaclovir

**VALGANCICLOVIR** – **Restricted** see terms below

- Tab 450 mg – 1% DV May-19 to 2021 ......................................................... 225.00 60 Valganciclovir Mylan

**Initiation – Transplant cytomegalovirus prophylaxis**

*Limited to 3 months* treatment

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

**Initiation – Lung transplant cytomegalovirus prophylaxis**

*Limited to 6 months* treatment

Both:

1. Patient has undergone a lung transplant; and
2. Either:

continued…
Initiation – Cytomegalovirus in immunocompromised patients
Both:
1 Patient is immunocompromised; and
2 Any of the following:
   2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
   2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
   2.3 Patient has cytomegalovirus retinitis.

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms below
Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)
– 1% DV Jun-19 to 2022 ................................................................. 61.15 30 Teva

Initiation – Confirmed HIV
Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission
Either:
1 Prevention of maternal foetal transmission; or
2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
1 Treatment course to be initiated within 72 hours post exposure; and
2 Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

Initiation – Pre-exposure prophylaxis
Re-assessment required after 3 months
Both:
1 Patient has tested HIV negative; and
2 Either:
   2.1 All of the following:
      2.1.1 Patient is male or transgender; and
      2.1.2 Patient has sex with men; and
      2.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      2.1.4 Any of the following:
         2.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
         2.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         2.1.4.3 Patient has used methamphetamine in the last three months; or
   2.2 All of the following:

continued…
Continuation – Pre-exposure prophylaxis

Re-assessment required after 3 months

All of the following:
1. Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis; and
2. Patient has undergone testing for HIV, syphilis, and a full STI screen in the previous two weeks; and
3. Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months; and
4. Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5. Patient has tested HIV negative; and
6. Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and
      6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      6.1.4 Any of the following:
         6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
         6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         6.1.4.3 Patient has used methamphetamine in the last three months; or
   6.2 All of the following:
      6.2.1 Patient has a regular partner who has HIV infection; and
      6.2.2 Partner is either not on treatment or has a detectable viral load; and
      6.2.3 Condoms have not been consistently used.

Influenza

OSELTAMIVIR – Restricted see terms below

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Tab 75 mg
- Powder for oral suspension 6 mg per ml

Initiation

Either:
1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.
ZANAMIVIR

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Powder for inhalation 5 mg..............................................................37.38 20 dose Relenza Rotadisk

**Initiation**

Either:

1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

---

**Immune Modulators**

**INTERFERON ALFA-2A**

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

**INTERFERON ALFA-2B**

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

**INTERFERON GAMMA** – **Restricted** see terms below

- Inj 100 mcg in 0.5 ml vial

**PEGYLATED INTERFERON ALFA-2A** – **Restricted** see terms below

- Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020................................500.00 4 Pegasys

---

**Notes:**

Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

**Continuation – Chronic hepatitis C - genotype 1 infection**

Gastroenterologist, infectious disease specialist or general physician

*Re-assessment required after 48 weeks*

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Either:
   3.1 Patient has responder relapsed; or
continued...

3.2 Patient was a partial responder; and
4 Patient is to be treated in combination with boceprevir.

**Initiation – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

1 Patient has chronic hepatitis C, genotype 1; and
2 Patient has had previous treatment with pegylated interferon and ribavirin; and
3 Any of the following:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; or
   3.3 Patient received interferon treatment prior to 2004; and
4 Patient is to be treated in combination with boceprevir.

**Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV**

*Limited to 6 months treatment*

Patient has chronic hepatitis C, genotype 2 or 3 infection.

**Initiation – Hepatitis B**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
2 Patient is Hepatitis B treatment-naive; and
3 ALT > 2 times Upper Limit of Normal; and
4 HBV DNA < 10 log10 IU/ml; and
5 Either:
   5.1 HBeAg positive; or
   5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
6 Compensated liver disease; and
7 No continuing alcohol abuse or intravenous drug use; and
8 Not co-infected with HCV, HIV or HDV; and
9 Neither ALT nor AST > 10 times upper limit of normal; and
10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes: Approved dose is 180 mcg once weekly.
The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.
In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
Pegylated Interferon alfa-2a is not approved for use in children.
**MUSCULOSKELETAL SYSTEM**

### Anticholinesterases

<table>
<thead>
<tr>
<th>Name</th>
<th>Formulation</th>
<th>Price (Per Brand or Generic Manufacturer)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EDROPHONIUM CHLORIDE</strong> – Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="Image" alt="Inj 10 mg per ml, 15 ml vial" /></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="Image" alt="Inj 10 mg per ml, 1 ml ampoule" /></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>![Restricted (RS1015)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For the diagnosis of myasthenia gravis.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NEOSTIGMINE METILSULFATE</strong></td>
<td><img src="Image" alt="Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020" /></td>
<td>98.00</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td><strong>NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE</strong></td>
<td><img src="Image" alt="Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule" /></td>
<td>20.90</td>
<td>Max Health</td>
</tr>
<tr>
<td><strong>PYRIDOSTIGMINE BROMIDE</strong></td>
<td><img src="Image" alt="Tab 60 mg – 1% DV Nov-19 to 2022" /></td>
<td>45.79</td>
<td>Mestinon</td>
</tr>
</tbody>
</table>

### Antirheumatoid Agents

<table>
<thead>
<tr>
<th>Name</th>
<th>Formulation</th>
<th>Price (Per Brand or Generic Manufacturer)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HYDROXYCHLOROQUINE</strong></td>
<td><img src="Image" alt="Tab 200 mg – 1% DV Sep-18 to 2021" /></td>
<td>7.98</td>
<td>Plaquenil</td>
</tr>
<tr>
<td><strong>LEFLUNOMIDE</strong></td>
<td><img src="Image" alt="Tab 10 mg – 1% DV Jun-17 to 2020" /></td>
<td>2.90</td>
<td>Apo-Leflunomide</td>
</tr>
<tr>
<td><img src="Image" alt="Tab 20 mg – 1% DV Jun-17 to 2020" /></td>
<td></td>
<td></td>
<td>Apo-Leflunomide</td>
</tr>
<tr>
<td><strong>PENICILLAMINE</strong></td>
<td><img src="Image" alt="Tab 125 mg" /></td>
<td>67.23</td>
<td>D-Penamine</td>
</tr>
<tr>
<td><img src="Image" alt="Tab 250 mg" /></td>
<td></td>
<td></td>
<td>D-Penamine</td>
</tr>
<tr>
<td><strong>SODIUM AUROTHIOMALATE</strong></td>
<td><img src="Image" alt="Inj 10 mg in 0.5 ml ampoule" /></td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="Image" alt="Inj 20 mg in 0.5 ml ampoule" /></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="Image" alt="Inj 50 mg in 0.5 ml ampoule" /></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Drugs Affecting Bone Metabolism

#### Bisphosphonates

<table>
<thead>
<tr>
<th>Name</th>
<th>Formulation</th>
<th>Price (Per Brand or Generic Manufacturer)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALENDRONATE SODIUM</strong></td>
<td><img src="Image" alt="Tab 70 mg – 1% DV Apr-19 to 2022" /></td>
<td>2.44</td>
<td>Fosamax</td>
</tr>
<tr>
<td><strong>ALENDRONATE SODIUM WITH COLECALCIFEROL</strong></td>
<td><img src="Image" alt="Tab 70 mg with colecaciferol 5,600 lu – 1% DV Apr-19 to 2022" /></td>
<td>1.51</td>
<td>Fosamax Plus</td>
</tr>
<tr>
<td><strong>PAMIDRONATE DISODIUM</strong></td>
<td><img src="Image" alt="Inj 3 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020" /></td>
<td>5.98</td>
<td>Pamisol</td>
</tr>
<tr>
<td><img src="Image" alt="Inj 6 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020" /></td>
<td></td>
<td></td>
<td>Pamisol</td>
</tr>
<tr>
<td><img src="Image" alt="Inj 9 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020" /></td>
<td></td>
<td></td>
<td>Pamisol</td>
</tr>
<tr>
<td><strong>RISEDRONATE SODIUM</strong></td>
<td><img src="Image" alt="Tab 35 mg – 1% DV Oct-19 to 2022" /></td>
<td>3.10</td>
<td>Risedronate Sandoz</td>
</tr>
<tr>
<td><strong>ZOLEDRONIC ACID</strong></td>
<td><img src="Image" alt="Inj 5 mg per 100 ml, vial – 1% DV Oct-19 to 2022" /></td>
<td>60.00</td>
<td>Aclasta</td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
Restricted (RS1663)

Initiation – Inherited bone fragility disorders
Any specialist
Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

Initiation – Osteoporosis
Any specialist
Therapy limited to 3 doses
Both:

1. Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score greater than or equal to -3.0 (see Note); or
   1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initiation – glucocorticosteroid therapy
Any specialist
Re-assessment required after 12 months
All of the following:

1. The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2. Any of the following:
   2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

3. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – glucocorticosteroid therapy
Any specialist
Re-assessment required after 12 months
Both:

1. The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initiation – Paget’s disease
Any specialist
Re-assessment required after 12 months
All of the following:

1. Paget’s disease; and

continued...
continued...

2 Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications; or
   2.5 Preparation for orthopaedic surgery; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – Paget’s disease

Any specialist

Re-assessment required after 12 months

Both:

1 Any of the following:
   1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
   1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
   1.3 Symptomatic disease (prescriber determined); and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

DENOSUMAB – Restricted see terms below

If Inj 60 mg prefilled syringe.................................................................326.00 1 Prolia

← Restricted (RS1665)

Initiation

All of the following:

1 The patient has severe, established osteoporosis; and

2 Either:
   2.1 The patient is female and postmenopausal; or
   2.2 The patient is male or non-binary; and

3 Any of the following:
   3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or

continued…
continued...

3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or

3.3 History of two significant osteoporotic fractures demonstrated radiologically; or

3.4 Documented T-Score less than or equal to -3.0 (see Note); or

3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or

3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and

5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and

6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

5 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

RALOXIFENE – Restricted see terms below

Tab 60 mg.......................................................................................................53.76 28 Evista

Restricted (RS1666)

Initiation

Any of the following:

1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or

2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or

3 History of two significant osteoporotic fractures demonstrated radiologically; or

4 Documented T-Score greater than or equal to -3.0 (see Notes); or

5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or

continued...
continued…

6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE – Restricted see terms below

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 250 mcg per ml, 2.4 ml cartridge</td>
<td>$490.00 1 Forteo</td>
</tr>
</tbody>
</table>

Initiation

Limited to 18 months treatment

All of the following:

1 The patient has severe, established osteoporosis; and

2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and

3 The patient has had two or more fractures due to minimal trauma; and

4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antisresorptive agent at adequate doses (see Notes).

Notes:

1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg – 1% DV Jan-18 to 2020</td>
<td>$4.54 500 DP-Allopurinol</td>
</tr>
<tr>
<td>Tab 300 mg – 1% DV Jan-18 to 2020</td>
<td>$10.35 500 DP-Allopurinol</td>
</tr>
</tbody>
</table>
BENZBROMARONE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg........................................................................</td>
</tr>
<tr>
<td><strong>Benzbromaron AL 100</strong></td>
</tr>
</tbody>
</table>

**Initiation**

Any specialist

All of the following:

1. Patient has been diagnosed with gout; and
2. Any of the following:
   1. The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2. The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   3. Both:
      1. The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
      2. The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
3. The patient is receiving monthly liver function tests.

**Notes:** Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/

---

**COLCHICINE**

Tab 500 mcg – 1% DV Jan-19 to 2021........................................................................................................9.58 100 Colgout

**FEBUXOSTAT – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 80 mg........................................................................</td>
</tr>
<tr>
<td><strong>Adenuric</strong></td>
</tr>
<tr>
<td>Tab 120 mg.......................................................................</td>
</tr>
<tr>
<td><strong>Adenuric</strong></td>
</tr>
</tbody>
</table>

**Initiation**

Any specialist

Both:

1. Patient has been diagnosed with gout; and
2. Any of the following:
   1. The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2. The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   3. The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

**Note:** In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be...
continued…

effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID
Tab 500 mg

RASBURICASE – Restricted see terms below

<table>
<thead>
<tr>
<th>Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Brand indicates brand example only. It is not a contracted product.</td>
</tr>
</tbody>
</table>

### Muscle Relaxants and Related Agents

<table>
<thead>
<tr>
<th>Name</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATRACURIUM BESYLATE</td>
<td>Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Jun-18 to 2021</td>
<td>250.00</td>
<td>5</td>
</tr>
<tr>
<td>BACLOFEN</td>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>4.20</td>
<td>100</td>
</tr>
<tr>
<td>CLOSTRIDIUM BOTULINUM TYPE A TOXIN</td>
<td>Inj 2 mg per ml, 5 ml ampoule – 1% DV Apr-19 to 2021</td>
<td>372.98</td>
<td>5</td>
</tr>
<tr>
<td>DANTROLENE</td>
<td>Cap 25 mg</td>
<td>65.00</td>
<td>100</td>
</tr>
<tr>
<td>MIVACURIUM CHLORIDE</td>
<td>Inj 100 u vial</td>
<td>467.50</td>
<td>1</td>
</tr>
<tr>
<td>ORPHENADRINE CITRATE</td>
<td>Tab 100 mg – 1% DV Jun-18 to 2021</td>
<td>18.54</td>
<td>100</td>
</tr>
<tr>
<td>PANCURONIUM BROMIDE</td>
<td>Inj 2 mg per ml, 2 ml ampoule</td>
<td>260.00</td>
<td>50</td>
</tr>
<tr>
<td>ROCURONIUM BROMIDE</td>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td>25.95</td>
<td>10</td>
</tr>
<tr>
<td>SUXAMETHONIUM CHLORIDE</td>
<td>Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-17 to 2020</td>
<td>78.00</td>
<td>50</td>
</tr>
<tr>
<td>VECURONIUM BROMIDE</td>
<td>Inj 10 mg vial</td>
<td>33.92</td>
<td>5</td>
</tr>
</tbody>
</table>

### Reversers of Neuromuscular Blockade

<table>
<thead>
<tr>
<th>Name</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUGAMMADEX</td>
<td>Inj 100 mg per ml, 2 ml vial</td>
<td>1,200.00</td>
<td>10</td>
</tr>
</tbody>
</table>

1 Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)
**MUSCULOSKELETAL SYSTEM**

**Price**
(ex man. excl. GST) $ Per
Brand or Generic Manufacturer

---

**→ Restricted (RS1370)**

**Initiation**

Any of the following:

1. Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
2. Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
3. Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
4. The duration of the patient's surgery is unexpectedly short; or
5. Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
6. Patient has a partial residual block after conventional reversal.

---

**Non-Steroidal Anti-Inflammatory Drugs**

**CELECOXIB**

Note - The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.
- Cap 100 mg .......................................................... 3.63 60 Celecoxib Pfizer
- Cap 200 mg – 1% DV Aug-17 to 2020 .......................... 2.30 30 Celecoxib Pfizer

**DICLOFENAC SODIUM**
- Tab EC 25 mg – 1% DV Oct-18 to 2021 .................. 1.23 50 Diclofenac Sandoz
- Tab 50 mg dispersible .............................................. 1.50 20 Voltaren D
- Tab EC 50 mg – 1% DV Oct-18 to 2021 .................. 1.23 50 Diclofenac Sandoz
- Tab long-acting 75 mg – 1% DV Oct-18 to 2021 .......... 22.80 500 Apo-Diclo SR
- Tab long-acting 100 mg – 1% DV Oct-18 to 2021 ...... 25.15 500 Apo-Diclo SR
- Inj 25 mg per ml, 3 ml ampoule ............................... 13.20 5 Voltaren
- Suppos 12.5 mg ...................................................... 2.04 10 Voltaren
- Suppos 25 mg ...................................................... 2.44 10 Voltaren
- Suppos 50 mg ........................................................ 4.22 10 Voltaren
- Suppos 100 mg ...................................................... 7.00 10 Voltaren

**ETORICOXIB – Restricted see terms below**
- Tab 30 mg
- Tab 60 mg
- Tab 90 mg
- Tab 120 mg

**→ Restricted (RS1290)**

**Initiation**

For in-vivo investigation of allergy only.

**IBUPROFEN**
- Tab 200 mg – 1% DV Feb-18 to 2020 .................. 11.71 1,000 Relieve
- Tab 400 mg – Restricted: For continuation only
- Tab 600 mg – Restricted: For continuation only
- Tab long-acting 800 mg ............................................. 7.99 30 Brufen SR
- Oral liq 20 mg per ml – 1% DV May-19 to 2021 ........ 1.88 200 ml Ethics
- Inj 5 mg per ml, 2 ml ampoule
- Inj 10 mg per ml, 2 ml vial

**INDOMETHACIN**
- Cap 25 mg
- Cap 50 mg
- Cap long-acting 75 mg
- Inj 1 mg vial
- Suppos 100 mg

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>KETOPROFEN</td>
<td>Cap long-acting 200 mg</td>
<td>$12.07</td>
<td>28</td>
<td>Oruvail SR</td>
</tr>
<tr>
<td>MEFENAMIC ACID</td>
<td>Restricted: For continuation only</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cap 250 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAPROXEN</td>
<td>Tab 250 mg – 1% DV Dec-18 to 2021</td>
<td>$32.69</td>
<td>500</td>
<td>Noflam 250</td>
</tr>
<tr>
<td></td>
<td>Tab 500 mg – 1% DV Dec-18 to 2021</td>
<td>$22.19</td>
<td>250</td>
<td>Noflam 500</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 750 mg – 1% DV Oct-18 to 2021</td>
<td>$6.16</td>
<td>28</td>
<td>Naproxy SR 750</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 1 g – 1% DV Oct-18 to 2021</td>
<td>$8.21</td>
<td>28</td>
<td>Naproxy SR 1000</td>
</tr>
<tr>
<td>PARECOXIB</td>
<td>Inj 40 mg vial</td>
<td>$100.00</td>
<td>10</td>
<td>Dynastat</td>
</tr>
<tr>
<td>SULINDAC</td>
<td>Tab 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TENOXICAM</td>
<td>Tab 20 mg – 1% DV Oct-19 to 2022</td>
<td>$9.15</td>
<td>100</td>
<td>Tilocotil</td>
</tr>
<tr>
<td></td>
<td>Inj 20 mg vial</td>
<td>$9.95</td>
<td>1</td>
<td>AFT</td>
</tr>
</tbody>
</table>

### Topical Products for Joint and Muscular Pain

| CAPSAICIN      | Restricted see terms below               |                           |     |                               |
| Crm 0.025%     |                                          | $9.95                     | 45 g| Zostrix                       |
| Restricted (RS1309) |                                      |                           |     |                               |

**Initiation**

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.
# NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

## Agents for Parkinsonism and Related Disorders

### Agents for Essential Tremor, Chorea and Related Disorders

**RILUZOLE – Restricted** see terms below

| Tab 50 mg – 1% DV Aug-18 to 2021 | 130.00 56 | **Rilutek** |

**Restricted (RS1351)**

**Initiation**
Neurologist or respiratory specialist

**Re-assessment required after 6 months**

All of the following:
1. The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
2. The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
3. The patient has not undergone a tracheostomy; and
4. The patient has not experienced respiratory failure; and
5. Any of the following:
   5.1 The patient is ambulatory; or
   5.2 The patient is able to use upper limbs; or
   5.3 The patient is able to swallow.

**Continuation**

*Re-assessment required after 18 months*

All of the following:
1. The patient has not undergone a tracheostomy; and
2. The patient has not experienced respiratory failure; and
3. Any of the following:
   3.1 The patient is ambulatory; or
   3.2 The patient is able to use upper limbs; or
   3.3 The patient is able to swallow.

**TETRABENAZINE**

| Tab 25 mg – 1% DV Oct-19 to 2022 | 91.10 112 | **Motetis** |

**Anticholinergics**

**BENZATROPINE MESYLATE**

| Tab 2 mg | 7.99 60 | **Benztrop** |
| Inj 1 mg per ml, 2 ml ampoule | 95.00 5 | **Cogentin** |

**PROCYCLIDINE HYDROCHLORIDE**

| Tab 5 mg |  |

**Dopamine Agonists and Related Agents**

**AMANTADINE HYDROCHLORIDE**

| Cap 100 mg | 38.24 60 | **Symmetrel** |

**APOMORPHINE HYDROCHLORIDE**

| Inj 10 mg per ml, 2 ml ampoule | 119.00 5 | **Movapo** |

**BROMOCRIPTINE**

| Tab 2.5 mg |  |
| Cap 5 mg |  |

**ENTACAPONE**

| Tab 200 mg – 1% DV Sep-18 to 2021 | 22.00 100 | **Entapone** |

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Nervous System

<table>
<thead>
<tr>
<th><strong>Brand or Generic</strong></th>
<th><strong>Price</strong>&lt;br&gt;<strong>Per</strong>&lt;br&gt;<strong>(ex man. excl. GST)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LEVODOPA WITH BENSERAZIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab dispersible 50 mg with benserazide 12.5 mg</td>
<td>$13.25</td>
</tr>
<tr>
<td>Cap 50 mg with benserazide 12.5 mg</td>
<td>$13.75</td>
</tr>
<tr>
<td>Cap 100 mg with benserazide 25 mg</td>
<td>$15.80</td>
</tr>
<tr>
<td>Cap long-acting 100 mg with benserazide 25 mg</td>
<td>$22.85</td>
</tr>
<tr>
<td>Cap 200 mg with benserazide 50 mg</td>
<td>$26.25</td>
</tr>
<tr>
<td><strong>LEVODOPA WITH CARBIDOPA</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020</td>
<td>$17.97</td>
</tr>
<tr>
<td>Tab long-acting 100 mg with carbidopa 25 mg</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 200 mg with carbidopa 50 mg – 1% DV Feb-18 to 2020</td>
<td>$37.15</td>
</tr>
<tr>
<td>Tab 250 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020</td>
<td>$32.67</td>
</tr>
<tr>
<td><strong>RAMIPEXOLE HYDROCHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 0.25 mg – 1% DV Oct-19 to 2022</td>
<td>$6.12</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Oct-19 to 2022</td>
<td>$20.73</td>
</tr>
<tr>
<td><strong>ROPINIROLE HYDROCHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 0.25 mg</td>
<td>$2.78</td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>$5.00</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>$7.72</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>$16.51</td>
</tr>
<tr>
<td><strong>SELEGILINE HYDROCHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td></td>
</tr>
<tr>
<td><strong>TOLCAPONE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>$132.50</td>
</tr>
</tbody>
</table>

### Anaesthetics

#### General Anaesthetics

<table>
<thead>
<tr>
<th><strong>Brand or Generic</strong></th>
<th><strong>Price</strong>&lt;br&gt;<strong>Per</strong>&lt;br&gt;<strong>(ex man. excl. GST)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DESFLURANE</strong></td>
<td></td>
</tr>
<tr>
<td>Soln for inhalation 100%, 240 ml bottle – 1% DV Sep-16 to 2020</td>
<td>$1,350.00</td>
</tr>
<tr>
<td><strong>DEXMEDETOMIDINE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mcg per ml, 2 ml vial – 1% DV Sep-17 to 2020</td>
<td>$357.00</td>
</tr>
<tr>
<td><strong>ETOMIDATE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
<td></td>
</tr>
<tr>
<td><strong>ISOFLURANE</strong></td>
<td></td>
</tr>
<tr>
<td>Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020</td>
<td>$1,020.00</td>
</tr>
<tr>
<td><strong>KETAMINE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Feb-20 to 2022</td>
<td>$270.00</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml syringe – 1% DV Feb-20 to 2022</td>
<td>$70.00</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial – 1% DV Jan-19 to 2021</td>
<td>$31.50</td>
</tr>
<tr>
<td></td>
<td>155.60</td>
</tr>
<tr>
<td><strong>METHOHEXITAL SODIUM</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 50 ml vial</td>
<td></td>
</tr>
<tr>
<td><strong>PROPOFOL</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 20 ml ampoule – 10% DV Dec-19 to 2022</td>
<td>$4.35</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 20 ml vial – 10% DV Dec-19 to 2022</td>
<td>$5.27</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 50 ml vial – 10% DV Oct-19 to 2022</td>
<td>$19.50</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml vial – 10% DV Oct-19 to 2022</td>
<td>$39.00</td>
</tr>
</tbody>
</table>

*(Provive MCT-LCT 1% Inj 10 mg per ml, 20 ml vial to be delisted 1 December 2019)*
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEVOFLURANE</td>
<td>$ Per Brand or Generic Manufacturer</td>
</tr>
<tr>
<td>Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020</td>
<td>840.00 6 Baxter</td>
</tr>
<tr>
<td>THIOPENTAL [THIOPENTONE] SODIUM</td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg ampoule</td>
<td></td>
</tr>
</tbody>
</table>

**Local Anaesthetics**

**ARTICAINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Inj 1%</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARTICAINE HYDROCHLORIDE WITH ADRENALINE</td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge</td>
</tr>
</tbody>
</table>

**BENZOCAINE**

<table>
<thead>
<tr>
<th>Gel 20%</th>
</tr>
</thead>
</table>

**BUPIVACAINE HYDROCHLORIDE**

| Inj 5 mg per ml, 4 ml ampoule – 1% DV Sep-17 to 2020 | 50.00 5 Marcain Isobaric |
| Inj 2.5 mg per ml, 20 ml ampoule | |
| Inj 2.5 mg per ml, 20 ml ampoule sterile pack | 29.20 5 Marcain |
| Inj 5 mg per ml, 10 ml ampoule sterile pack | 20.25 5 Marcain |
| Inj 5 mg per ml, 20 ml ampoule | |
| Inj 5 mg per ml, 20 ml ampoule sterile pack | 20.70 5 Marcain |
| Inj 1.25 mg per ml, 100 ml bag | |
| Inj 1.25 mg per ml, 200 ml bag | |
| Inj 2.5 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020 | 150.00 5 Marcain |
| Inj 2.5 mg per ml, 200 ml bag | |
| Inj 2.5 mg per ml, 200 ml bag | |
| Inj 1.25 mg per ml, 500 ml bag | |

**BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE**

| Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Aug-19 to 2022 | 94.50 5 Marcain with Adrenaline |
| Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Aug-19 to 2022 | 80.50 5 Marcain with Adrenaline |

**BUPIVACAINE HYDROCHLORIDE WITH FENTANYL**

| Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag | |
| Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag | |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe | |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022 | 225.00 10 Bupafen |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Nov-19 to 2022 | 235.00 10 Bupafen |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe | |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe | 72.00 10 Biomed |
| Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe | 92.00 10 Biomed |

**BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE**

| Inj 0.5% with glucose 8%, 4 ml ampoule | 38.00 5 Marcain Heavy |
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### COCAINE HYDROCHLORIDE
- Paste 5%
  - Soln 15%, 2 ml syringe
  - Soln 4%, 2 ml syringe ........................................ $25.46 1 Biomed

### COCAINE HYDROCHLORIDE WITH ADRENALINE
- Paste 15% with adrenaline 0.06%
- Paste 25% with adrenaline 0.06%

### ETHYL CHLORIDE
- Spray 100%

### LIDOCAINE [LIGNOCAINE]
- Crm 4% ........................................................................... $5.40 5 g LMX4
  - 27.00 30 g LMX4

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE
- Gel 2% – 1% DV Nov-18 to 2021 .................................... $4.87 20 g Orion
- Soln 4%
- Spray 10% – 1% DV Jul-19 to 2022 ................................ $75.00 50 ml Xylocaine
- Oral (gel) soln 2% – 1% DV Oct-17 to 2020 .................. $38.00 200 ml Mucosoothe
- Inj 1%, 20 ml ampoule, sterile pack
- Inj 2%, 20 ml ampoule, sterile pack
- Inj 1%, 5 ml ampoule ........................................... $8.75 25 Lidocaine-Claris
- Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022 ................. $6.20 5 Lidocaine-Claris
- Inj 2%, 5 ml ampoule – 1% DV Nov-19 to 2022 ......... $8.25 25 Lidocaine-Claris
- Inj 2%, 20 ml vial – 1% DV Jul-19 to 2022 ............... $6.45 5 Lidocaine-Claris
- Gel 2%, 10 ml urethral syringe – 1% DV Nov-19 to 2022 $105.00 25 Cathejell
  - 81.50 10 Pfizer

*(Pfizer Gel 2%, 10 ml urethral syringe to be delisted 1 November 2019)*

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE
- Inj 1% with adrenaline 1:100,000, 5 ml ampoule – 1% DV Nov-19 to 2022 .................................. $29.00 10 Xylocaine
- Inj 1% with adrenaline 1:200,000, 20 ml vial ................ $50.00 5 Xylocaine
- Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge
- Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge
- Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge
- Inj 2% with adrenaline 1:100,000, 5 ml ampoule ........... $60.00 5 Xylocaine

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE
- Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Sep-17 to 2020 ............... $17.50 1 Topicaine

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE
- Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe ........................................ $81.50 10 Pfizer

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE
- Nasal spray 5% with phenylephrine hydrochloride 0.5%

### LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE
- Crm 2.5% with prilocaine 2.5% ................................... $45.00 30 g EMLA
- Patch 25 mcg with prilocaine 25 mcg ......................... $115.00 20 EMLA
- Crm 2.5% with prilocaine 2.5%, 5 g ......................... $45.00 5 EMLA

### MEPIVACAINE HYDROCHLORIDE
- Inj 3%, 1.8 ml dental cartridge ....................................... $43.60 50 Scandonest 3%
- Inj 3%, 2.2 ml dental cartridge ....................................... $43.60 50 Scandonest 3%

*Item restricted (see ➨ above); Item restricted (see ➨ below)
e.g. Brand indicates brand example only. It is not a contracted product.*
### NERVOUS SYSTEM

#### Price

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

#### PRILOCAINE HYDROCHLORIDE

- Inj 0.5%, 50 ml vial: $100.00 5 Citanest
- Inj 2%, 5 ml ampoule: $55.00 10 Citanest

*(Citanest Inj 2%, 5 ml ampoule to be delisted 1 October 2019)*

#### PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN

- Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge
- Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge

#### ROPIVACAINE HYDROCHLORIDE

- Inj 2 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020: $8.80 5 Ropivacaine Kabi
- Inj 2 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020: $9.20 5 Ropivacaine Kabi
- Inj 2 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020: $29.50 5 Ropivacaine Kabi
- Inj 2 mg per ml, 200 ml bag – 1% DV Sep-17 to 2020: $39.00 5 Ropivacaine Kabi
- Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020: $9.90 5 Ropivacaine Kabi
- Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020: $12.15 5 Ropivacaine Kabi
- Inj 10 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020: $10.55 5 Ropivacaine Kabi
- Inj 10 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020: $15.80 5 Ropivacaine Kabi

#### ROPIVACAINE HYDROCHLORIDE WITH FENTANYL

- Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag: $198.50 5 Naropin
- Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag: $270.00 5 Naropin

#### TETRACAINE [AMETHOCAINE] HYDROCHLORIDE

- Gel 4%

### Analgesics

#### Non-Opioid Analgesics

**ASPIRIN**
- Tab dispersible 300 mg – 1% DV Oct-19 to 2022: $4.50 100 Ethics Aspirin

**CAPSAICIN** – Restricted see terms below
- Crm 0.075%: $12.50 45 g Zostrix HP

**METHOXYFLURANE** – Restricted see terms below
- Soln for inhalation 99.9%, 3 ml bottle

**NEFOPAM HYDROCHLORIDE**
- Tab 30 mg

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
PARACETAMOL – Some items restricted see terms below

Tab soluble 500 mg
Tab 500 mg
Oral liq 120 mg per 5 ml – 1% DV Dec-17 to 2020 ......................................... $5.35 1,000 ml Paracare
Oral liq 250 mg per 5 ml – 20% DV Aug-18 to 2020 ......................................... $5.81 1,000 ml Paracare Double Strength

Inj 10 mg per ml, 100 ml vial – 1% DV Sep-17 to 2020 ......................................... $8.40 10 Paracetamol Kabi
Suppos 25 mg – 1% DV Nov-19 to 2022 .......................................................... $58.50 20 Biomed
Suppos 50 mg – 1% DV Nov-19 to 2022 .......................................................... $58.50 20 Biomed
Suppos 125 mg – 1% DV Nov-18 to 2021 .......................................................... $ 3.29 10 Gacet
Suppos 250 mg – 1% DV Nov-18 to 2021 .......................................................... $ 3.79 10 Gacet
Suppos 500 mg – 1% DV Feb-19 to 2021 .......................................................... $12.40 50 Gacet

⇒ Restricted (RS1146)

Initiation
Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

SUCROSE
Oral liq 25% – 1% DV Feb-20 to 2022 ............................................................... $13.00 25 ml Biomed

Opioid Analgesics

ALFENTANIL
Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020 .......................... $34.38 10 Hameln

CODEINE PHOSPHATE
Tab 15 mg ................................................................. $5.75 100 PSM
Tab 30 mg ................................................................. $6.80 100 PSM
Tab 60 mg ................................................................. $13.50 100 PSM

DIHYDROCODEINE TARTRATE
Tab long-acting 60 mg – 1% DV Oct-19 to 2022 ................................................ $8.60 60 DHC Continus

FENTANYL
Inj 10 mcg per ml, 10 ml syringe
Inj 50 mcg per ml, 2 ml ampoule – 1% DV Nov-18 to 2021 ........................ $3.56 10 Boucher and Muir
Inj 10 mcg per ml, 50 ml bag ........................................................................ 210.00 10 Biomed
Inj 50 mcg per ml, 50 ml syringe ................................................................. $165.00 10 Biomed
Inj 10 mcg per ml, 10 ml ampoule – 1% DV Nov-18 to 2021 ........................ $4.91 10 Boucher and Muir
Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022 ............................... $220.00 10 Biomed
Inj 20 mcg per ml, 50 ml syringe – 1% DV Oct-18 to 2021 ............................ $18.74 1 Biomed
Inj 20 mcg per ml, 100 ml bag
Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020 ........................................ $2.95 5 Fentanyl Sandoz
Patch 25 mcg per hour – 1% DV Oct-17 to 2020 ........................................... $3.66 5 Fentanyl Sandoz
Patch 50 mcg per hour – 1% DV Oct-17 to 2020 ........................................... $6.65 5 Fentanyl Sandoz
Patch 75 mcg per hour – 1% DV Oct-17 to 2020 ........................................... $9.25 5 Fentanyl Sandoz
Patch 100 mcg per hour – 1% DV Oct-17 to 2020 ....................................... $11.40 5 Fentanyl Sandoz

METHADONE HYDROCHLORIDE
Tab 5 mg – 1% DV Sep-19 to 2022 ............................................................... $1.40 10 Methatabs
Tab 5 mg – bottle pack ................................................................................. $1.40 10 Methatabs
Oral liq 2 mg per ml – 1% DV Oct-18 to 2021 ................................................ $5.79 200 ml Biodone
Oral liq 5 mg per ml – 1% DV Oct-18 to 2021 ................................................ $5.79 200 ml Biodone Forte
Oral liq 10 mg per ml – 1% DV Oct-18 to 2021 ............................................... $6.79 200 ml Biodone Extra Forte
Inj 10 mg per ml, 1 ml vial ............................................................................. $61.00 10 AFT

(Methatabs Tab 5 mg - bottle pack to be delisted 1 December 2019)
### MORPHINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA-Morph</td>
<td>$9.28 Per 200 ml</td>
</tr>
<tr>
<td>RA-Morph</td>
<td>$16.24 Per 200 ml</td>
</tr>
<tr>
<td>RA-Morph</td>
<td>$19.44 Per 200 ml</td>
</tr>
<tr>
<td>RA-Morph</td>
<td>$27.74 Per 200 ml</td>
</tr>
</tbody>
</table>

### MORPHINE SULPHATE

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrow-Morphine LA</td>
<td>$1.93 Per 10 10 mg</td>
</tr>
<tr>
<td>Sevredol</td>
<td>$2.80 Per 10 20 mg</td>
</tr>
<tr>
<td>Arrow-Morphine LA</td>
<td>$5.25 Per 10 30 mg</td>
</tr>
<tr>
<td>Arrow-Morphine LA</td>
<td>$5.60 Per 10 60 mg</td>
</tr>
<tr>
<td>Arrow-Morphine LA</td>
<td>$6.10 Per 10 100 mg</td>
</tr>
<tr>
<td>m-Eslon</td>
<td>$1.70 Per 10 10 mg</td>
</tr>
<tr>
<td>m-Eslon</td>
<td>$2.50 Per 10 30 mg</td>
</tr>
<tr>
<td>m-Eslon</td>
<td>$5.40 Per 10 60 mg</td>
</tr>
<tr>
<td>m-Eslon</td>
<td>$6.38 Per 10 100 mg</td>
</tr>
<tr>
<td>Biomed</td>
<td>$97.25 Per 5 100 ml bag</td>
</tr>
<tr>
<td>Biomed</td>
<td>$24.00 Per 5 10 ml syringe</td>
</tr>
<tr>
<td>Biomed</td>
<td>$50.75 Per 5 50 ml syringe</td>
</tr>
<tr>
<td>DBL Morphine Sulphate</td>
<td>$135.00 Per 10 3 ml syringe</td>
</tr>
<tr>
<td>DBL Morphine Sulphate</td>
<td>$6.27 Per 5 1 ml ampoule</td>
</tr>
<tr>
<td>DBL Morphine Sulphate</td>
<td>$4.47 Per 5 1 ml ampoule</td>
</tr>
<tr>
<td>DBL Morphine Sulphate</td>
<td>$4.76 Per 5 1 ml ampoule</td>
</tr>
<tr>
<td>DBL Morphine Tartrate</td>
<td>$42.72 Per 5 1.5 ml ampoule</td>
</tr>
</tbody>
</table>

### OXYCODONE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>OxyNorm</td>
<td>$2.15 Per 20 5 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$2.15 Per 20 10 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$2.15 Per 20 20 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$3.20 Per 20 40 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$10.98 Per 20 80 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$1.88 Per 20 5 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$3.32 Per 20 10 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$5.81 Per 20 20 mg</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$11.20 Per 250 ml</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$7.28 Per 5 1 ml ampoule</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$14.36 Per 5 2 ml ampoule</td>
</tr>
<tr>
<td>OxyNorm</td>
<td>$30.60 Per 5 1 ml ampoule</td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td><strong>PARACETAMOL WITH CODEINE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab paracetamol 500 mg with codeine phosphate 8 mg – 1% DV</td>
<td></td>
</tr>
<tr>
<td>Sep-17 to 2020 ................................................................. 18.21 1,000 Paracetamol + Codeine (Relieve)</td>
<td></td>
</tr>
</tbody>
</table>

| PETHIDINE HYDROCHLORIDE |
| Tab 50 mg – 1% DV Sep-18 to 2021 .................................................. 4.46 10 PSM |
| Inj 5 mg per ml, 10 ml syringe |
| Inj 5 mg per ml, 100 ml bag |
| Inj 10 mg per ml, 100 ml bag |
| Inj 10 mg per ml, 50 ml syringe |
| Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020 .................. 4.98 5 DBL Pethidine Hydrochloride |
| Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020 .................. 5.12 5 DBL Pethidine Hydrochloride |

| REMIFENTANIL |
| Inj 1 mg vial – 1% DV Oct-17 to 2020 ........................................... 13.95 5 Remifentanil-AFT |
| Inj 2 mg vial – 1% DV Oct-17 to 2020 ........................................... 19.95 5 Remifentanil-AFT |

| TRAMADOL HYDROCHLORIDE |
| Tab sustained-release 100 mg – 1% DV Sep-17 to 2020 ................ 1.55 20 Tramal SR 100 |
| Tab sustained-release 150 mg – 1% DV Sep-17 to 2020 ................ 2.10 20 Tramal SR 150 |
| Tab sustained-release 200 mg – 1% DV Sep-17 to 2020 ................ 2.75 20 Tramal SR 200 |
| Cap 50 mg – 1% DV Sep-17 to 2020 ............................................. 2.25 100 Arrow-Tramadol |
| Oral soln 10 mg per ml |
| Inj 10 mg per ml, 100 ml bag |
| Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020 .......... 4.50 5 Tramal 50 |
| Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020 .......... 4.50 5 Tramal 100 |

**Antidepressants**

**Cyclic and Related Agents**

| AMITRIPTYLINE |
| Tab 10 mg – 1% DV Apr-18 to 2020 ........................................... 1.96 100 Arrow-Amitriptyline |
| Tab 25 mg – 1% DV Apr-18 to 2020 ........................................... 1.52 100 Arrow-Amitriptyline |
| Tab 50 mg – 1% DV Apr-18 to 2020 ........................................... 2.51 100 Arrow-Amitriptyline |

| CLOMIPRAMINE HYDROCHLORIDE |
| Tab 10 mg – 1% DV Oct-18 to 2021 ............................................ 13.99 100 Apo-Clomipramine |
| Tab 25 mg – 1% DV Oct-18 to 2021 ............................................ 9.46 100 Apo-Clomipramine |

| DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Restricted: For continuation only |
| Tab 75 mg ................................................................. 11.19 100 Dopress |
| Cap 25 mg ................................................................. 6.45 100 Dopress |

(Dopress Tab 75 mg to be delisted 1 August 2020)

(Dopress Cap 25 mg to be delisted 1 January 2020)

| DOXEPIN HYDROCHLORIDE – Restricted: For continuation only |
| Cap 10 mg |
| Cap 25 mg |
| Cap 50 mg |

| IMIPRAMINE HYDROCHLORIDE |
| Tab 10 mg ................................................................. 5.48 50 Tofranil |
| Tab 25 mg ................................................................. 6.58 60 Tofranil |
| Tab 50 mg ................................................................. 8.80 50 Tofranil |

*Item restricted (see ➥ above); Item restricted (see ➥ below)*
*E.g. Brand indicates brand example only. It is not a contracted product.*
### NERVOUS SYSTEM

#### MAPROTLINE HYDROCHLORIDE
- Tab 25 mg
- Tab 75 mg

#### MIANSERIN HYDROCHLORIDE  – **Restricted:** For continuation only
- Tab 30 mg

#### NORTRIPTYLINE HYDROCHLORIDE
- Tab 10 mg – 1% DV Oct-19 to 2022: $2.44 100 Norpress
- Tab 25 mg – 1% DV Oct-19 to 2022: $5.98 180 Norpress

#### Monoamine-Oxidase Inhibitors - Non-Selective

##### PHENELZINE SULPHATE
- Tab 15 mg

##### TRANYLCYPROMINE SULPHATE
- Tab 10 mg

#### Monoamine-Oxidase Type A Inhibitors

##### MOCLOBEMIDE
- Tab 150 mg – 1% DV Apr-19 to 2021: $6.40 60 Aurorix
- Tab 300 mg – 1% DV Apr-19 to 2021: $9.80 60 Aurorix

#### Other Antidepressants

##### MIRTAZAPINE
- Tab 30 mg – 1% DV Oct-18 to 2021: $2.63 30 Apo-Mirtazapine
- Tab 45 mg – 1% DV Oct-18 to 2021: $3.48 30 Apo-Mirtazapine

##### VENLAFAXINE
- Cap 37.5 mg – 1% DV Jun-17 to 2020: $6.38 84 Enlafax XR
- Cap 75 mg – 1% DV Jun-17 to 2020: $8.11 84 Enlafax XR
- Cap 150 mg – 1% DV Jun-17 to 2020: $11.16 84 Enlafax XR

#### Selective Serotonin Reuptake Inhibitors

##### CITALOPRAM HYDROBROMIDE
- Tab 20 mg – 1% DV Sep-18 to 2021: $1.52 84 PSM Citalopram

##### ESCITALOPRAM
- Tab 10 mg – 1% DV Dec-17 to 2020: $1.11 28 Escitalopram-Apotex
- Tab 20 mg – 1% DV Dec-17 to 2020: $1.90 28 Escitalopram-Apotex

##### FLUOXETINE HYDROCHLORIDE
- Tab dispersible 20 mg, scored: $2.47 30 Arrow-Fluoxetine
- Cap 20 mg: $1.99 90 Arrow-Fluoxetine

##### PAROXETINE
- Tab 20 mg: $4.02 90 Apo-Paroxetine

##### SERTRALINE
- Tab 50 mg: $3.05 90 Arrow-Sertraline
- Tab 100 mg: $5.25 90 Arrow-Sertraline

---

**Products with Hospital Supply Status (HSS) are in bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Antiepilepsy Drugs

### Agents for the Control of Status Epilepticus

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLONAZEPAM</strong></td>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td>$21.00</td>
<td>5 Rivotril</td>
</tr>
<tr>
<td><strong>DIAZEPAM</strong></td>
<td>Inj 5 mg per ml, 2 ml ampoule</td>
<td>$11.83</td>
<td>5 Hospira</td>
</tr>
<tr>
<td></td>
<td>Rectal tubes 5 mg</td>
<td>$40.87</td>
<td>5 Stesolid</td>
</tr>
<tr>
<td></td>
<td>Rectal tubes 10 mg</td>
<td>$40.87</td>
<td>5 Stesolid</td>
</tr>
<tr>
<td><strong>LORAZEPAM</strong></td>
<td>Inj 2 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 4 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PARALDEHYDE</strong></td>
<td>Inj 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PHENYTOIN SODIUM</strong></td>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td>$88.63</td>
<td>5 Hospira</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg per ml, 5 ml ampoule</td>
<td>$133.92</td>
<td>5 Hospira</td>
</tr>
</tbody>
</table>

### Control of Epilepsy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARBAMAZEPINE</strong></td>
<td>Tab 200 mg</td>
<td>$14.53</td>
<td>100 Tegretol</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 200 mg</td>
<td>$16.98</td>
<td>100 Tegretol CR</td>
</tr>
<tr>
<td></td>
<td>Tab 400 mg</td>
<td>$34.58</td>
<td>100 Tegretol</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 400 mg</td>
<td>$39.17</td>
<td>100 Tegretol CR</td>
</tr>
<tr>
<td></td>
<td>Oral liq 20 mg per ml</td>
<td>$26.37</td>
<td>250 ml Tegretol</td>
</tr>
<tr>
<td><strong>CLOBAZAM</strong></td>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLONAZEPAM</strong></td>
<td>Oral drops 2.5 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHOSUXIMIDE</strong></td>
<td>Cap 250 mg</td>
<td>$140.88</td>
<td>100 Zarontin</td>
</tr>
<tr>
<td></td>
<td>Oral liq 50 mg per ml</td>
<td>$56.35</td>
<td>200 ml Zarontin</td>
</tr>
<tr>
<td><strong>GABAPENTIN</strong></td>
<td>Note: Gabapentin not to be given in combination with pregabalin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cap 100 mg – 1% DV Aug-18 to 2021</td>
<td>$2.65</td>
<td>100 Apo-Gabapentin</td>
</tr>
<tr>
<td></td>
<td>Cap 300 mg – 1% DV Aug-18 to 2021</td>
<td>$4.07</td>
<td>100 Apo-Gabapentin</td>
</tr>
<tr>
<td></td>
<td>Cap 400 mg – 1% DV Aug-18 to 2021</td>
<td>$5.64</td>
<td>100 Apo-Gabapentin</td>
</tr>
<tr>
<td><strong>LACOSAMIDE</strong></td>
<td>Restricted see terms on the next page</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg</td>
<td>$25.04</td>
<td>14 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Tab 100 mg</td>
<td>$50.06</td>
<td>14 Vimpat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>200.24</td>
<td>56 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Tab 150 mg</td>
<td>$75.10</td>
<td>14 Vimpat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300.40</td>
<td>56 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Tab 200 mg</td>
<td>$400.55</td>
<td>56 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 20 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ‣ above); ‣ Item restricted (see ‣ below*)

*e.g. Brand indicates brand example only. It is not a contracted product.*
**NERVOUS SYSTEM**

### Price

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

### Restricted (RS1151)

**Initiation**

*Re-assessment required after 15 months*

**Both:**

1. Patient has partial-onset epilepsy; and
2. Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

### Continuation

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

#### LAMOTRIGINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab dispersible 2 mg</td>
<td>6.74</td>
<td>30</td>
</tr>
<tr>
<td>Tab dispersible 5 mg</td>
<td>15.00</td>
<td>56</td>
</tr>
<tr>
<td>Tab dispersible 25 mg</td>
<td>20.40</td>
<td>56</td>
</tr>
<tr>
<td>Tab dispersible 50 mg</td>
<td>34.70</td>
<td>56</td>
</tr>
<tr>
<td>Tab dispersible 100 mg</td>
<td>59.90</td>
<td>56</td>
</tr>
</tbody>
</table>

*Note: Arrow-Lamotrigine Tab dispersible 25 mg to be delisted 1 October 2019*

#### LEVETIRACETAM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>4.99</td>
<td>60</td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>8.79</td>
<td>60</td>
</tr>
<tr>
<td>Tab 750 mg</td>
<td>14.39</td>
<td>60</td>
</tr>
<tr>
<td>Tab 1,000 mg</td>
<td>18.59</td>
<td>60</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td>44.78</td>
<td>300 ml</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 5 ml vial</td>
<td>38.95</td>
<td>10</td>
</tr>
</tbody>
</table>

*Note: Levetiracetam-AFT*

#### PHENOBARBITONE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 15 mg</td>
<td>40.00</td>
<td>500</td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td>40.00</td>
<td>500</td>
</tr>
</tbody>
</table>

#### PHENYTOIN

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: Levetiracetam-AFT*
NERVOUS SYSTEM

Price
(ex man. excl. GST) $ Per

Brand or
Generic Manufacturer

PHENYTOIN SODIUM
Cap 30 mg
Cap 100 mg
Oral liq 6 mg per ml

PREGABALIN
Note: Pregabalin not to be given in combination with gabapentin
Cap 25 mg – 1% DV Jul-18 to 2021 ................................. 2.25 56 Pregabalin Pfizer
Cap 75 mg – 1% DV Jul-18 to 2021 ................................. 2.65 56 Pregabalin Pfizer
Cap 150 mg – 1% DV Jul-18 to 2021 ............................... 4.01 56 Pregabalin Pfizer
Cap 300 mg – 1% DV Jul-18 to 2021 ............................... 7.38 56 Pregabalin Pfizer

PRIMIDONE
Tab 250 mg

SODIUM VALPROATE
Tab 100 mg
Tab EC 200 mg
Tab EC 500 mg
Oral liq 40 mg per ml
Inj 100 mg per ml, 4 ml vial – 1% DV Sep-18 to 2021 ........................................ 9.98 1 Epilim IV

STIRIPENTOL – Restricted see terms below
Cap 250 mg ........................................................................ 509.29 60 Diacomit
Powder for oral liq 250 mg sachet ...................................... 509.29 60 Diacomit

STIRIPENTOL – Restricted (RS1152)
Initiation
Paediatric neurologist
Re-assessment required after 6 months
Both:
1. Patient has confirmed diagnosis of Dravet syndrome; and
2. Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Continuation
Paediatric neurologist
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE
Tab 25 mg ........................................................................ 11.07 60 Arrow-Topiramate
........................................................................ 26.04 Topamax
........................................................................ 11.07 Topiramate Actavis
Tab 50 mg ........................................................................ 18.81 60 Arrow-Topiramate
........................................................................ 44.26 Topamax
........................................................................ 18.81 Topiramate Actavis
Tab 100 mg ....................................................................... 31.99 60 Arrow-Topiramate
........................................................................ 75.25 Topamax
........................................................................ 31.99 Topiramate Actavis
Tab 200 mg ..................................................................... 55.19 60 Arrow-Topiramate
........................................................................ 129.85 Topamax
........................................................................ 55.19 Topiramate Actavis
Cap sprinkle 15 mg .......................................................... 20.84 60 Topamax
Cap sprinkle 25 mg .......................................................... 26.04 60 Topamax

VIGABATRIN – Restricted see terms on the next page
Cap 500 mg
NERVOUS SYSTEM

**Price** (ex man. excl. GST) $ Per Brand or Generic Manufacturer

---

→ **Restricted (RS1153)**

**Initiation**

*Re-assessment required after 15 months*

**Both:**

1. **Either:**
   1.1 Patient has infantile spasms; or
   1.2 Both:
      1.2.1 Patient has epilepsy; and
      1.2.2 Either:
         1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
         1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2. **Either:**
   2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

**Vigabatrin** is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Continuation**

**Both:**

1. The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
2. **Either:**
   2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective.

**Vigabatrin** is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

### Antimigraine Preparations

#### Acute Migraine Treatment

**Dihydroergotamine Mesylate**

*Inj 1 mg per ml, 1 ml ampoule*

**Ergotamine Tartrate with Caffeine**

*Tab 1 mg with caffeine 100 mg*

**Metoclopramide Hydrochloride with Paracetamol**

*Tab 5 mg with paracetamol 500 mg*

**Rizatriptan**

*Tab orodispersible 10 mg – 1% DV Sep-17 to 2020* 

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5.26</td>
<td>Rizamelt</td>
</tr>
</tbody>
</table>

**Sumatriptan**

*Tab 50 mg – 1% DV Oct-19 to 2022*

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$24.44</td>
<td>Apo-Sumatriptan</td>
</tr>
<tr>
<td>$46.23</td>
<td>Apo-Sumatriptan</td>
</tr>
</tbody>
</table>

*Tab 100 mg – 1% DV Oct-19 to 2022*

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$81.15</td>
<td>Clustran</td>
</tr>
</tbody>
</table>

*Inj 12 mg per ml, 0.5 ml prefilled pen*
Prophylaxis of Migraine

PIZOTIFEN
Tab 500 mcg....................................................................................................23.21 100 Sandomigran

Antinausea and Vertigo Agents

APREPIANT – Restricted see terms below

Cap 2 × 80 mg and 1 × 125 mg – 1% DV Jul-18 to 2021.........................84.00 3 Emend Tri-Pack

Initiation
Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE
Tab 16 mg – 1% DV Sep-17 to 2020......................................................2.89 84 Vergo 16

CYCLIZINE HYDROCHLORIDE
Tab 50 mg – 1% DV Jan-19 to 2021.......................................................0.55 10 Nausicalm

CYCLIZINE LACTATE
Inj 50 mg per ml, 1 ml ampoule..............................................................14.95 5 Nausicalm

DOMPERIDONE
Tab 10 mg – 1% DV Mar-19 to 2021.....................................................2.25 100 Pharmacy Health

DROPERIDOL
Inj 2.5 mg per ml, 1 ml ampoule.............................................................35.00 10 Droperidol Panpharma

GRANISETRON
Inj 1 mg per ml, 3 ml ampoule – 1% DV Dec-18 to 2020.......................0.40 1 Deva

HYOSCINE HYDROBROMIDE
Inj 400 mcg per ml, 1 ml ampoule.........................................................46.50 5 Hospira

Patch 1.5 mg..........................................................14.11 2 Scopoderm TTS

METOCLOPRAMIDE HYDROCHLORIDE
Tab 10 mg – 1% DV Jan-18 to 2020.......................................................1.30 100 Metoclopramide

Oral liq 5 mg per 5 ml
Inj 5 mg per ml, 2 ml ampoule............................................................13.56 10 Pfizer
## NERVOUS SYSTEM

### Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONDANSETRON</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 4 mg</td>
<td>3.36</td>
<td>50</td>
<td>Apo-Ondansetron</td>
</tr>
<tr>
<td>Tab dispersible 4 mg – 1% DV Apr-18 to 2020</td>
<td>0.95</td>
<td>10</td>
<td>Ondansetron OD-DRLA</td>
</tr>
<tr>
<td>Tab 8 mg</td>
<td>4.77</td>
<td>50</td>
<td>Apo-Ondansetron</td>
</tr>
<tr>
<td>Tab dispersible 8 mg – 1% DV Apr-18 to 2020</td>
<td>1.43</td>
<td>10</td>
<td>Ondansetron OD-DRLA</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 2 ml ampoule</td>
<td>1.50</td>
<td>5</td>
<td>Ondansetron-Claris</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 4 ml ampoule</td>
<td>2.20</td>
<td>5</td>
<td>Ondansetron Kabi</td>
</tr>
<tr>
<td>PROCHLORPERAZINE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab buccal 3 mg</td>
<td>6.35</td>
<td>250</td>
<td>Nausafix</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Mar-18 to 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 12.5 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suppos 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TROPISETRON</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>8.95</td>
<td>1</td>
<td>Tropisetron-AFT</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td>13.95</td>
<td>1</td>
<td>Tropisetron-AFT</td>
</tr>
</tbody>
</table>

### Antipsychotic Agents

#### General

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMISULPRIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Nov-19 to 2022</td>
<td>5.15</td>
<td>30</td>
<td>Sulprix</td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Nov-19 to 2022</td>
<td>14.96</td>
<td>60</td>
<td>Sulprix</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>27.70</td>
<td>60</td>
<td>Sulprix</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td>65.53</td>
<td>60 ml</td>
<td>Solian</td>
</tr>
<tr>
<td><strong>(Solian Oral liq 100 mg per ml to be delisted 1 July 2020)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARIPIPRAZOLE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 30 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>CHLORPROMAZINE HYDROCHLORIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jan-20 to 2022</td>
<td>14.83</td>
<td>100</td>
<td>Largactil</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-20 to 2022</td>
<td>15.62</td>
<td>100</td>
<td>Largactil</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Jan-20 to 2022</td>
<td>36.73</td>
<td>100</td>
<td>Largactil</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 20 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>30.79</td>
<td>10</td>
<td>Largactil</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLOZAPINE</strong></td>
</tr>
<tr>
<td>Tab 25 mg</td>
</tr>
<tr>
<td>Tab 50 mg</td>
</tr>
<tr>
<td>Tab 100 mg</td>
</tr>
<tr>
<td>Tab 200 mg</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
</tr>
<tr>
<td><strong>HALOPERIDOL</strong></td>
</tr>
<tr>
<td>Tab 500 mcg – 1% DV Oct-19 to 2022</td>
</tr>
<tr>
<td>Tab 1.5 mg – 1% DV Oct-19 to 2022</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-19 to 2022</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Oct-19 to 2022</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-19 to 2022</td>
</tr>
<tr>
<td><strong>LEVOMEPROMAZINE</strong></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Sep-19 to 2022</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-19 to 2022</td>
</tr>
<tr>
<td><strong>LEVOMEPROMAZINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 1 ml ampoule</td>
</tr>
<tr>
<td><strong>LITHIUM CARBONATE</strong></td>
</tr>
<tr>
<td>Tab long-acting 400 mg</td>
</tr>
<tr>
<td>Tab 250 mg</td>
</tr>
<tr>
<td><strong>OLANZAPINE</strong></td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Tab orodispersible 5 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Tab orodispersible 10 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Inj 10 mg vial</td>
</tr>
<tr>
<td><strong>PERICYZINE</strong></td>
</tr>
<tr>
<td>Tab 2.5 mg</td>
</tr>
<tr>
<td>Tab 10 mg</td>
</tr>
<tr>
<td><strong>QUETIAPINE</strong></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>Tab 300 mg – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td><strong>RISPERIDONE</strong></td>
</tr>
<tr>
<td>Tab 0.5 mg – 1% DV Dec-17 to 2020</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Dec-17 to 2020</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Dec-17 to 2020</td>
</tr>
<tr>
<td>Tab 3 mg – 1% DV Dec-17 to 2020</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Dec-17 to 2020</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Sep-17 to 2020</td>
</tr>
</tbody>
</table>

*Item restricted (see ➨ above); Item restricted (see ➨ below)*

e.g. Brand indicates brand example only. It is not a contracted product.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

ZIPRASIDONE

- Cap 20 mg – 1% DV Dec-18 to 2021 ........................................ 14.50 60 Zuddone
- Cap 40 mg – 1% DV Sep-18 to 2021 ........................................ 24.70 60 Zuddone
- Cap 60 mg – 1% DV Sep-18 to 2021 ........................................ 33.80 60 Zuddone
- Cap 80 mg – 1% DV Sep-18 to 2021 ........................................ 39.70 60 Zuddone

ZUCLOPENTHIXOL ACETATE

- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

ZUCLOPENTHIXOL HYDROCHLORIDE

- Tab 10 mg ................................................................................. 31.45 100 Clopixol

**Depot Injections**

FLUPENTHIXOL DECANOATE

- Inj 20 mg per ml, 1 ml ampoule .............................................. 13.14 5 Fluanxol
- Inj 20 mg per ml, 2 ml ampoule .............................................. 20.90 5 Fluanxol
- Inj 100 mg per ml, 1 ml ampoule ............................................. 40.87 5 Fluanxol

HALOPERIDOL DECANOATE

- Inj 50 mg per ml, 1 ml ampoule .............................................. 28.39 5 Haldol
- Inj 100 mg per ml, 1 ml ampoule ............................................ 55.90 5 Haldol Concentrate

OLANZAPINE – Restricted see terms below

Stephen  
1. Inj 210 mg vial – 1% DV Oct-18 to 2021 ............................... 252.00 1 Zyprexa Relprevv
2. Inj 300 mg vial – 1% DV Oct-18 to 2021 ............................... 414.00 1 Zyprexa Relprevv
3. Inj 405 mg vial – 1% DV Oct-18 to 2021 ............................... 504.00 1 Zyprexa Relprevv

- Restricted (RS1379)

Initiation

Re-assessment required after 12 months

Either:
1. The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
2. All of the following:
   2.1 The patient has schizophrenia; and
   2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE – Restricted see terms below

Stephen  
1. Inj 25 mg syringe ............................................................... 194.25 1 Invega Sustenna
2. Inj 50 mg syringe ............................................................... 271.95 1 Invega Sustenna
3. Inj 75 mg syringe ............................................................... 357.42 1 Invega Sustenna
4. Inj 100 mg syringe ............................................................. 435.12 1 Invega Sustenna
5. Inj 150 mg syringe ............................................................. 435.12 1 Invega Sustenna

- Restricted (RS1381)

Initiation

Re-assessment required after 12 months

Either:

continued...
1. The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
2. All of the following:
   2.1. The patient has schizophrenia or other psychotic disorder; and
   2.2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE – Restricted: For continuation only

- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE – Restricted see terms below

- Inj 25 mg vial .................................................................135.98 1 Risperdal Consta
- Inj 37.5 mg vial ...............................................................178.71 1 Risperdal Consta
- Inj 50 mg vial .................................................................217.56 1 Risperdal Consta

- Restricted (RS1380)

Initiation

Re-assessment required after 12 months

Either:

1. The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
2. All of the following:
   2.1. The patient has schizophrenia or other psychotic disorder; and
   2.2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE

- Inj 200 mg per ml, 1 ml ampoule .........................................................19.80 5 Clopixol
- Inj 500 mg per ml, 1 ml ampoule

Anxiolytics

BUSPIRONE HYDROCHLORIDE

- Tab 5 mg – 1% DV Sep-18 to 2021 .........................................................20.23 100 Orion
- Tab 10 mg – 1% DV Sep-18 to 2021 .......................................................13.16 100 Orion

CLONAZEPAM

- Tab 500 mcg – 1% DV Jun-18 to 2021 .....................................................5.64 100 Paxam
- Tab 2 mg – 1% DV Jun-18 to 2021 .........................................................10.78 100 Paxam

DIAZEPAM

- Tab 2 mg – 1% DV Mar-18 to 2020 .........................................................15.05 500 Arrow-Diazepam
- Tab 5 mg – 1% DV Mar-18 to 2020 .........................................................16.18 500 Arrow-Diazepam

LORAZEPAM

- Tab 1 mg – 1% DV Sep-18 to 2021 .........................................................9.72 250 Ativan
- Tab 2.5 mg – 1% DV Sep-18 to 2021 .......................................................12.50 100 Ativan

---

* Item restricted (see above); Item restricted (see below)
* e.g. Brand indicates brand example only. It is not a contracted product.
NERVOUS SYSTEM

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

### OXAZEPAM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tab 10 mg</strong> – 1% DV Sep-17 to 2020</td>
<td>...............................................................$6.17</td>
<td>100</td>
</tr>
<tr>
<td><strong>Tab 15 mg</strong> – 1% DV Sep-17 to 2020</td>
<td>...............................................................$8.53</td>
<td>100</td>
</tr>
</tbody>
</table>

### Multiple Sclerosis Treatments

**DIMETHYL FUMARATE** – **Restricted** see terms below

- Cap 120 mg ...................................................................................................$520.00 14 Tecfidera
- Cap 240 mg ..................................................................................................$2,000.00 56 Tecfidera

**Initiation**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

**FINGOLIMOD** – **Restricted** see terms below

- Cap 0.5 mg .................................................................................................$2,200.00 28 Gilenya

**Initiation**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

**NATALIZUMAB** – **Restricted** see terms below

- Inj 20 mg per ml, 15 ml vial ...........................................................................$1,750.00 1 Tysabri

**Initiation**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

**TERIFLUNOMIDE** – **Restricted** see terms below

- Tab 14 mg ..................................................................................................$1,582.62 28 Aubagio

**Initiation**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

### Other Multiple Sclerosis Treatments

**GLATIRAMER ACETATE** – **Restricted** see terms above

- Inj 40 mg prefilled syringe ...........................................................................$2,275.00 12 Copaxone

**INTERFERON BETA-1-ALPHA** – **Restricted** see terms above

- Inj 6 million iu in 0.5 ml pen injector ......................................................................$1,170.00 4 Avonex Pen
- Inj 6 million iu in 0.5 ml syringe ....................................................................$1,170.00 4 Avonex

**INTERFERON BETA-1-BETA** – **Restricted** see terms above

- Inj 8 million iu per ml, 1 ml vial
Sedatives and Hypnotics

CHLORAL HYDRATE
Oral liq 100 mg per ml
Oral liq 200 mg per ml

LORMETAZEPAM – Restricted: For continuation only
→ Tab 1 mg

MELATONIN – Restricted see terms below
↓ Tab modified-release 2 mg.................................................................28.22 30 Circadin
↓ Tab 3 mg
Note: Only for use in compounding an oral liquid formulation, for in-hospital use only.

→ Restricted (RS1576)

Initiation – insomnia secondary to neurodevelopmental disorder
Psychiatrist, paediatrician, neurologist or respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder); and
2 Behavioural and environmental approaches have been tried or are inappropriate; and
3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
4 Patient is aged 18 years or under.

Continuation – insomnia secondary to neurodevelopmental disorder
Psychiatrist, paediatrician, neurologist or respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Patient is aged 18 years or under; and
2 Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
3 Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
4 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Initiation – insomnia where benzodiazepines and zopiclone are contraindicated
Both:
1 Patient has insomnia and benzodiazepines and zopiclone are contraindicated; and
2 For in-hospital use only.

MIDAZOLAM
Tab 7.5 mg
Oral liq 2 mg per ml
Inj 1 mg per ml, 5 ml ampoule – 1% DV Jan-19 to 2021 .........................2.98 10 Mylan Midazolam
Inj 5 mg per ml, 3 ml ampoule – 1% DV Jan-19 to 2021 .........................2.36 5 Mylan Midazolam

NITRAZEPAM – Restricted: For continuation only
→ Tab 5 mg .................................................................5.22 100 Nitrados
(Nitrados Tab 5 mg to be delisted 1 September 2020)

PHENOBARBITONE
Inj 200 mg per ml, 1 ml ampoule

TEMAZEPAM
Tab 10 mg – 1% DV Sep-17 to 2020..................................................1.27 25 Normison

TRIAZOLAM – Restricted: For continuation only
→ Tab 125 mcg
→ Tab 250 mcg
ZOPICLONE
Tab 7.5 mg ................................................................. 0.98 30 Zopiclone Actavis

Stimulants / ADHD Treatments

ATOMOXETINE – Restricted see terms below

Cap 10 mg ................................................................. 107.03 28 Strattera
Cap 18 mg ................................................................. 107.03 28 Strattera
Cap 25 mg ................................................................. 107.03 28 Strattera
Cap 40 mg ................................................................. 107.03 28 Strattera
Cap 60 mg ................................................................. 107.03 28 Strattera
Cap 80 mg ................................................................. 139.11 28 Strattera
Cap 100 mg ................................................................. 139.11 28 Strattera

→ Restricted (RS1371)

Initiation

All of the following:
1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
2. Once-daily dosing; and
3. Any of the following:
   3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
   3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
   3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
   3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
4. The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

CAFFEINE
Tab 100 mg

DEXAMFETAMINE SULFATE – Restricted see terms below

Tab 5 mg – 1% DV Oct-18 to 2021 .................................................. 20.00 100 PSM

→ Restricted (RS1169)

Initiation – ADHD
Paediatrician or psychiatrist
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

Initiation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
Patient suffers from narcolepsy.

Continuation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
The treatment remains appropriate and the patient is benefiting from treatment.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
<tr>
<td>Methyldiphenidate Hydrochloride – Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 18 mg...........................................................................58.96 30 Concerta</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 27 mg...........................................................................65.44 30 Concerta</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 36 mg...........................................................................71.93 30 Concerta</td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 54 mg...........................................................................86.24 30 Concerta</td>
<td></td>
</tr>
<tr>
<td>Tab immediate-release 5 mg.............................................................................3.20 30 Rubifen</td>
<td></td>
</tr>
<tr>
<td>Tab immediate-release 10 mg...........................................................................3.00 30 Ritalin</td>
<td></td>
</tr>
<tr>
<td>Tab immediate-release 20 mg...........................................................................7.85 30 Rubifen</td>
<td></td>
</tr>
<tr>
<td>Tab sustained-release 20 mg..........................................................................50.00 100 Ritalin SR</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 10 mg ............................................................................15.60 30 Ritalin LA</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 20 mg ............................................................................20.40 30 Ritalin LA</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 30 mg ............................................................................25.52 30 Ritalin LA</td>
<td></td>
</tr>
<tr>
<td>Cap modified-release 40 mg ............................................................................30.60 30 Ritalin LA</td>
<td></td>
</tr>
</tbody>
</table>

MODAFINIL – Restricted (RS1171)

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg .....................................................................................................64.00 60 Modavigil</td>
<td></td>
</tr>
</tbody>
</table>

Initiation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months

All of the following:

continued…

- Item restricted (see above); Item restricted (see below)
- e.g. Brand indicates brand example only. It is not a contracted product.
continued...

1. The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and

2. Either:
   2.1. The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
   2.2. The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

3. Either:
   3.1. An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
   3.2. Methylphenidate and dexamphetamine are contraindicated.

Continuation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months
The treatment remains appropriate and the patient is benefitting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

Tab 5 mg – 1% DV Sep-17 to 2020 ........................................................... 4.34 90 Donepezil-Rex
Tab 10 mg – 1% DV Sep-17 to 2020 ........................................................ 6.64 90 Donepezil-Rex

RIVASTIGMINE – Restricted see terms below

- Patch 4.6 mg per 24 hour .......................................................... 90.00 30 Exelon
- Patch 9.5 mg per 24 hour .......................................................... 90.00 30 Exelon

- Restricted (RS1436)

Initiation
Re-assessment required after 6 months
Both:
1. The patient has been diagnosed with dementia; and
2. The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Continuation
Re-assessment required after 12 months
Both:
1. The treatment remains appropriate; and
2. The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Restricted see terms below

- Tab 2 mg with naloxone 0.5 mg ......................................................... 57.40 28 Suboxone
- Tab 8 mg with naloxone 2 mg ......................................................... 166.00 28 Suboxone

- Restricted (RS1172)

Initiation – Detoxification
All of the following:

1. Patient is opioid dependent; and
2. Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
3. Prescriber works in an opioid treatment service approved by the Ministry of Health.

continued...
continued…

Initiation – Maintenance treatment

All of the following:

1. Patient is opioid dependent; and
2. Patient will not be receiving methadone; and
3. Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
4. Prescriber works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg – 1% DV Jun-17 to 2020..............................11.00 30 Zyban

DISULFIRAM

Tab 200 mg ..............................................................................................75.57 100 Antabuse

NALTREXONE HYDROCHLORIDE – Restricted see terms below

↓ Tab 50 mg – 1% DV Sep-17 to 2020.......................................................112.55 30 Naltraccord

≤ Restricted (RS1173)

Initiation – Alcohol dependence

Both:

1. Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
2. Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

Initiation – Constipation

For the treatment of opioid-induced constipation.

NICOTINE – Some items restricted see terms below

↓ Oral spray 1 mg per dose

Lozenge 1 mg – 1% DV Apr-18 to 2020...............................................18.27 216 Habitrol

Lozenge 2 mg – 1% DV Apr-18 to 2020...............................................20.02 216 Habitrol

≤ Soln for inhalation 15 mg cartridge

Gum 2 mg – 1% DV Apr-18 to 2020......................................................36.39 384 Habitrol (Fruit)

Gum 4 mg – 1% DV Apr-18 to 2020......................................................42.07 384 Habitrol (Mint)

≤ Restricted (RS1310)

Initiation

Any of the following:

1. For perioperative use in patients who have a ‘nil by mouth’ instruction; or
2. For use within mental health inpatient units; or
3. For acute use in agitated patients who are unable to leave the hospital facilities.

VARENICLINE – Restricted see terms below

↓ Tab 0.5 mg x 11 and 1 mg x 42 – 1% DV Mar-19 to 2021.......................25.64 53 Varenicline Pfizer

≤ Tab 1 mg – 1% DV Mar-19 to 2021......................................................27.10 56 Varenicline Pfizer

≤ Restricted (RS1511)

Initiation

All of the following:

continued…
continued…

1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and

2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and

3 Either:
   3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
   3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and

4 The patient has not used funded varenicline in the last 12 months; and

5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and

6 The patient is not pregnant; and

7 The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.
Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – Restricted see terms below


1. Inj 25 mg vial ................................................................................................. 271.35 1 Ribomustin

2. Inj 100 mg vial ............................................................................................. 1,085.38 1 Ribomustin

Initiation – treatment naive CLL

All of the following:

1. The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
2. The patient is chemotherapy treatment naive; and
3. The patient is unable to tolerate toxicity of full-dose FCR; and
4. Patient has ECOG performance status 0-2; and
5. Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
6. Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

All of the following:

1. The patient has indolent low grade NHL requiring treatment; and
2. Patient has a WHO performance status of 0-2; and
3. Either:
   3.1 Both:
      3.1.1 Patient is treatment naive; and
      3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
   3.2 All of the following:
      3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
      3.2.2 The patient has not received prior bendamustine therapy; and
      3.2.3 Either:
         3.2.3.1 Both:
            3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
            3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
         3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Continuation – Indolent, Low-grade lymphomas

Re-assessment required after 9 months

Both:

1. Patients have not received a bendamustine regimen within the last 12 months; and
2. Either:
   2.1 Both:
       2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
       2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

continued…
2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients. Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/Waldenström's macroglobulinaemia.

<table>
<thead>
<tr>
<th>ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUSULFAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>89.25</td>
<td>100 Myleran</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARMUSTINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg vial</td>
<td>1,387.00</td>
<td>1 BiCNU</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bicnu Heritage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emcure</td>
</tr>
<tr>
<td>BUSULFAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg vial to be delisted 1 October 2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| CHLORAMBUCLIL                           |                           |                              |
| Tab 2 mg                                |                           |                              |

| CYCLOPHOSPHAMIDE                        |                           |                              |
| Tab 50 mg                               | 79.00                     | 50 Endoxan                   |
| Inj 1 g vial – 1% DV Oct-18 to 2021      | 35.65                     | 1 Endoxan                    |
| Inj 2 g vial – 1% DV Oct-18 to 2021      | 71.25                     | 1 Endoxan                    |

| IFOSFAMIDE                              |                           |                              |
| Inj 1 g vial                            | 96.00                     | 1 Holoxan                    |
| Inj 2 g vial                            | 180.00                    | 1 Holoxan                    |

| LOMUSTINE                               |                           |                              |
| Cap 10 mg                               | 132.59                    | 20 Ceenu                      |
| Cap 40 mg                               | 399.15                    | 20 Ceenu                      |

| MELPHALAN                               |                           |                              |
| Tab 2 mg                                |                           |                              |
| Inj 50 mg vial                          |                           |                              |

| THIOTEPA                                |                           |                              |
| Inj 15 mg vial                          |                           |                              |
| Inj 100 mg vial                         |                           |                              |

| Anthracyclines and Other Cytotoxic Antibiotics |                           |                              |
| BLEOMYCIN SULPHATE                      |                           |                              |
| Inj 15,000 iu vial – 1% DV Dec-18 to 2021 | 161.01                    | 1 DBL Bleomycin Sulfate       |

| DACTINOMYCIN [ACTINOMYCIN D]             |                           |                              |
| Inj 0.5 mg vial                         | 166.75                    | 1 Cosmegen                   |

| DAUNORUBICIN                            |                           |                              |
| Inj 2 mg per ml, 10 ml vial             | 130.00                    | 1 Pfizer                     |

| DOXORUBICIN HYDROCHLORIDE               |                           |                              |
| Inj 2 mg per ml, 5 ml vial              | 11.50                     | 1 Doxorubicin Ebewe          |
| Inj 2 mg per ml, 25 ml vial             | 23.00                     | 1 Doxorubicin Ebewe          |
| Inj 50 mg vial                          |                           |                              |
| Inj 2 mg per ml, 100 ml vial – 1% DV Jan-19 to 2021 | 56.15 | 1 Doxorubicin Ebewe          |
## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPIRUBICIN HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td></td>
<td>25.00</td>
<td>Epirubicin Ebewe</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 25 ml vial</td>
<td></td>
<td>30.00</td>
<td>Epirubicin Ebewe</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Apr-19 to 2021</td>
<td></td>
<td>85.00</td>
<td>Epirubicin Ebewe</td>
</tr>
<tr>
<td><strong>IDARUBICIN HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg vial – 1% DV Sep-18 to 2021</td>
<td></td>
<td>93.00</td>
<td>Zavedos</td>
</tr>
<tr>
<td>Inj 10 mg vial – 1% DV Sep-18 to 2021</td>
<td></td>
<td>198.00</td>
<td>Zavedos</td>
</tr>
<tr>
<td><strong>MITOMYCIN C</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg vial</td>
<td></td>
<td>204.08</td>
<td>Arrow</td>
</tr>
<tr>
<td><strong>MITOZANTRONE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml vial</td>
<td></td>
<td>97.50</td>
<td>Mitozantrone Ebewe</td>
</tr>
</tbody>
</table>

### Antimetabolites

#### AZACITIDINE – Restricted see terms below

- Inj 100 mg vial – 1% DV Dec-18 to 2021 | 139.00 | Azacitidine Dr Reddy's

- **Restricted (RS1418)**

Initiation

Haematologist

**Re-assessment required after 12 months**

All of the following:

1. Any of the following:
   1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
   1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
   1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and

2. The patient has performance status (WHO/ECOG) grade 0-2; and

3. The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and

4. The patient has an estimated life expectancy of at least 3 months.

Continuation

Haematologist

**Re-assessment required after 12 months**

Both:

1. No evidence of disease progression, and; and

2. The treatment remains appropriate and patient is benefitting from treatment.

#### CAPECITABINE

- Tab 150 mg | 11.15 | 60 | Brinov
- Tab 500 mg | 62.28 | 120 | Brinov

#### CLADRIBINE

- Inj 2 mg per ml, 5 ml vial
- Inj 1 mg per ml, 10 ml vial | 5,249.72 | 7 | Leustatin

#### CYTARABINE

- Inj 20 mg per ml, 5 ml vial | 400.00 | 5 | Pfizer
- Inj 100 mg per ml, 20 ml vial – 1% DV Dec-18 to 2021 | 41.36 | 1 | Pfizer

#### FLUDARABINE PHOSPHATE

- Tab 10 mg – 1% DV Sep-18 to 2021 | 412.00 | 20 | Fludara Oral
- Inj 50 mg vial – 1% DV Nov-19 to 2022 | 576.45 | 5 | Fludarabine Ebewe
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Expiry</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUOROURACIL</strong></td>
<td>Inj 50 mg per ml, 20 ml vial – 1% DV Oct-18 to 2021</td>
<td>12.00</td>
<td>1</td>
<td>Fluorouracil Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg per ml, 100 ml vial – 1% DV Oct-18 to 2021</td>
<td>30.00</td>
<td>1</td>
<td>Fluorouracil Ebewe</td>
</tr>
<tr>
<td><strong>GEMCITABINE</strong></td>
<td>Inj 10 mg per ml, 100 ml vial</td>
<td>15.89</td>
<td>1</td>
<td>Gemcitabine Ebewe</td>
</tr>
<tr>
<td><strong>MERCAPTOPURINE</strong></td>
<td>Tab 50 mg – 1% DV Jul-19 to 2022</td>
<td>37.00</td>
<td>25</td>
<td>Puri-nethol</td>
</tr>
<tr>
<td></td>
<td>Oral suspension 20 mg per ml</td>
<td>428.00</td>
<td>100 ml</td>
<td>Allmercap</td>
</tr>
<tr>
<td>‾ Restricted (RS1635)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation</strong></td>
<td>Paediatric haematologist or paediatric oncologist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-assessment required after 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The patient requires a total dose of less than one full 50 mg tablet per day.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Continuation</strong></td>
<td>Paediatric haematologist or paediatric oncologist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-assessment required after 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The patient requires a total dose of less than one full 50 mg tablet per day.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METHOTREXATE</strong></td>
<td>Tab 2.5 mg – 1% DV Jan-19 to 2021</td>
<td>8.05</td>
<td>90</td>
<td>Trexate</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg – 1% DV Jan-19 to 2021</td>
<td>31.75</td>
<td>90</td>
<td>Trexate</td>
</tr>
<tr>
<td></td>
<td>Inj 2.5 mg per ml, 2 ml vial</td>
<td></td>
<td>1</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 7.5 mg prefilled syringe</td>
<td>14.61</td>
<td>1</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg prefilled syringe</td>
<td>14.66</td>
<td>1</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 15 mg prefilled syringe</td>
<td>14.77</td>
<td>1</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 20 mg prefilled syringe</td>
<td>14.88</td>
<td>1</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg prefilled syringe</td>
<td>14.99</td>
<td>1</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 30 mg prefilled syringe</td>
<td>15.09</td>
<td>1</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg per ml, 2 ml vial</td>
<td>30.00</td>
<td>5</td>
<td>DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg per ml, 20 ml vial</td>
<td>45.00</td>
<td>1</td>
<td>DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 10 ml vial</td>
<td>25.00</td>
<td>1</td>
<td>Methotrexate Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 50 ml vial – 1% DV Sep-17 to 2020</td>
<td>79.99</td>
<td>1</td>
<td>Methotrexate Ebewe</td>
</tr>
<tr>
<td><strong>PEMETREXED</strong></td>
<td>– Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg vial</td>
<td>60.89</td>
<td>1</td>
<td>Juno Pemetrexed</td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg vial</td>
<td>217.77</td>
<td>1</td>
<td>Juno Pemetrexed</td>
</tr>
<tr>
<td>‾ Restricted (RS1596)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation – Mesothelioma</strong></td>
<td>Re-assessment required after 8 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Both:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 Patient has been diagnosed with mesothelioma; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Continuation – Mesothelioma</strong></td>
<td>Re-assessment required after 8 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All of the following:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 No evidence of disease progression; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 The treatment remains appropriate and the patient is benefitting from treatment; and</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

**Initiation – Non small cell lung cancer**

*Re-assessment required after 8 months*

Both:

1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and

2 Either:

   2.1 Both:

      2.1.1 Patient has chemotherapy-naive disease; and
      2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or

   2.2 All of the following:

      2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
      2.2.2 Patient has not received prior funded treatment with pemetrexed; and
      2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

**Continuation – Non small cell lung cancer**

*Re-assessment required after 8 months*

All of the following:

1 No evidence of disease progression; and

2 The treatment remains appropriate and the patient is benefitting from treatment; and

3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

**THIOGUANINE**

Tab 40 mg

**Other Cytotoxic Agents**

**AMSACRINE**

Inj 50 mg per ml, 1.5 ml ampoule
Inj 75 mg

**ANAGRELIDE HYDROCHLORIDE**

Cap 0.5 mg

**ARSENIC TRIOXIDE**

Inj 1 mg per ml, 10 ml vial……………………………………………………………………..4,817.00 10 Phenasen

**BORTEZOMIB – Restricted** see terms below

$ Inj 3.5 mg vial ……………………………………………………………………………1,892.50 1 Velcade

⇒ Restricted (RS1189)

**Initiation – treatment naive multiple myeloma/amyloidosis**

*Limited to 15 months* treatment

Both:

1 Either:

   1.1 The patient has treatment-naive symptomatic multiple myeloma; or
   1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis; and

2 Maximum of 9 treatment cycles.

**Initiation – relapsed/refractory multiple myeloma/amyloidosis**

*Re-assessment required after 8 months*

All of the following:

1 Either:

  continued…
continued...

1.1 The patient has relapsed or refractory multiple myeloma; or

1.2 The patient has relapsed or refractory systemic AL amyloidosis; and

2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and

3 The patient has not had prior publicly funded treatment with bortezomib; and

4 Maximum of 4 treatment cycles.

Continuation – relapsed/refractory multiple myeloma/amyloidosis

Re-assessment required after 8 months

Both:

1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and

2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

1 A known therapeutic chemotherapy regimen and supportive treatments; or

2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

Colestipol [L-Asparaginase]

Inj 10,000 IU vial .................................................................................................. 102.32 1 Leunase

Dacarbazine

Inj 200 mg vial .................................................................................................. 58.06 1 DBL Dacarbazine

Etoposide

Cap 50 mg – 1% DV Jul-19 to 2022 ................................................................. 340.73 20 Vepesid

Cap 100 mg – 1% DV Jul-19 to 2022 ................................................................. 340.73 10 Vepesid

Inj 20 mg per ml, 5 ml vial .............................................................................. 7.90 1 Rex Medical

Etoposide (As Phosphate)

Inj 100 mg vial ................................................................................................. 40.00 1 Etopophos

Hydroxyurea

Cap 500 mg ........................................................................................................ 31.76 100 Hydrea

Irinotecan Hydrochloride

Inj 20 mg per ml, 5 ml vial – 1% DV Apr-19 to 2021 ...................................... 71.44 1 Irinotecan Actavis 100

Lenalidomide – Restricted see terms below

Cap 10 mg ........................................................................................................ 6,207.00 21 Revlimid

Cap 15 mg ........................................................................................................ 7,239.18 21 Revlimid

Cap 25 mg ........................................................................................................ 7,627.00 21 Revlimid

Restricted (RS1419)

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

1 Patient has relapsed or refractory multiple myeloma with progressive disease; and

2 Either:

2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or

2.2 Both:

2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and

2.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and

continued…

Products with Hospital Supply Status (HSS) are in bold

expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued...

3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

**Continuation**

Haematologist

*Re-assessment required after 6 months*

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and patient is benefitting from treatment.

**Note:** Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

**PEGASPARGASE – Restricted** see terms below

- Inj 750 iu per ml, 5 ml vial.................................................................3,005.00 1 Oncaspar

**Initiation – Newly diagnosed ALL**

*Limited to 12 months treatment*

All of the following:

1. The patient has newly diagnosed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

**Initiation – Relapsed ALL**

*Limited to 12 months treatment*

All of the following:

1. The patient has relapsed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

**PENTOSTATIN [DEOXYCOFORMYCIN]**

Inj 10 mg vial

**PROCARBAZINE HYDROCHLORIDE**

Cap 50 mg...............................................................................................980.00 50 Natulan

**TEMOZOLOMIDE – Restricted** see terms below

- Cap 5 mg.................................................................10.20 5 Orion Temozolomide
- Cap 20 mg.................................................................18.30 5 Orion Temozolomide
- Cap 100 mg.................................................................40.20 5 Orion Temozolomide
- Cap 250 mg.................................................................96.80 5 Orion Temozolomide

**Initiation – High grade gliomas**

*Re-assessment required after 12 months*

All of the following:

1. Either:
   1.1 Patient has newly diagnosed glioblastoma multiforme; or
   1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
3. Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day.

continued…
Continuation – High grade gliomas
Re-assessment required after 12 months
Either:
1 Both:
   1.1 Patient has glioblastoma multiforme; and
   1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
2 All of the following:
   2.1 Patient has anaplastic astrocytoma*; and
   2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
   2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Initiation – Neuroendocrine tumours
Re-assessment required after 9 months
All of the following:
1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
2 Temozolomide is to be given in combination with capecitabine; and
3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
4 Temozolomide to be discontinued at disease progression.

Continuation – Neuroendocrine tumours
Re-assessment required after 6 months
Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Initiation – ewing’s sarcoma
Re-assessment required after 9 months
Patient has relapse or refractory Ewing’s sarcoma.

Continuation – ewing’s sarcoma
Re-assessment required after 6 months
Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high grade glioma.

THALIDOMIDE – Restricted see terms below

Cap 50 mg.....................................................................................................378.00 28 Thalomid
Cap 100 mg...................................................................................................756.00 28 Thalomid

Restricted (RS1192)

Initiation
Re-assessment required after 12 months
Any of the following:
1 The patient has multiple myeloma; or
2 The patient has systemic AL amyloidosis*; or
3 The patient has erythema nodosum leprosum.

Continuation
Patient has obtained a response from treatment during the initial approval period.
Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier
Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen
Indication marked with * is an unapproved indication
TRETINOIN
Cap 10 mg .....................................................................................................479.50 100 Vesananoid

Platinum Compounds

CARBOPLATIN
Inj 10 mg per ml, 45 ml vial – 1% DV Jun-19 to 2021 ...................................45.20 1 Carboplatin Ebeewe
CISPLATIN
Inj 1 mg per ml, 50 ml vial ............................................................................12.29 1 DBL Cisplatin
Inj 1 mg per ml, 100 ml vial – 1% DV Sep-18 to 2021 ...................................19.70 1 DBL Cisplatin
OXALIPLATIN
Inj 5 mg per ml, 20 ml vial – 1% DV Feb-20 to 2021 .....................................46.32 1 Oxaliccord

(Oxaliccord Inj 5 mg per ml, 20 ml vial to be delisted 1 February 2020)

Protein-Tyrosine Kinase Inhibitors

DASATINIB – Restricted see terms below
Tab 20 mg .................................................................................................3,774.06 60 Sprycel
Tab 50 mg .................................................................................................6,214.20 60 Sprycel
Tab 70 mg .................................................................................................7,692.58 60 Sprycel

Restricted (RS1685)

Initiation
Haematologist or any relevant practitioner on the recommendation of a haematologist
Re-assessment required after 6 months
Any of the following:
1 Both:
   1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
   1.2 Maximum dose of 140 mg/day; or
2 Both:
   2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
   2.2 Maximum dose of 140 mg/day; or
3 All of the following:
   3.1 The patient has a diagnosis of CML in chronic phase; and
   3.2 Maximum dose of 100 mg/day; and
   3.3 Any of the following:
      3.3.1 Patient has documented treatment failure* with imatinib; or
      3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
      3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
      3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

Continuation
Haematologist or any relevant practitioner on the recommendation of a haematologist
Re-assessment required after 6 months
All of the following:
1 Lack of treatment failure while on dasatinib*; and
2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up
https://www.cancertrialsnz.ac.nz/kiss/
**ERLOTINIB** – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$764.00</td>
<td>30 Tarceva</td>
</tr>
<tr>
<td>$1,146.00</td>
<td>30 Tarceva</td>
</tr>
</tbody>
</table>

**Initiation**

*Re-assessment required after 4 months*

All of the following:

1. Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
3. Either:
   3.1 Patient is treatment naive; or
   3.2 Both:
      3.2.1 The patient has discontinued gefitinib due to intolerance; and
      3.2.2 The cancer did not progress while on gefitinib; and
4. Erlotinib is to be given for a maximum of 3 months.

**Continuation**

*Re-assessment required after 6 months*

Both:

1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Erlotinib is to be given for a maximum of 3 months.

**GEFITINIB** – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,700.00</td>
<td>30 Iressa</td>
</tr>
</tbody>
</table>

**Initiation**

*Re-assessment required after 4 months*

All of the following:

1. Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. Either:
   2.1 Patient is treatment naive; or
   2.2 Both:
      2.2.1 The patient has discontinued erlotinib due to intolerance; and
      2.2.2 The cancer did not progress whilst on erlotinib; and
3. There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
4. Gefitinib is to be given for a maximum of 3 months.

**Continuation**

*Re-assessment required after 6 months*

Both:

1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Gefitinib is to be given for a maximum of 3 months.

**IMATINIB MESILATE**

*Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule*

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,400.00</td>
<td>60 Glivec</td>
</tr>
</tbody>
</table>

**Initiation**

*Re-assessment required after 12 months*

Both:

continued...
continued...

1 Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
2 Maximum dose of 400 mg/day.

Continuation

Re-assessment required after 12 months

Adequate clinical response to treatment with imatinib (prescriber determined).

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg – 1% DV Oct-17 to 2020</td>
<td>98.00 60 Imatinib-AFT</td>
</tr>
<tr>
<td>Cap 400 mg – 1% DV Oct-17 to 2020</td>
<td>197.50 30 Imatinib-AFT</td>
</tr>
</tbody>
</table>

LAPATINIB – Restricted see terms below

Initiation

Re-assessment required after 12 months

Either:

1 All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
   1.3 Lapatinib not to be given in combination with trastuzumab; and
   1.4 Lapatinib to be discontinued at disease progression; or

2 All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on trastuzumab; and
   2.4 Lapatinib not to be given in combination with trastuzumab; and
   2.5 Lapatinib to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
3 Lapatinib not to be given in combination with trastuzumab; and
4 Lapatinib to be discontinued at disease progression.

NILOTINIB – Restricted see terms below

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

继续…
continued...

1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and

2 Either:
   2.1 Patient has documented CML treatment failure* with imatinib; or
   2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and

3 Maximum nilotinib dose of 800 mg/day; and

4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Continuation

Haematologist

*Re-assessment required after 6 months*

All of the following:

1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and

2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and

3 Maximum nilotinib dose of 800 mg/day; and

4 Subsidised for use as monotherapy only.

PAZOPANIB – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg</td>
<td>1,334.70</td>
<td>30 Votrient</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>2,669.40</td>
<td>30 Votrient</td>
</tr>
</tbody>
</table>

⇒ Restricted (RS1198)

Initiation

*Re-assessment required after 3 months*

All of the following:

1 The patient has metastatic renal cell carcinoma; and

2 Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 Both:
      2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
      2.3.2 The cancer did not progress whilst on sunitinib; and

3 The patient has good performance status (WHO/ECOG grade 0-2); and

4 The disease is of predominant clear cell histology; and

5 All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis.

Continuation

*Re-assessment required after 3 months*

Both:

1 No evidence of disease progression; and

2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.
### RUXOLITINIB – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jakavi</td>
<td>2,500.00</td>
<td>56</td>
</tr>
<tr>
<td>Jakavi</td>
<td>5,000.00</td>
<td>56</td>
</tr>
</tbody>
</table>

**Initiation**
Haematologist

*Re-assessment required after 12 months*

All of the following:

1. The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocytopenia myelofibrosis; and
2. A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
3. A maximum dose of 20 mg twice daily is to be given.

**Continuation**
Haematologist

*Re-assessment required after 12 months*

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. A maximum dose of 20 mg twice daily is to be given.

### SUNITINIB – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutent</td>
<td>2,315.38</td>
<td>28</td>
</tr>
<tr>
<td>Sutent</td>
<td>4,630.77</td>
<td>28</td>
</tr>
<tr>
<td>Sutent</td>
<td>9,261.54</td>
<td>28</td>
</tr>
</tbody>
</table>

**Initiation – RCC**

*Re-assessment required after 3 months*

All of the following:

1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
   2.4 Both:
      2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
      2.4.2 The cancer did not progress whilst on pazopanib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
5. All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis; and
6. Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

continued…
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

**Continuation – RCC**

*Re-assessment required after 3 months*

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

**Initiation – GIST**

*Re-assessment required after 3 months*

Both:

1. The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Either:
   2.1 The patient’s disease has progressed following treatment with imatinib; or
   2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

**Continuation – GIST**

*Re-assessment required after 6 months*

Both:

The patient has responded to treatment or has stable disease as determined by Choi’s modified CT response evaluation criteria as follows:

1. Any of the following:
   1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
   1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
   1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and

2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: GIST - It is recommended that response to treatment be assessed using Choi’s modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

### Taxanes

**DOCETAXEL**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 2 ml vial – 1% DV Sep-17 to 2020</td>
<td>12.40</td>
<td>DBL Docetaxel</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 8 ml vial – 1% DV Sep-17 to 2020</td>
<td>26.95</td>
<td>DBL Docetaxel</td>
</tr>
</tbody>
</table>

**Paclitaxel**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020</td>
<td>47.30</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020</td>
<td>20.00</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 25 ml vial</td>
<td>26.69</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 50 ml vial – 1% DV Oct-17 to 2020</td>
<td>35.35</td>
<td>Paclitaxel Ebewe</td>
</tr>
</tbody>
</table>
## Treatment of Cytotoxic-Induced Side Effects

### CALCIUM FOLINATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBL Leucovorin Calcium</td>
<td>104.26</td>
<td>10</td>
</tr>
<tr>
<td>Calcium Folate Ebewe</td>
<td>18.25</td>
<td>5</td>
</tr>
<tr>
<td>Calcium Folate Sandoz</td>
<td>4.55</td>
<td>1</td>
</tr>
<tr>
<td>Calcium Folate Ebewe Sandoz</td>
<td>7.33</td>
<td>1</td>
</tr>
<tr>
<td>Calcium Folate Sandoz</td>
<td>9.49</td>
<td></td>
</tr>
<tr>
<td>Calcium Folate Sandoz</td>
<td>22.51</td>
<td>1</td>
</tr>
<tr>
<td>Calcium Folate Sandoz</td>
<td>67.51</td>
<td>1</td>
</tr>
<tr>
<td>Calcium Folate Sandoz</td>
<td>60.00</td>
<td></td>
</tr>
</tbody>
</table>

*(Calcium Folate Ebewe Inj 10 mg per ml, 10 ml vial to be delisted 1 January 2020)*

### DEXRAZOXANE – Restricted see terms below

- Inj 500 mg
  - Restricted (RS1695)

### Initiation

Medical oncologist, paediatric oncologist, haematologist or paediatric haematologist

All of the following:

1. Patient is to receive treatment with high dose anthracycline given with curative intent; and
2. Based on current treatment plan, patient’s cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater; and
3. Dexrazoxane to be administered only whilst on anthracycline treatment; and
4. Either:
   1. Treatment to be used as a cardioprotectant for a child or young adult; or
   2. Treatment to be used as a cardioprotectant for secondary malignancy.

### MESNA

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>314.00</td>
<td>50</td>
</tr>
<tr>
<td>Uromitexan</td>
<td>448.50</td>
<td>50</td>
</tr>
<tr>
<td>Uromitexan</td>
<td>177.45</td>
<td>15</td>
</tr>
<tr>
<td>Uromitexan</td>
<td>407.40</td>
<td>15</td>
</tr>
</tbody>
</table>

### Vinca Alkaloids

#### VINBLASTINE SULPHATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospira</td>
<td>186.46</td>
<td>5</td>
</tr>
</tbody>
</table>

#### VINCRISTINE SULPHATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBL Vincristine Sulfate</td>
<td>74.52</td>
<td>5</td>
</tr>
<tr>
<td>DBL Vincristine Sulfate</td>
<td>85.61</td>
<td>5</td>
</tr>
</tbody>
</table>

#### VINORELBINE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Navelbine</td>
<td>12.00</td>
<td>1</td>
</tr>
<tr>
<td>Navelbine</td>
<td>56.00</td>
<td>1</td>
</tr>
</tbody>
</table>

### Endocrine Therapy

#### ABIRATERONE ACETATE – Restricted see terms on the next page

- Tab 250 mg
  - 4,276.19

---

*Item restricted (see ➸ above); Item restricted (see ➸ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**Restricted (RS1658)**

**Initiation**

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has prostate cancer; and
2. Patient has metastases; and
3. Patient's disease is castration resistant; and
4. Either:

   4.1 All of the following:
      4.1.1 Patient is symptomatic; and
      4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
      4.1.3 Patient has ECOG performance score of 0-1; and
      4.1.4 Patient has not had prior treatment with taxane chemotherapy; or

4.2 All of the following:

   4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
   4.2.2 Patient has ECOG performance score of 0-2; and
   4.2.3 Patient has not had prior treatment with abiraterone.

**Continuation**

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 6 months*

All of the following:

1. Significant decrease in serum PSA from baseline; and
2. No evidence of clinical disease progression; and
3. No initiation of taxane chemotherapy with abiraterone; and
4. The treatment remains appropriate and the patient is benefiting from treatment.

**BICALUTAMIDE**

Tab 50 mg – 1% DV Feb-18 to 2020 .................................3.80 28  Binarex

**FLUTAMIDE**

Tab 250 mg ..................................................................................................119.50 100  Flutamin

**MEGESTROL ACETATE**

Tab 160 mg – 1% DV Oct-18 to 2021 ..........................................................63.53 30  Apo-Megestrol

**OCTREOTIDE – Some items restricted see terms below**

Inj 50 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 .........................30.64 5  DBL Octreotide

Inj 100 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 .......................18.69 5  DBL Octreotide

Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 .......................72.50 5  DBL Octreotide

Inj 10 mg vial ..............................................................................................1,772.50 1  Sandostatin LAR

Inj 20 mg vial ..............................................................................................2,358.75 1  Sandostatin LAR

Inj 30 mg vial ..............................................................................................2,951.25 1  Sandostatin LAR

**Restricted (RS1201)**

**Initiation – Malignant bowel obstruction**

All of the following:

1. The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
2. Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
3. Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

continued…
**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

continued...

Note: Indications marked with * are unapproved indications

**Initiation – acromegaly**

*Re-assessment required after 3 months*

Both:

1. The patient has acromegaly; and
2. Any of the following:
   2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
   2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
   2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

**Continuation – acromegaly**

Both:

1. IGF1 levels have decreased since starting octreotide; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

**Initiation – Other indications**

Any of the following:

1. VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
2. Both:
   2.1 Gastrinoma; and
   2.2 Either:
      2.2.1 Patient has failed surgery; or
      2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
3. Both:
   3.1 Insulinomas; and
   3.2 Surgery is contraindicated or has failed; or
4. For pre-operative control of hypoglycaemia and for maintenance therapy; or
5. Both:
   5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
   5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide

**TAMOXIFEN CITRATE**

Tab 10 mg – 1% DV Jan-19 to 2020 .................................11.75 60  Tamoxifen Sandoz
Tab 20 mg – 1% DV Jan-19 to 2020 .................................5.60 60  Tamoxifen Sandoz

**Aromatase Inhibitors**

**ANASTROZOLE**

Tab 1 mg – 1% DV Jan-18 to 2020 .................................5.04 30  Rolin

**EXEMESTANE**

Tab 25 mg – 1% DV Sep-17 to 2020 .................................14.50 30  Pfizer Exemestane

**LETROZOLE**

Tab 2.5 mg – 1% DV Nov-18 to 2021 .................................4.68 30  Letrole

---

* Item restricted (see above); ‡ Item restricted (see below)

e.g. Brand indicates brand example only. It is not a contracted product.
# Oncology Agents and Immunosuppressants

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

## Imaging Agents

**Aminolevulinic Acid Hydrochloride** – Restricted see terms below

- Powder for oral soln, 30 mg per ml, 1.5 g vial ............................................ 4,400.00  1  Gliolan
- 44,000.00  10  Gliolan

**Immunosuppressants**

### Calcineurin Inhibitors

**Ciclosporin**

- Cap 25 mg ................................................................. 44.63  50  Neoral
- Cap 50 mg ................................................................. 88.91  50  Neoral
- Cap 100 mg ................................................................. 177.81  50  Neoral
- Oral liq 100 mg per ml ............................................................ 198.13  50 ml  Neoral
- Inj 50 mg per ml, 5 ml ampoule ............................................................ 276.30  10  Sandimmun

**Tacrolimus** – Restricted see terms below

- Cap 0.5 mg ................................................................. 49.60  100  Tacrolimus Sandoz
- Cap 0.75 mg ................................................................. 99.30  100  Tacrolimus Sandoz
- Cap 1 mg ................................................................. 84.30  100  Tacrolimus Sandoz
- Cap 5 mg ................................................................. 248.20  50  Tacrolimus Sandoz
- Inj 5 mg per ml, 1 ml ampoule

**Enbrel**

- Inj 25 mg vial – 5% DV Sep-19 to 2024 ............................................................ 799.96  4  Enbrel
- Inj 50 mg autoinjector – 5% DV Sep-19 to 2024 .................................................. 1,599.96  4  Enbrel
- Inj 50 mg syringe – 5% DV Sep-19 to 2024 .................................................. 1,599.96  4  Enbrel

**Initiation – non-transplant indications**

- Any specialist

**Initiation – juvenile idiopathic arthritis**

- Rheumatologist or named specialist

**Re-assessment required after 6 months**

- Either:

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
146

Item restricted (see above); ❄️ Item restricted (see below)

**e.g. Brand** indicates brand example only. It is not a contracted product.
continued...

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:
   2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
   2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:
   2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:
   2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3. Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or

2. All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and

continued…
continued…

2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

2.5 Either:

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3. Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

1. Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2. All of the following:

2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

continued…
continued...

2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

2.4 Either:
   2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
   2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:
   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
   2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
1 Either:
   1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – severe chronic plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
All of the following:
1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from adalimumab; or
   2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and

3 Patient must be reassessed for continuation after 3 doses.

Initiation – severe chronic plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:
1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer continued…
continued...

than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – severe chronic plaque psoriasis**

Dermatologist

*Re-assessment required after 6 months*

Both:

1 Either:

   1.1 Both:

      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

      1.1.2 Either:

         1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or

         1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:

   1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

   1.2.2 Either:

      1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

      1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Initiation – pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

**Continuation – pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has shown clinical improvement; and

2 Patient continues to require treatment; and

3 A maximum of 4 doses.

continued…
continued...

Initiation – adult-onset Still's disease
Rheumatologist
Re-assessment required after 6 months
Either:

1. Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and

1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
   1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2. All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still's disease
Rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

Monoclonal Antibodies

ABCIXIMAB – Restricted see terms below

- Inj 2 mg per ml, 5 ml vial.................................................................579.53 1 ReoPro

➥ Restricted (RS1202)

Initiation
Either:

1. For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
2. For use in patients undergoing intra-cranial intervention.

ADALIMUMAB – Restricted see terms below

- Inj 20 mg per 0.4 ml syringe.............................................................1,599.96 2 Humira
- Inj 40 mg per 0.8 ml pen.................................................................1,599.96 2 HumiraPen
- Inj 40 mg per 0.8 ml syringe.............................................................1,599.96 2 Humira

➥ Restricted (RS1696)

Initiation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months
Either:

1. Either:
   1.1 Both:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued...

1.1.2 Either:

1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or

2 All of the following:

2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Continuation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 4 months

All of the following:

1 Patient has confirmed Crohn's disease; and
2 Either:

2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
2.2 Patient has one or more rectovaginal fistula(e); and
3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

Continuation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 6 months

Either:

1 The number of open draining fistulae have decreased from baseline by at least 50%; or

continued…
continued...

2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

**Initiation – Crohn's disease - adults**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Patient has severe active Crohn's disease; and
2. Any of the following:
   1.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
   1.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   1.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   1.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

**Continuation – Crohn's disease - adults**

Gastroenterologist

*Re-assessment required after 3 months*

Both:

1. Either:
   1.1 Either:
      1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
      1.1.2 CDAI score is 150 or less; or
   1.2 Both:
      1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
      1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – Crohn's disease - children**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Paediatric patient has severe active Crohn's disease; and
2. Either:
   2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

**Continuation – Crohn's disease - children**

Gastroenterologist

*Re-assessment required after 3 months*

Both:

1. Any of the following:
   1.1 PCDAI score has reduced by 100 points from the PCDAI score when the patient was initiated on adalimumab; or
   1.2 PCDAI score is 150 or less; or

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

continued...

1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2. All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:
   2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
   2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:
   2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:
   2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued…

Item restricted (see above); Item restricted (see below)
e.g. Brand indicates brand example only. It is not a contracted product.
continued...

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – ankylosing spondylitis**
Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2 All of the following:

2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

2.5 Either:
   2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
   2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

*Notes:* The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

**Continuation – ankylosing spondylitis**
Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1 Following 12 weeks’ initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is
continued...

less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – psoriatic arthritis**

*Rheumatologist*

*Re-assessment required after 6 months*

Either:

1 Both:

   1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and

   1.2 Either:

      1.2.1 The patient has experienced intolerable side effects from etanercept; or

      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or

2 All of the following:

   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

   2.4 Either:

      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

   2.5 Any of the following:

      2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

      2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

      2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Continuation – psoriatic arthritis**

*Rheumatologist*

*Re-assessment required after 6 months*

Both:

1 Either:

   1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – plaque psoriasis, prior TNF use**

*Dermatologist*

*Limited to 4 months treatment*

Both:

1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and

2 Either:

   2.1 The patient has experienced intolerable side effects from etanercept; or

continued…
continued...

2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis.

Initiation – plaque psoriasis, treatment-naive
Dermatologist

Limited to 4 months treatment
All of the following:

1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis
Dermatologist

Re-assessment required after 6 months
Both:

1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
      1.1.2 Either:
         1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
         1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

   1.2 Both:
      1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
      1.2.2 Either:
         1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
         1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

continued…
continued…

**Initiation – pyoderma gangrenosum**
Dermatologist
All of the following:
1. Patient has pyoderma gangrenosum*; and
2. Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
3. A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

**Continuation – pyoderma gangrenosum**
Dermatologist
All of the following:
1. Patient has shown clinical improvement; and
2. Patient continues to require treatment; and
3. A maximum of 4 doses.

**Initiation – adult-onset Still's disease**
Rheumatologist
Re-assessment required after 6 months
Either:
1. Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
2. All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Continuation – adult-onset Still's disease**
Rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

**Initiation – severe Behcet's disease**
Any relevant practitioner
Re-assessment required after 3 months
All of the following:
1. The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and
2. Either:
   2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
   2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and

continued…

---

* Item restricted (see [above]); † Item restricted (see [below])

**e.g. Brand** indicates brand example only. It is not a contracted product.
continued...

3 The patient is experiencing significant loss of quality of life; and
4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.


**Continuation – severe Behcet's disease**

Any relevant practitioner

*Re-assessment required after 6 months*

Both:

1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – severe ocular inflammation**

*Re-assessment required after 4 months*

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from infliximab; or
      1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or

2 Both:
   2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
   2.2 Any of the following:
      2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
      2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
      2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

**Continuation – severe ocular inflammation**

*Re-assessment required after 12 months*

Both:

1 Any of the following:
   1.1 The patient has had a good clinical response following 3 initial doses; or
   1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
   1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

**Initiation – chronic ocular inflammation**

*Re-assessment required after 4 months*

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and
   1.2 Either:
### 1.2.1 The patient has experienced intolerable side effects from infliximab; or
### 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation; or

2 Both:

2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and

2.2 Any of the following:

2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or

2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or

2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

### Continuation – chronic ocular inflammation

**Re-assessment required after 12 months**

Both:

1 Any of the following:

1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or

1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

### AFLIBERCEPT – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eylea</td>
<td></td>
</tr>
</tbody>
</table>
| Inj 40 mg per ml, 0.1 ml vial.                                           1,250.00 1 Eylea

- **Restricted (RS1659)**

### Initiation – Wet Age Related Macular Degeneration

**Ophthalmologist**

**Re-assessment required after 3 months**

Either:

1 All of the following:

1.1 Any of the following:

1.1.1 Wet age-related macular degeneration (wet AMD); or

1.1.2 Polypoidal choroidal vasculopathy; or

1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and

1.2 Either:

1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or

1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

1.3 There is no structural damage to the central fovea of the treated eye; and

1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or

continued…
continued…

2 Either:
   2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
   2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 12 months
All of the following:
   1 Documented benefit must be demonstrated to continue; and
   2 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
   3 There is no structural damage to the central fovea of the treated eye.

Initiation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 4 months
All of the following:
   1 Patient has centre involving diabetic macular oedema (DMO); and
   2 Patient’s disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
   3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
   4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
   5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
   1 There is stability or two lines of Snellen visual acuity gain; and
   2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
   3 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
   4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
   5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

BASILIXIMAB – Restricted see terms below

- Inj 20 mg vial ..............................................................................................2,560.00 1 Simulect

➡ Restricted (RS1203)

Initiation
For use in solid organ transplants.

BEVACIZUMAB – Restricted see terms below

- Inj 25 mg per ml, 4 ml vial
- Inj 25 mg per ml, 16 ml vial

➡ Restricted (RS1691)

Initiation – Recurrent Respiratory Papillomatosis
Otolaryngologist
Re-assessment required after 12 months
All of the following:
   1 Maximum of 6 doses; and
continued…

2 The patient has recurrent respiratory papillomatosis; and
3 The treatment is for intra-lesional administration.

**Continuation – Recurrent Respiratory Papillomatosis**

Otolaryngologist

*Re-assessment required after 12 months*

All of the following:

1 Maximum of 6 doses; and
2 The treatment is for intra-lesional administration; and
3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

**Initiation – ocular conditions**

Either:

1 Ocular neovascularisation; or
2 Exudative ocular angiopathy.

**CETUXIMAB – Restricted** see terms below

- Inj 5 mg per ml, 20 ml vial………………………………………364.00 1 Erbitux
- Inj 5 mg per ml, 100 ml vial…………………………………1,820.00 1 Erbitux

*Restricted (RS1613)*

**Initiation**

Medical oncologist

All of the following:

1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
2 Patient is contraindicated to, or is intolerant of, cisplatin; and
3 Patient has good performance status; and
4 To be administered in combination with radiation therapy.

**INFLIXIMAB – Restricted** see terms below

- Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020……………………………………….806.00 1 Remicade

*Restricted (RS1697)*

**Initiation – Graft vs host disease**

Patient has steroid-refractory acute graft vs. host disease of the gut.

**Initiation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

**Continuation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

continued…
continued...

2 Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initiation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 3 months
Both:
  1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
  2 Either:
     2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
     2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months
All of the following:
  1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
  2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
  3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation – psoriatic arthritis
Rheumatologist
Re-assessment required after 4 months
Both:
  1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
  2 Either:
     2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
     2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
  1 Either:
     1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
     1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
  2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – severe ocular inflammation
Re-assessment required after 3 doses
Either:
  1 Both:
     1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
continued...

1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for severe ocular inflammation; or

2 Both:
   2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
   2.2 Any of the following:
      2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
      2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
      2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation – severe ocular inflammation
Re-assessment required after 12 months

Any of the following:
1 The patient has had a good clinical response following 3 initial doses; or
2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – chronic ocular inflammation
Re-assessment required after 3 doses

Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

2 Both:
   2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
   2.2 Any of the following:
      2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
      2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or
      2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation
Re-assessment required after 12 months

Any of the following:
1 The patient has had a good clinical response following 3 initial doses; or

continued…
continued...

2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – Pulmonary sarcoidosis
Both:

1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and

2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation – Crohn’s disease (adults)
Gastroenterologist
Re-assessment required after 3 months
All of the following:

1 Patient has severe active Crohn’s disease; and

2 Any of the following:
   2.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate; and

5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation – Crohn’s disease (adults)
Gastroenterologist
Re-assessment required after 6 months
Both:

1 Any of the following:
   1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
   1.2 CDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – Crohn’s disease (children)
Gastroenterologist
Re-assessment required after 3 months
All of the following:

1 Paediatric patient has severe active Crohn’s disease; and

2 Either:
   2.1 Patient has a Paediatric Crohn’s Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and

continued…
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate; and
5 Patient must be reassessed for continuation after 3 months of therapy.

**Continuation – Crohn’s disease (children)**
Gastroenterologist
*Re-assessment required after 6 months*

Both:

1 Any of the following:
   1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
   1.2 PCDAI score is 15 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – fistulising Crohn’s disease**
Gastroenterologist
*Re-assessment required after 4 months*

Both:

1 Patient has confirmed Crohn’s disease; and
2 Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e).

**Continuation – fistulising Crohn’s disease**
Gastroenterologist
*Re-assessment required after 6 months*

Both:

1 Either:
   1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
   1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – acute severe fulminant ulcerative colitis**
Gastroenterologist
*Limited to 6 weeks treatment*

Both:

1 Patient has acute, severe fulminant ulcerative colitis; and
2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

**Continuation – severe fulminant ulcerative colitis**
Gastroenterologist
*Re-assessment required after 6 months*

Both:

1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
continued...

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 3 months
All of the following:
1 Patient has histologically confirmed ulcerative colitis; and
2 Either:
   2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
   2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
All of the following:
1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
2 Either:
   2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
   2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – plaque psoriasis
Dermatologist
Re-assessment required after 3 doses
Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
      1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or
2 All of the following:
   2.1 Either:
      2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
      2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

continued…
2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – plaque psoriasis**

*Note: This section continues on the next page.*

---

**Initiation – neurosarcoïdosis**

*Note: This section continues on the next page.*
continued...

2 All of the following:
   2.1 A withdrawal period has been considered but would not be clinically appropriate; and
   2.2 There has been a marked reduction in prednisone dose; and
   2.3 Either:
      2.3.1 There has been an improvement in MRI appearances; or
      2.3.2 Marked improvement in other symptomology.

Initiation – severe Behcet's disease
Re-assessment required after 4 months

All of the following:

1. The patient has severe Behcet's disease which is significantly impacting the patient’s quality of life (see Notes); and
2. Either:
   2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
   2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
3. The patient is experiencing significant loss of quality of life.

Notes:

2. Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Continuation – severe Behcet's disease
Re-assessment required after 6 months

Both:

1. Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

OBINUTUZUMAB – Restricted see terms below

Inj 25 mg per ml, 40 ml vial.................................................................5,910.00 1 Gazyva

Initiation
Haematologist
Limited to 6 months treatment

All of the following:

1. The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
2. The patient is obinutuzumab treatment naive; and
3. The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
4. Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
5. Patient has good performance status; and
6. Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other continued…
than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to 1.5 × 10^9/L and platelets greater than or equal to 75 × 10^9/L

OMALIZUMAB – **Restricted** see terms below

- **Inj 150 mg prefilled syringe** ............................................................................ 450.00 1 Xolair
- **Inj 150 mg vial** ............................................................................................... 450.00 1 Xolair

**OMALIZUMAB – Restricted (RS1652)**

*Initiation – severe asthma*

Clinical immunologist or respiratory specialist

*Re-assessment required after 6 months*

All of the following:

1. Patient must be aged 6 years or older; and
2. Patient has a diagnosis of severe asthma; and
3. Past or current evidence of atopy, documented by skin prick testing or RAST; and
4. Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
5. Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
6. Either:
   6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
   6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
7. Patient has an Asthma Control Test (ACT) score of 10 or less; and
8. Baseline measurements of the patient’s asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

**Continuation – severe asthma**

Respiratory specialist

*Re-assessment required after 6 months*

Both:

1. An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
2. A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

*Initiation – severe chronic spontaneous urticaria*

Clinical immunologist or dermatologist

*Re-assessment required after 6 months*

All of the following:

1. Patient must be aged 12 years or older; and
2. Either:
   2.1 Both:
      2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
      2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
3. Any of the following:
   3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
   3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic...
continued…

corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or

3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and

4 Either:

4.1 Treatment to be stopped if inadequate response* following 4 doses; or

4.2 Complete response* to 6 doses of omalizumab.

Continuation – severe chronic spontaneous urticaria
Clinical immunologist or dermatologist
*Re-assessment required after 6 months

Either:

1 Patient has previously had a complete response* to 6 doses of omalizumab; or

2 Both:

2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and

2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – Restricted see terms below

↓ Inj 30 mg per ml, 14 ml vial…………………………………………………………………..3,927.00 1 Perjeta

⇒ Restricted (RS1551)

Initiation
*Re-assessment required after 12 months

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:

2.1 Patient is chemotherapy treatment naive; or

2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and

3 The patient has good performance status (ECOG grade 0-1); and

4 Pertuzumab to be administered in combination with trastuzumab; and

5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and

6 Pertuzumab to be discontinued at disease progression.

Continuation
*Re-assessment required after 12 months

Both:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB – Restricted see terms below

↓ Inj 10 mg per ml, 0.23 ml vial

↓ Inj 10 mg per ml, 0.3 ml vial

⇒ Restricted (RS1637)

Initiation – Wet Age Related Macular Degeneration
Ophthalmologist
*Re-assessment required after 3 months

Either:

continued…
1. All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or
      1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
      1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3 There is no structural damage to the central fovea of the treated eye; and
   1.4 Patient has not previously been treated with afiblercept for longer than 3 months; or
2. Patient has current approval to use afiblercept for treatment of wAMD and was found to be intolerant to afiblercept within 3 months.

Continuation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 12 months
All of the following:
1. Documented benefit must be demonstrated to continue; and
2. Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
3. There is no structural damage to the central fovea of the treated eye.

RITUXIMAB – Restricted see terms below
Inj 10 mg per ml, 10 ml vial..............................................................1,075.50 2 Mabthera
Inj 10 mg per ml, 50 ml vial.............................................................2,688.30 1 Mabthera

Initiation – haemophilia with inhibitors
Haematologist
Any of the following:
1. Patient has mild congenital haemophilia complicated by inhibitors; or
2. Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
3. Patient has acquired haemophilia.

Continuation – haemophilia with inhibitors
Haematologist
All of the following:
1. Patient was previously treated with rituximab for haemophilia with inhibitors; and
2. An initial response lasting at least 12 months was demonstrated; and

Initiation – post-transplant
Both:
1. The patient has B-cell post-transplant lymphoproliferative disorder*; and
2. To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Continuation – post-transplant
All of the following:
1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has B-cell post-transplant lymphoproliferative disorder*; and

continued…
continued...

3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

**Initiation – indolent, low-grade lymphomas or hairy cell leukaemia***

*Re-assessment required after 9 months*

Either:

1 Both:
   1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
   1.2 To be used for a maximum of 6 treatment cycles; or

2 Both:
   2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Continuation – indolent, low-grade lymphomas or hairy cell leukaemia***

*Re-assessment required after 9 months*

All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and
2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Initiation – aggressive CD20 positive NHL**

*Either:

1 All of the following:
   1.1 The patient has treatment naive aggressive CD20 positive NHL; and
   1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
   1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:
   2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Continuation – aggressive CD20 positive NHL**

All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and
2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Initiation – Chronic lymphocytic leukaemia**

*Re-assessment required after 12 months*

All of the following:

1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2 The patient is rituximab treatment naive; and
3 Either:
   3.1 The patient is chemotherapy treatment naive; or

continued…
continued…

3.2 Both:

3.2.1 The patient’s disease has relapsed following no more than three prior lines of chemotherapy treatment; and
3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and

4 The patient has good performance status; and
5 The patient does not have chromosome 17p deletion CLL; and
6 Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles; and
7 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Continuation – Chronic lymphocytic leukaemia
Re-assessment required after 12 months
All of the following:

1 The patient’s disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
2 The patient has had an interval of 36 months or more since the commencement of initial rituximab treatment; and
3 The patient does not have chromosome 17p deletion CLL; and
4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
5 Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation – rheumatoid arthritis - prior TNF inhibitor use
Rheumatologist
Limited to 4 months treatment
All of the following:

1 Both:

1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
1.2 Either:

1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:

2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – rheumatoid arthritis - TNF inhibitors contraindicated
Rheumatologist
Limited to 4 months treatment
All of the following:

1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and

continued…
continued...

2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

5 Any of the following:
   5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
   5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

6 Either:
   6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:
   7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:
   8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in ‘partial responders’ to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

1 Any of the following:
   1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:
   3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in ‘responders’ to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

continued…
continued…

1 Either:

1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Patient has cold haemagglutinin disease*; and

2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are unapproved indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:

2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and

2.2 An initial response lasting at least 12 months was demonstrated; and

2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Patient has warm autoimmune haemolytic anaemia*; and

2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are unapproved indications.

Continuation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:

2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and

continued…
continued...

2.2 An initial response lasting at least 12 months was demonstrated; and
2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Either:
   1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
   1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and

2 Any of the following:
   2.1 Treatment with steroids and splenectomy have been ineffective; or
   2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
   2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with * are unapproved indications.

Continuation – immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
2 All of the following:
   2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 4 weeks

All of the following:

1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
2 An initial response lasting at least 12 months was demonstrated; and
3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

continued...
continued…

**Initiation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

**Continuation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

**Initiation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. The total rituximab dose would not exceed the equivalent of 375 mg/m^2^ of body-surface area per week for a total of 4 weeks; and
3. Any of the following:
   3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
   3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
   3.3 Cyclophosphamide and methotrexate are contraindicated; or
   3.4 Patient is a female of child-bearing potential; or
   3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

**Continuation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3. The total rituximab dose would not exceed the equivalent of 375 mg/m^2^ of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

**Initiation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1. The patient has severe, immediately life- or organ-threatening SLE*; and
2. The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
3. The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
4. Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Continuation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1. Patient’s SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
2. The disease has subsequently relapsed; and

continued…
continued...

3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Initiation – Antibody-mediated renal transplant rejection**

Nephrologist

Patient has been diagnosed with antibody-mediated renal transplant rejection*.

Note: Indications marked with * are unapproved indications.

**Initiation – ABO-incompatible renal transplant**

Nephrologist

Patient is to undergo an ABO-incompatible renal transplant*.

Note: Indications marked with * are unapproved indications.

**Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient is a child with SDNS* or FRNS*; and
2. Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
3. Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
4. Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
5. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

**Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

**Initiation – Steroid resistant nephrotic syndrome (SRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
2. Treatment with tacrolimus for at least 3 months has been ineffective; and
3. Genetic causes of nephrotic syndrome have been excluded; and
4. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

**Continuation – Steroid resistant nephrotic syndrome (SRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

continued...
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued…

1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

**Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)**

Relevant specialist or medical practitioner on the recommendation of a Relevant specialist

*Re-assessment required after 6 months*

Both:

1. One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
2. Either:
   2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
   2.2 All of the following:
      2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
      2.2.2 The patient is receiving treatment with mycophenolate; and
      2.2.3 The patient is receiving treatment with corticosteroids.

**Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)**

Relevant specialist or medical practitioner on the recommendation of a Relevant specialist

*Re-assessment required after 2 years*

All of the following:

1. One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
2. The patient has responded to the most recent course of rituximab; and
3. The patient has not received rituximab in the previous 6 months.

**Initiation – Severe Refractory Myasthenia Gravis**

Neurologist or medical practitioner on the recommendation of a Neurologist

*Re-assessment required after 2 years*

Both:

1. One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
2. Either:
   2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
   2.2 Both:
      2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
      2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

**Continuation – Severe Refractory Myasthenia Gravis**

Neurologist or medical practitioner on the recommendation of a Neurologist

*Re-assessment required after 2 years*

All of the following:

1. One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
2. An initial response lasting at least 12 months was demonstrated; and

continued…
continued...

3 Either:
   3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
   3.2 Both:
      3.2.1 The patient’s myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
      3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

SECUKINUMAB – Restricted see terms below

Initiation – severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
   2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Continuation – severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initiation – severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

1 Either:
   1.1 Patient has “whole body” severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most

continued…
continued…

recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – severe chronic plaque psoriasis, first-line biologic**

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

**SILTUXIMAB – Restricted** see terms below

Initiation

Haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and

2 Treatment with an adequate trial of corticosteroids has proven ineffective; and

3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

**Continuation**

Haematologist or rheumatologist

Re-assessment required after 12 months

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

**TOCILIZUMAB – Restricted** see terms below

Initiation – Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1 All of the following:

1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and

continued…
continued...

1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
   1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or
   etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and

1.3 Either:
   1.3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor;
   or
   1.3.2 Both:
     1.3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance
     with the Section H rules; and
     1.3.2.2 Either:
       1.3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
       1.3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient
       benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or

2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient
   is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Tocilizumab is to be used as monotherapy; and
   2.3 Either:
     2.3.1 Treatment with methotrexate is contraindicated; or
     2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
   2.4 Either:
     2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of
     cyclosporin alone or in combination with another agent; or
     2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of
     leflunomide alone or in combination with another agent; and
   2.5 Either:
     2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender
     joints; or
     2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the
     following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.6 Either:
     2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the
     date of this application; or
     2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of
     greater than 5 mg per day and has done so for more than three months.

Continuation – Rheumatoid Arthritis
Rheumatologist
Re-assessment required after 6 months
Either:
   1 Following 6 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a
   clinically significant response to treatment in the opinion of the physician; or
   2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from
   baseline and a clinically significant response to treatment in the opinion of the physician.
Initiation – systemic juvenile idiopathic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Continuation – systemic juvenile idiopathic arthritis
Rheumatologist
Re-assessment required after 6 months
Either:
1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Initiation – adult-onset Still's disease
Rheumatologist
Re-assessment required after 6 months
Either:
1 Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still's disease
Rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

Initiation – polyarticular juvenile idiopathic arthritis
Rheumatologist
Re-assessment required after 4 months
Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
2 All of the following:
2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2.5 Both:
   2.5.1 Either:
   2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
   2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
   2.5.2 Physician's global assessment indicating severe disease.

Continuation – polyarticular juvenile idiopathic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – idiopathic multicentric Castleman's disease
Haematologist or rheumatologist
Re-assessment required after 6 months
All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Continuation – idiopathic multicentric Castleman's disease
Haematologist or rheumatologist
Re-assessment required after 12 months
The treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

Initiation – cytokine release syndrome
Therapy limited to 3 doses
Either:

1 All of the following:
   1.1 The patient is enrolled in the Children's Oncology Group AALL1331 trial; and
   1.2 The patient has developed grade 3 or 4 cytokine release syndrome (CRS) associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
   1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses; or
2 All of the following:
   2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
continued...

2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and

2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

TRASTUZUMAB – Restricted see terms below

Inj 150 mg vial ................................................................. 1,350.00 1 Herceptin

Inj 440 mg vial ................................................................. 3,875.00 1 Herceptin

Restricted (RS1554)

Initiation – Early breast cancer

Limited to 12 months treatment

All of the following:

1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Maximum cumulative dose of 106 mg/kg (12 months’ treatment); and

3 Any of the following:

3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or

3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or

3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or

3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or

3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation – metastatic breast cancer (trastuzumab-naive patients)

Limited to 12 months treatment

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:

2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or

2.2 Both:

2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and

2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:

3.1 Trastuzumab will not be given in combination with pertuzumab; or

3.2 All of the following:

3.2.1 Trastuzumab to be administered in combination with pertuzumab; and

3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and

3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

Initiation – metastatic breast cancer (patients previously treated with trastuzumab)

Limited to 12 months treatment

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:

2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price
(ex man. excl. GST)
$ Per
Brand or
Generic
Manufacturer

continued...
2.2 Both:
   2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 
       3 months of starting treatment due to intolerance; and
   2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of 
          at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast 
          cancer; and
      3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and
5 Trastuzumab to be discontinued at disease progression.

Continuation – metastatic breast cancer
Re-assessment required after 12 months

All of the following:
1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
3 Trastuzumab not to be given in combination with lapatinib; and
4 Trastuzumab to be discontinued at disease progression.

Programmed Cell Death-1 (PD-1) Inhibitors

NIVOLUMAB – Restricted see terms below

- Inj 10 mg per ml, 4 ml vial.................................................................1,051.98 1  Opdivo
- Inj 10 mg per ml, 10 ml vial.............................................................2,629.96 1  Opdivo

Initiation
Medical oncologist
Re-assessment required after 4 months
All of the following:
1 Patient has metastatic or unresectable melanoma stage III or IV; and
2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
3 The patient has ECOG performance score of 0-2; and
4 Either:
   4.1 Patient has not received funded pembrolizumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued 
           pembrolizumab within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on pembrolizumab; and

5 Nivolumab is to be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles); and
6 Baseline measurement of overall tumour burden is documented (see Note); and
7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of 
   nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

continued…
Continuation

Medical oncologist

Re-assessment required after 4 months

All of the following:

1 Any of the following:
   1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
   1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
   1.3 Patient has stable disease according to RECIST criteria (see Note); and

2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and

3 No evidence of progressive disease according to RECIST criteria (see Note); and

4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and

5 Nivolumab will be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – Restricted see terms below

- Inj 25 mg per ml, 4 ml vial...............................................................4,680.00 1 Keytruda
- Inj 50 mg vial ..............................................................................2,340.00 1 Keytruda

(Keytruda Inj 50 mg vial to be delisted 1 October 2019)

- Restricted (RS1584)

Initiation

Medical oncologist

Re-assessment required after 4 months

All of the following:

1 Patient has metastatic or unresectable melanoma stage III or IV; and

2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and

3 The patient has ECOG performance score of 0-2; and

4 Either:
   4.1 Patient has not received funded nivolumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab

continued…
continued...

5. Pembrolizumab is to be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles); and
6. Baseline measurement of overall tumour burden is documented (see Note); and
7. Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

Continuation

Medical oncologist
Re-assessment required after 4 months
All of the following:

1. Any of the following:
   1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
   1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
   1.3 Patient has stable disease according to RECIST criteria (see Note); and

2. Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and

3. No evidence of progressive disease according to RECIST criteria (see Note); and

4. The treatment remains clinically appropriate and the patient is benefitting from the treatment; and

5. Pembrolizumab will be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)
Inj 50 mg per ml, 5 ml ampoule ......................................................... 2,351.25  5  ATGAM

ANTITHYMOCYTE GLOBULIN (RABBIT)
Inj 25 mg vial
AZATHIOPRINE
Tab 25 mg – 1% DV Jan-20 to 2022 ................................................................. 7.35  60  Azamun
Tab 50 mg – 1% DV Jan-20 to 2022 ................................................................. 9.66  100  Imuran
Tab 50 mg vial – 1% DV Nov-19 to 2022 .......................................................... 199.00  1  Imuran

(Imuran Tab 25 mg to be delisted 1 January 2020)
(Imuran Tab 50 mg to be delisted 1 January 2020)

BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below
Inj 2-8 × 10^8 CFU vial ............................................................................... 149.37  1  OncoTICE

VEROLIMUS – Restricted see terms below
Tab 5 mg ......................................................................................................... 4,555.76  30  Afinitor
Tab 10 mg ....................................................................................................... 6,512.29  30  Afinitor

SIROLIMUS – Restricted see terms below
Tab 1 mg ......................................................................................................... 749.99  100  Rapamune
Tab 2 mg ......................................................................................................... 1,499.99  100  Rapamune
Oral liq 1 mg per ml ..................................................................................... 449.99  60 ml  Rapamune

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

MYCOPHENOLATE MOFETIL
Tab 500 mg ..................................................................................................... 25.00  50  CellCept
Cap 250 mg ................................................................................................... 25.00  100  CellCept
Powder for oral liq 1 g per 5 ml ................................................................. 187.25  165 ml  CellCept
Inj 500 mg vial .............................................................................................. 133.33  4  CellCept

PICIBANIL
Inj 100 mg vial
Tab 1 mg ......................................................................................................... 749.99  100  Rapamune
Tab 2 mg ......................................................................................................... 1,499.99  100  Rapamune
Oral liq 1 mg per ml ..................................................................................... 449.99  60 ml  Rapamune

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant

continued…
continued...

to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease
### Antiallergy Preparations

#### Allergic Emergencies

ICATIBANT – Restricted see terms below

- **Inj 10 mg per ml, 3 ml prefilled syringe**

  - Restricted (RS1501)

  **Initiation**

  Clinical immunologist or relevant specialist

  *Re-assessment required after 12 months*

  Both:

  1. Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and

  2. The patient has undergone product training and has agreed upon an action plan for self-administration.

**Continuation**

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

#### Allergy Desensitisation

BEE VENOM – Restricted see terms below

- **Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent**

  - Restricted (RS1117)

  **Initiation**

  Both:

  1. RAST or skin test positive; and

  2. Patient has had severe generalised reaction to the sensitising agent.

PAPER WASP VENOM – Restricted see terms below

- **Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent**

  - Restricted (RS1118)

  **Initiation**

  Both:

  1. RAST or skin test positive; and

  2. Patient has had severe generalised reaction to the sensitising agent.

YELLOW JACKET WASP VENOM – Restricted see terms below

- **Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent**

  - Restricted (RS1119)

  **Initiation**

  Both:

  1. RAST or skin test positive; and

  2. Patient has had severe generalised reaction to the sensitising agent.

#### Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE

- **Nasal spray 50 mcg per dose**

  - $5.26 200 dose Alanase

- **Nasal spray 100 mcg per dose**

  - $6.00 200 dose Alanase

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. Brand indicates brand example only. It is not a contracted product.
### RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th><strong>BUDESONIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal spray 50 mcg per dose – 1% DV Oct-18 to 2020</td>
<td>$2.59</td>
<td>SteroClear</td>
</tr>
<tr>
<td>Nasal spray 100 mcg per dose  – 1% DV Oct-18 to 2020</td>
<td>$2.87</td>
<td>SteroClear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>FLUTICASONE PROPIONATE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal spray 50 mcg per dose – 1% DV Nov-18 to 2021</td>
<td>$1.98</td>
<td>Flixonase Hayfever &amp; Allergy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>IPRATROPIUM BROMIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aqueous nasal spray 0.03% – 1% DV Oct-17 to 2020</td>
<td>$4.61</td>
<td>Univent</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>SODIUM CROMOGLICATE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal spray 4%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antihistamines

<table>
<thead>
<tr>
<th><strong>CETIRIZINE HYDROCHLORIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Nov-19 to 2022</td>
<td>$1.12</td>
<td>Zista</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml</td>
<td>$2.99</td>
<td>Histaclear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CHLORPHENIRAMINE MALEATE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 0.4 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CYPROHEPTADINE HYDROCHLORIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>FEXOFENADINE HYDROCHLORIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 60 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 120 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 180 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>LORATADINE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td>$1.28</td>
<td>Lorafix</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml</td>
<td>$2.15</td>
<td>Lorfast</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>PROMETHAZINE HYDROCHLORIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td>$1.68</td>
<td>Allersoothe</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Sep-18 to 2021</td>
<td>$1.89</td>
<td>Allersoothe</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Sep-18 to 2021</td>
<td>$2.69</td>
<td>Allersoothe</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td>$15.54</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

#### Anticholinergic Agents

<table>
<thead>
<tr>
<th><strong>IPRATROPIUM BROMIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler 20 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 250 mcg per ml, 1 ml ampoule</td>
<td>$3.35</td>
<td>Univent</td>
</tr>
<tr>
<td>Nebuliser soln 250 mcg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>$11.73</td>
<td>Univent</td>
</tr>
</tbody>
</table>

#### Anticholinergic Agents with Beta-Adrenoceptor Agonists

<table>
<thead>
<tr>
<th><strong>SALBUTAMOL WITH IPRATROPIUM BROMIDE</strong></th>
<th><strong>Price</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>$5.20</td>
<td>Duolin</td>
</tr>
</tbody>
</table>

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Long-Acting Muscarinic Agents

**GLYCOPYRRONIUM**
Note: inhaled glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium or umeclidinium.
Powder for inhalation 50 mcg per dose ........................................................... 61.00 30 dose Seebri Breezhaler

**TIOTROPIUM BROMIDE**
Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.
Soln for inhalation 2.5 mcg per dose ............................................................... 50.37 60 dose Spiriva Respimat
Powder for inhalation 18 mcg per dose ........................................................... 50.37 30 dose Spiriva

**UMECLIDINIUM**
Note: Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.
Powder for inhalation 62.5 mcg per dose ........................................................ 61.50 30 dose Incruse Ellipta

### Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

**GLYCOPYRRONIUM WITH INDACATEROL** – **Restricted** see terms above

1. Powder for Inhalation 50 mcg with indacaterol 110 mcg ......................... 81.00 30 dose Ultibro Breezhaler

**TIOTROPIUM BROMIDE WITH OLODATEROL** – **Restricted** see terms above

1. Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg ............................. 81.00 60 dose Spiolto Respimat

**UMECLIDINIUM WITH VILANTEROL** – **Restricted** see terms above

1. Powder for inhalation 62.5 mcg with vilanterol 25 mcg ......................... 77.00 30 dose Anoro Ellipta

### Antifibrotics

**NINTEDANIB** – **Restricted** see terms below

1. Cap 100 mg ............................................................................................... 2,554.00 60 Ofev
2. Cap 150 mg ............................................................................................... 3,870.00 60 Ofev

**Restricted (RS1654)**

Initiation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:

continued…
1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2 Forced vital capacity is between 50% and 90% predicted; and
3 Nintedanib is to be discontinued at disease progression (See Note); and
4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
5 Any of the following:
   5.1 The patient has not previously received treatment with pirfenidone; or
   5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
   5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

**Continuation – idiopathic pulmonary fibrosis**
Respiratory specialist
*Re-assessment required after 12 months*
All of the following:
1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – **Restricted** see terms below

Cap 267 mg .................................................................................................................. 3,645.00 270 Esbriet

**Restricted (RS1655)**

**Initiation – idiopathic pulmonary fibrosis**
Respiratory specialist
*Re-assessment required after 12 months*
All of the following:
1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2 Forced vital capacity is between 50% and 80% predicted; and
3 Pirfenidone is to be discontinued at disease progression (See Notes); and
4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
5 Any of the following:
   5.1 The patient has not previously received treatment with nintedanib; or
   5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
   5.3 Patient has previously received nintedanib, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

**Continuation – idiopathic pulmonary fibrosis**
Respiratory specialist
*Re-assessment required after 12 months*
All of the following:
1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.
**RESPIRATORY SYSTEM AND ALLERGIES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Beta-Adrenoceptor Agonists

**SALBUTAMOL**
- Oral liq 400 mcg per ml – 1% DV Nov-18 to 2021 ........................................ 20.00 150 ml Ventolin
- Inj 500 mcg per ml, 1 ml ampoule
- Inj 1 mg per ml, 5 ml ampoule
- Aerosol inhaler, 100 mcg per dose .......................................................... 3.80 200 dose SalAir
- Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021 ........... 3.93 20 Asthalin
- Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021 ........... 4.03 20 Asthalin

**TERBUTALINE SULPHATE**
- Powder for inhalation 250 mcg per dose
- Inj 0.5 mg per ml, 1 ml ampoule

### Cough Suppressants

**PHOLCODINE**
- Oral liq 1 mg per ml

### Decongestants

**OXYMETAZOLINE HYDROCHLORIDE**
- Aqueous nasal spray 0.25 mg per ml
- Aqueous nasal spray 0.5 mg per ml

**PSEUDOEPHEDRINE HYDROCHLORIDE**
- Tab 60 mg

**SODIUM CHLORIDE**
- Aqueous nasal spray isotonic

**SODIUM CHLORIDE WITH SODIUM BICARBONATE**
- Soln for nasal irrigation

**XYLOMETAZOLINE HYDROCHLORIDE**
- Aqueous nasal spray 0.05%
- Aqueous nasal spray 0.1%
- Nasal drops 0.05%
- Nasal drops 0.1%

### Inhaled Corticosteroids

**BECLOMETHASONE DIPROPIONATE**
- Aerosol inhaler 50 mcg per dose ............................................................. 8.54 200 dose Beclazone 50
- Aerosol inhaler 100 mcg per dose ......................................................... 9.30 200 dose Qvar
- Aerosol inhaler 250 mcg per dose ......................................................... 12.50 200 dose Beclazone 100
- Aerosol inhaler 500 mcg per dose ......................................................... 15.50 200 dose Beclazone 250

**BUDESONIDE**
- Nebuliser soln 250 mcg per ml, 2 ml ampoule
- Nebuliser soln 500 mcg per ml, 2 ml ampoule
- Powder for inhalation 100 mcg per dose
- Powder for inhalation 200 mcg per dose
- Powder for inhalation 400 mcg per dose

---

1. Item restricted (see above);
2. Item restricted (see below)

*E.g.* *Brand* indicates brand example only. It is not a contracted product.
FLUTICASONE

Aerosol inhaler 50 mcg per dose ................................................................. 7.50 120 dose Flixotide
Powder for inhalation 50 mcg per dose .................................................. 4.68 60 dose Floair
Powder for inhalation 100 mcg per dose .............................................. 8.67 60 dose Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose ....................................................... 13.78 120 dose Flixotide Accuhaler
Aerosol inhaler 250 mcg per dose ....................................................... 27.20 120 dose Flixotide
Powder for inhalation 250 mcg per dose ............................................. 10.18 60 dose Floair

Leukotriene Receptor Antagonists

MONTELUKAST
Tab 4 mg – 1% DV Jan-20 to 2022 ................................................................. 5.25 28 Apo-Montelukast
4.47 Montelukast Mylan
Tab 5 mg – 1% DV Jan-20 to 2022 ................................................................. 5.50 28 Apo-Montelukast
4.25 Montelukast Mylan
Tab 10 mg – 1% DV Jan-20 to 2022 ......................................................... 5.65 28 Apo-Montelukast
3.95 Montelukast Mylan

(Apo-Montelukast Tab 4 mg to be delisted 1 January 2020)
(Apo-Montelukast Tab 5 mg to be delisted 1 January 2020)
(Apo-Montelukast Tab 10 mg to be delisted 1 January 2020)

Long-Acting Beta-Adrenoceptor Agonists

EFORMOTEROL FUMARATE
Powder for inhalation 12 mcg per dose

EFORMOTEROL FUMARATE DIHYDRATE
Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose)

INDACATEROL
Powder for inhalation 150 mcg per dose .................................................. 61.00 30 dose Onbrez Breezhaler
Powder for inhalation 300 mcg per dose .................................................. 61.00 30 dose Onbrez Breezhaler

SALMETEROL
Aerosol inhaler 25 mcg per dose ............................................................. 9.90 120 dose Meterol
25.00 Serevent
Powder for inhalation 50 mcg per dose ............................................... 25.00 60 dose Serevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFOMOTEROL
Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg
Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg
Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

FLUTICASONE FUROATE WITH VILANTEROL
Powder for inhalation 100 mcg with vilanterol 25 mcg .................................. 44.08 30 dose Breo Ellipta
RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUTICASONE WITH SALMETEROL</td>
</tr>
<tr>
<td>Aerosol inhaler 50 mcg with salmeterol 25 mcg .......................... 14.58 120 dose RexAir</td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg with salmeterol 50 mcg ......................... 33.74 60 dose Seretide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg with salmeterol 25 mcg .......................... 16.83 120 dose RexAir</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg with salmeterol 50 mcg ......................... 44.08 60 dose Seretide Accuhaler</td>
</tr>
</tbody>
</table>

**Mast Cell Stabilisers**

**NEDOCROMIL**
Aerosol inhaler 2 mg per dose

**SODIUM CROMOGLICATE**
Aerosol inhaler 5 mg per dose

**Methylxanthines**

**AMINOPHYLLINE**
Inj 25 mg per ml, 10 ml ampoule – 1% DV Nov-17 to 2020 ......................... 124.37 5 DBL Aminophylline

**CAFFEINE CITRATE**
Oral liq 20 mg per ml (caffeine 10 mg per ml) – 1% DV Nov-19 to 2022 ........... 15.10 25 ml Biomed
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – 1% DV Nov-19 to 2022 ........................................... 63.25 5 Biomed

**THEOPHYLLINE**
Tab long-acting 250 mg – 1% DV Jan-20 to 2022 .................................... 23.02 100 Nuelin-SR
Oral liq 80 mg per 15 ml – 1% DV Jan-20 to 2022 .................................. 16.60 500 ml Nuelin

**Mucolytics and Expectorants**

**DORNASE ALFA** – Restricted see terms below

↓ Restricted (RS1352)
Nebuliser soln 2.5 mg per 2.5 ml ampoule ........................................... 250.00 6 Pulmozyme

**SODIUM CHLORIDE**
Nebuliser soln 7%, 90 ml bottle – 1% DV Nov-19 to 2022 ................................ 24.50 90 ml Biomed

**Pulmonary Surfactants**

**BERACTANT**
Soln 200 mg per 8 ml vial
<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PORACTANT ALFA</td>
<td>Soln 120 mg per 1.5 ml vial</td>
<td>$425.00</td>
<td>1</td>
<td>Curosurf</td>
</tr>
<tr>
<td></td>
<td>Soln 240 mg per 3 ml vial</td>
<td>$695.00</td>
<td>1</td>
<td>Curosurf</td>
</tr>
</tbody>
</table>

**Respiratory Stimulants**

**DOXAPRAM**
Inj 20 mg per ml, 5 ml vial

**Sclerosing Agents**

**TALC**
Powder
Soln (slurry) 100 mg per ml, 50 ml

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Anti-Infective Preparations

#### Antibacterials

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHLORAMPHENICOL</td>
<td>Eye oint 1%</td>
<td>2.48</td>
<td>4 g Chlorsig</td>
</tr>
<tr>
<td></td>
<td>Ear drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.5% – 1% DV Nov-19 to 2022</td>
<td>1.54</td>
<td>10 ml Chlorafast</td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CIPROFLOXACIN</td>
<td>Eye drops 0.3% – 1% DV Jun-18 to 2020</td>
<td>9.99</td>
<td>5 ml Ciprofloxacin Teva</td>
</tr>
<tr>
<td>FRAMYCETIN SULPHATE</td>
<td>Ear/eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GENTAMICIN SULPHATE</td>
<td>Eye drops 0.3%</td>
<td>11.40</td>
<td>5 ml Genoptic</td>
</tr>
<tr>
<td>PROPAMIDINE ISETHIONATE</td>
<td>Eye drops 0.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM FUSIDATE [FUSIDIC ACID]</td>
<td>Eye drops 1%</td>
<td>5.29</td>
<td>5 g Fucithalmic</td>
</tr>
<tr>
<td>SULPHACETAMIDE SODIUM</td>
<td>Eye drops 10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOBRAMYCIN</td>
<td>Eye oint 0.3%</td>
<td>10.45</td>
<td>3.5 g Tobrex</td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.3%</td>
<td>11.48</td>
<td>5 ml Tobrex</td>
</tr>
</tbody>
</table>

#### Antifungals

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>NATAMYCIN</td>
<td>Eye drops 5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antivirals

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACICLOVIR</td>
<td>Eye oint 3%</td>
<td>14.92</td>
<td>4.5 g ViruPOS</td>
</tr>
</tbody>
</table>

#### Combination Preparations

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIPROFLOXACIN WITH HYDROCORTISONE</td>
<td>Ear drops ciprofloxacin 0.2% with 1% hydrocortisone</td>
<td>16.30</td>
<td>10 ml Ciproxin HC Otic</td>
</tr>
<tr>
<td>DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN</td>
<td>Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE</td>
<td>Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g</td>
<td>5.39</td>
<td>3.5 g Maxitrol</td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml</td>
<td>4.50</td>
<td>5 ml Maxitrol</td>
</tr>
<tr>
<td>DEXAMETHASONE WITH TOBRAMYCIN</td>
<td>Eye drops 0.1% with tobramycin 0.3%</td>
<td>12.64</td>
<td>5 ml Tobradex</td>
</tr>
</tbody>
</table>

---

*Note: *Brand indicates brand example only. It is not a contracted product.

*Item restricted (see § above); Item restricted (see § below)*
FLUMETASONE PIVALATE WITH Clioquinol
Ear drops 0.02% with clioquinol 1%

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and
gramicidin 250 mcg per g ................................................................. 5.16 7.5 ml Kenacomb

Anti-Inflammatory Preparations

Corticosteroids

DEXAMETHASONE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye oint 0.1%</td>
<td>5.86</td>
<td>Maxidex</td>
</tr>
<tr>
<td>Eye drops 0.1%</td>
<td>4.50</td>
<td>Maxidex</td>
</tr>
<tr>
<td>Ocular implant 700 mcg</td>
<td>1,444.50</td>
<td>Ozurdex</td>
</tr>
</tbody>
</table>

Restricted (RS1606)
Initiation – Diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
1. Patients have diabetic macular oedema with pseudophakic lens; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Either:
   3.1 Patient’s disease has progressed despite 3 injections with bevacizumab; or
   3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Continuation – Diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
Both:
1. Patient’s vision is stable or has improved (prescriber determined); and
2. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Initiation – Women of child bearing age with diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
1. Patients have diabetic macular oedema; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Patient is of child bearing potential and has not yet completed a family; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Continuation – Women of child bearing age with diabetic macular oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:
1. Patient’s vision is stable or has improved (prescriber determined); and
2. Patient is of child bearing potential and has not yet completed a family; and
3. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.
## SENSORY ORGANS

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUOROMETHOLONE</td>
<td>Eye drops 0.1%</td>
<td>FML</td>
<td>3.09</td>
<td>5 ml</td>
</tr>
<tr>
<td>PREDNISOLONE ACETATE</td>
<td>Eye drops 0.12%</td>
<td>Pred Forte</td>
<td>7.00</td>
<td>5 ml</td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%</td>
<td></td>
<td>3.93</td>
<td>10 ml</td>
</tr>
<tr>
<td>PREDNISOLONE SODIUM PHOSPHATE</td>
<td>Eye drops 0.5%, single dose</td>
<td>Minims Prednisolone</td>
<td>38.50</td>
<td>20 dose</td>
</tr>
<tr>
<td></td>
<td>(preservative free)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Steroidal Anti-Inflammatory Drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DICLOFENAC SODIUM</td>
<td>Eye drops 0.1%</td>
<td>Voltaren Ophtha</td>
<td>13.80</td>
<td>5 ml</td>
</tr>
<tr>
<td>KETOROLAC TROMETAMOL</td>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decongestants and Antiallergics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiallergic Preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEVOCABASTINE</td>
<td>Eye drops 0.05%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LODOXAMIDE</td>
<td>Eye drops 0.1%</td>
<td>Lomide</td>
<td>8.71</td>
<td>10 ml</td>
</tr>
<tr>
<td>OLOPATADINE</td>
<td>Eye drops 0.1%</td>
<td>Patanol</td>
<td>10.00</td>
<td>5 ml</td>
</tr>
<tr>
<td>SODIUM CROMOGLICATE</td>
<td>Eye drops 2% – 1%</td>
<td>Rexacrom</td>
<td>1.79</td>
<td>5 ml</td>
</tr>
<tr>
<td></td>
<td>DV Jan-20 to 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decongestants</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAPHAZOLINE HYDROCHLORIDE</td>
<td>Eye drops 0.1%</td>
<td>Naphcon Forte</td>
<td>4.15</td>
<td>15 ml</td>
</tr>
<tr>
<td>Diagnostic and Surgical Preparations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnostic Dyes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLUORESCIN SODIUM</td>
<td>Eye drops 2%, single dose</td>
<td>Fluorescite</td>
<td>125.00</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Inj 10%, 5 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ophthalmic strips 1 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLUORESCIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE</td>
<td>Eye drops 0.25% with lignocaine hydrochloride 4%, single dose</td>
<td>Fluorescite</td>
<td>125.00</td>
<td>12</td>
</tr>
<tr>
<td>LISSAMINE GREEN</td>
<td>Ophthalmic strips 1.5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROSE BENGAL SODIUM</td>
<td>Ophthalmic strips 1%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Irrigation Solutions

**MIXED SALT SOLUTION FOR EYE IRRIGATION**

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle ............... 5.00 15 ml Balanced Salt Solution

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml e.g. Balanced Salt Solution

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle ..................... 10.50 500 ml Balanced Salt Solution

### Ocular Anaesthetics

**OXYBUPROCAINE HYDROCHLORIDE**

Eye drops 0.4%, single dose

**PROXYMETACAINE HYDROCHLORIDE**

Eye drops 0.5%

**TETRACAINE [AMETHOCAINE] HYDROCHLORIDE**

Eye drops 0.5%, single dose

Eye drops 1%, single dose

### Viscoelastic Substances

**HYPROMELLOSE**

Inj 2%, 1 ml syringe

Inj 2%, 2 ml syringe

**SODIUM HYALURONATE [HYALURONIC ACID]**

Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022............. 50.00 1 Healon GV

Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-19 to 2022............. 50.00 1 Healon GV

Inj 23 mg per ml, 0.6 ml syringe – 1% DV Oct-19 to 2022............. 60.00 1 Healon

Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022............. 28.50 1 Healon

**SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE**

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe ........................................ 64.00 1 Duovisc

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe ........................................ 74.00 1 Duovisc

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe...... 67.00 1 Viscoat

### Other

**DISODIUM EDETATE**

Inj 150 mg per ml, 20 ml ampoule

Inj 150 mg per ml, 20 ml vial

Inj 150 mg per ml, 100 ml vial
<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
</tr>
<tr>
<td>(ex man. excl. GST)</td>
</tr>
</tbody>
</table>

### Sensory Organs

**RIBOFLAVIN 5-PHOSPHATE**
- Soln trans epithelial riboflavin
- Inj 0.1%
- Inj 0.1% plus 20% dextran T500

### Glaucoma Preparations

#### Beta Blockers

**BETAXOLOL**
- Eye drops 0.25% ................................................................. 11.80 5 ml Betoptic S
- Eye drops 0.5% ................................................................. 7.50 5 ml Betoptic

**TIMOLOL**
- Eye drops 0.25% – 1% DV Sep-17 to 2020 ........................................ 1.43 5 ml Arrow-Timolol
- Eye drops 0.25%, gel forming ................................................. 3.30 2.5 ml Timoptol XE
- Eye drops 0.5% – 1% DV Sep-17 to 2020 ........................................ 1.43 5 ml Arrow-Timolol
- Eye drops 0.5%, gel forming .................................................. 3.78 2.5 ml Timoptol XE

*(Timoptol XE Eye drops 0.25%, gel forming to be delisted 1 January 2020)*

#### Carbonic Anhydrase Inhibitors

**ACETAZOLAMIDE**
- Tab 250 mg – 1% DV Sep-17 to 2020 ........................................ 17.03 100 Diamox
- Inj 500 mg

**BRINZOLAMIDE**
- Eye drops 1%

**DORZOLAMIDE**
- Eye drops 2%

**DORZOLAMIDE WITH TIMOLOL**
- Eye drops 2% with timolol 0.5% – 1% DV Jan-19 to 2021 ................. 2.87 5 ml Dortimopt

#### Miotics

**ACETYLCHOLINE CHLORIDE**
- Inj 20 mg vial with diluent

**CARBACHOL**
- Inj 150 mcg vial

**PILOCARPINE HYDROCHLORIDE**
- Eye drops 1% ................................................................. 4.26 15 ml Isopto Carpine
- Eye drops 2% ................................................................. 5.35 15 ml Isopto Carpine
- Eye drops 2%, single dose
- Eye drops 4% ................................................................. 7.99 15 ml Isopto Carpine

#### Prostaglandin Analogues

**BIMATOPROST**
- Eye drops 0.03% – 1% DV Feb-19 to 2021 .................................... 3.30 3 ml Bimatoprost Multichem

**LATANOPROST**
- Eye drops 0.005% – 1% DV Apr-19 to 2021 .................................. 1.57 2.5 ml Teva

**TRAVOPROST**
- Eye drops 0.004% – 1% DV Jan-18 to 2020 ................................ 7.30 5 ml Travopt
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRACLONIDINE</td>
<td>Eye drops 0.5%</td>
<td>$19.77 5 ml</td>
<td>Iopidine</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE</td>
<td>Eye drops 0.2% – 1% DV Feb-18 to 2020</td>
<td>$4.29 5 ml</td>
<td>Arrow-Brimonidine</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE WITH TIMOLOL</td>
<td>Eye drops 0.2% with timolol 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Mydriatics and Cycloplegics**

**Anticholinergic Agents**

| ATROPINE SULPHATE | Eye drops 0.5% | |
| Eye drops 1%, single dose |  |
| Eye drops 1% – 1% DV Sep-17 to 2020 | $17.36 15 ml | Atropt |

| CYCLOPENTOLATE HYDROCHLORIDE | Eye drops 0.5%, single dose | |
| Eye drops 1% |  |
| Eye drops 1%, single dose |  |

| TROPICAMIDE | Eye drops 0.5% | |
| Eye drops 0.5%, single dose |  |
| Eye drops 1% |  |
| Eye drops 1%, single dose |  |

**Sympathomimetics**

| PHENYLEPHRINE HYDROCHLORIDE | Eye drops 2.5%, single dose | |
| Eye drops 10%, single dose | |

**Ocular Lubricants**

| CARBOMER | Ophthalmic gel 0.3%, single dose | $8.25 30 | Poly Gel |
| Ophthalmic gel 0.2% |  |

| CARMELLOSE SODIUM WITH PECTIN AND GELATINE | Eye drops 0.5% | |
| Eye drops 0.5%, single dose |  |
| Eye drops 1% |  |
| Eye drops 1%, single dose |  |

| HYPROMELLOSE | Eye drops 0.5% | |
|  | 3.92 15 ml | Methopt |

| HYPROMELLOSE WITH DEXTRAN | Eye drops 0.3% with dextran 0.1% |  |
| Eye drops 0.3% with dextran 0.1%, single dose |  |

<p>| MACROGOL 400 AND PROPYLENE GLYCOL | Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose |  |
| 4.30 24 | Systane Unit Dose |</p>
<table>
<thead>
<tr>
<th>Sensory Organs</th>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paraffin Liquid with Soft White Paraffin</strong></td>
<td>3.63 3.5 g Poly-Visc</td>
<td></td>
</tr>
<tr>
<td>Eye oint 42.5% with soft white paraffin 57.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Paraffin Liquid with Wool Fat</strong></td>
<td>3.68 15 ml Vistil Forte</td>
<td></td>
</tr>
<tr>
<td>Eye oint 3% with wool fat 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(Vistil Forte Eye drops 3% to be delisted 1 January 2020)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Polyvinyl Alcohol</strong></td>
<td>3.68 15 ml Vistil Forte</td>
<td></td>
</tr>
<tr>
<td>Eye drops 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(Vistil Forte Eye drops 3% to be delisted 1 January 2020)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Polyvinyl Alcohol with Povidone</strong></td>
<td>3.80 5 g VitA-POS</td>
<td></td>
</tr>
<tr>
<td>Eye drops 1.4% with povidone 0.6%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Retinol Palmitate</strong></td>
<td>3.80 5 g VitA-POS</td>
<td></td>
</tr>
<tr>
<td>Oint 138 mcg per g</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sodium Hyaluronate [Hyaluronic Acid]</strong></td>
<td>22.00 10 ml Hylo-Fresh</td>
<td></td>
</tr>
<tr>
<td>Eye drops 1 mg per ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Other Otological Preparations**

| Acetic Acid with Propylene Glycol                                                                 |                             |
| Ear drops 2.3% with propylene glycol 2.8%                                                          |                             |
| **Docusate Sodium**                                                                               |                             |
| Ear drops 0.5%                                                                                    |                             |
### Agents Used in the Treatment of Poisonings

#### Antidotes

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACETYLICYSTEINE</strong></td>
<td>Tab eff 200 mg</td>
<td>$58.76</td>
<td></td>
<td>DBL Acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>Inj 200 mg per ml. 10 ml ampoule – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AMYL NITRITE</strong></td>
<td>Liq 98% in 3 ml capsule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DIGOXIN IMMUNE FAB</strong></td>
<td>Inj 38 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 40 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHANOL</strong></td>
<td>Liq 96%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHANOL WITH GLUCOSE</strong></td>
<td>Inj 10% with glucose 5%, 500 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHANOL, DEHYDRATED</strong></td>
<td>Inj 100%, 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 96%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FLUMAZENIL</strong></td>
<td>Inj 0.1 mg per ml. 5 ml ampoule – 1% DV Dec-18 to 2021</td>
<td>$132.68</td>
<td></td>
<td>Hameln</td>
</tr>
<tr>
<td><strong>HYDROXOCOBALAMIN</strong></td>
<td>Inj 5 g vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 2.5 g vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NALOXONE HYDROCHLORIDE</strong></td>
<td>Inj 400 mcg per ml. 1 ml ampoule – 1% DV Aug-18 to 2021</td>
<td>$22.60</td>
<td></td>
<td>DBL Naloxone Hydrochloride</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PRASTODOXIME IODIDE</strong></td>
<td>Inj 25 mg per ml. 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM NITRITE</strong></td>
<td>Inj 30 mg per ml. 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM THIOSULFATE</strong></td>
<td>Inj 250 mg per ml. 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 250 mg per ml. 50 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg per ml. 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg per ml. 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SOYA OIL</strong></td>
<td>Inj 20%, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 20%, 500 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antitoxins

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BOTULISM ANTITOXIN</strong></td>
<td>Inj 250 ml vial</td>
</tr>
<tr>
<td><strong>DIPHTHERIA ANTITOXIN</strong></td>
<td>Inj 10,000 iu vial</td>
</tr>
</tbody>
</table>
### Antivenoms

**RED BACK SPIDER ANTIVENOM**  
*Inj 500 u vial*

**SNAKE ANTIVENOM**  
*Inj 50 ml vial*

### Removal and Elimination

**CHARCOAL**
- Oral liq 200 mg per ml ................................................................. 43.50  
  250 ml  Carbasorb-X

**DEFERASIROX – Restricted** see terms below
- Tab 125 mg dispersible ................................................................. 276.00  
  28  Exjade
- Tab 250 mg dispersible ................................................................. 552.00  
  28  Exjade
- Tab 500 mg dispersible ................................................................. 1,105.00  
  28  Exjade

> Restricted (RS1444)

**Initiation**

Haematologist  
*Re-assessment required after 2 years*

All of the following:
1. The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
2. Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
3. Any of the following:
   3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
   3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
   3.3 Treatment with deferiprone has resulted in arthritis; or
   3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per µL).

**Continuation**

Haematologist  
*Re-assessment required after 2 years*

Either:
1. For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
2. For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels. 

**DEFERIPRONE – Restricted** see terms below
- Tab 500 mg ................................................................. 533.17  
  100  Ferriprox
- Oral liq 100 mg per ml ................................................................. 266.59  
  250 ml  Ferriprox

> Restricted (RS1445)

**Initiation**

Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

**DESFERRIOXAMINE MESILATE**  
*Inj 500 mg vial – 1% DV Mar-19 to 2021* ................................................................. 84.53  
  10  DBL Desferrioxamine Mesylate for Inj BP

**DICOBALT EDETATE**  
*Inj 15 mg per ml, 20 ml ampoule*
VARIOUS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

DIMERCAPROL
Inj 50 mg per ml, 2 ml ampoule

DIMERCAPTOSUCCINIC ACID
Cap 100 mg
e.g. PCNZ, Optimus Healthcare, Chemet
Cap 200 mg
e.g. PCNZ, Optimus Healthcare, Chemet

SODIUM CALCIUM EDTATE
Inj 200 mg per ml, 2.5 ml ampoule
Inj 200 mg per ml, 5 ml ampoule

Antiseptics and Disinfectants

CHLORHEXIDINE
Soln 4% .......................................................... 1.86 50 ml healthE
Soln 5% .......................................................... 15.50 500 ml healthE

CHLORHEXIDINE WITH CETRIMIDE
Crm 0.1% with cetrimide 0.5%
Foaming soln 0.5% with cetrimide 0.5%

CHLORHEXIDINE WITH ETHANOL
Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml .................................. 2.65 1 healthE
Soln 2% with ethanol 70%, non-staining (pink) 100 ml .................................. 3.54 1 healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml .................................. 1.55 1 healthE
Soln 0.5% with ethanol 70%, staining (red) 100 ml ........................................ 2.90 1 healthE
Soln 2% with ethanol 70%, staining (red) 100 ml ........................................ 3.86 1 healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml ................................ 5.45 1 healthE
Soln 0.5% with ethanol 70%, staining (red) 500 ml ...................................... 5.90 1 healthE
Soln 2% with ethanol 70%, staining (red) 500 ml ...................................... 9.56 1 healthE

IODINE WITH ETHANOL
Soln 1% with ethanol 70%, 100 ml .......................................................... 9.30 1 healthE

ISOPROPYL ALCOHOL
Soln 70%, 500 ml .......................................................... 5.65 1 healthE

POVIDONE-IODINE
Vaginal tab 200 mg
Restricted (RS1354)
Initiation
Rectal administration pre-prostate biopsy.
Oint 10% .......................................................... 3.27 25 g Betadine
Soln 10% – 1% DV Nov-19 to 2021 .......................................................... 6.20 500 ml Betadine
Soln 5% .......................................................................... 2.55 100 ml Riodine
Soln 7.5% ........................................................................ 6.20 500 ml Riodine
Pad 10%
Swab set 10%

POVIDONE-IODINE WITH ETHANOL
Soln 10% with ethanol 30% .......................................................... 10.00 500 ml Betadine Skin Prep
Soln 10% with ethanol 70%
## Contrast Media

### Iodinated X-ray Contrast Media

#### DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE

- **Oral liq** 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle... $22.50 100 ml Gastrografin
- **Inj** 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle... $80.00 1 Urografin

#### DIATRIZOATE SODIUM

- **Oral liq** 370 mg per ml, 10 ml sachet... $156.12 50 Ioscan

#### IODISED OIL

- **Inj** 38% w/w (480 mg per ml), 10 ml ampoule... $410.00 1 Lipiodol Ultra Fluid

#### IODIXANOL

- **Inj** 270 mg per ml (iodine equivalent), 50 ml bottle... $220.00 10 Visipaque
- **Inj** 300 mg per ml (iodine equivalent), 20 ml bottle... $57.00 10 Omnipaque
- **Inj** 300 mg per ml (iodine equivalent), 50 ml bottle... $75.00 10 Omnipaque
- **Inj** 300 mg per ml (iodine equivalent), 100 ml bottle... $150.00 10 Omnipaque
- **Inj** 350 mg per ml (iodine equivalent), 20 ml bottle... $59.00 10 Omnipaque
- **Inj** 350 mg per ml (iodine equivalent), 50 ml bottle... $75.00 10 Omnipaque
- **Inj** 350 mg per ml (iodine equivalent), 75 ml bottle... $114.00 10 Omnipaque
- **Inj** 350 mg per ml (iodine equivalent), 100 ml bottle... $150.00 10 Omnipaque
- **Inj** 350 mg per ml (iodine equivalent), 200 ml bottle... $290.00 10 Omnipaque

### Non-iodinated X-ray Contrast Media

#### BARIUM SULPHATE

- Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet... $507.50 50 E-Z-Cat Dry
- **Oral liq** 400 mg per ml (40% w/v, 30% w/w), bottle... $17.39 148 g Varibar - Thin Liquid
- **Oral liq** 600 mg per g (60% w/v), tube... $36.51 454 g E-Z-Paste
- **Oral liq** 400 mg per ml (40% w/v), bottle... $155.35 250 ml Varibar - Honey
- **Enema** 1,250 mg per ml (125% w/v), 500 ml bag... $282.30 12 Liquibar
- **Oral liq** 22 mg per g (2.2% w/v), 250 ml bottle... $175.00 24 CT Plus+
- **Oral liq** 22 mg per g (2.2% w/v), 450 ml bottle... $220.00 24 CT Plus+
- **Oral liq** 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle... $441.12 24 Volumen
- **Oral liq** 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle... $140.94 24 Readi-CAT 2
- **Powder** for oral soln 97.65% w/w, 300 g bottle... $237.77 24 X-Opaque-HD
- **Oral liq** 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle... $52.35 3 Tagitol V
- **Oral liq** 1,250 mg per ml (125% w/v), 2,000 ml bottle... $91.77 1 Liquibar

#### BARIUM SULPHATE WITH SODIUM BICARBONATE

- **Grans** eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet... $102.93 50 E-Z-Gas II

---

*Item restricted (see above); Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CITRIC ACID WITH SODIUM BICARBONATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Paramagnetic Contrast Media</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GADOBENIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 334 mg per ml, 10 ml vial..........................</td>
<td>324.74</td>
<td>Multihance</td>
</tr>
<tr>
<td>Inj 334 mg per ml, 20 ml vial..........................</td>
<td>636.28</td>
<td>Multihance</td>
</tr>
<tr>
<td>GADOBUTROL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mmol per ml, 15 ml vial..........................</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe ......................................</td>
<td>120.00</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe ......................................</td>
<td>180.00</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe ......................................</td>
<td>700.00</td>
<td>Gadovist 1.0</td>
</tr>
<tr>
<td>GADODIAMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 287 mg per ml, 10 ml prefilled syringe .................</td>
<td>200.00</td>
<td>Omniscan</td>
</tr>
<tr>
<td>Inj 287 mg per ml, 10 ml vial..........................</td>
<td>170.00</td>
<td>Omniscan</td>
</tr>
<tr>
<td>Inj 287 mg per ml, 5 ml vial..........................</td>
<td>120.00</td>
<td>Omniscan</td>
</tr>
<tr>
<td>Inj 287 mg per ml, 15 ml prefilled syringe .................</td>
<td>320.00</td>
<td>Omniscan</td>
</tr>
<tr>
<td>GADOTERIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe ......................................</td>
<td>24.50</td>
<td>Dotarem</td>
</tr>
<tr>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle ......................................</td>
<td>34.50</td>
<td>Dotarem</td>
</tr>
<tr>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe ......................................</td>
<td>41.00</td>
<td>Dotarem</td>
</tr>
<tr>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe ......................................</td>
<td>55.00</td>
<td>Dotarem</td>
</tr>
<tr>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle ......................................</td>
<td>23.20</td>
<td>Dotarem</td>
</tr>
<tr>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle ......................................</td>
<td>46.30</td>
<td>Dotarem</td>
</tr>
<tr>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle ......................................</td>
<td>12.30</td>
<td>Dotarem</td>
</tr>
<tr>
<td>GADOXETATE DISODIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe ......................................</td>
<td>300.00</td>
<td>Primovist</td>
</tr>
<tr>
<td>MEGLUMINE GADODPENTETATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 469 mg per ml, 10 ml prefilled syringe .................</td>
<td>95.00</td>
<td>Magnevist</td>
</tr>
<tr>
<td>Inj 469 mg per ml, 10 ml vial..........................</td>
<td>185.00</td>
<td>Magnevist</td>
</tr>
<tr>
<td>MEGLUMINE IOTROXATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 105 mg per ml, 100 ml bottle ......................</td>
<td>150.00</td>
<td>Biliscopin</td>
</tr>
<tr>
<td><strong>Ultrasound Contrast Media</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PERFLUTREN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.1 mg per ml, 1.5 ml vial..........................</td>
<td>180.00</td>
<td>Definity</td>
</tr>
<tr>
<td>Inj 1.1 mg per ml, 1.5 ml vial..........................</td>
<td>720.00</td>
<td>Definity</td>
</tr>
<tr>
<td><strong>Diagnostic Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARGinine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 500 ml bottle..........................</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 300 ml bottle..........................</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
VARIOUS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

HISTAMINE ACID PHOSPHATE
- Nebuliser soln 0.6%, 10 ml vial
- Nebuliser soln 2.5%, 10 ml vial
- Nebuliser soln 5%, 10 ml vial

MANNITOL
- Powder for inhalation
  e.g. Aridol

METHACHOLINE CHLORIDE
- Powder 100 mg

SECRETIN PENTAHYDROCHLORIDE
- Inj 100 u ampoule

SINCALIDE
- Inj 5 mcg per vial

**Diagnostic Dyes**

BONNEY'S BLUE DYE
- Soln

INDIGO CARMINE
- Inj 4 mg per ml, 5 ml ampoule
- Inj 8 mg per ml, 5 ml ampoule

INDOCYANINE GREEN
- Inj 25 mg vial

METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]
- Inj 5 mg per ml, 10 ml ampoule
  240.35  5 Proveblue

PATENT BLUE V
- Inj 2.5%, 2 ml ampoule
  440.00  5 Obex Medical

**Irrigation Solutions**

CHLORHEXIDINE WITH CETRIMIDE
  - Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

- **Restricted (RS1683)**

  **Initiation**
  *Re-assessment required after 3 months*
  All of the following:
  1. Patient has burns that are greater than 30% of total body surface area (BSA); and
  2. For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
  3. The use of 30 ml ampoules is impractical due to the size of the area to be covered.

  **Continuation**
  *Re-assessment required after 3 months*
  The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

  Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule
  - **1% DV**
  - Aug-18 to 2021
  - 29.76  30 Pfizer

GLYCINE
- Irrigation soln 1.5%, 3,000 ml bag
  - **1% DV**
  - Sep-18 to 2021
  - 31.20  4 B Braun
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>26.80</td>
<td>4</td>
<td>B Braun</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 30 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>7.00</td>
<td>20</td>
<td>Interpharma</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>14.90</td>
<td>10</td>
<td>Baxter Sodium Chloride 0.9%</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
<td>12</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>WATER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irrigation soln, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>28.80</td>
<td>4</td>
<td>B Braun</td>
</tr>
<tr>
<td>Irrigation soln, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>17.30</td>
<td>10</td>
<td>Baxter Water for Irrigation</td>
</tr>
<tr>
<td>Irrigation soln, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
<td>12</td>
<td>Fresenius Kabi</td>
</tr>
</tbody>
</table>

**Surgical Preparations**

- **BISMUTH SUBNITRATE AND IODOFORM PARAFFIN**
  - Paste
- **DIMETHYL SULFOXIDE**
  - Soln 50%
  - Soln 99%
- **PHENOL**
  - Inj 6%, 10 ml ampoule
- **PHENOL WITH IOXAGLIC ACID**
  - Inj 12%, 10 ml ampoule
- **TROMETAMOL**
  - Inj 36 mg per ml, 500 ml bottle

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Cardioplegia Solutions

#### ELECTROLYTES

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MONOSODIUM GLUTAMATE WITH SODIUM ASPARATE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle</td>
<td></td>
</tr>
<tr>
<td><strong>MONOSODIUM L-ASPARTATE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 14 mmol per 10 ml</td>
<td></td>
</tr>
</tbody>
</table>

**Cold Storage Solutions**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SODIUM WITH POTASSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag</td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➔ above); Item restricted (see ➔ below)

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Extemporaneously Compounded Preparations

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACETIC ACID</strong></td>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ALUM</strong></td>
<td>Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ARACHIS OIL [PEANUT OIL]</strong></td>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ASCORBIC ACID</strong></td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BENZoin</strong></td>
<td>Tincture compound BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BISMUTH SUBGALLATE</strong></td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BORIC ACID</strong></td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CARBOXYMETHYLCELLULOSE</strong></td>
<td>Soln 1.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CETRIMIDE</strong></td>
<td>Soln 40%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHLORHEXIDINE GLUCONATE</strong></td>
<td>Soln 20 %</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHLOROFORM</strong></td>
<td>Liq BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CITRIC ACID</strong></td>
<td>Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLOVE OIL</strong></td>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COAL TAR</strong></td>
<td>Soln BP – 1% DV Nov-19 to 2022</td>
<td>200 ml</td>
<td>36.25</td>
</tr>
<tr>
<td><strong>CODEINE PHOSPHATE</strong></td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COLLODION FLEXIBLE</strong></td>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COMPOUND HYDROXYBENzoATE</strong></td>
<td>Soln – 1% DV Aug-19 to 2022</td>
<td>100 ml</td>
<td>30.00</td>
</tr>
<tr>
<td><strong>CYSTEAMINE HYDROCHLORIDE</strong></td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE</strong></td>
<td>Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DITHRANOL</strong></td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLUCOSE [DEXTROSE]</strong></td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
| GLYCERIN WITH SODIUM SACCHARIN | Suspension – 1% DV Jul-19 to 2022 | 30.95 | 473 ml | Ora-Sweet SF |
| GLYCERIN WITH SUCROSE | Suspension – 1% DV Jul-19 to 2022 | 30.95 | 473 ml | Ora-Sweet |
| GLYCEROL | Liq – 1% DV Sep-17 to 2020 | 3.28 | 500 ml | healthE Glycerol BP Liquid |
| HYDROCORTISONE | Powder – 1% DV Sep-17 to 2020 | 49.95 | 25 g | ABM |
| LACTOSE | Powder |
| MAGNESIUM HYDROXIDE | Paste |
| MENTHOL | Crystals |
| METHADONE HYDROCHLORIDE | Powder |
| METHYL HYDROXYBENZOATE | Powder – 1% DV Jul-19 to 2022 | 8.98 | 25 g | Midwest |
| METHYLCELLULOSE | Powder – 1% DV Jul-19 to 2022 | 36.95 | 100 g | Midwest |
| METHYLCELLULOSE | Suspension – 1% DV Jul-19 to 2022 | 30.95 | 473 ml | Ora-Plus |
| METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN | Suspension – 1% DV Jul-19 to 2022 | 30.95 | 473 ml | Ora-Blend SF |
| METHYLCELLULOSE WITH GLYCERIN AND SUCROSE | Suspension – 1% DV Jul-19 to 2022 | 30.95 | 473 ml | Ora-Blend |
| OLIVE OIL | Liq |
| PARAFFIN | Liq |
| PHENOBARBITONE SODIUM | Powder |
| PHENOL | Liq |
| PILOCARPINE NITRATE | Powder |
| POLYHEXAMETHYLENE BIGUANIDE | Liq |
| POVIDONE K30 | Powder |
| SALICYLIC ACID | Powder |
| SILVER NITRATE | Crystals |
| SODIUM BICARBONATE | Powder BP – 1% DV Jan-20 to 2022 | 10.05 | 500 g | Midwest |

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CITRATE</td>
<td>Powder</td>
<td>$14.95</td>
<td>500 ml Midwest</td>
</tr>
<tr>
<td>SODIUM METABISULFITE</td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STARCH</td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULPHUR</td>
<td>Precipitated Sublimed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYRUP</td>
<td>Liq (pharmaceutical grade) – 1% <strong>DV Jan-20 to 2022</strong></td>
<td>$14.95</td>
<td>500 ml Midwest</td>
</tr>
<tr>
<td>THEOBROMA OIL</td>
<td>Oint</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRI-SODIUM CITRATE</td>
<td>Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRICHLORACETIC ACID</td>
<td>Grans</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UREA</td>
<td>Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOOL FAT</td>
<td>Oint, anhydrous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XANTHAN</td>
<td>Gum 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZINC OXIDE</td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Food Modules

Carbohydrate

**Restricted (RS1467)**

Initiation – Use as an additive

Any of the following:

1. Cystic fibrosis; or
2. Chronic kidney disease; or
3. Cancer in children; or
4. Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
5. Faltering growth in an infant/child; or
6. Bronchopulmonary dysplasia; or
7. Premature and post premature infant; or
8. Inborn errors of metabolism.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**CARBOHYDRATE SUPPLEMENT – Restricted** see terms above

1. Powder 95 g carbohydrate per 100 g, 368 g can
2. Powder 96 g carbohydrate per 100 g, 400 g can

   *e.g. Polycal*

Fat

**Restricted (RS1468)**

Initiation – Use as an additive

Any of the following:

1. Patient has inborn errors of metabolism; or
2. Faltering growth in an infant/child; or
3. Bronchopulmonary dysplasia; or
4. Fat malabsorption; or
5. Lymphangiectasia; or
6. Short bowel syndrome; or
7. Infants with necrotising enterocolitis; or
8. Biliary atresia; or
9. For use in a ketogenic diet; or
10. Chyle leak; or
11. Ascites; or
12. Patient has increased energy requirements, and for whom dietary measures have not been successful.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted** see terms above

1. Liquid 50 g fat per 100 ml, 200 ml bottle
2. Liquid 50 g fat per 100 ml, 500 ml bottle

   *e.g. Calogen*
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT** – **Restricted** see terms on the previous page
- Liquid 50 g fat per 100 ml, 250 ml bottle
- Liquid 95 g fat per 100 ml, 500 ml bottle
  - e.g. Liquigen
  - e.g. MCT Oil

**WALNUT OIL** – **Restricted** see terms on the previous page
- Liq

### Protein

- **Restricted (RS1469)**
  - **Initiation – Use as an additive**
    - Either:
      1. Protein losing enteropathy; or
      2. High protein needs.
  - **Initiation – Use as a module**
    - For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.
    - Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

- **PROTEIN SUPPLEMENT** – **Restricted** see terms above
  - Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can
  - Powder 6 g protein per 7 g, can
  - Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 g, 225 g can
e.g. Protifar

### Other Supplements

**BREAST MILK FORTIFIER**
- Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet
- Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet
- Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet
  - e.g. FM 85
  - e.g. S26 Human Milk Fortifier
  - e.g. Nutricia Breast Milk Fortifer

**CARBOHYDRATE AND FAT SUPPLEMENT** – **Restricted** see terms below
- Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can
e.g. Super Soluble Duocal

- **Restricted (RS1212)**
  - **Initiation**
    - Both:
      1. Infant or child aged four years or under; and
      2. Any of the following:
        2.1 Cystic fibrosis; or
        2.2 Cancer in children; or
        2.3 Faltering growth; or
        2.4 Bronchopulmonary dysplasia; or
        2.5 Premature and post premature infants.
NOTE:
While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:
• use was established prior to 1 July 2013; and
• the product has not been specifically considered and excluded by PHARMAC; and
• use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN
Powder
e.g. Feed Thickener
Karicare Aptamil

GUAR GUM
Powder
e.g. Guarcol

MAIZE STARCH
Powder
e.g. Resource Thicken
Up; Nutilis

MALTODEXTRIN WITH XANTHAN GUM
Powder
e.g. Instant Thick

MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID
Powder
e.g. Easy Thick

Metabolic Products

Restricted (RS1232)

Initiation
Any of the following:
1. For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
2. Patient has adrenoleukodystrophy; or
3. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – Restricted see terms above

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
e.g. GA1 Anamix Infant

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
e.g. XLYS Low TRY
Maxamaid
Homocystinuria Products

**AMINO ACID FORMULA (WITHOUT METHIONINE) – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. HCU Anamix Infant</td>
</tr>
<tr>
<td></td>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XMET Maxamaid</td>
</tr>
<tr>
<td></td>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XMET Maxamum</td>
</tr>
<tr>
<td></td>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle</td>
<td>e.g. HCU Anamix Junior LQ</td>
</tr>
</tbody>
</table>

Isovaleric Acidaemia Products

**AMINO ACID FORMULA (WITHOUT LEUCINE) – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. IVA Anamix Infant</td>
</tr>
<tr>
<td></td>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XLEU Maxamaid</td>
</tr>
<tr>
<td></td>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XLEU Maxamum</td>
</tr>
</tbody>
</table>

Maple Syrup Urine Disease Products

**AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. MSUD Anamix Infant</td>
</tr>
<tr>
<td></td>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. MSUD Maxamum</td>
</tr>
<tr>
<td></td>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle</td>
<td>e.g. MSUD Anamix Junior LQ</td>
</tr>
</tbody>
</table>
### Phenylketonuria Products

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – Restricted** see terms on page 220

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Brand Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 8.33 mg</td>
<td>Powder 20 g protein, 2.5 g carbohydrate and 0.22 g fibre per 27.8 g sachet</td>
<td>e.g. Phlexy-10</td>
</tr>
<tr>
<td>Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet</td>
<td>e.g. PKU Lophlex Powder (unflavoured)</td>
<td></td>
</tr>
<tr>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. PKU Anamix Infant (van/choc/unfl)</td>
<td></td>
</tr>
<tr>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XP Maxamum</td>
<td></td>
</tr>
<tr>
<td>Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet</td>
<td>e.g. Phlexy-10</td>
<td></td>
</tr>
<tr>
<td>Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle</td>
<td>e.g. PKU Lophlex LQ 10</td>
<td></td>
</tr>
<tr>
<td>Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle</td>
<td>e.g. PKU Lophlex LQ 20</td>
<td></td>
</tr>
<tr>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle</td>
<td>PKU Anamix Junior LQ (Berry)</td>
<td></td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle</td>
<td>PKU Anamix Junior LQ (Orange)</td>
<td></td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle</td>
<td>PKU Anamix Junior LQ (Unflavoured)</td>
<td></td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle</td>
<td>e.g. Easiphen</td>
<td></td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle</td>
<td>e.g. PKU Lophlex LQ 20</td>
<td></td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 2 g fat per 100 ml, 250 ml carton</td>
<td>e.g. PKU Lophlex Sensations 20 (berries)</td>
<td></td>
</tr>
<tr>
<td>Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Propionic Acidaemia and Methylmalonic Acidaemia Products

**AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – Restricted** see terms on page 220

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Brand Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. MMA/PA Anamix Infant</td>
<td></td>
</tr>
<tr>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XMTVI Maxamaid</td>
<td></td>
</tr>
<tr>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XMTVI Maxamum</td>
<td></td>
</tr>
</tbody>
</table>
### Protein Free Supplements

**PROTEIN FREE SUPPLEMENT** – **Restricted** see terms on page 220

- **Powder** nil added protein and 67 g carbohydrate per 100 g, 400 g can
  - *e.g.* Energivit

### Tyrosinaemia Products

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)** – **Restricted** see terms on page 220

- **Powder** 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet
  - *e.g.* TYR Anamix Junior

- **Powder** 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - *e.g.* TYR Anamix Infant

- **Powder** 25 g protein and 51 g carbohydrate per 100 g, 400 g can
  - *e.g.* XPHEN, TYR Maxamaid

- **Liquid** 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle
  - *e.g.* TYR Anamix Junior LQ

### Urea Cycle Disorders Products

**AMINO ACID SUPPLEMENT** – **Restricted** see terms on page 220

- **Powder** 25 g protein and 65 g carbohydrate per 100 g, 200 g can
  - *e.g.* Dialamine

- **Powder** 79 g protein per 100 g, 200 g can
  - *e.g.* Essential Amino Acid Mix

### X-Linked Adrenoleukodystrophy Products

**GLYCEROL TRIERUCATE** – **Restricted** see terms on page 220

- **Liquid** 1,000 ml bottle

**GLYCEROL TRIOLEATE** – **Restricted** see terms on page 220

- **Liquid** 500 ml bottle

### Specialised Formulas

#### Diabetic Products

**Restricted (RS1215)**

**Initiation**

Any of the following:

1. For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2. For patients with pancreatic insufficiency; or
3. For patients who have, or are expected to, eat little or nothing for 5 days; or
4. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
5. For use pre- and post-surgery; or
6. For patients being tube-fed; or
7. For tube-feeding as a transition from intravenous nutrition.

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Special Foods

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Low-GI Enteral Feed 1 KCAL/ML – Restricted</strong></td>
<td>Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle</td>
<td>$7.50</td>
<td>Glucerna Select RTH (Vanilla)</td>
</tr>
<tr>
<td></td>
<td>Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag</td>
<td></td>
<td>e.g. Nutrison Advanced Diason</td>
</tr>
<tr>
<td><strong>Low-GI Oral Feed 1 KCAL/ML – Restricted</strong></td>
<td>Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, 1,000 ml bottle</td>
<td>$2.10</td>
<td>Sustagen Diabetic (Vanilla)</td>
</tr>
<tr>
<td></td>
<td>Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle</td>
<td>$1.88</td>
<td>Glucerna Select (Vanilla)</td>
</tr>
<tr>
<td></td>
<td>Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, 237 ml bottle</td>
<td>$2.10</td>
<td>Resource Diabetic (Vanilla)</td>
</tr>
<tr>
<td></td>
<td>Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle</td>
<td></td>
<td>e.g. Diasip</td>
</tr>
</tbody>
</table>

### Elemental and Semi-Elemental Products

#### Restricted (RS1216)

**Initiation**

Any of the following:

1. Malabsorption; or
2. Short bowel syndrome; or
3. Enterocutaneous fistulas; or
4. Eosinophilic enteritis (including oesophagitis); or
5. Inflammatory bowel disease; or
6. Acute pancreatitis where standard feeds are not tolerated; or
7. Patients with multiple food allergies requiring enteral feeding.

**Amino Acid Oral Feed – Restricted** | see terms above
---
| Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet | $4.50 | Vivonex TEN |

**Amino Acid Oral Feed 0.8 KCAL/ML – Restricted** | see terms above
---
| Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton | | e.g. Elemental 028 Extra |

**Peptide-Based Enteral Feed 1 KCAL/ML – Restricted** | see terms above
---
| Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag | | e.g. Nutrison Advanced Peptisorb |

**Peptide-Based Enteral Feed 1.5 KCAL/ML – Restricted** | see terms above
---
| Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle | $18.06 | Vital |

**Peptide-Based Oral Feed – Restricted** | see terms above
---
| Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 400 g can | | e.g. Peptamen Junior |
| Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can | | e.g. MCT Pepdite; MCT Pepdite 1+ |

Item restricted (see above); Item restricted (see below)

*E.g. Brand indicates brand example only. It is not a contracted product.*
Fat Modified Products

FAT-MODIFIED FEED – Restricted see terms below

 Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can
 e.g. Monogen

Restricted (RS1470)
Initiation
Any of the following:
  1 Patient has metabolic disorders of fat metabolism; or
  2 Patient has a chyle leak; or
  3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Hepatic Products

Restricted (RS1217)
Initiation
For children (up to 18 years) who require a liver transplant.

HEPATIC ORAL FEED – Restricted see terms above

 Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can .......... 78.97 400 g Heparon Junior

High Calorie Products

Restricted (RS1317)
Initiation
Any of the following:
  1 Patient is fluid volume or rate restricted; or
  2 Patient requires low electrolyte; or
  3 Both:
    3.1 Any of the following:
      3.1.1 Cystic fibrosis; or
      3.1.2 Any condition causing malabsorption; or
      3.1.3 Faltering growth in an infant/child; or
      3.1.4 Increased nutritional requirements; and
    3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – Restricted see terms above

 Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle .......... 5.50 500 ml Nutrison Concentrated

 Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle ................................................................. 11.00 1,000 ml TwoCal HN RTH (Vanilla)

ORAL FEED 2 KCAL/ML – Restricted see terms above

 Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle ................................................................. 1.90 200 ml Two Cal HN
High Protein Products

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – Restricted see terms below
- Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml,
  1,000 ml bag
e.g. Nutrison Protein Plus

⇒ Restricted (RS1327)
Initiation
Both:
1 The patient has a high protein requirement; and
2 Any of the following:
  2.1 Patient has liver disease; or
  2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  2.3 Patient is fluid restricted; or
  2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – Restricted see terms below
- Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per
  100 ml, 1,000 ml bag
e.g. Nutrison Protein Plus Multi Fibre

⇒ Restricted (RS1327)
Initiation
Both:
1 The patient has a high protein requirement; and
2 Any of the following:
  2.1 Patient has liver disease; or
  2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  2.3 Patient is fluid restricted; or
  2.4 Patient's needs cannot be more appropriately met using high calorie product.

Infant Formulas

AMINO ACID FORMULA – Restricted see terms below
- Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml,
  400 g can
e.g. Neocate

- Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can
e.g. Neocate SYNEO unflavoured

- Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can
e.g. Neocate Junior

- Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can .......53.00 400 g Neocate Gold
  (Unflavoured)

- Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can ..............43.60 400 g Alfamino Junior

- Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can .............53.00 400 g Neocate Junior Vanilla

- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ...........53.00 400 g Elecare LCP
  (Unflavoured)

- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can.............53.00 400 g Elecare (Unflavoured)

⇒ Restricted (RS1471)
Initiation
Any of the following:
continued…

Item restricted (see ⇒ above); Item restricted (see ⇒ below)
e.g. Brand indicates brand example only. It is not a contracted product.
continued...

1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
2 History of anaphylaxis to cows’ milk protein formula or dairy products; or
3 Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

Continuation

Both:

1 An assessment as to whether the infant can be transitioned to a cows’ milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

EXTENSIVELY HYDROLYSED FORMULA – Restricted see terms below

Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can

→ Restricted (RS1502)

Initiation

Any of the following:

1 Both:
   1.1 Cows’ milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
   1.2 Either:
       1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
       1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or

2 Severe malabsorption; or
3 Short bowel syndrome; or
4 Intractable diarrhoea; or
5 Biliary atresia; or
6 Cholestatic liver diseases causing malabsorption; or
7 Cystic fibrosis; or
8 Proven fat malabsorption; or
9 Severe intestinal motility disorders causing significant malabsorption; or
10 Intestinal failure; or
11 For step down from Amino Acid Formula.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

Continuation

Both:

1 An assessment as to whether the infant can be transitioned to a cows’ milk protein or soy infant formula has been undertaken; and
2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

FRUCTOSE-BASED FORMULA

Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can

LACTOSE-FREE FORMULA

Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can

Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can

→ Restricted (RS1502)

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.
LOW-CALCIUM FORMULA

Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per 100 ml, bottle</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Locasol</td>
<td>$2.35</td>
<td>125 ml Infatrini</td>
</tr>
</tbody>
</table>

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML

Initiation – Fluid restricted or volume intolerance with faltering growth

Both:

1. Either:
   1.1 The patient is fluid restricted or volume intolerant; or
   1.2 The patient has increased nutritional requirements due to faltering growth; and

2. Patient is under 18 months old and weighs less than 8kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

PRETERM FORMULA – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per 100 ml, bottle</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Pre Nan Gold RTF</td>
<td>$0.75</td>
<td>100 ml S26 LBW Gold RTF</td>
</tr>
<tr>
<td>e.g. Karicare Aptamil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gold+Preterm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

THICKENED FORMULA

Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can

Ketogenic Diet Products

HIGH FAT FORMULA – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per 300 g, bottle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketocal</td>
<td>$35.50</td>
<td>4:1 (Unflavoured)</td>
</tr>
<tr>
<td>Ketocan 4:1 (Vanilla)</td>
<td></td>
<td>3:1 (Unflavoured)</td>
</tr>
</tbody>
</table>

Paediatric Products

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per 300 g, bottle</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Ketocal</td>
<td></td>
<td>4:1 (Unflavoured)</td>
</tr>
<tr>
<td>Ketocan 4:1 (Vanilla)</td>
<td></td>
<td>3:1 (Unflavoured)</td>
</tr>
</tbody>
</table>

Paediatric Products

Initiation

Both:
continued...

1. Child is aged one to ten years; and
2. Any of the following:
   2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
   2.2 Any condition causing malabsorption; or
   2.3 Faltering growth in an infant/child; or
   2.4 Increased nutritional requirements; or
   2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or
   2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

### Paediatric Enteral Feed

**PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted** see terms on the previous page
- Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag
- **Price:** $4.00 500 ml
- **Brand:** Nutrini Low Energy Multifibre RTH

**PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted** see terms on the previous page
- Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag
- **Price:** $2.68 500 ml
- **Brand:** Pediasure RTH
  - e.g. Nutrini RTH

**PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms on the previous page
- Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag
- **Price:** $6.00 500 ml
- **Brand:** Nutrini Energy Multi Fibre
  - e.g. Nutrini Energy RTH

**PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted** see terms on the previous page
- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle
- **Price:** $1.07 200 ml
- **Brand:** Pediasure (Chocolate)
  - Pediasure (Strawberry)
  - Pediasure (Vanilla)

**PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted** see terms on the previous page
- Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle
- **Price:** $1.34 250 ml
- **Brand:** e.g. Fortini
  - e.g. Fortini Multifibre

### Renal Products

**LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted** see terms below
- Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle
- **Price:** $6.08 500 ml
- **Brand:** Nepro HP RTH
  - **Initiation:** For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED – Restricted** see terms below
- Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can
- **Price:** e.g. Kindergen
  - **Initiation:** For children (up to 18 years) with acute or chronic kidney disease.
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML

Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton ..................................................... $2.67 220 ml Nepro HP (Strawberry) Nepro HP (Vanilla)

.Restricted (RS1228)

Initiation
For patients with acute or chronic kidney disease.

LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below

Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton .............. $3.31 237 ml Novasource Renal (Vanilla)

Liquid 3 g protein, 25.5 g carbohydrate and 10 g fat per 100 ml, 237 ml bottle

Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton

.Restricted (RS1228)

Initiation
For patients with acute or chronic kidney disease.

Respiratory Products

LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – Restricted see terms below

Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle .......... $1.66 237 ml Pulmocare (Vanilla)

.Restricted (RS1230)

Initiation
For patients with CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

Surgical Products

HIGH ARGININE ORAL FEED 1.4 KCAL/ML – Restricted see terms below

Liquid 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton .............................................................................. $4.00 178 ml Impact Advanced Recovery

.Restricted (RS1231)

Initiation
Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery.

PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – Restricted see terms below

Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle ............................................................................. $6.80 4 preOp

.Restricted (RS1415)

Initiation
Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

Standard Feeds

.Restricted (RS1214)

Initiation
Any of the following:

continued…
For patients with malnutrition, defined as any of the following:

1. Any of the following:
   1.1 BMI < 18.5; or
   1.2 Greater than 10% weight loss in the last 3-6 months; or
   1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
2. For patients who have, or are expected to, eat little or nothing for 5 days; or
3. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4. For use pre- and post-surgery; or
5. For patients being tube-fed; or
6. For tube-feeding as a transition from intravenous nutrition; or
7. For any other condition that meets the community Special Authority criteria.

**ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Per 1,000 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrison Energy</td>
<td>$7.00</td>
</tr>
<tr>
<td>Nutrison Multi Fibre</td>
<td></td>
</tr>
</tbody>
</table>

**ENTERAL FEED 1 KCAL/ML – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Per 1,000 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osmolite RTH</td>
<td>$5.29</td>
</tr>
<tr>
<td>Jevity RTH</td>
<td></td>
</tr>
</tbody>
</table>

**ENTERAL FEED 1.2 KCAL/ML – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Per 1,000 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jevity Plus RTH</td>
<td>$5.29</td>
</tr>
<tr>
<td>Nutrison Multi Fibre</td>
<td></td>
</tr>
</tbody>
</table>

**ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Description</th>
<th>Per 1,000 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrison 800 Complete Multi Fibre</td>
<td>$5.29</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### SPECIAL FOODS

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORAL FEED – Restricted</strong> see terms on page 230</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can ........ 26.00 850 g</td>
<td>Ensure (Chocolate)</td>
<td></td>
</tr>
<tr>
<td>1 Powder 20.8 g protein, 61 g carbohydrate and 9.4 g fat per 100 g, can ........ 8.54 857 g</td>
<td>Ensure (Vanilla)</td>
<td></td>
</tr>
<tr>
<td>1 Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can .......... 26.00 840 g</td>
<td>Fortisip (Vanilla)</td>
<td></td>
</tr>
</tbody>
</table>

Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer’s surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.

### ORAL FEED 1 KCAL/ML – Restricted see terms on page 230

| 1 Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton | e.g. Resource Fruit Beverage |

### ORAL FEED 1.5 KCAL/ML – Restricted see terms on page 230

| 1 Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can .......... 1.33 237 ml | Ensure Plus (Vanilla) |
| 1 Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton .......................................................................................................... 1.26 200 ml | Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla) e.g. Fortijuice |

- Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle
- Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle e.g. Fortisip
- Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle e.g. Fortisip Multi Fibre
## Bacterial and Viral Vaccines

### Diptheria, Tetanus, Pertussis and Polio Vaccine – **Restricted** see terms below

- **Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe**
  - **0% DV Sep-17 to 2020**
  
  **Initiation**

  Any of the following:
  1. A single dose for children up to the age of 7 who have completed primary immunisation; or
  2. A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
  3. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
  4. Five doses will be funded for children requiring solid organ transplantation.

  **Note:** Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

### Diptheria, Tetanus, Pertussis, Polio, Hepatitis B and Haemophilus Influenzae Type B Vaccine – **Restricted** see terms below

- **Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe** (1) and **inj 10 mcg haemophilus influenzae type B vaccine vial**
  - **0% DV Sep-17 to 2020**

  **Initiation**

  Any of the following:
  1. Up to four doses for children up to and under the age of 10 for primary immunisation; or
  2. An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
  3. Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

  **Note:** A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

### Bacterial Vaccines

### Adult Diptheria and Tetanus Vaccine

- **Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe**
  - **0% DV Jul-17 to 2020**

  **Initiation**

  Any of the following:
  1. For vaccination of patients aged 45 and 65 years old; or
  2. For vaccination of previously unimmunised or partially immunised patients; or
## VACCINES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### continued...

3. For revaccination following immunosuppression; or
4. For boosting of patients with tetanus-prone wounds; or
5. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**BACILLUS CALMETTE-GUERIN VACCINE** – **Restricted** see terms below

$ Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent..................................................................................................0.00 10 BCG Vaccine

**Initiation**

All of the following:

1. Living in a house or family with a person with current or past history of TB; and
2. Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and
3. During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.


**DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE** – **Restricted** see terms below

$ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemaglutinin and 2.5 mcg pertactin in 0.5 ml syringe – **0% DV Sep-17 to 2020** ........................................0.00 1 Boostrix

**Initiation**

Any of the following:

1. A single dose for pregnant women in the second or third trimester of each pregnancy; or or
2. A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or or
3. A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or
4. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**HAEMOPHILUS INFLUENZAE TYPE B VACCINE** – **Restricted** see terms below

$ Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml – **0% DV Sep-17 to 2020** ........................................0.00 1 Hiberix

**Initiation**

*Therapy limited to 1 dose*

Any of the following:

1. For primary vaccination in children; or

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

---

* Item restricted (see above); ** Item restricted (see below)

*e.g. Brand indicates brand example only. It is not a contracted product.*
VACCINES

Price
(ex man. excl. GST) $ Per

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued...

2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or

3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted see terms below

\[ \text{Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of}\]

\[ \text{approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial –} \]

\[ 0\% \text{ DV Jul-17 to 2020} \]

\[ \text{0.00 1 Menactra} \]

Initiation

Any of the following:

1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 One dose for close contacts of meningococcal cases; or

3 A maximum of two doses for bone marrow transplant patients; or

4 A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – Restricted see terms below

\[ \text{Inj 10 mcg in 0.5 ml syringe –} \]

\[ 0\% \text{ DV Jul-17 to 2020} \]

\[ \text{0.00 1 Neisvac-C} \]

Initiation

Any of the following:

1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 One dose for close contacts of meningococcal cases; or

3 A maximum of two doses for bone marrow transplant patients; or

4 A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – Restricted see terms below

\[ \text{mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V,} \]

\[ \text{14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4,} \]

\[ \text{18C and 19F in 0.5 ml prefilled syringe –} \]

\[ 0\% \text{ DV Sep-17 to 2020} \]

\[ \text{0.00 10 Synflorix} \]

Initiation

Either:

1 A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or

2 Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV13.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted see terms on the next page

\[ \text{Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A,} \]

\[ 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe} \]

\[ \text{0.00 1 Prevenar 13} \]

10 Prevenar 13

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**VACCINES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**→ Restricted (RS1586)**

**Initiation – High risk children who have received PCV10**

*Therapy limited to 1 dose*

One dose is funded for high risk children (over the age of 17 months and under 18 years) who have previously received four doses of PCV10.

**Initiation – High risk children aged under 5 years**

*Therapy limited to 4 doses*

Both:

1. Up to an additional four doses (as appropriate) are funded for children aged under 5 years for (re-)immunisation; and
2. Any of the following:
   2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2.2 With primary immune deficiencies; or
   2.3 With HIV infection; or
   2.4 With renal failure, or nephrotic syndrome; or
   2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   2.6 With cochlear implants or intracranial shunts; or
   2.7 With cerebrospinal fluid leaks; or
   2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   2.10 Pre term infants, born before 28 weeks gestation; or
   2.11 With cardiac disease, with cyanosis or failure; or
   2.12 With diabetes; or
   2.13 With Down syndrome; or
   2.14 Who are pre-or post-splenectomy, or with functional asplenia.

**Initiation – High risk adults and children 5 years and over**

*Therapy limited to 4 doses*

Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solids organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

**Initiation – Testing for primary immunodeficiency diseases**

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – *Restricted* see terms below

- Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – 0% DV Jul-17 to 2020 ................................................................. 0.00 1  Pneumovax 23

**→ Restricted (RS1587)**

**Initiation – High risk patients**

*Therapy limited to 3 doses*

For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

continued…
continued...

**Initiation – High risk children**
*Therapy limited to 2 doses*

Both:

1. Patient is a child under 18 years for (re-)immunisation; and
2. Any of the following:
   1. On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2. With primary immune deficiencies; or
   3. With HIV infection; or
   4. With renal failure, or nephrotic syndrome; or
   5. Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   6. With cochlear implants or intracranial shunts; or
   7. With cerebrospinal fluid leaks; or
   8. Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   9. With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   10. Pre term infants, born before 28 weeks gestation; or
   11. With cardiac disease, with cyanosis or failure; or
   12. With diabetes; or
   13. With Down syndrome; or
   14. Who are pre-or post-splenectomy, or with functional asplenia.

**Initiation – Testing for primary immunodeficiency diseases**

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

**SALMONELLA TYPHI VACCINE – Restricted see terms below**

- Inj 25 mcg in 0.5 ml syringe
  
  **Restricted (RS1243)**

**Initiation**

For use during typhoid fever outbreaks.

**Viral Vaccines**

**HEPATITIS A VACCINE – Restricted see terms below**

- Inj 720 ELISA units in 0.5 ml syringe – 0% DV Sep-17 to 2020
  
  **0.00 1**
  
  **Havrix Junior**

- Inj 1440 ELISA units in 1 ml syringe – 0% DV Sep-17 to 2020
  
  **0.00 1**
  
  **Havrix**

  **Restricted (RS1638)**

**Initiation**

Any of the following:

1. Two vaccinations for use in transplant patients; or
2. Two vaccinations for use in children with chronic liver disease; or
3. One dose of vaccine for close contacts of known hepatitis A cases.

**HEPATITIS B RECOMBINANT VACCINE**

- Inj 5 mcg in 0.5 ml vial – 0% DV Jul-17 to 2020
  
  **0.00 1**
  
  **HBvaxPRO**

  **Restricted (RS1588)**

**Initiation**

Any of the following:

...
**VACCINES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

| Inj 10 mcg in 1 ml vial | $ 0.00 | 1 HBvaxPRO |

- **Restricted (RS1588)**

**Initiation**

Any of the following:

1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. For patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury.

| Inj 20 mcg per 1 ml prefilled syringe | $ 0.00 | 1 Engerix-B |

- **Restricted (RS1671)**

**Initiation**

Any of the following:

1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. For patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury; or
11. For dialysis patients; or
12. For liver or kidney transplant patients.

| Inj 40 mcg per 1 ml vial – 0% DV Jul-17 to 2020 | $ 0.00 | 1 HBvaxPRO |

- **Restricted (RS1413)**

**Initiation**

Both:

1. For dialysis patients; and
2. For liver or kidney transplant patient.

---

*Item restricted (see ➼ above); Item restricted (see ➼ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
VACCINES

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] – Restricted see terms below

Inj 270 mcg in 0.5 ml syringe – 0% DV Jun-17 to 2020
0.00 10 Gardasil 9

Initiation – Children aged 14 years and under

Therapy limited to 2 doses
Children aged 14 years and under.

Initiation – other conditions

Either:
1. Up to 3 doses for people aged 15 to 26 years inclusive; or
2. Both:
   2.1 People aged 9 to 26 years inclusive; and
   2.2 Any of the following:
      2.2.1 Up to 3 doses for confirmed HIV infection; or
      2.2.2 Up to 3 doses for transplant (including stem cell) patients; or
      2.2.3 Up to 4 doses for Post chemotherapy.

Initiation – Recurrent Respiratory Papillomatosis

All of the following:
1. Either:
   1.1 Maximum of two doses for children aged 14 years and under; or
   1.2 Maximum of three doses for people aged 15 years and over; and
2. The patient has recurrent respiratory papillomatosis; and
3. The patient has not previously had an HPV vaccine.

INFLUENZA VACCINE

Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)
9.00 1 Fluarix Tetra

Initiation – cardiovascular disease for patients aged 6 months to 35 months

Any of the following:
1. Ischaemic heart disease; or
2. Congestive heart failure; or
3. Rheumatic heart disease; or
4. Congenital heart disease; or
5. Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

Initiation – chronic respiratory disease for patients aged 6 months to 35 months

Either:
1. Asthma, if on a regular preventative therapy; or
2. Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

Initiation – Other conditions for patients aged 6 months to 35 months

Any of the following:
1. Diabetes; or
2. Chronic renal disease; or
3. Any cancer, excluding basal and squamous skin cancers if not invasive; or
4. Autoimmune disease; or
5. Immune suppression or immune deficiency; or
6. HIV; or

continued…
continued…

7 Transplant recipient; or
8 Neuromuscular and CNS diseases/disorders; or
9 Haemoglobinopathies; or
10 Is a child on long term aspirin; or
11 Has a cochlear implant; or
12 Errors of metabolism at risk of major metabolic decompensation; or
13 Pre and post splenectomy; or
14 Down syndrome; or
15 Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness.

Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)................................................. 90.00 10 Influvac Tetra

Restricted (RS1674)

Initiation – People over 65
The patient is 65 years of age or over.

Initiation – cardiovascular disease for patients 3 years and over
Any of the following:
1 Ischaemic heart disease; or
2 Congestive heart failure; or
3 Rheumatic heart disease; or
4 Congenital heart disease; or
5 Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

Initiation – chronic respiratory disease for patients 3 years and over
Either:
1 Asthma, if on a regular preventative therapy; or
2 Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

Initiation – Other conditions for patients 3 years and over
Either:
1 Any of the following:
   1.1 Diabetes; or
   1.2 chronic renal disease; or
   1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
   1.4 Autoimmune disease; or
   1.5 Immune suppression or immune deficiency; or
   1.6 HIV; or
   1.7 Transplant recipient; or
   1.8 Neuromuscular and CNS diseases/disorders; or
   1.9 Haemoglobinopathies; or
   1.10 Is a child on long term aspirin; or
   1.11 Has a cochlear implant; or
   1.12 Errors of metabolism at risk of major metabolic decompensation; or
   1.13 Pre and post splenectomy; or
   1.14 Down syndrome; or
   1.15 Is pregnant; or
   1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital.
MEASLES, MUMPS AND RUBELLA VACCINE – Restricted see terms below
 Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50,
 Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent
 0.5 ml – 0% DV Sep-17 to 2020 .......................................................... 0.00 10 Priorix

→ Restricted (RS1487)
Initiation – first dose prior to 12 months
 Therapy limited to 3 doses
 Any of the following:
 1 For primary vaccination in children; or
 2 For revaccination following immunosuppression; or
 3 For any individual susceptible to measles, mumps or rubella.

Initiation – first dose after 12 months
 Therapy limited to 2 doses
 Any of the following:
 1 For primary vaccination in children; or
 2 For revaccination following immunosuppression; or
 3 For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

POLIOMYELITIS VACCINE – Restricted see terms below
 Injection 80 D-antigen units in 0.5 ml syringe – 0% DV Jul-17 to 2020 ................. 0.00 1 IPOL

→ Restricted (RS1398)
Initiation
 Therapy limited to 3 doses
 Either:
 1 For partially vaccinated or previously unvaccinated individuals; or
 2 For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

RABIES VACCINE
 Inj 2.5 IU vial with diluent

ROTAVIRUS ORAL VACCINE – Restricted see terms below
 Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose,
 prefilled oral applicator – 0% DV Sep-17 to 2020 ......................................... 0.00 10 Rotarix

→ Restricted (RS1590)
Initiation
 Therapy limited to 2 doses
 Both:
 1 First dose to be administered in infants aged under 14 weeks of age; and
 2 No vaccination being administered to children aged 24 weeks or over.

VARICELLA VACCINE [CHICKENPOX VACCINE] – Restricted see terms below
 Injection 2000 PFU prefilled syringe plus vial – 0% DV Sep-17 to 2020 ................. 0.00 1 10 Varilrix

→ Restricted (RS1591)
Initiation – primary vaccinations
 Therapy limited to 1 dose
 Either:
 1 Any infant born on or after 1 April 2016; or
 2 For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella

continued…
continued…

infection (chickenpox).

Initiation – other conditions

*Therapy limited to 2 doses*

Any of the following:

1. Any of the following:
   
   for non-immune patients:
   
   1.1 With chronic liver disease who may in future be candidates for transplantation; or
   
   1.2 With deteriorating renal function before transplantation; or
   
   1.3 Prior to solid organ transplant; or
   
   1.4 Prior to any elective immunosuppression*; or
   
   1.5 For post exposure prophylaxis who are immune competent inpatients; or

2. For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or

3. For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or

4. For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or

5. For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or

6. For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or

7. For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] – Restricted see terms below

Varicella zoster virus (Oka strain) live attenuated vaccine [shingles vaccine] ......................................................................................................0.00 1 Zostavax

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] – Restricted (RS1619)

Initiation – people aged 65 years

*Therapy limited to 1 dose*

One dose for all people aged 65 years.

Initiation – people aged between 66 and 80 years

*Therapy limited to 1 dose*

One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 March 2020.

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST

Inj 5 TU per 0.1 ml, 1 ml vial – 0% DV Jul-17 to 2020 ........................................0.00 1 Tubersol
## Optional Pharmaceuticals

### BLOOD GLUCOSE DIAGNOSTIC TEST METER
- 1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips: $20.00
- 10.00 Caresens N
- 10.00 Caresens N POP

### BLOOD GLUCOSE DIAGNOSTIC TEST STRIP
- Blood glucose test strips: $10.56
- Test strips: 10.56
- 50 test CareSens N
- 50 test CareSens PRO

### BLOOD KETONE DIAGNOSTIC TEST STRIP
- Test strips: $15.50
- 10 strip KetoSens

### DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER
- Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic test strips: $20.00
- 1 CareSens Dual

### MASK FOR SPACER DEVICE
- Small: $2.20
- 1 e-chamber Mask

### PEAK FLOW METER
- Low Range: $9.54
- 1 Mini-Wright AFS Low Range
- Normal Range: $9.54
- 1 Mini-Wright Standard

### PREGNANCY TEST - HCG URINE
- Cassette: $12.00
- 40 test Smith BioMed Rapid Pregnancy Test

### SODIUM NITROPRUSSIDE
- Test strip: $22.00
- 50 strip Ketostix

### SPACER DEVICE
- 220 ml (single patient): $2.95
- 1 e-chamber Turbo
- 510 ml (single patient): $5.12
- 1 e-chamber La Grande
- 800 ml: $6.50
- 1 Volumatic

---

**NOTE:**
In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at [www.pharmac.govt.nz](http://www.pharmac.govt.nz). The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

**Products with Hospital Supply Status (HSS) are in bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INDEX: Generic Chemicals and Brands

- Symbols -

8-methoxypsoralen.......................... 55

- A -

A-Scabies ........................................ 52
Abacavir sulphate ......................... 86
Abacavir sulphate with lamivudine .......... 86
Abciximab ........................................ 151
Abiraterone acetate ......................... 142
Acarbose ........................................ 8
Accectic 10 ....................................... 37
Accectic 20 ....................................... 37
Acetazolamide .................................. 204
Acetic acid
Extemporaneously Compounded Preparations .................................... 215
Genito-Urinary .................................... 57
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid .......................... 57
Acetic acid with propylene glycol ............... 206
Acetilcholine chloride ......................... 204
Acetylcysteine .................................... 207
Aclidoliv
Infections ........................................ 89
Sensory ........................................... 200
Aclidoliv-Claris .................................. 89
Acid Citrate Dextrose A ......................... 30
Aciclay ............................................. 5
Acipimox .......................................... 45
Acitretin .......................................... 55
Aclastal ............................................ 94
Actemra ............................................ 182
Actinomycin D .................................... 129
Adalat 10 .......................................... 42
Adalat Oros ........................................ 42
Adalimumab .................................... 151
Adalat-O ............................................ 52
Adefovir dipivoxil ................................ 88
Adenocor ......................................... 39
Adenosine ......................................... 39
Adenuric ......................................... 99
Adrenaline ........................................ 46
ADT Booster .................................... 233
Adult diphtheria and tetanus vaccine ............. 233
Advellant ......................................... 54
Advate ............................................ 28
Adyvanate ........................................ 28
Aerax ............................................ 104
Afinitor .......................................... 190
Afibercept ....................................... 160
Agents Affecting the Renin-Angiotensin System .................................. 37
Agents for Parkinsonism and Related Disorders ........................................ 103
Agents Used in the Treatment of Poisonings ........................................ 207
Ajmaline .......................................... 39
Alase ............................................. 192
Albendazole ...................................... 83
Aldurazyme ....................................... 15
Aleronate sodium ................................ 94
Aleronate sodium with colecalciferol .............. 94
Alfacalcidol ....................................... 21
Alfamino Junior ................................ 226
Aldantil ............................................ 108
Aldriocid ........................................... 13
Aline ............................................. 84
Allersothe ........................................ 193
Allmercap ........................................ 131
Ampuroin ........................................ 98
Alpha tocopheryl ................................ 21
Alpha tocopheryl acetate ................. 22
Alph-Arenoscept Blockers .................... 38
Alphamox 125 .................................. 76
Alphamox 250 .................................. 76
Alprolix ........................................... 27
Alprostadil hydrochloride ..................... 47
Alteplase .......................................... 32
Alum ............................................. 215
Aluminium chloride ......................... 25
Aluminium hydroxide ......................... 5
Aluminium hydroxide with magnesium hydroxide and simeticone ............. 5
Amantadine hydrochloride ................ 103
AmBisome ........................................ 80
Ambriquat ....................................... 48
Amethocaine .................................... 107
Nervous .......................................... 203
Sensory ........................................... 37
Amikacin ......................................... 72
Amlodil hydrochloride ....................... 44
Amlodil hydrochloride with furosemide ......... 43
Amlodil hydrochloride with hydrochlorothiazide .................... 43
Aminolevulinic acid
hydrochloride .................................. 145
Aminophylline ................................ 198
Amiodarone hydrochloride .............. 39
Amisulpride .................................... 117
Amiretriptiline ................................ 110
Amlodipine ...................................... 42
Amorolfine ...................................... 51
Amoxicillin ...................................... 76
Amoxicillin with clavulanic acid .......... 76
Amphotericin B
Alimentary ....................................... 19
Infections ....................................... 80
Amascrine ....................................... 132
Amil nitrite ....................................... 207
Anabolic Agents ................................. 62
Anaesthetics ..................................... 104
Anagrelide hydrochloride .................... 132
Analgesics ....................................... 107
Anastzole ....................................... 144
Andriol Testocaps .............................. 62
Androderm ....................................... 62
Androgen Agonists and Antagonists ............ 62
Anoro Ellipta .................................... 194
Antabuse ......................................... 126
Antacids and Antiflatulents ..................... 5
Anti-Infective Agents ......................... 57
Anti-Infective Preparations ................. 200
Anti-Inflammatory Preparations ............. 201
Antiacne Preparations ....................... 52
Antiallergy Preparations ..................... 192
Antianaemics .................................... 23
Antiarhythms .................................... 39
Antibacterials ................................... 72
Anticholinergic Agents ....................... 193
Anticholinesterases ............................ 94
Antidepressants .................................. 110
Antidiarrhoeals and Intestinal
Anti-Inflammatory Agents ................. 5
Antiepilepsy Drugs ............................ 112
Antifibrinolytics, Haemostatics and Local Sclerosants .......................... 25
Antifibrinolics .................................. 194
Antifungals ...................................... 80
Antihypotensives ................................ 40
Antimigraine Preparations .................. 115
Antimycobacterials .............................. 82
Antinausea and Vertigo Agents ............ 116
Antiparasitics .................................... 83
Antipruritic Preparations ..................... 52
Antipsychotic Agents .......................... 117
Antiretrovirals .................................. 85
Antirheumatoid Agents ....................... 94
Antisepsics and Disinfectants ............. 209
Antispasmodics and Other Agents
Altering Gut Motility .............. 7
Antithrombectics ............................... 29
Antithymocyte globulin
(equine) ......................................... 189
Antithymocyte globulin (rabbit) .......... 189
## INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aripimpramine</td>
<td>Sandoz</td>
</tr>
<tr>
<td>Argipressin</td>
<td>[Vasopressin]</td>
</tr>
<tr>
<td>Arginine</td>
<td>Aqueous cream</td>
</tr>
<tr>
<td>Apresoline</td>
<td></td>
</tr>
<tr>
<td>Aprepitant</td>
<td></td>
</tr>
<tr>
<td>Apraclonidine</td>
<td></td>
</tr>
<tr>
<td>Apo-Amlodipine</td>
<td></td>
</tr>
<tr>
<td>Apo-Amoxi</td>
<td></td>
</tr>
<tr>
<td>Apo-Azithromycin</td>
<td></td>
</tr>
<tr>
<td>Apo-Ciclopiox</td>
<td></td>
</tr>
<tr>
<td>Apo-Cilazapril</td>
<td></td>
</tr>
<tr>
<td>Apo-Cilazapril / Hydrochlorothiazide</td>
<td>37</td>
</tr>
<tr>
<td>Apo-Clarithromycin</td>
<td>75</td>
</tr>
<tr>
<td>Apo-Clomipramine</td>
<td>110</td>
</tr>
<tr>
<td>Apo-Diclo SR</td>
<td>101</td>
</tr>
<tr>
<td>Apo-Diltiazem CD</td>
<td>42</td>
</tr>
<tr>
<td>Apo-Doxazosin</td>
<td>38</td>
</tr>
<tr>
<td>Apo-Folic Acid</td>
<td>24</td>
</tr>
<tr>
<td>Apo-Furosemide</td>
<td>43</td>
</tr>
<tr>
<td>Apo-Gabapentin</td>
<td>112</td>
</tr>
<tr>
<td>Apo-Leflunomide</td>
<td>94</td>
</tr>
<tr>
<td>Apo-Megestrol</td>
<td>143</td>
</tr>
<tr>
<td>Apo-Metoprolol</td>
<td>41</td>
</tr>
<tr>
<td>Apo-Mirtazapine</td>
<td>111</td>
</tr>
<tr>
<td>Apo-Montelukast</td>
<td>197</td>
</tr>
<tr>
<td>Apo-Nadolol</td>
<td>41</td>
</tr>
<tr>
<td>Apo-Nicotinic Acid</td>
<td>45</td>
</tr>
<tr>
<td>Apo-Onandsetron</td>
<td>117</td>
</tr>
<tr>
<td>Apo-Oxybutynin</td>
<td>60</td>
</tr>
<tr>
<td>Apo-Paroxetine</td>
<td>111</td>
</tr>
<tr>
<td>Apo-Pindoprill</td>
<td>37</td>
</tr>
<tr>
<td>Apo-Pindolol</td>
<td>41</td>
</tr>
<tr>
<td>Apo-Pravastatin</td>
<td>45</td>
</tr>
<tr>
<td>Apo-Prazosin</td>
<td>39</td>
</tr>
<tr>
<td>Apo-Prednisone</td>
<td>64</td>
</tr>
<tr>
<td>Apo-Propranolol</td>
<td>41</td>
</tr>
<tr>
<td>Apo-Pyridoxine</td>
<td>21</td>
</tr>
<tr>
<td>Apo-Ropinrole</td>
<td>104</td>
</tr>
<tr>
<td>Apo-Sumatriptan</td>
<td>115</td>
</tr>
<tr>
<td>Apo-Terazosin</td>
<td>39</td>
</tr>
<tr>
<td>Apomorphine hydrochloride</td>
<td>103</td>
</tr>
<tr>
<td>Apraclonidine</td>
<td>205</td>
</tr>
<tr>
<td>Aprepitant</td>
<td>116</td>
</tr>
<tr>
<td>Apresoline</td>
<td>47</td>
</tr>
<tr>
<td>Aprotin</td>
<td>25</td>
</tr>
<tr>
<td>Aqueous cream</td>
<td>53</td>
</tr>
<tr>
<td>Arachis oil [Peanut oil]</td>
<td>215</td>
</tr>
<tr>
<td>Arac</td>
<td>39</td>
</tr>
<tr>
<td>Arginine</td>
<td>Alimentary</td>
</tr>
<tr>
<td>Various</td>
<td>211</td>
</tr>
<tr>
<td>Argipressin [Vasopressin]</td>
<td>71</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>117</td>
</tr>
<tr>
<td>Aripiprazole Sandoz</td>
<td>117</td>
</tr>
<tr>
<td>Aristocort</td>
<td>55</td>
</tr>
<tr>
<td>Arrow - Clopid</td>
<td>31</td>
</tr>
<tr>
<td>Arrow-Amitriptyline</td>
<td>110</td>
</tr>
<tr>
<td>Arrow-Bendrofluazide</td>
<td>44</td>
</tr>
<tr>
<td>Arrow-Brimonidine</td>
<td>205</td>
</tr>
<tr>
<td>Arrow-Calcium</td>
<td>17</td>
</tr>
<tr>
<td>Arrow-Diazepam</td>
<td>120</td>
</tr>
<tr>
<td>Arrow-Fluoxetine</td>
<td>111</td>
</tr>
<tr>
<td>Arrow-Lamotrigine</td>
<td>113</td>
</tr>
<tr>
<td>Arrow-Losartan &amp; Hydrochlorothiazide</td>
<td>38</td>
</tr>
<tr>
<td>Arrow-Morphine LA</td>
<td>109</td>
</tr>
<tr>
<td>Arrow-Norfloxacin</td>
<td>77</td>
</tr>
<tr>
<td>Arrow-Omidaze</td>
<td>84</td>
</tr>
<tr>
<td>Arrow-Quinapril 10</td>
<td>37</td>
</tr>
<tr>
<td>Arrow-Quinapril 20</td>
<td>37</td>
</tr>
<tr>
<td>Arrow-Quinapril 5</td>
<td>37</td>
</tr>
<tr>
<td>Arrow-Roxithromycin</td>
<td>75</td>
</tr>
<tr>
<td>Arrow-Sertraline</td>
<td>111</td>
</tr>
<tr>
<td>Arrow-Timolol</td>
<td>204</td>
</tr>
<tr>
<td>Arrow-Tolterodine</td>
<td>61</td>
</tr>
<tr>
<td>Arrow-Topiramate</td>
<td>114</td>
</tr>
<tr>
<td>Arrow-Tramadol</td>
<td>110</td>
</tr>
<tr>
<td>Arsenic trioxide</td>
<td>132</td>
</tr>
<tr>
<td>Arteether with lumefantrine</td>
<td>84</td>
</tr>
<tr>
<td>Artesunate</td>
<td>84</td>
</tr>
<tr>
<td>Articaine hydrochloride</td>
<td>105</td>
</tr>
<tr>
<td>Articaine hydrochloride with adrenaline</td>
<td>105</td>
</tr>
<tr>
<td>Asacol</td>
<td>6</td>
</tr>
<tr>
<td>Asamax</td>
<td>6</td>
</tr>
<tr>
<td>Ascorbic acid</td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>Blood</td>
</tr>
<tr>
<td></td>
<td>Nervous</td>
</tr>
<tr>
<td>Asthalin</td>
<td>196</td>
</tr>
<tr>
<td>Atazanavir sulphate</td>
<td>87</td>
</tr>
<tr>
<td>Atenolol</td>
<td>40</td>
</tr>
<tr>
<td>Atenolol-AFT</td>
<td>40</td>
</tr>
<tr>
<td>ATGAM</td>
<td>189</td>
</tr>
<tr>
<td>Ativan</td>
<td>120</td>
</tr>
<tr>
<td>Atomoxetine</td>
<td>123</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>44</td>
</tr>
<tr>
<td>Atovaquone with proguanil hydrochloride</td>
<td>84</td>
</tr>
<tr>
<td>Atracurium besylate</td>
<td>100</td>
</tr>
<tr>
<td>Atropine sulphate</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td></td>
<td>Sensory</td>
</tr>
<tr>
<td>Azactam</td>
<td>78</td>
</tr>
<tr>
<td>Azamun</td>
<td>190</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>190</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>74</td>
</tr>
<tr>
<td>Azol</td>
<td>65</td>
</tr>
<tr>
<td>AZT</td>
<td>86</td>
</tr>
<tr>
<td>Aztreamonam</td>
<td>78</td>
</tr>
<tr>
<td>Bacillus calmette-guerin (BCG)</td>
<td>190</td>
</tr>
<tr>
<td>Bacillus calmette-guerin vaccine</td>
<td>234</td>
</tr>
<tr>
<td>Bactofen</td>
<td>100</td>
</tr>
<tr>
<td>Bacterial and Viral Vaccines</td>
<td>233</td>
</tr>
<tr>
<td>Bacterial Vaccines</td>
<td>233</td>
</tr>
<tr>
<td>Balanced Salt Solution</td>
<td>203</td>
</tr>
<tr>
<td>Barium sulphate</td>
<td>210</td>
</tr>
<tr>
<td>Barium sulphate with sodium bicarbonate</td>
<td>210</td>
</tr>
<tr>
<td>Barrier Creams and Emollients</td>
<td>52</td>
</tr>
<tr>
<td>Basiliximab</td>
<td>161</td>
</tr>
<tr>
<td>BCG Vaccine</td>
<td>234</td>
</tr>
<tr>
<td>BD PosiFlush</td>
<td>35</td>
</tr>
<tr>
<td>Beclazone 100</td>
<td>196</td>
</tr>
<tr>
<td>Beclazone 250</td>
<td>196</td>
</tr>
<tr>
<td>Beclazone 50</td>
<td>196</td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>192, 196</td>
</tr>
<tr>
<td>Bee venom</td>
<td>192</td>
</tr>
<tr>
<td>Bendamustine hydrochloride</td>
<td>128</td>
</tr>
<tr>
<td>Bendrofluazide</td>
<td>144</td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>[Bendrofluazide]</td>
</tr>
<tr>
<td>BeneFIX</td>
<td>28</td>
</tr>
<tr>
<td>Benzathine benzylpenicillin</td>
<td>76</td>
</tr>
<tr>
<td>Benzatropine mesylate</td>
<td>103</td>
</tr>
<tr>
<td>Benzbramaron AL 100</td>
<td>99</td>
</tr>
<tr>
<td>Benzbramaronone</td>
<td>99</td>
</tr>
<tr>
<td>Benzocaine</td>
<td>105</td>
</tr>
<tr>
<td>Benzoil</td>
<td>215</td>
</tr>
<tr>
<td>Benzyl alcohol</td>
<td>52</td>
</tr>
<tr>
<td>Benztrop</td>
<td>103</td>
</tr>
<tr>
<td>Benzydamine hydrochloride</td>
<td>18</td>
</tr>
<tr>
<td>Benzydamine hydrochloride with cetylpyridinium chloride</td>
<td>18</td>
</tr>
<tr>
<td>Benzylpenicillin sodium [Penicillin G]</td>
<td>76</td>
</tr>
<tr>
<td>Beraclant</td>
<td>198</td>
</tr>
<tr>
<td>Beta-Cream</td>
<td>54</td>
</tr>
<tr>
<td>Beta Ointment</td>
<td>54</td>
</tr>
<tr>
<td>Beta Scalp</td>
<td>55</td>
</tr>
<tr>
<td>Beta-Adrenoceptor Agonists</td>
<td>196</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

- Beta-Adrenoceptor Blockers........................................... 40
- Betadine........................................................................ 209
- Betadine Skin Prep....................................................... 209
- Betahistine dihydrochloride......................................... 116
- Betaine......................................................................... 14
- Betaloc CR................................................................. 41
- Betamethasone ............................................................ 63
- Betamethasone dipropionate ......................................... 54
- Betamethasone dipropionate with calcipotriol............... 55
- Betamethasone sodium phosphate with betamethasone acetate...... 63
- Betamethasone valerate................................................ 54–55
- Betamethasone valerate with clobetasol............................. 55
- Betamethasone valerate with sodium fusidate [Fusidic acid]....... 55
- Betaxolol...................................................................... 204
- Betnove................................................................. 54
- Betoptic...................................................................... 204
- Betoptic S................................................................... 204
- Bevacizumab............................................................... 161
- Bezfafibrate................................................................ 44
- Bezalip........................................................................ 44
- Bezalip Retard............................................................ 44
- Bicalutamide .................................................................. 143
- Bicalutamide LA .......................................................... 76
- BICNU......................................................................... 129
- Bicnu Heritage............................................................ 129
- Bile and Liver Therapy................................................... 8
- Biliscopin................................................................... 211
- Bimatoprost............................................................... 204
- Bimatoprost Multichem ................................................... 204
- Binarex .................................................................... 143
- Binocrit................................................................. 23
- Biodone....................................................................... 108
- Biodone Extra Forte.................................................... 108
- Biodone Forte............................................................. 108
- Biotin......................................................................... 14
- Bisacodyl..................................................................... 13
- Bismuth subgallate........................................................ 215
- Bismuth subnitrate and iodoform paraffin............................. 213
- Bisoprolol fumarate....................................................... 40
- Bivalirudin................................................................... 29
- Bleomycin sulphate....................................................... 129
- Blood glucose diagnostic test meter................................... 243
- Blood glucose diagnostic test strip.................................... 243
- Blood ketone diagnostic test strip..................................... 243
- Bonney’s blue dye......................................................... 212
- Boostrix...................................................................... 234
- Boric acid.................................................................... 215
- Bortezomib................................................................ 132
- Bosentan...................................................................... 48
- Bosentan Dr Reddy’s..................................................... 48
- Bosvate....................................................................... 40
- Botox.......................................................................... 100
- Botulism antitoxin......................................................... 207
- Bplex........................................................................... 21
- Bree Ellipta................................................................. 197
- Bridion......................................................................... 100
- Brilinta....................................................................... 32
- Brimonidine tartrate...................................................... 205
- Brimonidine tartrate with timolol.................................... 205
- Brinol .......................................................................... 130
- Brinzolamide.............................................................. 204
- Bromocriptine............................................................. 103
- Brufen SR ................................................................. 101
- Budesonide.................................................................. 5
- Budesonide with efomoterol............................................ 197
- Burtalan................................................................. 43
- Bupafiren................................................................. 105
- Bupivacaine hydrochloride............................................ 105
- Bupivacaine hydrochloride with adrenaline....................... 105
- Bupivacaine hydrochloride with fentanyl........................... 105
- Bupivacaine hydrochloride with glucose........................... 105
- Buprenorphine with naloxone........................................ 125
- Bupropion hydrochloride............................................. 126
- Burinex...................................................................... 43
- Buscopan.................................................................... 7
- Buserelin................................................................. 66
- Buspirone hydrochloride.............................................. 120
- Busulfan..................................................................... 129
- Cabergoline.................................................................. 65
- Caffeine...................................................................... 123
- Caffeine citrate............................................................ 198
- Calamine.................................................................... 52
- Calcipotriol............................................................... 55
- Calcitonin................................................................. 62
- Calcitriol..................................................................... 21
- Calcitriol-AFT ............................................................ 21
- Calcium carbonate....................................................... 5, 17
- Calcium Channel Blockers............................................. 42
- Calcium chloride......................................................... 33
- Calcium folinate........................................................ 142
- Calcium Folinate Ebewe............................................... 142
- Calcium Folinate Sandoz.............................................. 142
- Calcium gluconate.......................................................... Blood..... 33
- Dermatological............................................................. 56
- Calcium Homeostasis.................................................. 62
- Calcium polystyrene sulphonate..................................... 36
INDEX: Generic Chemicals and Brands

Cyclophosphamide ......................... 129
Cycloserine ..................................... 82
Cyklokapron ..................................... 26
Cyrene ........................................... 89
Cyproheptadine hydrochloride ............ 193
Cyproterone acetate ........................... 62
Cyproterone acetate with ethinyloestradiol.. 57
Cystadane ........................................ 14
Cysteamine hydrochloride ................. 215
Cytarbaine ....................................... 130
Cytotec ........................................ 7

- D -
D-Penamine ..................................... 94
Dabigitran ....................................... 29
Dacarbazine ..................................... 133
Dactinomycin [Actinomycin D] .......... 129
Daiobet ........................................ 55
Dainone ......................................... 55
Dalacin C ......................................... 78
Dalteparin ....................................... 29
Danaparoid ...................................... 29
Danazol .......................................... 65
Dantrium ......................................... 100
Dantrium IV ..................................... 100
Dantrolene ...................................... 100
Daonil ............................................ 10
Dapa-Tabs ....................................... 44
Dapsone ......................................... 82
Daptomycin ..................................... 78
Darunavir ....................................... 87
Dasatinib ......................................... 136
Daunorubicin ................................... 129
DBL Acetylcysteine ......................... 207
DBL Amikacin .................................. 72
DBL Aminophylline ......................... 198
DBL Bleomycin Sulfate ..................... 129
DBL Cefotaxime ................................ 73
DBL Cisplatin .................................. 136
DBL Dacarbazine ............................... 133
DBL Desferrioxamine Mesylate for Inj BP.. 208
DBL Docetaxel .................................. 208
DBL Ergometrine ............................... 59
DBL Gentamicin ................................ 72
DBL Leucovorin Calcium ................. 142
DBL Methotrexate Onco-Vial ............. 131
DBL Morphine Sulfate ....................... 109
DBL Morphine Tartrate ..................... 109
DBL Naloxone Hydrochloride .......... 207
DBL Octreotide ................................ 143
DBL Pethidine Hydrochloride ............ 110
DBL Rocuronium Bromide ................. 100
DBL Vincristine Sulfate .................... 142
De-Worm ....................................... 83
Decongestants ................................. 196
Decongestants and Antiallergics ......... 202
Decoziol ........................................ 19
Decosars ......................................... 208
Deferiprone ..................................... 208
Defibrotide ..................................... 30
Definity .......................................... 211
Demeclocycline hydrochloride ........... 78
Denosumab ...................................... 96
Deoate ........................................... 82
Deoxycoformycin ............................. 134
Depo-Medrol .................................... 64
Depo-Provera ................................... 58
Depo-Testosterone ............................. 62
Deprin ............................................ 79
DermAssist ..................................... 54
Dermol ........................................ 54, 56
Desferrioxamine mesilate ............... 208
Desfluran ....................................... 104
Desmopressin acetaete ..................... 71
Desmopressin-PH&T .......................... 71
Dexamethasone ............................... 63
Dexamethasone phosphate .............. 63
Dexamethasone with framyetin and
  granicinid .................................. 200
Dexamethasone with neomycin
  sulphate and polymyxin B
  sulphate ...................................... 200
Dexamethasone with
  tobramycin ................................ 200
Dexamethasone with
  dexametanamide ................. 123
Dexamethasone .............................. 104
Dexamethone ................................ 63
Dexrazoxane ................................ 142
Dextrose .........................................
  Alimentary .................................. 9
  Blood ............................................. 33–34, 36
  Extemporaneously Compounded
  Preparations ................................. 215
  Dextrose with sodium citrate and
  citric acid [Acid Citrate Dextrose
  A] .............................................. 30
  DHC Continus ................................ 108
  Diabetes ....................................... 8
  Diacomin .................................... 114
  Diagnostic Agents
  Vaccines ..................................... 242
  Various ...................................... 211
  Diagnostic and Surgical
  Preparations ................................ 202
  Diamide Relief ............................... 5
  Diamox ....................................... 204
  Diamor ....................................... 204
  Diamor ....................................... 204
  Diamox ....................................... 204
  Dihydrocodeine tartrate .............. 108
  Dihydrogen phosphate ............... 207
  Dihydrogen phosphate with
  sodium dihydrogen phosphate .... 215
  Diflucortolone valerate ............... 54
  DiGel ......................................... 10
  Digoxin ....................................... 39
  Diltiazem hydrochloride ............. 42
  Dilzem ....................................... 42
  Dimedrol ..................................... 6
  Dimethicone ................................. 51–52
  Dimethyl fumarate ....................... 121
  Dimethyl sulfoxide ....................... 213
  Dinoprostone ................................ 59
  Dipentum ..................................... 6
  Diphenidol .................................. 56
  Diphenoxylate hydrochloride .. 56
  Diphenoxylate hydrochloride with
  atropine sulphate ....................... 5
  Diphenoxylate hydrochloride with
  atropine sulphate ....................... 5
  Diphenoxylate hydrochloride with
  atropine sulphate ....................... 5
  Diphenoxylate hydrochloride with
  atropine sulphate ....................... 5
  Diphenoxylate hydrochloride with
  atropine sulphate ....................... 5
  Diphtheria antitoxin ..................... 207
  Diphtheria, tetanus and pertussis
  vaccine ..................................... 234
  Diphtheria, tetanus and pertussis
  polio vaccine ............................. 233
  Diphtheria, tetanus, pertussis, polio,
  hepatitis B and haemophilus
  influenzae type B vaccine .......... 233
  Dipyridamole ............................... 31
  Disodium edetate ......................... 203
  Disodium hydrogen phosphate with
  sodium dihydrogen phosphate .... 215
  Disopyramide phosphate ............. 39
  Disulfiram .................................. 126
  Dithranol ................................... 215
  Diuretics ................................... 43
  Diurin 40 .................................. 43
  Dobutamine ................................ 46
  Dobutamine-hemel ................................
  Docusate sodium ............................ 141
  Docusate sodium ............................ 141
  Docusate sodium with
  Alimentary ................................ 12
  Sensory ...................................... 206
INDEX: Generic Chemicals and Brands

Felodipine ........................................ 42
Fentanyl ........................................ 108
Fentanyl Sandoz ................................ 108
Ferinject .......................................... 17
Ferodan ........................................... 17
Ferric carboxymaltose ....................... 17
Ferric subsulfate ............................... 26
Ferriprox ......................................... 208
Ferro-F-Tabs ..................................... 17
Ferro-tab .......................................... 17
Ferrograd ......................................... 17
Ferroig ............................................. 17
Ferrous fumarate ............................... 17
Ferrous fumarate with folic acid ......... 17
Ferrous gluconate with ascorbic acid ... 17
Ferrous sulfate .................................. 17
Ferrous sulphate with ascorbic acid ... 17
Ferrum H .......................................... 17
Fexofenadine hydrochloride ............... 193
Figrastim ......................................... 33
Finasteride ....................................... 60
Fingolimod ....................................... 121
Firazyr ........................................... 192
Flagyl ............................................... 84
Flagyl-S ........................................... 84
Flamazine ........................................ 51
Flecainide acetae .............................. 40
Flecainide BNM ................................. 40
Flecainide Controlled Release Teva ... 40
Fleet Phosphate Enema ....................... 12
Flixonase Hayfever & Allergy .......... 193
Flixotide ......................................... 197
Flixotide Accuhaler ......................... 197
Floair .............................................. 197
Florinef .......................................... 63
Fluanxol .......................................... 119
Fluaxir Tetra ................................... 239
Flucil .............................................. 76
Flucloxacillin .................................. 76
Fluclozin ......................................... 76
Fluconazole ..................................... 80
Fluconazole-Claris ............................ 80
Flucytosine ...................................... 82
Fludara Oral .................................... 130
Fludarabine Ebewe ......................... 130
Fludarabine phosphate ...................... 130
Fludrocortisone acetate .................... 63
Fluids and Electrolytes ...................... 33
Flumazenil ....................................... 207
Flumetasone pivalate with ciloquinol ... 201
Flucortolone caproate with.............. 201

Fluocortolone pivalate and cinchocholine ........................................ 6
Fluorescein sodium .......................... 202
Fluorescein sodium with lignocaine hydrochloride ................................ 202
Fluospecte ....................................... 202
Flurometholone ................................ 202
Flourouracil ..................................... 131
Flourouracil Ebewe ......................... 131
Flourouracil sodium ......................... 56
Fluoxetine hydrochloride ................... 111
Flupenthixol decanoate .......................... 119
Flumathilde ..................................... 143
Flutamid .......................................... 143
Flutacasone ...................................... 197
Flutacasone furate with vilanterol ........ 197
Flutacasone propionate ..................... 193
Flutacasone with salmeterol ............... 198
FML ................................................. 202
Foban .............................................. 51
Folic acid ........................................ 24
Fondaparinux sodium ....................... 30
Food Modules .................................. 218
Food/Fluid Thickeners ...................... 220
Forteo ............................................. 98
Fortisip (Vanilla) ............................. 232
Fosamax ......................................... 94
Fosamax Plus ................................... 94
Foscarnet sodium .............................. 89
Fosfomycin ...................................... 78
Framcin .......................................... 29
Framycetin sulphate ......................... 200
Fresenius Kabi
Blood............................................. 34-36
Various......................................... 213
Fresolol 1% MCT/LCT ......................... 104
Frusenide ....................................... 43
Frusenide-Claris ............................... 43
Fucidin ........................................... 79
Fucithalmic ..................................... 200
Fungilin ......................................... 19
Furosemide [Frusenide] ...................... 43
Fusidic acid Dermatological ............... 51, 55
Fusidic acid Infections .......................... 79
Fusidic acid Sensory .............................. 200
Gabapentin ...................................... 112
Gacett ............................................. 108
Galbendic acid .................................. 211
Gabadutrol ...................................... 211
Gadodiamide ................................... 211
Gadoteric acid .................................. 211
Gadovist 1.0 .................................... 211
Gadoxetate disodium ......................... 211
Galsulfase ....................................... 14
Galvumet ....................................... 10
Galous .............................................. 10
Ganciclovir ..................................... 89
Gardasil 9 ........................................ 239
Gastrodenol ...................................... 8
Gastrografin .................................... 210
Gazyva .......................................... 169
Gefitinib ......................................... 137
Gelatine, succinylated ....................... 36
Gelofusine ....................................... 36
Gemcitabine .................................... 131
Gemcitabine Ebewe ......................... 131
Gemfibrozil ..................................... 44
Genoptic ......................................... 200
Gentamicin sulphate .......................... 32
Infections ......................................... 72
Sensory ............................................ 200
Gestrinone ....................................... 65
Gilena ............................................. 121
Ginet .............................................. 57
Glattiraner acetate ......................... 121
Glucoma Preparations ....................... 204
Glecaprevir with pibrentasvir ............. 89
Gibenclamide .................................... 10
Gliclazide ........................................ 10
Gliolan ........................................... 145
Glipizide ......................................... 10
Glivec ............................................. 137
Glizide ............................................ 10
Glucagen Hypokit .............................. 9
Glucagon hydrochloride .................... 9
Glucerna Select (Vanilla) .................. 224
Glucerna Select RTH (Vanilla) .......... 224
Glucobay ......................................... 8
Glucose [Dextrose]
Alimentary ........................................ 9
Blood ............................................. 34
Extemporaneously Compounded
Preparations .................................. 215
Glucose with potassium chloride .......... 34
Glucose with potassium chloride and sodium chloride ......................... 34
Glucose with sodium chloride .......... 34
Glucose with sucrose and
fructose ........................................... 9
Glycerin with sodium saccharin .......... 216
Glycerin with sucrose ................. 216
Glycerol
Alimentary ........................................ 12
Extemporaneously Compounded
Preparations .................................. 216
Glycerol with paraffin ....................... 53
Glyceryl trinitrate
Alimentary ........................................ 7
Cardiovascular .................................. 46
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycine .................................. 212</td>
</tr>
<tr>
<td>Glycopyrronium ........................... 194</td>
</tr>
<tr>
<td>Glycopyrronium bromide .................. 7</td>
</tr>
<tr>
<td>Glycopyrronium with indacaterol ....... 194</td>
</tr>
<tr>
<td>Glypressin .................................. 71</td>
</tr>
<tr>
<td>Glytrin ...................................... 46</td>
</tr>
<tr>
<td>Gonadorelin .................................. 66</td>
</tr>
<tr>
<td>Goserelin ................................... 66</td>
</tr>
<tr>
<td>Granisetron .................................. 116</td>
</tr>
<tr>
<td>-H-</td>
</tr>
<tr>
<td>Habitrol .................................... 126</td>
</tr>
<tr>
<td>Habitrol (Fruit) .......................... 126</td>
</tr>
<tr>
<td>Habitrol (Mint) ............................ 126</td>
</tr>
<tr>
<td>Haem arginate .................................. 14</td>
</tr>
<tr>
<td>Haemophilus influenzae type B vaccine .... 234</td>
</tr>
<tr>
<td>Haldol ....................................... 119</td>
</tr>
<tr>
<td>Haldol Concentrate ....................... 119</td>
</tr>
<tr>
<td>Haloperidol ................................ 118</td>
</tr>
<tr>
<td>Haloperidol decanoate .................... 119</td>
</tr>
<tr>
<td>Hartmann's solution ....................... 34</td>
</tr>
<tr>
<td>Harvon ...................................... 89</td>
</tr>
<tr>
<td>Havrix ....................................... 237</td>
</tr>
<tr>
<td>Havrix Junior ............................... 237</td>
</tr>
<tr>
<td>HBVaxPRO ..................................... 237-238</td>
</tr>
<tr>
<td>Healon ....................................... 203</td>
</tr>
<tr>
<td>Healon 5 ..................................... 203</td>
</tr>
<tr>
<td>Healon GV .................................... 203</td>
</tr>
<tr>
<td>healthE Calamine Aqueous Cream BP .... 52</td>
</tr>
<tr>
<td>healthE Dimethicone 10% ................. 52</td>
</tr>
<tr>
<td>healthE Dimethicone 4% Lotion .......... 51</td>
</tr>
<tr>
<td>healthE Dimethicone 5% .................. 52</td>
</tr>
<tr>
<td>healthE Fatty Cream ...................... 53</td>
</tr>
<tr>
<td>healthE Glycerol BP Liquid .............. 216</td>
</tr>
<tr>
<td>healthE Urea Cream ....................... 54</td>
</tr>
<tr>
<td>Heparin sodium .......................... 30</td>
</tr>
<tr>
<td>Heparinised saline ........................ 30</td>
</tr>
<tr>
<td>Heparon Junior ............................ 225</td>
</tr>
<tr>
<td>Hepatitis A vaccine ...................... 237</td>
</tr>
<tr>
<td>Hepatitis B recombinant vaccine .......... 237</td>
</tr>
<tr>
<td>Hepsara .................................... 88</td>
</tr>
<tr>
<td>Herceptin .................................. 186</td>
</tr>
<tr>
<td>Hexamine hippurate ....................... 79</td>
</tr>
<tr>
<td>Hiberix ...................................... 234</td>
</tr>
<tr>
<td>Histaclear .................................. 193</td>
</tr>
<tr>
<td>Histamine acid phosphate ............... 212</td>
</tr>
<tr>
<td>Holoxan .................................... 129</td>
</tr>
<tr>
<td>Hormone Replacement Therapy .......... 64</td>
</tr>
<tr>
<td>HPV ......................................... 239</td>
</tr>
<tr>
<td>Humalog Mix 25 ......................... 9</td>
</tr>
<tr>
<td>Humalog Mix 50 ........................... 9</td>
</tr>
<tr>
<td>Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine .......... 237</td>
</tr>
<tr>
<td>[HPV] ...................................... 239</td>
</tr>
<tr>
<td>Humatin ..................................... 72</td>
</tr>
<tr>
<td>Humira ...................................... 151</td>
</tr>
<tr>
<td>HumiraPen ................................... 151</td>
</tr>
<tr>
<td>Hyaluronic acid ............................ 19</td>
</tr>
<tr>
<td>Sensory ...................................... 203, 206</td>
</tr>
<tr>
<td>Hyaluronic acid with lidocaine [lignocaine] ........................................ 19</td>
</tr>
<tr>
<td>Hyaluronidase ................................ 98</td>
</tr>
<tr>
<td>Hybloc ....................................... 41</td>
</tr>
<tr>
<td>Hydralazine hydrochloride .............. 47</td>
</tr>
<tr>
<td>Hydrea ...................................... 133</td>
</tr>
<tr>
<td>Hydrocortisone ........................... 54</td>
</tr>
<tr>
<td>Dermatological ............................ 54</td>
</tr>
<tr>
<td>Extemporarily Compounded Preparations ........................................ 216</td>
</tr>
<tr>
<td>Hydrocortisone acetate .................. 6</td>
</tr>
<tr>
<td>Alimentary .................................. 6</td>
</tr>
<tr>
<td>Hydrocortisone butyrate ................ 54, 56</td>
</tr>
<tr>
<td>Hydrocortisone with miconazole ....... 55</td>
</tr>
<tr>
<td>Hydrocortisone with natamycin and neomycin ........................................ 55</td>
</tr>
<tr>
<td>Hydrogen peroxide ....................... 51</td>
</tr>
<tr>
<td>Hydrocortisone and paraffin liquid and lanolin ........................................ 54</td>
</tr>
<tr>
<td>Hydrocortisone acetate with pramoxine hydrochloride ................................ 6</td>
</tr>
<tr>
<td>Hydrocortisone with miconazole ....... 55</td>
</tr>
<tr>
<td>Hydrocortisone with natamycin and neomycin ........................................ 55</td>
</tr>
<tr>
<td>Hydrocortisone acetate .................. 54, 56</td>
</tr>
<tr>
<td>Hydrocortisone butyrate ................ 54, 56</td>
</tr>
<tr>
<td>Hydrocortisone with miconazole ....... 55</td>
</tr>
<tr>
<td>Hydrocortisone with natamycin and neomycin ........................................ 55</td>
</tr>
<tr>
<td>Hydrogen peroxide ....................... 51</td>
</tr>
<tr>
<td>Hydrocortisone acetate .................. 54, 56</td>
</tr>
<tr>
<td>Hydrocortisone butyrate ................ 54, 56</td>
</tr>
<tr>
<td>Hydrocortisone with miconazole ....... 55</td>
</tr>
<tr>
<td>Hydrocortisone with natamycin and neomycin ........................................ 55</td>
</tr>
<tr>
<td>Hydrogen peroxide ....................... 51</td>
</tr>
<tr>
<td>Hydroxycobalamin ....................... 20</td>
</tr>
<tr>
<td>Hydroxychloroquine ...................... 207</td>
</tr>
<tr>
<td>Hydroxyurea ................................ 133</td>
</tr>
<tr>
<td>Hygroton .................................... 44</td>
</tr>
<tr>
<td>Hylo-Fresh .................................. 206</td>
</tr>
<tr>
<td>Hyoscine butylbromide .................. 7</td>
</tr>
<tr>
<td>Hyoscine hydrobromide ................. 116</td>
</tr>
<tr>
<td>Hyperuricaemia and Antigout ........... 98</td>
</tr>
<tr>
<td>Hypermellose ............................... 203, 205</td>
</tr>
<tr>
<td>Hypermellose with dextran .............. 205</td>
</tr>
<tr>
<td>I -</td>
</tr>
<tr>
<td>Ibiamox .................................... 76</td>
</tr>
<tr>
<td>Ibuprofen .................................. 101</td>
</tr>
<tr>
<td>Icatibant .................................. 192</td>
</tr>
<tr>
<td>Idburicin hydrochloride ............... 130</td>
</tr>
<tr>
<td>Idarucizumab ............................. 26</td>
</tr>
<tr>
<td>Iduracil .................................... 15</td>
</tr>
<tr>
<td>Ifosfamide .................................. 129</td>
</tr>
<tr>
<td>Ikorel ...................................... 47</td>
</tr>
<tr>
<td>Iloprost .................................... 50</td>
</tr>
<tr>
<td>Imaging Agents ............................ 145</td>
</tr>
<tr>
<td>Imatinib mesilate ......................... 137</td>
</tr>
<tr>
<td>Imatinib-AFT .............................. 138</td>
</tr>
<tr>
<td>Imipenem with cilastatin ............... 72</td>
</tr>
<tr>
<td>Imipenem+Cilastatin RBX ............... 72</td>
</tr>
<tr>
<td>Imipramine hydrochloride .............. 110</td>
</tr>
<tr>
<td>Imiquimod ................................ 56</td>
</tr>
<tr>
<td>Immune Modulators ....................... 92</td>
</tr>
<tr>
<td>Immunosuppressants ...................... 145</td>
</tr>
<tr>
<td>Impact Advanced Recovery .............. 230</td>
</tr>
<tr>
<td>Imuran .................................... 190</td>
</tr>
<tr>
<td>Incruse Elipta ................................ 194</td>
</tr>
<tr>
<td>Indacaterol ................................ 197</td>
</tr>
<tr>
<td>Indapamide .................................. 44</td>
</tr>
<tr>
<td>Indigo carmine ........................... 212</td>
</tr>
<tr>
<td>Indinavir .................................... 87</td>
</tr>
<tr>
<td>Indocyanine green ....................... 212</td>
</tr>
<tr>
<td>Indomethacin .............................. 101</td>
</tr>
<tr>
<td>Infanrix-IPV ............................... 233</td>
</tr>
<tr>
<td>Infanrix-hexa ................................ 233</td>
</tr>
<tr>
<td>Infatini ..................................... 228</td>
</tr>
<tr>
<td>Infliximab .................................. 162</td>
</tr>
<tr>
<td>Influenza vaccine ......................... 239</td>
</tr>
<tr>
<td>Influvac Tetra ............................ 240</td>
</tr>
<tr>
<td>Inhaled Corticosteroids ................. 196</td>
</tr>
<tr>
<td>Inspra ...................................... 44</td>
</tr>
<tr>
<td>Insulin aspart ............................. 9</td>
</tr>
<tr>
<td>Insulin aspart with insulin aspart protamine ........................................ 9</td>
</tr>
<tr>
<td>Insulin glargine .......................... 9</td>
</tr>
<tr>
<td>Insulin glulisine .......................... 10</td>
</tr>
<tr>
<td>Insulin isophane .......................... 9</td>
</tr>
<tr>
<td>Insulin lispro ............................. 10</td>
</tr>
<tr>
<td>Insulin lispro with insulin lispro protamine ........................................ 9</td>
</tr>
<tr>
<td>Insulin neutral ............................ 10</td>
</tr>
<tr>
<td>Insulin neutral with insulin isophane ........................................ 9</td>
</tr>
<tr>
<td>Integritil .................................. 31</td>
</tr>
<tr>
<td>Intolerance ................................ 85</td>
</tr>
<tr>
<td>Interferon alfa-2a ....................... 92</td>
</tr>
<tr>
<td>Interferon alfa-2b ....................... 92</td>
</tr>
<tr>
<td>Interferon beta-1-alpha ................. 121</td>
</tr>
<tr>
<td>Interferon beta-1-beta ................. 121</td>
</tr>
<tr>
<td>Interferon gamma ......................... 92</td>
</tr>
<tr>
<td>Intra-uterine device ...................... 58</td>
</tr>
<tr>
<td>Invanz .................................... 72</td>
</tr>
<tr>
<td>Invega Sustenna .......................... 119</td>
</tr>
<tr>
<td>Iodine ..................................... 70</td>
</tr>
<tr>
<td>Iodine with ethanol ...................... 209</td>
</tr>
<tr>
<td>Iodised oil .................................. 210</td>
</tr>
<tr>
<td>Iodixanol .................................. 210</td>
</tr>
<tr>
<td>Ihoxel ..................................... 210</td>
</tr>
<tr>
<td>Iopidine .................................. 205</td>
</tr>
<tr>
<td>Ioscan ..................................... 210</td>
</tr>
<tr>
<td>IPOL ........................................ 241</td>
</tr>
<tr>
<td>Irraproprium bromide .................... 193</td>
</tr>
<tr>
<td>Irressa ..................................... 137</td>
</tr>
<tr>
<td>Irinotecan Actavis 100 ................. 133</td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
</tr>
<tr>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Irinotecan hydrochloride ............ 133</td>
</tr>
<tr>
<td>Iron polymaltose ..................... 17</td>
</tr>
<tr>
<td>Iron sucrose .......................... 18</td>
</tr>
<tr>
<td>Irrigation Solutions .................. 212</td>
</tr>
<tr>
<td>Isentress .............................. 88</td>
</tr>
<tr>
<td>Isentress HD ............................ 88</td>
</tr>
<tr>
<td>Ismo 40 Retard ......................... 46</td>
</tr>
<tr>
<td>Ismo-20 .................................. 46</td>
</tr>
<tr>
<td>Isoflurane ................................ 104</td>
</tr>
<tr>
<td>Isoniazid .................................. 83</td>
</tr>
<tr>
<td>Isoniazid with rifampicin .............. 83</td>
</tr>
<tr>
<td>Isoprenaline [Isoproterenol] ........... 46</td>
</tr>
<tr>
<td>Isopropyl alcohol ...................... 209</td>
</tr>
<tr>
<td>Isoproterenol ............................ 46</td>
</tr>
<tr>
<td>Isopropyl alcohol ...................... 43</td>
</tr>
<tr>
<td>Isopto Carpine ......................... 204</td>
</tr>
<tr>
<td>Isosorbide mononitrate ............... 46</td>
</tr>
<tr>
<td>Isotretinoin ............................ 52</td>
</tr>
<tr>
<td>Ispaghula (psyllium) husk ............. 11</td>
</tr>
<tr>
<td>Isradipine ................................ 42</td>
</tr>
<tr>
<td>Itch-Soothe ................................ 52</td>
</tr>
<tr>
<td>Itraconazole ............................ 80</td>
</tr>
<tr>
<td>Itrazole ................................... 80</td>
</tr>
<tr>
<td>Ivabradine ................................ 40</td>
</tr>
<tr>
<td>Ivermectin ............................... 83</td>
</tr>
<tr>
<td>Jadelle .................................... 58</td>
</tr>
<tr>
<td>Jak ........................................... 140</td>
</tr>
<tr>
<td>Jevity HiCal RTH ....................... 231</td>
</tr>
<tr>
<td>Jevity RTH ................................. 231</td>
</tr>
<tr>
<td>Juno Pemetrexed ....................... 131</td>
</tr>
<tr>
<td>Kaletra .................................... 87</td>
</tr>
<tr>
<td>Kenacomb .................................. 201</td>
</tr>
<tr>
<td>Kenacort-A 10 ......................... 64</td>
</tr>
<tr>
<td>Kenacort-A 40 ......................... 64</td>
</tr>
<tr>
<td>Kenalog in Orabase ..................... 19</td>
</tr>
<tr>
<td>Ketalar .................................... 104</td>
</tr>
<tr>
<td>Ketamine ................................... 104</td>
</tr>
<tr>
<td>Ketamine-Claris ...................... 104</td>
</tr>
<tr>
<td>Ketocid 3:1 (Unflavoured) .......... 228</td>
</tr>
<tr>
<td>Ketocid 4:1 (Unflavoured) .......... 228</td>
</tr>
<tr>
<td>Ketocid 4:1 (Vanilla) ................. 228</td>
</tr>
<tr>
<td>Ketoconazole ........................... 80</td>
</tr>
<tr>
<td>Dermatological ......................... 51</td>
</tr>
<tr>
<td>Infections ................................ 80</td>
</tr>
<tr>
<td>Ketoprofen ............................... 102</td>
</tr>
<tr>
<td>Ketorolac trometamol ................ 202</td>
</tr>
<tr>
<td>KestoSens .................................. 243</td>
</tr>
<tr>
<td>Ketostix .................................... 243</td>
</tr>
<tr>
<td>Keytruda ................................... 188</td>
</tr>
<tr>
<td>Kivexa ..................................... 86</td>
</tr>
<tr>
<td>Klacid ...................................... 75</td>
</tr>
<tr>
<td>Klean Prep ............................... 11</td>
</tr>
<tr>
<td>Kogenate FS ............................. 28</td>
</tr>
<tr>
<td>Konakion MM ............................. 29</td>
</tr>
<tr>
<td>Konsyl-D ................................. 11</td>
</tr>
<tr>
<td>Kuvan ..................................... 15</td>
</tr>
<tr>
<td>L-asparginase ....................... 133</td>
</tr>
<tr>
<td>L-ornithine L-aspartate ............. 8</td>
</tr>
<tr>
<td>Labetalol .................................. 41</td>
</tr>
<tr>
<td>Lacosamide .............................. 112</td>
</tr>
<tr>
<td>Lactose ................................... 216</td>
</tr>
<tr>
<td>Lactulose .................................. 12</td>
</tr>
<tr>
<td>Laevolac .................................. 12</td>
</tr>
<tr>
<td>Lamictal .................................. 113</td>
</tr>
<tr>
<td>Lamivudine .............................. 86, 88</td>
</tr>
<tr>
<td>Lamotrigine ............................. 113</td>
</tr>
<tr>
<td>Lanoxin ................................... 39</td>
</tr>
<tr>
<td>Lanoxin PG ............................... 39</td>
</tr>
<tr>
<td>Lansoprazole ............................ 7</td>
</tr>
<tr>
<td>Latus ....................................... 9</td>
</tr>
<tr>
<td>Lantus SoloStar ....................... 9</td>
</tr>
<tr>
<td>Lanzol Relief ......................... 7</td>
</tr>
<tr>
<td>Lapatinib ................................ 138</td>
</tr>
<tr>
<td>Largactil .................................. 117</td>
</tr>
<tr>
<td>Laronidase .............................. 15</td>
</tr>
<tr>
<td>Lasix ....................................... 43</td>
</tr>
<tr>
<td>Latanoprost ............................ 204</td>
</tr>
<tr>
<td>Lax-Suppositories ..................... 13</td>
</tr>
<tr>
<td>Lax-Tab .................................... 13</td>
</tr>
<tr>
<td>Laxatives ............................... 11</td>
</tr>
<tr>
<td>Lebovax ................................. 12</td>
</tr>
<tr>
<td>Ledipasvir with sofosbuvir ........ 89</td>
</tr>
<tr>
<td>Leflunomide ............................ 94</td>
</tr>
<tr>
<td>Lenalidomide ........................... 133</td>
</tr>
<tr>
<td>Letrozole ............................... 144</td>
</tr>
<tr>
<td>Leukotriene Receptor Protectors : Antagonists ............................. 197</td>
</tr>
<tr>
<td>Leunase ................................. 133</td>
</tr>
<tr>
<td>Leuprorelin acetate ................. 66</td>
</tr>
<tr>
<td>Leustatin ............................... 130</td>
</tr>
<tr>
<td>Levetiracetam ......................... 113</td>
</tr>
<tr>
<td>Leviteracetam-AFT .................... 113</td>
</tr>
<tr>
<td>Levlen ED ............................... 57</td>
</tr>
<tr>
<td>Levocabastine ......................... 202</td>
</tr>
<tr>
<td>Levocameline ........................... 15</td>
</tr>
<tr>
<td>Levodopa with benserazide .......... 104</td>
</tr>
<tr>
<td>Levodopa with carbidopa .......... 104</td>
</tr>
<tr>
<td>Levomepromazine ..................... 118</td>
</tr>
<tr>
<td>Levomepromazine hydrochloride .... 118</td>
</tr>
<tr>
<td>Levonorgestrel ....................... 58</td>
</tr>
<tr>
<td>Levosimendan ......................... 46</td>
</tr>
<tr>
<td>Levothryoxine ......................... 70</td>
</tr>
<tr>
<td>Lidocaine .............................. 106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] .......... 106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with adrenaline .... 106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with chlorhexidine .... 106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with phentolamine .... 106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] with prilocaine .......... 106</td>
</tr>
<tr>
<td>Lidocaine-Claris ..................... 106</td>
</tr>
<tr>
<td>lignocaine ............................. 19</td>
</tr>
<tr>
<td>Lipozene .................................. 19</td>
</tr>
<tr>
<td>Lincomycin ................................ 79</td>
</tr>
<tr>
<td>Linezolid .................................. 79</td>
</tr>
<tr>
<td>Linezolid Kabi ......................... 79</td>
</tr>
<tr>
<td>Lioresal Intrathecal .................. 100</td>
</tr>
<tr>
<td>Lithotryonide sodium ............... 70</td>
</tr>
<tr>
<td>Lipafran ................................. 44</td>
</tr>
<tr>
<td>Lipid-Modifying Agents ............ 44</td>
</tr>
<tr>
<td>Lipiodol Ultra Fluid ............... 210</td>
</tr>
<tr>
<td>Liquibac ................................. 210</td>
</tr>
<tr>
<td>Lisinopril .................................. 37</td>
</tr>
<tr>
<td>Lissamine green ....................... 202</td>
</tr>
<tr>
<td>Lithicarb FC ........................... 118</td>
</tr>
<tr>
<td>Lithium carbonate .................... 118</td>
</tr>
<tr>
<td>LMX4 ..................................... 106</td>
</tr>
<tr>
<td>Local Preparations for Anal and Rectal Disorders ...................... 6</td>
</tr>
<tr>
<td>Locoid ..................................... 54, 56</td>
</tr>
<tr>
<td>Locoid Crelo ......................... 54</td>
</tr>
<tr>
<td>Locoid Lipocream .................... 54</td>
</tr>
<tr>
<td>Lodil ....................................... 39</td>
</tr>
<tr>
<td>Lodoxamide ............................ 202</td>
</tr>
<tr>
<td>Logem ...................................... 113</td>
</tr>
<tr>
<td>Lomide .................................... 202</td>
</tr>
<tr>
<td>Lomustine .............................. 129</td>
</tr>
<tr>
<td>Long-Acting Beta-Adrenoceptor Agonists ............................. 197</td>
</tr>
<tr>
<td>Loniten .................................... 47</td>
</tr>
<tr>
<td>Loperamide hydrochloride ........ 5</td>
</tr>
<tr>
<td>Lopinavir with ritonavir .......... 87</td>
</tr>
<tr>
<td>Lorafax .................................... 193</td>
</tr>
<tr>
<td>Loratadine ............................. 193</td>
</tr>
<tr>
<td>Lorazepam .............................. 112, 120</td>
</tr>
<tr>
<td>Lorfast .................................... 193</td>
</tr>
<tr>
<td>Lormetazepam .......................... 122</td>
</tr>
<tr>
<td>Lorstat .................................... 44</td>
</tr>
<tr>
<td>Losartan Actavis ...................... 38</td>
</tr>
<tr>
<td>Losartan potassium ................ 38</td>
</tr>
<tr>
<td>Losartan potassium with hydrochlorothiazide .... 38</td>
</tr>
<tr>
<td>Lovir ...................................... 89</td>
</tr>
<tr>
<td>Lucrin Depot 1-month ............ 66</td>
</tr>
<tr>
<td>Lucrin Depot 3-month ............ 66</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Lyderm...........................................52
Lysine acetylsalicylate [Lysine asprin]..............31
Lysine asprin ................................31

M - M -

m-Amoxiclav ....................................76
m-Eston .........................................109
Mabthera .......................................172

Macroglol 3350 with ascorbic acid, potassium chloride and sodium chloride ..........................11
Macroglol 3350 with potassium chloride, sodium bicarbonate and sodium chloride ................12
Macroglol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate ..............................................................11
Macroglol 400 and propylene glycol ..................205
Madopar 125 ....................................104
Madopar 250 ....................................104
Madopar 62.5 ....................................104
Madopar HBS ....................................104
Madopar Rapid ..................................104
Mafenide acetate ................................51
Magnesium amino acid chelate ...............18
Magnesium chloride ............................18
Magnesium hydroxide
Alimentary ........................................18
Extemporaneously Compounded
Preparations ....................................216
Magnesium oxide ................................18
Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate ..................................................................................................................18
Magnesium sulphate .............................18
Magnesium sulphate with magnesium aspartate ...............................18
Magnesium sulphate with magnesium aspartate, magnesium amino acid chelate and magnesium citrate ..................................................................................................................18
Malignostat ......................................18
Malathion [Maldison] .........................52
Maldison .........................................52
Mannitol
Cardiovascular ..................................43
Various ............................................212
Mantoux ..........................................242
Maprotiline hydrochloride .....................111
Marclain .........................................105
Marclain Heavy ..................................105
Marclain Isobotic ...............................105
Marclain with Adrenaline ......................105
Marevan .........................................31
Marine Blue Lotion SPF 50+ .............56
Mask for spacer device ....................243
Mast Cell Stabilisers ...................198

Maviret...............................................89
Maxidex .........................................201
Maxitrol .........................................200
Measles, mumps and rubella vaccine ...............241
Mebendazole ....................................83
Mebeverine hydrochloride ...................7
Medrol .............................................64
Medroxyprogesterone ........................65
Medroxyprogesterone acetate
Genito-Urinary ..................................58
Hormone Preparations ....................65
Melenamic acid ...............................102
Mefloquine ......................................84
Megestrol acetate .............................143
Meglumine gadopentetate .................211
Meglumine iotroxate .........................211
Melatonin .......................................122
Meilphanal ......................................129
Menactra .......................................235
Meningococcal (A, C, Y and W-135) conjugate vaccine ..................................................235
Meningococcal C conjugate vaccine .......235
Menthol ..........................................216
Mepivacaine hydrochloride ...............106
Mercaptopurine ...............................131
Meropenem .....................................73
Meropenem Ranbaxy .........................73
Mesalazine ......................................6
Mesna ...........................................142
Mestinon .........................................94
Metabolic Disorder Agents ..............13
Metabolic Products .........................220
Metaraminol ...................................47
Meterol ..........................................197
Meflozin hydrogen hydrochloride ..........10
Methadone hydrochloride .................212
Methadoxone .................................212
Methadone hydrochloride
Extemporaneously Compounded
Preparations ....................................216
Nervous ..........................................108
Methathabs ....................................108
Methadoxone .................................104
Methopt ..........................................205
Methotrexate ..................................131
Methotrexate Ebewa .........................131
Methotrexate Sandoz .......................131
Methoxsalen
[8-methoxysoralen] .....................55
Methoxylfluorane .........................107
Methyl aminoavulinate hydrochloride ...56
Methyl hydroxybenzoate ...............216
Methylcellulose .............................216
Methylcellulose with glycerin and sodium saccharin ...............216
Methylcellulose with glycerin and sucrose ....216
Methyldopa ..................................105
Methyldopa Mylan ..........................104
Methylene blue ................................212
Methylnaltrexone bromide .............12
Methylenepididate ER - Teva .............124
Methylenepididate hydrochloride .....124
Methylprednisolone (as sodium succinate) ......64
Methylprednisolone aceponate ...........54
Methylprednisolone acetate ...............64
Methylenthioninium chloride [Methylene blue] ...........212
Methyloxanthines .........................198
Metoclopramide Actavis ....................116
Metoclopramide hydrochloride ........116
Metoclopramide hydrochloride with paracetamol ..........................115
Metolazone .....................................44
Metoprolol succinate ......................41
Metoprolol tartrate .........................41
Metronidazole ...............................158

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: Generic Chemicals and Brands

INDEX: G
INDEX: Generic Chemicals and Brands

Mitomycin C ....................................... 130
Mitozantrone ...................................... 130
Mitozantrone Ebeve ................................ 130
Mivacron ........................................... 100
Mivacurium chloride ............................. 100
Mixed salt solution for eye irrigation ............ 203
Moclubemide ...................................... 111
Modafinil .......................................... 124
Modavigil .......................................... 124
Moxol.................................................. 12
Mometasone furoate ............................... 54
Monosodium glutamate with sodium aspartate . 214
Monosodium l-aspartate .......................... 214
Montelukast ....................................... 197
Montelukast Mylan ................................ 197
Morocotoc alfa [Recombinant factor VIII] ....... 207
Morphine hydrochloride ......................... 109
Morphine sulphate ................................ 109
Morphine tartrate ................................ 109
Morelix .............................................. 103
Mouth and Throat ................................. 18
Movap................................................. 103
Moxifloxacin ...................................... 77
Mozobil ............................................. 32
Mucolytics and Expectorants ................. 198
Mucosoothe ....................................... 106
Multihance ......................................... 211
Multiple Sclerosis Treatments ............... 121
Multivitamin and mineral supplement ...... 19
Multivitamin renal ................................ 19
Multivitamins ..................................... 20
Mupirocin .......................................... 51
Muscle Relaxants and Related Agents ...... 100
Mvite ............................................... 20
Myambutol ........................................ 82
Myocutan .......................................... 83
MycoNail ........................................... 51
Mycophenolate mofetil ......................... 190
Mydriacyl .......................................... 205
Mydriatics and Cycloplegics ................. 205
Mylan Atenolol ................................ 40
Mylan Clomiphene ................................ 65
Mylan Midazolam ................................. 122
Myleran .......................................... 129
Myozone ........................................... 13
--- N ---
Nadolol ............................................ 41
Naglazyme .......................................... 14
Naloxone hydrochloride ....................... 207
Naltracod .......................................... 126
Naltrexone hydrochloride ..................... 126
Naphazoline hydrochloride ................... 202
Naphcon Forte ................................... 202
Naprosyn SR 1000 ............................... 102
Naprosyn SR 750 ................................ 102
Naproxen .......................................... 102
Naropin ........................................... 107
Natalizumab ...................................... 121
Natamycin ......................................... 200
Natulan ........................................... 134
Nausafax .......................................... 117
Nausacalm ........................................ 116
Navelbine ......................................... 142
Nedocromil ...................................... 198
Nefopam hydrochloride ....................... 107
Neisvac-C ........................................ 235
Neo-B12 ........................................... 20
Neocate Gold (Unflavoured) .................. 226
Neocate Junior Vanilla ....................... 226
Neoral ............................................. 145
Neostigmine metilsulfate ...................... 94
Neostigmine metilsulfate with glycopyrronium bromide . 94
Neosynephrine HCL ............................. 47
Nepro HP (Strawberry) ......................... 230
Nepro HP (Vanilla) .............................. 230
Nepro HP RTH .................................. 229
Neulastim ......................................... 33
Neupogen ......................................... 33
NeuTab ............................................ 17
Nevirapine ....................................... 86
Nevirapine Alphapharm ......................... 86
Nicardipine hydrochloride .................... 42
Nicorandil ........................................ 47
Nicotinic acid .................................... 45
Nifedipine ........................................ 42
Nifuran ............................................ 79
Nilotinib .......................................... 138
Nilstat ............................................. 187
Oestradiol valerate ............................. 64
Ocular Lubricants ............................... 65
Octreotide ........................................ 53
Obinutuzumab ................................... 169
Obstetric Preparations ......................... 59
Octocotoc alfa [Recombinant factor VIII] (Advate) ...... 28
Octocotoc alfa [Recombinant factor VIII] (Kogenate FS) ..... 28
Octreotide ........................................ 143
OcuLab .......................... 205
Ozarex.............................................. 64
Ozarex ................................. 64
Ozocomp .......................................... 64
Ozocomp ................................. 64
Ozogar............................................. 64
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensory................................................. 205</td>
</tr>
<tr>
<td>Phenytoin.................................................. 113</td>
</tr>
<tr>
<td>Phenytoin sodium................................. 112, 114</td>
</tr>
<tr>
<td>Pholcodine.............................................. 196</td>
</tr>
<tr>
<td>Phosphorus................................................. 36</td>
</tr>
<tr>
<td>Phytomenadione........................................... 29</td>
</tr>
<tr>
<td>Pliciban.................................................... 190</td>
</tr>
<tr>
<td>Plicarpine hydrochloride.................... 204</td>
</tr>
<tr>
<td>Plicarpine nitrate........................................ 216</td>
</tr>
<tr>
<td>Pimafucort............................................... 55</td>
</tr>
<tr>
<td>Pindolol..................................................... 41</td>
</tr>
<tr>
<td>Pine tar with trolamine laurilsulfate and fluorescein........ 55</td>
</tr>
<tr>
<td>Pinetasol.................................................... 55</td>
</tr>
<tr>
<td>Pioglitazone............................................... 10</td>
</tr>
<tr>
<td>Pipacillin with tazobactam.................... 76</td>
</tr>
<tr>
<td>Pipithiazine palmitate............................ 120</td>
</tr>
<tr>
<td>PipTaz Sandoz........................................... 76</td>
</tr>
<tr>
<td>Pifrenidone............................................... 195</td>
</tr>
<tr>
<td>Pituitary and Hypothalamic Hormones and Analogues...... 66</td>
</tr>
<tr>
<td>Pivmecillinam............................................. 79</td>
</tr>
<tr>
<td>Pizotifen.................................................... 116</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Berry).................. 222</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Orange).................. 222</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Unflavoured).......... 222</td>
</tr>
<tr>
<td>Plaquelin.................................................... 94</td>
</tr>
<tr>
<td>Plasma-Lyte 148........................................ 33</td>
</tr>
<tr>
<td>Plasma-Lyte 148 &amp; 5% Glucose............... 33</td>
</tr>
<tr>
<td>Plendi ER.................................................... 42</td>
</tr>
<tr>
<td>Periixar®.................................................... 32</td>
</tr>
<tr>
<td>Pneumococcal (PCV10) conjugate vaccine........ 235</td>
</tr>
<tr>
<td>Pneumococcal (PCV13) conjugate vaccine........ 235</td>
</tr>
<tr>
<td>Pneumococcal (PPV23) polysaccharide vaccine...... 236</td>
</tr>
<tr>
<td>Pneumovax 23............................................. 236</td>
</tr>
<tr>
<td>Podophyllotoxin........................................... 56</td>
</tr>
<tr>
<td>Polidocanol............................................... 26</td>
</tr>
<tr>
<td>Poliomyelitis vaccine............................ 241</td>
</tr>
<tr>
<td>Poloxamer................................................... 12</td>
</tr>
<tr>
<td>Poly Gel..................................................... 205</td>
</tr>
<tr>
<td>Poly-Tears.................................................. 205</td>
</tr>
<tr>
<td>Poly-Visc.................................................... 206</td>
</tr>
<tr>
<td>Polyhexamethylene biguanide................. 216</td>
</tr>
<tr>
<td>Polyvinyl alcohol........................................ 206</td>
</tr>
<tr>
<td>Polyvinyl alcohol with povidone............ 206</td>
</tr>
<tr>
<td>Poractant alfa............................................. 199</td>
</tr>
<tr>
<td>Posaconazole.............................................. 80</td>
</tr>
<tr>
<td>Postinor-1.................................................. 58</td>
</tr>
<tr>
<td>Potassium chloride......................... 34, 36</td>
</tr>
<tr>
<td>Potassium chloride with sodium chloride.. 34</td>
</tr>
<tr>
<td>Potassium citrate................... 60</td>
</tr>
<tr>
<td>Potassium dihydrogen phosphate............... 35</td>
</tr>
<tr>
<td>Potassium iodate........................................ 17</td>
</tr>
<tr>
<td>Potassium iodate with iodiode.......... 17</td>
</tr>
<tr>
<td>Potassium perchlorate............................ 70</td>
</tr>
<tr>
<td>Potassium permanganate........................ 55</td>
</tr>
<tr>
<td>Povidone K30.............................................. 216</td>
</tr>
<tr>
<td>Povidone-iodine........................................ 209</td>
</tr>
<tr>
<td>Povidone-iodine with ethanol.............. 209</td>
</tr>
<tr>
<td>Pradaxa..................................................... 29</td>
</tr>
<tr>
<td>Pralidoxime iodide............................. 207</td>
</tr>
<tr>
<td>Pramipexole hydrochloride............... 104</td>
</tr>
<tr>
<td>Prasugrel................................................... 31</td>
</tr>
<tr>
<td>Pravastatin............................................... 45</td>
</tr>
<tr>
<td>Prmbind..................................................... 26</td>
</tr>
<tr>
<td>Praziqantel............................................... 84</td>
</tr>
<tr>
<td>Prazosin..................................................... 39</td>
</tr>
<tr>
<td>Precedex.................................................... 104</td>
</tr>
<tr>
<td>Pregabalin............................................... 207</td>
</tr>
<tr>
<td>Pregabalin Pfizer............................... 114</td>
</tr>
<tr>
<td>Pregnancy test - hCG urine................ 243</td>
</tr>
<tr>
<td>PreOp......................................................... 230</td>
</tr>
<tr>
<td>Presolol.................................................... 41</td>
</tr>
<tr>
<td>Prevenar 13.............................................. 235</td>
</tr>
<tr>
<td>Prezista..................................................... 87</td>
</tr>
<tr>
<td>Prilocaine hydrochloride................... 107</td>
</tr>
<tr>
<td>Prilocaine hydrochloride with felypressin..... 107</td>
</tr>
<tr>
<td>Primacor................................................... 47</td>
</tr>
<tr>
<td>Primaqaine phosphate....................... 84</td>
</tr>
<tr>
<td>Primidone................................................... 114</td>
</tr>
<tr>
<td>Primolut N.................................................. 65</td>
</tr>
<tr>
<td>Primovist................................................... 211</td>
</tr>
<tr>
<td>Priorix....................................................... 241</td>
</tr>
<tr>
<td>Probenecid................................................. 100</td>
</tr>
<tr>
<td>Procarbazine hydrochloride............. 134</td>
</tr>
<tr>
<td>Prochlorperazine.............................. 117</td>
</tr>
<tr>
<td>Proctosedyl............................................... 6</td>
</tr>
<tr>
<td>Procyclidine hydrochloride............... 103</td>
</tr>
<tr>
<td>Procytox..................................................... 129</td>
</tr>
<tr>
<td>Progesterone............................................. 59</td>
</tr>
<tr>
<td>Progicem.................................................... 8</td>
</tr>
<tr>
<td>Proglycem.................................................. 8</td>
</tr>
<tr>
<td>Progynova................................................. 64</td>
</tr>
<tr>
<td>Prolia......................................................... 96</td>
</tr>
<tr>
<td>Promethazine hydrochloride......... 193</td>
</tr>
<tr>
<td>Propafenone hydrochloride................... 40</td>
</tr>
<tr>
<td>Propamidine isethionate.................. 200</td>
</tr>
<tr>
<td>Propofol.................................................... 104</td>
</tr>
<tr>
<td>Propranolol................................................. 41</td>
</tr>
<tr>
<td>Propylthiouracil..................................... 70</td>
</tr>
<tr>
<td>Prostin E2................................................. 59</td>
</tr>
<tr>
<td>Prostin VR................................................. 47</td>
</tr>
<tr>
<td>Protamine sulphate.................................. 30</td>
</tr>
<tr>
<td>Prolia......................................................... 83</td>
</tr>
<tr>
<td>Protanol..................................................... 71</td>
</tr>
<tr>
<td>Proveblue............................................... 212</td>
</tr>
<tr>
<td>Provera...................................................... 65</td>
</tr>
<tr>
<td>Proveha HD................................................. 65</td>
</tr>
<tr>
<td>Provan MCT-LCT 1%............................... 104</td>
</tr>
<tr>
<td>Proxymetacaine hydrochloride.......... 203</td>
</tr>
<tr>
<td>Pseudoephedrine........................... 196</td>
</tr>
<tr>
<td>PSM Citalopram................................. 111</td>
</tr>
<tr>
<td>Psoriasis and Eczema Preparations........ 55</td>
</tr>
<tr>
<td>PTU......................................................... 230</td>
</tr>
<tr>
<td>Pulmocare (Vanilla).............................. 210</td>
</tr>
<tr>
<td>Pulmonary Surfactants......................... 198</td>
</tr>
<tr>
<td>Pulmozyme............................................... 198</td>
</tr>
<tr>
<td>Puri-nethol................................................. 131</td>
</tr>
<tr>
<td>Puria......................................................... 21</td>
</tr>
<tr>
<td>Pyrazanamide............................................ 83</td>
</tr>
<tr>
<td>Pyridostigmine bromide...................... 94</td>
</tr>
<tr>
<td>Pyridoxal-5-phosphate................. 15</td>
</tr>
<tr>
<td>Pyridoxine hydrochloride................. 21</td>
</tr>
<tr>
<td>Pyrimethamine........................................... 85</td>
</tr>
<tr>
<td>Pytazene SR............................................. 31</td>
</tr>
<tr>
<td>Q 300......................................................... 85</td>
</tr>
<tr>
<td>Quetapine................................................... 118</td>
</tr>
<tr>
<td>Quetiapine................................................. 118</td>
</tr>
<tr>
<td>Quinapril.................................................... 37</td>
</tr>
<tr>
<td>Quinapril with hydrochlorothiazide........ 37</td>
</tr>
<tr>
<td>Quinine dihydrochloride.................. 85</td>
</tr>
<tr>
<td>Quinine sulphate.................................. 85</td>
</tr>
<tr>
<td>Qvar......................................................... 196</td>
</tr>
<tr>
<td>RA-Morph............................................... 109</td>
</tr>
<tr>
<td>Rabies vaccine....................................... 241</td>
</tr>
<tr>
<td>Raloxifene................................................. 97</td>
</tr>
<tr>
<td>Raltegravir potassium..................... 88</td>
</tr>
<tr>
<td>Ramipex..................................................... 104</td>
</tr>
<tr>
<td>Ranbaxy-Cefaclor............................... 73</td>
</tr>
<tr>
<td>Ranibizumab............................................. 171</td>
</tr>
<tr>
<td>Ranitidine.................................................. 7</td>
</tr>
<tr>
<td>Ranitidine Relief................................. 7</td>
</tr>
<tr>
<td>Rapamune................................................. 190</td>
</tr>
<tr>
<td>Rasburicase.............................................. 100</td>
</tr>
<tr>
<td>Readi-CAT 2........................................... 210</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

- S -

Silver nitrate...........................................56
Dermatological...........................................
Extemporaneously Compounded Preparations......

Simeticone.............................................5
Simulect..................................................161
Simvastatin.............................................45
Simvastatin Mylan..................................45
Sincalide................................................212
Sinemet....................................................104
Sinemet CR.............................................104
Sirolimus...............................................190
Siterone.....................................................62
Slow-Lopresor.........................................41
Smith BioMed Rapid Pregnancy Test................243
Snake antivenom....................................208
Sodibic.....................................................36
Sodium acetate.......................................35
Sodium acid phosphate...........................35
Sodium alginic acid.................................5
Sodium alginic acid with magnesium alginic........

Rogerotham...............................................208
Sodium bicarbonate.................................5
Sodium bicarbonate.................................5

RoeoPro...................................................151
Resonium A...............................................36
Resource Beneprotein.............................219
Resource Diabetic (Vanilla).......................224
Respiratory Stimulants.............................199
Retinol.....................................................20
Retinol Palmitate...................................206
ReTrieve...................................................52
Retrovir....................................................86
Retrovir IV...............................................86
Revlivid....................................................133
Revolade...................................................25
Rexacrom.................................................202
RexAir........................................................198
Riboflavin 5-phosphate.........................204
Ribomustin...............................................128
Rict.........................................................60
Rifabutin.....................................................83
Rifadin.....................................................83
Rifampicin.................................................83
Rifaximin...................................................8
Rifaxin......................................................83
Rilutek.....................................................103
Riluzole....................................................103
Ringer's solution.......................................35
Riodine....................................................209
Risedronate Sandoz....................................94
Risedronate sodium....................................94
Risperdal Consta.......................................120
Risperidone..............................................118
Risperon...................................................118
Ritalin......................................................124
Ritalin LA..................................................124
Ritalin SR..................................................124
Ritonavir...................................................87
Rituximab................................................172
Rivaroxaban.............................................30
Rivastigmine.............................................125
Rivotril.....................................................112
RIXUBIS...................................................28
Rizamelt....................................................115
Rizatriptan................................................115
Rocuronium bromide...............................100
Rolin........................................................144
Ropinirole hydrochloride.........................104
Ropivacaine hydrochloride.......................107
Ropivacaine hydrochloride with fentanyl..........107
Ropivacaine Kabi......................................107
Rose bengal sodium...................................202
Rotarix.....................................................241
Rotavirus oral vaccine..............................241
Roxane.....................................................5
Rubifen.....................................................75
Rubifen SR................................................124
Rulide D....................................................75
Rurioticocog alfa pegol [Recombinant factor VIII]...
Ruxolitinib................................................140
Ruxolitinib..............................................140

S26 LBW Gold RTF....................................228
Sacubitril with valsartan..........................38
SalAIR.....................................................196
Salazopyrin...............................................6
Salazopyrin EN..........................................6
Salbutamol..............................................196
Salbutamol with ipratropium bromide.............193
Salicylic acid...........................................216
Salmonella typhi vaccine..........................237
Sandimmun..............................................145
Sandostatin LAR......................................143
Sapropterin Dihydrochloride....................15
Scalp Preparations....................................55
Scandeston 3%..........................................106
Sclerosing Agents.....................................199
Scopoderm TTS.........................................116
Sebizole....................................................51
Secretin pentahydrochloride......................212
Secukinumab.............................................181
Sedatives and Hypnotics............................122
Seepr Breezhaler....................................194
Selegline hydrochloride..........................104
Sennosides.............................................13
Senspar...................................................62
Serenace..................................................118
Sere tide...................................................198
Sere tide Accuhaler...................................198
Serevent.................................................197
Serevent Accuhaler...................................197
Sertotraine..............................................111
Sevoflurane.............................................105
Sildenafil.................................................49
Siliximus................................................182

Sodium acid phosphate............................35
Sodium acetate.........................................35
Sodium alginate......................................209
Sodium alginate with magnesium alginate..........5
Bicarbonate...............................................
Extemporaneously Compounded Preparations......216
Sodium chloride.......................................
Bicarbonate............................................
Extemporaneously Compounded Preparations......217
Sodium citrate...........................................
Sodium citrate with sodium chloride and potassium chloride....30
Sodium citrate with sodium laurylsulphoacetate...12
Sodium citrate with sulphoglycolic acid...............
Sodium cromoglicate...................................
Sodium fluoride........................................17

Various...................................................213

Sodium chloride with sodium bicarbonate...........
Alimentary...............................................5
Exttemporaneously Compounded Preparations......217
Sodium citrate with sodium chloride and potassium chloride....30
Sodium citrate with sodium laurylsulphoacetate...12
Sodium citrate with sulphoglycolic acid.............
Sodium cromoglicate...................................
Sodium fluoride........................................17

INDEX: Generic Chemicals and Brands

- S -

Silver nitrate...........................................56
Dermatological...........................................
Extemporaneously Compounded Preparations......

Simeticone.............................................5
Simulect..................................................161
Simvastatin.............................................45
Simvastatin Mylan..................................45
Sincalide................................................212
Sinemet....................................................104
Sinemet CR.............................................104
Sirolimus...............................................190
Siterone.....................................................62
Slow-Lopresor.........................................41
Smith BioMed Rapid Pregnancy Test................243
Snake antivenom....................................208
Sodibic.....................................................36
Sodium acetate.........................................35
Sodium acid phosphate............................35
Sodium alginate......................................209
Sodium alginate with magnesium alginate..........5
Bicarbonate...............................................
Extemporaneously Compounded Preparations......216
Sodium chloride.......................................
Bicarbonate............................................
Extemporaneously Compounded Preparations......217
Sodium citrate with sodium chloride and potassium chloride....30
Sodium citrate with sodium laurylsulphoacetate...12
Sodium citrate with sulphoglycolic acid.............
Sodium cromoglicate...................................
Sodium fluoride........................................17

INDEX: Generic Chemicals and Brands

- S -

Silver nitrate...........................................56
Dermatological...........................................
Extemporaneously Compounded Preparations......

Simeticone.............................................5
Simulect..................................................161
Simvastatin.............................................45
Simvastatin Mylan..................................45
Sincalide................................................212
Sinemet....................................................104
Sinemet CR.............................................104
Sirolimus...............................................190
Siterone.....................................................62
Slow-Lopresor.........................................41
Smith BioMed Rapid Pregnancy Test................243
Snake antivenom....................................208
Sodibic.....................................................36
Sodium acetate.........................................35
Sodium acid phosphate............................35
Sodium alginate......................................209
Sodium alginate with magnesium alginate..........5
Bicarbonate...............................................
Extemporaneously Compounded Preparations......216
Sodium chloride.......................................
Bicarbonate............................................
Extemporaneously Compounded Preparations......217
Sodium citrate with sodium chloride and potassium chloride....30
Sodium citrate with sodium laurylsulphoacetate...12
Sodium citrate with sulphoglycolic acid.............
Sodium cromoglicate...................................
Sodium fluoride........................................17

INDEX: Generic Chemicals and Brands

- S -

Silver nitrate...........................................56
Dermatological...........................................
Extemporaneously Compounded Preparations......

Simeticone.............................................5
Simulect..................................................161
Simvastatin.............................................45
Simvastatin Mylan..................................45
Sincalide................................................212
Sinemet....................................................104
Sinemet CR.............................................104
Sirolimus...............................................190
Siterone.....................................................62
Slow-Lopresor.........................................41
Smith BioMed Rapid Pregnancy Test................243
Snake antivenom....................................208
Sodibic.....................................................36
Sodium acetate.........................................35
Sodium acid phosphate............................35
Sodium alginate......................................209
Sodium alginate with magnesium alginate..........5
Bicarbonate...............................................
Extemporaneously Compounded Preparations......216
Sodium chloride.......................................
Bicarbonate............................................
Extemporaneously Compounded Preparations......217
Sodium citrate with sodium chloride and potassium chloride....30
Sodium citrate with sodium laurylsulphoacetate...12
Sodium citrate with sulphoglycolic acid.............
Sodium cromoglicate...................................
Sodium fluoride........................................17

INDEX: Generic Chemicals and Brands

- S -

Silver nitrate...........................................56
Dermatological...........................................
Extemporaneously Compounded Preparations......

Simeticone.............................................5
Simulect..................................................161
Simvastatin.............................................45
Simvastatin Mylan..................................45
Sincalide................................................212
Sinemet....................................................104
Sinemet CR.............................................104
Sirolimus...............................................190
Siterone.....................................................62
Slow-Lopresor.........................................41
Smith BioMed Rapid Pregnancy Test................243
Snake antivenom....................................208
Sodibic.....................................................36
Sodium acetate.........................................35
Sodium acid phosphate............................35
Sodium alginate......................................209
Sodium alginate with magnesium alginate..........5
Bicarbonate...............................................
Extemporaneously Compounded Preparations......216
Sodium chloride.......................................
Bicarbonate............................................
Extemporaneously Compounded Preparations......217
Sodium citrate with sodium chloride and potassium chloride....30
Sodium citrate with sodium laurylsulphoacetate...12
Sodium citrate with sulphoglycolic acid.............
Sodium cromoglicate...................................
Sodium fluoride........................................17
INDEX: Generic Chemicals and Brands

Sodium fusidate [Fusidic acid]
  Dermatological .................................. 51
  Infections....................................... 79
  Sensory......................................... 200
Sodium hyaluronate [Hyaluronic acid]
  Alimentary....................................... 19
  Sensory......................................... 203, 206
Sodium hyaluronate [Hyaluronic acid]
  with chondroitin sulphate ............... 203
Sodium hypochlorite......................... 210
Sodium metabisulphite........................ 217
Sodium nitrile.................................. 207
Sodium nitroprusside
  Cardiovascular.................................. 47
  Optional Pharmaceuticals.................. 243
Sodium phenylbutyrate...................... 16
Sodium phosphate with phosphoric
  acid............................................... 12
Sodium polystyrene sulphonate............ 36
Sodium stibogluconate...................... 85
Sodium tetradecyl sulphate................ 26
Sodium thiosulfate.............................. 207
Sodium valproate................................ 114
Sodium with potassium....................... 214
Sollan.............................................. 117
Solifenacin Mylan................................ 60
Solifenacin succinate.......................... 60
Solu-Cortef...................................... 63
Solu-Medrol...................................... 64
Solu-Medrol Act-O-Vial....................... 64
Somatropin....................................... 66
Sotalol............................................ 41
Soya oil.......................................... 207
Spacer device.................................... 243
Span-K............................................. 36
Specialised Formulas.......................... 223
Spiolto Respimat................................. 194
Spiractin.......................................... 44
Spiramycin........................................ 85
Spiriva........................................... 194
Spiriva Respimat................................. 194
Spironolactone................................... 44
Sпрyl................................................ 136
Standard Feeds................................... 230
Staphlex.......................................... 76
Starch............................................. 217
Stavudine.......................................... 86
Sterculia with frangula....................... 12
SteroClear......................................... 193
Stesolid........................................... 112
Stimulants / ADHD Treatments ............ 123
Striplent........................................... 114
Stocrin............................................. 85
Strattera......................................... 123
Streptomycin sulphate....................... 72
Stromectol........................................ 83
Suboxone .......................................... 125
Sucralfate........................................ 8
Sucrose........................................... 108
Sugammadex...................................... 100
Sulfa-diazine silver............................ 51
Sulfasalazine.................................... 6
Sulinadac.......................................... 102
Sulphacetamide sodium........................ 200
Sulphadiazine.................................... 79
Sulphur............................................ 217
Sulpri.............................................. 117
Sumatriptan....................................... 115
Sunitinib.......................................... 140
Sunscreen, proprietary ....................... 56
Suprane........................................... 104
Surgical Preparations....................... 213
Sustagen Diabetic (Vanilla).................. 224
Sustagen Hospital Formula Active
  (Choc).......................................... 232
Sustagen Hospital Formula Active
  (Van)........................................... 232
Sutent............................................. 140
Suxamethonium chloride..................... 100
Sylvant.......................................... 182
Symmetrel........................................ 103
Sympathomimetics................................ 46
Synaech.......................................... 66
Synaech Depot................................... 66
Synflorix.......................................... 235
Syntometrine..................................... 59
Syrup............................................... 217
Systane Unit Dose............................... 205

- T -
Tacrolimus........................................ 145
Tacrolimus Sandoz.............................. 145
Tacroliums Sandoz............................. 145
Tagitol V.......................................... 210
Talc................................................ 199
Taliglucerase alfa.............................. 17
Tambocor......................................... 40
Tambocor CR..................................... 40
Tamoxifen citrate.............................. 144
Tamoxifen Sandoz............................... 144
Tamsulosin hydrochloride................... 60
Tamsulosin-Rex.................................. 60
Tarceva........................................... 137
Tasigna........................................... 138
Tasmar............................................ 104
Tecfidera......................................... 121
Tegretol........................................... 112
Tegretol CR....................................... 112
Teicoplanin...................................... 79
Temazepam....................................... 122
Temozolomide.................................... 134
Tenecteplase.................................... 32
Tenofovir disoproxil......................... 88

Tenofovir Disoproxil Teva................... 88
Tenoxicam........................................ 102
Terazosin......................................... 39
Terbinafine....................................... 82
Terbutaline....................................... 59
Terbutaline sulphate......................... 196
Teriflunomide.................................... 121
Teriparatide...................................... 98
Terlipressin...................................... 71
Testosterone..................................... 62
Testosterone cipionate....................... 62
Testosterone esters........................... 62
Testosterone undecanoate................... 62
Tetrahydrozine................................. 103
Tetracaine [Amethocaine] hydrochloride
  Nervous......................................... 107
Sensory.......................................... 203
Tetracosactride [Tetracosactrin]........... 66
Tetrahydrozine................................. 66
Tetracyclin Wahl................................. 78
Tetracycline..................................... 78
Thalidomide...................................... 135
Thalomid......................................... 135
Theobroma oil.................................... 217
Theophylline..................................... 198
Thiamine hydrochloride...................... 21
Thioguanine...................................... 132
Thiopenal [Thiopentone] sodium........... 105
Thiopenal......................................... 105
Thiotepa.......................................... 129
Thrombin......................................... 26
Thymol............................................ 19
Thyroid and Antithyroid
  Preparations................................... 70
Thyrotropin alfa............................... 66
Ticagrelor........................................ 32
Ticaricillin with clavulanic acid......... 76
Ticlopidine....................................... 32
Tigecycline....................................... 78
Tiloutil........................................... 102
Timolol............................................ 204
Timolol maleate................................ 41
Timoptol XE...................................... 204
Tiotropium bromide......................... 194
Tiotropium bromide with
  olodaterol.................................... 194
Tivicay............................................. 88
TMP............................................... 79
TOBI.............................................. 72
Tobradex.......................................... 200
Tobramycin...................................... 194
Infections....................................... 72
Sensory........................................... 200
Tobramycin Mylan.............................. 72
Tobrex............................................ 200

258
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tocilizumab ........................................ 182</td>
</tr>
<tr>
<td>Tofranil ............................................ 110</td>
</tr>
<tr>
<td>Tolcapone ........................................... 104</td>
</tr>
<tr>
<td>Tolterodine tartrate ...................... 61</td>
</tr>
<tr>
<td>Topamax .............................................. 114</td>
</tr>
<tr>
<td>Topicaine .......................................... 106</td>
</tr>
<tr>
<td>Topical Products for Joint and Muscular Pain .................................. 102</td>
</tr>
<tr>
<td>Topiramate .......................................... 114</td>
</tr>
<tr>
<td>Topiramate Actavis ................................. 114</td>
</tr>
<tr>
<td>Tracrium .............................................. 100</td>
</tr>
<tr>
<td>Tramadol hydrochloride ................. 110</td>
</tr>
<tr>
<td>Tramal 50 ........................................... 110</td>
</tr>
<tr>
<td>Tramal SR 100 ....................................... 110</td>
</tr>
<tr>
<td>Tramal SR 150 ....................................... 110</td>
</tr>
<tr>
<td>Tranexamic acid ................................... 26</td>
</tr>
<tr>
<td>Tranexamic-AFT ................................... 26</td>
</tr>
<tr>
<td>Tranylcypromine sulphate ................ 111</td>
</tr>
<tr>
<td>Trastuzumab ........................................ 186</td>
</tr>
<tr>
<td>Travigart ........................................... 204</td>
</tr>
<tr>
<td>Tramadol ............................................. 204</td>
</tr>
<tr>
<td>Trexate .............................................. 131</td>
</tr>
<tr>
<td>Tri-sodium citrate ......................... 217</td>
</tr>
<tr>
<td>Triamcinolone acetonide Alimentary ............ 19</td>
</tr>
<tr>
<td>Triamcinolone acetonide Dermatological .......... 55</td>
</tr>
<tr>
<td>Hormone Preparations ..................... 64</td>
</tr>
<tr>
<td>Triamcinolone acetonide with glicentin, neomycin and nystatin ............. 201</td>
</tr>
<tr>
<td>Triamcinolone acetonide with neomycin sulphate, glicentin and nystatin .... 55</td>
</tr>
<tr>
<td>Triamcinolone hexacetonide ............. 64</td>
</tr>
<tr>
<td>Triazolam ............................................ 122</td>
</tr>
<tr>
<td>Trichloroacetic acid ....................... 217</td>
</tr>
<tr>
<td>Trichochol ................................. 84</td>
</tr>
<tr>
<td>Trientine dihydrochloride .................. 17</td>
</tr>
<tr>
<td>Trimethoprim ....................................... 79</td>
</tr>
<tr>
<td>Trimethoprim with sulphamethoxazole [Co-trimoxazole] .................. 79</td>
</tr>
<tr>
<td>Trometamol ......................................... 213</td>
</tr>
<tr>
<td>Tropicamide ......................................... 205</td>
</tr>
<tr>
<td>Tropisetron ....................................... 117</td>
</tr>
<tr>
<td>Tropisetron-AFT ................................... 117</td>
</tr>
<tr>
<td>Tuberculin PPD [Mantoux] test ............... 242</td>
</tr>
<tr>
<td>Tubersol ........................................... 242</td>
</tr>
<tr>
<td>Two CalHN ....................................... 225</td>
</tr>
<tr>
<td>TwoCal HN RTH (Vanilla) .............. 225</td>
</tr>
<tr>
<td>Tykerb ............................................... 138</td>
</tr>
<tr>
<td>Tysabri ............................................ 121</td>
</tr>
<tr>
<td>- U - ..................................................... 121</td>
</tr>
<tr>
<td>Ultibo Breezhaler ......................... 194</td>
</tr>
<tr>
<td>Ultracortate .................................... 6</td>
</tr>
<tr>
<td>Umeclidinium .................................. 194</td>
</tr>
<tr>
<td>Umeclidinium with vilanterol .......... 194</td>
</tr>
<tr>
<td>Univent .......................................... 193</td>
</tr>
<tr>
<td>Ural .............................................. 60</td>
</tr>
<tr>
<td>Urea Dermatological ......................... 54</td>
</tr>
<tr>
<td>- Extemporaneously Compound -</td>
</tr>
<tr>
<td>Urease Preparations ...................... 217</td>
</tr>
<tr>
<td>Ure X Forte ................................... 43</td>
</tr>
<tr>
<td>Urogafin ....................................... 210</td>
</tr>
<tr>
<td>Urokinase ..................................... 32</td>
</tr>
<tr>
<td>Urolodics ....................................... 60</td>
</tr>
<tr>
<td>Uromitexan .................................. 142</td>
</tr>
<tr>
<td>Ursodeoxycholic acid ................... 10</td>
</tr>
<tr>
<td>Ursosan ......................................... 10</td>
</tr>
<tr>
<td>Utrogestan ................................... 59</td>
</tr>
<tr>
<td>- V - ..................................................... 59</td>
</tr>
<tr>
<td>Vaclovir ...................................... 89</td>
</tr>
<tr>
<td>Valaciclovir .................................. 89</td>
</tr>
<tr>
<td>Valganclovir .................................. 89</td>
</tr>
<tr>
<td>Valganclovir Mylan ....................... 89</td>
</tr>
<tr>
<td>Vancomycin .................................. 79</td>
</tr>
<tr>
<td>Varencline .................................... 126</td>
</tr>
<tr>
<td>Varencline Policr ......................... 126</td>
</tr>
<tr>
<td>Varibar - Honey ................................ 210</td>
</tr>
<tr>
<td>Varibar - Nectar ............................... 210</td>
</tr>
<tr>
<td>Varibar - Pudding .............................. 210</td>
</tr>
<tr>
<td>Varibar - Thin Liquid ...................... 210</td>
</tr>
<tr>
<td>Varicella vaccine [Chickenpox vaccine] ........ 241</td>
</tr>
<tr>
<td>Varicella zoster vaccine [Shingles vaccine] ........ 242</td>
</tr>
<tr>
<td>Varilix ....................................... 241</td>
</tr>
<tr>
<td>Vasodilators .................................. 47</td>
</tr>
<tr>
<td>Vasopressin .................................... 71</td>
</tr>
<tr>
<td>Vasopressin Agents ....................... 71</td>
</tr>
<tr>
<td>Vecuronium bromide ...................... 100</td>
</tr>
<tr>
<td>Vedafil ........................................ 49</td>
</tr>
<tr>
<td>Velcade ....................................... 132</td>
</tr>
<tr>
<td>Veletri ........................................ 50</td>
</tr>
<tr>
<td>Venlafaxine .................................. 111</td>
</tr>
<tr>
<td>Venofer ........................................ 18</td>
</tr>
<tr>
<td>Ventavis ....................................... 50</td>
</tr>
<tr>
<td>Ventolin ..................................... 196</td>
</tr>
<tr>
<td>Vepesid ....................................... 133</td>
</tr>
<tr>
<td>Verapamil hydrochloride ............. 43</td>
</tr>
<tr>
<td>Vergo 16 ...................................... 116</td>
</tr>
<tr>
<td>Verpanil SR .................................. 43</td>
</tr>
<tr>
<td>Vesnadoy ..................................... 136</td>
</tr>
<tr>
<td>Vesazone ..................................... 10</td>
</tr>
<tr>
<td>Vfend ........................................ 81</td>
</tr>
<tr>
<td>Vigabatrin ................................... 114</td>
</tr>
<tr>
<td>Vildagliptin .................................. 10</td>
</tr>
<tr>
<td>Vildagliptin with metformin hydrochloride ........ 10</td>
</tr>
<tr>
<td>Vimpat ...................................... 112</td>
</tr>
<tr>
<td>Vinblastine sulphate .................... 142</td>
</tr>
<tr>
<td>Vincristine sulphate ..................... 142</td>
</tr>
<tr>
<td>Vinorelbine ................................ 142</td>
</tr>
<tr>
<td>Viral Vaccines ................................ 237</td>
</tr>
<tr>
<td>Viramune Suspension ...................... 86</td>
</tr>
<tr>
<td>ViruPOS .................................... 200</td>
</tr>
<tr>
<td>Viscoate .................................... 203</td>
</tr>
<tr>
<td>Visipaque ................................... 210</td>
</tr>
<tr>
<td>Vistil Forte .................................. 206</td>
</tr>
<tr>
<td>Vit.D3 ...................................... 21</td>
</tr>
<tr>
<td>VitA-POS .................................. 206</td>
</tr>
<tr>
<td>Vital ......................................... 224</td>
</tr>
<tr>
<td>Vitamin A with vitamins D and C ........ 20</td>
</tr>
<tr>
<td>Vitamin B complex ......................... 21</td>
</tr>
<tr>
<td>Vitamin B6 25 .................................. 21</td>
</tr>
<tr>
<td>Vitamins .................................... 19</td>
</tr>
<tr>
<td>Vivonex TEN .................................. 224</td>
</tr>
<tr>
<td>Volibris .................................... 48</td>
</tr>
<tr>
<td>Voltaren ..................................... 101</td>
</tr>
<tr>
<td>Voltaren D ................................ 101</td>
</tr>
<tr>
<td>Voltaren Ophtha ............................. 202</td>
</tr>
<tr>
<td>Volumatic .................................. 243</td>
</tr>
<tr>
<td>Volune .................................... 210</td>
</tr>
<tr>
<td>Voriconazole ................................ 81</td>
</tr>
<tr>
<td>Votrient ..................................... 139</td>
</tr>
<tr>
<td>Vttack ...................................... 81</td>
</tr>
<tr>
<td>- W - ..................................................... 81</td>
</tr>
<tr>
<td>Warfarin sodium ................................ 31</td>
</tr>
<tr>
<td>Wart Preparations ......................... 56</td>
</tr>
<tr>
<td>Water .......................................... 56</td>
</tr>
<tr>
<td>Blood ......................................... 36</td>
</tr>
<tr>
<td>Various .................................... 213</td>
</tr>
<tr>
<td>Wool fat ...................................... 213</td>
</tr>
<tr>
<td>Dermatological ................................ 54</td>
</tr>
<tr>
<td>- Extemporaneously Compound -</td>
</tr>
<tr>
<td>Preparations ............................... 217</td>
</tr>
<tr>
<td>X-Opaque-HD .................................. 210</td>
</tr>
<tr>
<td>Xanthan .................................... 217</td>
</tr>
<tr>
<td>Xarleto .................................... 30</td>
</tr>
<tr>
<td>Xifaxan ...................................... 8</td>
</tr>
<tr>
<td>Xolair ...................................... 170</td>
</tr>
<tr>
<td>Xylocaine .................................. 106</td>
</tr>
<tr>
<td>Xylometazoline hydrochloride .......... 196</td>
</tr>
<tr>
<td>Xyntha .................................... 27</td>
</tr>
<tr>
<td>- Y - ..................................................... 27</td>
</tr>
<tr>
<td>Yellow jacket wasp venom .......... 192</td>
</tr>
<tr>
<td>- Z - ..................................................... 92</td>
</tr>
<tr>
<td>Zanamivir .................................. 92</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Zantac................................................... 7
Zapril.................................................... 37
Zarontin ............................................ 112
Zavedos............................................. 130
Zeffix.................................................. 88
Zetlan.................................................. 88
Ziagen................................................ 86
Zidovudine [AZT]................................... 86
Zidovudine [AZT] with
  lamivudine ........................................ 86
Zimybe................................................ 45
Zinc
  Alimentary ...................................... 18
  Dermatological ............................... 52
Zinc and castor oil .............................. 53
Zinc chloride .................................... 18
Zinc oxide ......................................... 217
Zinc sulphate ................................... 18
Zinc with wool fat ............................... 53
Zincaps............................................ 18
Zinforo.............................................. 74
Zinnat............................................... 73
Ziprasidone....................................... 119
Zista............................................... 193
Zithromax......................................... 74
Zoladex............................................. 66
Zoledronic acid
  Hormone Preparations ....................... 63
  Musculoskeletal ............................... 94
Zoledronic acid Mylan ......................... 63
Zopiclone.......................................... 123
Zopiclone Actavis ............................... 123
Zostavax........................................... 242
Zostrix.............................................. 102
Zostrix HP ......................................... 107
Zuclopenthixol acetate ......................... 119
Zuclopenthixol decanoate ..................... 120
Zuclopenthixol hydrochloride ............... 119
Zusdone........................................... 119
Zyban.............................................. 126
Zypine............................................. 118
Zypine ODT ....................................... 118
Zyprexa Relprevv ............................... 119
Zytiga............................................. 142
Zyvox............................................. 79